LXR-ligand induced genes and proteins

ABSTRACT

The present invention features nucleic acids and polypeptides encoding LXR-Ligand Induced I (LXRLI1). Treatment of human cells with acetylpodocarpic dimer, a LXR-agonist compound, results in an increase in LXRLI1 gene expression. The cDNA sequence of LXRLI1 is provided by SEQ ID NO 1. The amino acid sequence for LXRLI1 is provided by SEQ ID NO 2. The present invention also defines an LXR-ligand induced gene and provides methods for using gene expression profiles of this set of LXR regulated genes to measure LXR activity in a subject, to diagnose a disease or disorder involving LXR activity, to screen for compounds that change the activity of LXR and to classify LXR ligands.

BACKGROUND OF THE INVENTION

[0001] The references cited herein are not admitted to be prior art to the claimed invention.

[0002] Cholesterol is used for the synthesis of bile acids in the liver, the manufacture and repair of cell membranes, and the synthesis of steroid hormones. There are both exogenous and endogenous sources of cholesterol. The average American consumes about 450 mg of cholesterol each day and produces an additional 500 to 1,000 mg in the liver and other tissues. Another source is the 500 to 1,000 mg of biliary cholesterol that is secreted into the intestine daily; about 50 percent is reabsorbed (enterohepatic circulation). Excess accumulation of cholesterol in the arterial walls can result in atherosclerosis, which is characterized by plaque formation. The plaques inhibit blood flow, promote clot formation and can ultimately cause heart attacks, stroke and claudication. Development of therapeutic agents for the treatment of atherosclerosis and other diseases associated with cholesterol metabolism has been focused on achieving a more complete understanding of the biochemical pathways involved.

[0003] Atherosclerosis is the leading cause of death in western industrialized countries. The risk of developing atherosclerosis is directly related to plasma levels of LDL cholesterol and inversely related to HDL cholesterol levels. It is generally accepted that HDL is involved in the transport of cholesterol from extrahepatic tissues to the liver, a process known as reverse cholesterol transport (RCT), as described by Pieters, et al. (1994 Biophys. Acta 1225:125), and mediates the transport of cholesteryl ester to steroidogenic tissues for hormone synthesis, as described by Andersen and Dietschy (1981 J. Biol. Chem. 256:7362). High density lipoprotein (HDL) and low density lipoprotein (LDL) are cholesterol transport particles whose plasma concentrations are directly (LDL) and inversely (HDL) correlated with risk for atherosclerosis.

[0004] Recently, liver X receptors (LXRs) and genes transcriptionally regulated by LXRs were identified as key components in cholesterol homeostasis. The LXRs were first identified as orphan members of the nuclear receptor superfamily whose ligands and functions were unknown. Two LXR proteins (α and β) are known to exist in mammals. The expression of LXRα is restricted, with the highest levels being found in the liver, and lower levels found in kidney, intestine, spleen, and adrenals (see Willy, et al., 1995 Genes Dev. 9:1033-45). LXRβ is rather ubiquitous, being found in nearly all tissues examined. Recent studies on the LXRs indicate that they are activated by certain naturally occurring, oxidized derivatives of cholesterol, including 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24, 25(S)-epoxycholesterol and 27-OH cholesterol (see Spencer et al, 2001 J. Med. Chem. 44:886-97; Lehmann, et al., 1997 J. Biol. Chem. 272:3137-40; Janowski et al., 1996 Nature 383:728-31; and Fu et al., 2001 J. Biol. Chem. 276:38378-87). The expression pattern of LXRs and their oxysterol ligands provided the first hint that these receptors may play a role in cholesterol metabolism (see Janowski, et al., 1996 Nature 383:728-31).

[0005] As noted above, cholesterol metabolism in mammals occurs via conversion into steroid hormones or bile acids. The role of LXRs in cholesterol homeostasis was first postulated to involve the pathway of bile acid synthesis, in which cholesterol 7α-hydroxylase (CYP7A) operates in a rate-limiting manner. Support for this proposal was provided when additional experiments found that the CYP7A promoter contained a functional LXR response element that could be activated by LXR/retinoid X receptor (RXR) heterodimers in an oxysterol- and retinoid-dependent manner. Confirmation of LXR function as a transcriptional control point in cholesterol metabolism was made using knockout mice, particularly those lacking the gene encoding oxysterol receptor LXRα (see Peet, et al., 1998 Cell 93:693-704).

[0006] Mice lacking the receptor LXRα (e.g., knockout or (−/−) mice) lost their ability to respond normally to increases in dietary cholesterol and were unable to tolerate any cholesterol in excess of that synthesized de novo. LXRα (−/−) mice did not induce transcription of the gene encoding CYP7A when fed diets containing additional cholesterol. This resulted in an accumulation of large amounts of cholesterol and impaired hepatic function in the livers of LXRα (−/−) mice. These results, and others, further established the role of LXRα as an essential regulatory component of cholesterol homeostasis, in particular reverse cholesterol transport. Indeed, it is now well established that LXR regulated gene products play an integral role in both lipid and cholesterol homeostasis (Edwards, et al., 2002 J. Lipid Res. 43:2-12; Sparrow, et al., 2002 J. Biol. Chem. 277: 10021-7; Chawla, et al., 2001 Science 294:1866-70; Schultz, et al., 2000 Genes & Dev. 14:2831-8; and Menke et al., July 2002 Endocrinology, in press).

[0007] Because of the key role of cholesterol and lipid metabolism in the development of atherosclerosis and other heart diseases, much effort has been given to identifying ligand molecules that bind to LXRs and thereby modulate the expression of genes that are transcriptionally activated by LXR/RXR (see, for example, U.S. Pat. No. 6,316,503; WO 01/41704; Repa, et al., 2000 Science 289:1524-9; Schultz, et al., 2000 Genes & Dev. 14:2831-8; and Sparrow, et al., 2002 J. Biol. Chem. 277: 10021-7). Such LXR agonist and antagonists compounds are useful as therapeutic agents for the treatment of disorders associated with bile acid and cholesterol metabolism, including cholesterol gallstones, atherosclerosis, lipid storage diseases, obesity, and diabetes. Modulators of LXR activity can also be used to treat disease states associated with serum hypercholesterolemia, such as coronary heart disease. For example, LXR ligands that increase the expression of the ABCA1 gene have utility as drugs to increase the levels of high density lipoproteins (HDL) and thereby decrease the risk of atherosclerosis, myocardial infarction and related conditions such as peripheral vascular disease, ischemic stroke (WO 01/41704).

[0008] A number of genes have been shown to be transcriptionally activated by LXR upon exposure of cells to naturally occurring, oxidized derivatives of cholesterol, and by synthetic compounds, such as acetylpodocarpic dimer (APD) (Sparrow, et al., 2002 J. Biol. Chem. 10.1074/jbc.M1108225200) and nonsteroidal LXR ligand compounds T1317 and GW3965 (Joseph, et al., 2002 J. Biol. Chem. 10.1074/jbc.M111041200), all of which activate LXR and induce increased expression of LXR regulated genes. For example, APD has been shown to induce ABCA1, a lipid pump that effluxes cholesterol and phospholipid out of cells (Sparrow, et al., 2002 J. Biol. Chem. 10.1074/jbc.M1108225200). Other genes that have been reported as being regulated by LXRs are: ABCG1, encoding a transmembrane lipid pump protein (Venkateswaran, et al., 2000 J. Biol. Chem. 275:14700-7; Kennedy, et al., 2001 J. Biol. Chem. 276:39438-47); SCD-1, encoding a stearoyl-CoA desaturase involved in fatty acid biosynthesis ( Schultz, et al., 2000 Genes & Development 14:2831-38); apoE, encoding apolipoprotein E (Laffitte, et al., 2001 Proc. Nat. Acad. Sci. 98:507-12); FAS, encoding fatty acid synthase (Joseph, et al., 2002 J. Biol. Chem. /jbc.M111041200); and LPL, encoding lipoprotein lipase (Zhang, et al., 2001, 276:43018-24).

SUMMARY OF THE INVENTION

[0009] Gene expression profiles have been evaluated to identify genes that are coregulated over many reference conditions as a method for gene discovery and functional characterization of ESTs, partial cDNA, and computationally predicted coding sequences whose functions are unknown. In particular, several different cell types were treated with a LXR-ligand to identify new genes that are coregulated with genes known to be transcriptionally regulated by LXR. Using this method transcripts have been identified, cloned and sequenced that bridge sequence regions that were previously identified as representing distinct transcripts. The novel polynucleotides of the present invention encode a novel polypeptide and are transcriptionally induced by the LXR-agonist compound APD.

[0010] More specifically, the present invention features polynucleotides encoding LXR-Ligand Induced 1 (LXRLI1) and LXRLI1 polypeptides. LXRLI1 is transcriptionally activated by compounds that are capable of binding to nuclear receptor LXR which in turn activates transcription of target genes. The cDNA sequence encoding LXRLI1 is provided by SEQ ID NO 1. The amino acid sequence for LXRLI1 is provided by SEQ ID NO 2.

[0011] Thus, a first aspect of the present invention describes a purified LXRLI1 nucleic acid. The nucleic acid comprises SEQ ID NO 1 or the complement thereof. Reference to the presence of one region does not indicate that another region is not present. For example, in different embodiments the nucleic acid can comprise or consist of a nucleic acid encoding for SEQ ID NO 2 and can comprise or consist of the nucleic acid sequence of SEQ ID NO 1.

[0012] Another aspect of the present invention describes a purified LXRLI1 polypeptide. The polypeptide can comprise or consist of the amino acid sequence of SEQ ID NO 2.

[0013] Another aspect of the present invention describes an expression vector. The expression vector comprises a nucleotide sequence encoding a polypeptide comprising or consisting of SEQ ID NO 2, wherein the nucleotide sequence is transcriptionally coupled to an exogenous promoter. Alternatively, the nucleotide sequence comprises or consists of SEQ ID NO 1 and is transcriptionally coupled to an exogenous promoter.

[0014] Another aspect of the present invention describes a recombinant cell comprising an expression vector comprising or consisting of the above-described sequences and the promoter is recognized by an RNA polymerase present in the cell. Another aspect of the present invention, describes a recombinant cell made by a process comprising the step of introducing into the cell an expression vector comprising a nucleotide sequence comprising or consisting of SEQ ID NO 1, or a nucleotide sequence encoding a polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO 2, wherein the nucleotide sequence is transcriptionally coupled to an exogenous promoter. The expression vector can be used to insert recombinant nucleic acid into the host genome or can exist as an autonomous piece of nucleic acid.

[0015] Another aspect of the present invention describes a method of producing a LXRLI1 polypeptide comprising at least nine contiguous amino acids of SEQ ID NO 2. The method involves the step of growing a recombinant cell containing an inventive expression vector under conditions wherein the polypeptide is expressed from the expression vector.

[0016] Another aspect of the present invention features a purified antibody preparation comprising an antibody that binds to LXRLI1.

[0017] Another aspect of the invention provides a method of estimating LXR activity in a subject, comprising the steps of: A method of estimating LXR activity in a subject, comprising: measuring a transcript level in a sample of mRNA or nucleic acid derived therefrom from the subject, wherein the transcript comprises a nucleotide sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, SEQ ID NO 21, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37, SEQ ID NO 39, SEQ ID NO 41, SEQ ID NO 43, SEQ ID NO 45, SEQ ID NO 47,SEQ ID NO 49, SEQ ID NO 51, SEQ ID NO 53, SEQ ID NO 55, SEQ ID NO 57, SEQ ID NO 59, SEQ ID NO 61, SEQ ID NO 63, SEQ ID NO 65, SEQ ID NO 67, SEQ ID NO 69, SEQ ID NO 71, SEQ ID NO 73, SEQ ID NO 74, SEQ ID NO 76, SEQ ID NO 77, SEQ ID NO 79, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 84, SEQ ID NO 85, SEQ ID NO 86, SEQ ID NO 87, SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 90, SEQ ID NO 91, SEQ ID NO 92, SEQ ID NO 93, SEQ ID NO 94 and SEQ ID NO 95; and comparing the measured level of the transcript to the level of the transcript measured in a control sample; wherein the level of transcript measured in the sample from the subject as compared to the level of transcript measured in the control sample provides an estimate of LXR activity in the subject sample.

[0018] In another aspect of the invention a method is provided for estimating LXR activity in a subject comprising the steps of: detecting the presence of transcripts in a sample comprising mRNA or nucleic acid derived therefrom from a subject, wherein said transcript encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO 2, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ID NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 30, SEQ ID NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ID NO 40, SEQ ID NO 42, SEQ ID NO 44, SEQ ID NO 46,SEQ ID NO 48,SEQ ID NO 50, SEQ ID NO 52, SEQ ID NO 54, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 60, SEQ ID NO 62, SEQ ID NO 64, SEQ ID NO 66,SEQ ID NO 68,SEQ ID NO 70,SEQ ID NO 72,SEQ ID NO 75, SEQ ID NO 78, SEQ ID NO 80, SEQ ID NO 83, and SEQ ID NO 96; and comparing the measured level of the transcript to the level of the transcript measured in a control sample; wherein the level of transcript measured in the sample from the subject as compared to the level of transcript measured in the control sample provides an estimate of LXR activity in the subject sample.

[0019] In another embodiment of the invention, the above described methods of measuring LXR activity are used to diagnose a disease or disorder involving LXR activity in a sample by detecting increased or decreased in transcript level relative to the amount present in an analogous sample from a subject not having the disease or disorder, or not subjected to therapy.

[0020] Alternatively, the above-described methods of measuring LXR activity are used to screen for a compound that changes the activity of LXR, wherein the compound changes the level of LXR activity in a sample from the subject contacted with the compound relative to the level of LXR activity present in an analogous sample from the subject not contacted with the compound.

[0021] Yet another aspect of the present invention provides a method for classifying a test LXR-ligand comprising detecting a difference in the expression of a plurality of genes in a first cell sample contacted by the test LXR-ligand compared to the expression of the plurality of genes a second cell sample contacted by a reference LXR-ligand, the plurality of genes consisting of at least five genes corresponding to markers listed in Tables 1, wherein the test LXR-ligand is classified as a full activity LXR-ligand if each gene in the plurality of genes is similarly regulated in the first and second cell samples, and, the test LXR-ligand is classified as a partial activity LXR-ligand if fewer than all of the genes in the plurality of genes are similarly regulated in the first cell sample as compared to the second cell sample.

[0022] Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

BRIEF DESCRIPTION OF THE FIGURES

[0023]FIG. 1 illustrates co-clustering of expression profiles for genes that were known to be regulated by LXR-ligands with other genes, ESTs and predicted transcripts (collectively “markers”) whose regulation by LXR-ligands was unknown. FlexJet® microarrays representing 25,000 mRNA and EST clusters were hybridized to a mixture of cRNAs from untreated versus treated cells of various types. A total of 297 markers were identified as being differentially regulated with a log ratio of >0.2 with a P-value of <0.01 in at least two of the twelve experiments. These gene expression profiles comprising differentially expressed array markers meeting these criteria were then analyzed using a two dimensional hierarchical clustering algorithm. Markers were grouped by greatest similarity of regulation over all experiments (Y-axis) and the experiments showing the greatest similarities in gene regulation (X-axis). Only a section of the total data set is shown in FIG. 1 (55 genes and 12 experiments). The numbers on the Y-axis correspond to the various cell types and compound treatments the cells received prior to measurement of gene expression, as follows:

[0024] 1) THP-1 cells, no compound vs. exposure to 0.1 μM Zaragozic Acid for 6 hours;

[0025] 2) THP-1 cells, no compound vs. exposure to 0.1 μM Zaragozic Acid for 20 hours;

[0026] 3) THP-1 cells, no compound vs. exposure to 0.1 μM Acetyl-Podocarpic Dimer (APD) for 6 hours;

[0027] 4) THP-1 cells, no compound vs. exposure to 0.1 μM APD for 20 hours;

[0028] 5) Macrophage cells, no compound vs. exposure to 0.1 μM APD for 24 hours;

[0029] 6) Hepatocytes, no compound vs. exposure to 0.1 μM APD for 24 hours;

[0030] 7) Hepatocytes, no compound vs. exposure to 0.01 μM APD for 24 hours;

[0031] 8) Hepatocytes, no compound vs. exposure to 0.001 μM APD for 24 hours;

[0032] 9) Hepatocytes, no compound vs. exposure to 0.1 mM Fenofibrate for 24 hours;

[0033] 10) Hepatocytes, no compound vs. exposure to 0.03 mM Fenofibrate for 24 hours;

[0034] 11) Hepatocytes, no compound vs. exposure to 0.01 mM Fenofibrate for 24 hours; and

[0035] 12) Hepatocytes, no compound vs. exposure to 0.1 μM Glucagon for 24 hours.

[0036] On the top X-axis, sequence annotation designations are provided for each marker represented in the LXR-ligand induced geneset. Markers up-regulated in a particular experiment are colored light-gray; markers down-regulated in that experiment are colored black; and markers showing no regulation in a particular experiment are colored medium-gray.

[0037]FIG. 2 illustrates the use of gene expression profiles comprising the fifty-five markers identified in FIG. 2 to classify compounds affecting cholesterol metabolism. The numbers on the Y-axis correspond to the various cell types and compound treatments the cells received prior to measurement of gene expression, as follows:

[0038] 1) THP-1 cells, no compound vs. exposure to 0.1 μM APD for 6 hours;

[0039] 2) THP-1 cells, no compound vs. exposure to 0.1 μM APD for 20 hours;

[0040] 3) Macrophage cells, no compound vs. exposure to 0.1 μM APD for 24 hours;

[0041] 4) Hepatocytes, no compound vs. exposure to 0.001 μM APD for 24 hours;

[0042] 5) Hepatocytes, no compound vs. exposure to 0.01 μM APD for 24 hours;

[0043] 6) Hepatocytes, no compound vs. exposure to 0.1 μM APD for 24 hours;

[0044] 7) THP-1 cells, no compound vs. exposure to 10 μM 22(R)-hydroxycholesterol (22RHC) for 3 hours;

[0045] 8) THP-1 cells, no compound vs. exposure to 10 μM 22RHC for 6 hours;

[0046] 9) THP-1 cells, no compound vs. exposure to 10 μM 22RHC for 20 hours;

[0047] 10) THP-1 cells, no compound vs. exposure to 200 μg protein/ml Acetylated Low Density Lipoprotein (AcLDL) for 3 hours;

[0048] 11) THP-1 cells, no compound vs. exposure to 200 μg protein/ml AcLDL for 6 hours;

[0049] 12) THP-1 cells, no compound vs. exposure to 200 μg protein/ml AcLDL for 20 hours;

[0050] 13) THP-1 cells, no compound vs. exposure to 0.5 mM CD and Cholesterol at 24 μg/ml for 3 hours;

[0051] 14) THP-1 cells, no compound vs. exposure to 0.5 mM CD and Cholesterol at 24 μg/ml for 6 hours;

[0052] 15) THP-1 cells, no compound vs. exposure to 0.5 mM CD and Cholesterol at 24 μg/ml for 20 hours;

[0053] 16) THP-1 cells, no compound vs. exposure to 0.1 μM Zaragozic Acid for 6 hours;

[0054] 17) THP-1 cells, no compound vs. exposure to 0.1 μM Zaragozic Acid for 20 hours;

[0055] 18) THP-1 cells, no compound vs. exposure to 2.0 mM Methyl-β-Cyclodextrin (CD) for 1 hour followed by recovery for 3 hours;

[0056] 19) THP-1 cells, no compound vs. exposure to 2.0 mM CD for 1 hour followed by recovery for 3 hours; and

[0057] 20) THP-1 cells, no compound vs. exposure to 2.0 mM CD for 1 hour followed by recovery for 3 hours.

[0058] On the top X-axis, sequence annotation designations are provided for each marker represented in the LXR-ligand classification geneset. Markers up-regulated in a particular experiment are colored light-gray; markers down-regulated in that experiment are colored black; and markers showing no regulation in a particular experiment are colored medium-gray.

DEFINITIONS

[0059] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.

[0060] As used herein, underscoring or italicizing the name of a gene shall indicate the gene, in contrast to its encoded protein product which is indicated by the name of the gene in the absence of any underscoring or italicizing. For example, “LXRLI1” shall mean polynucleotides encoding the protein product “LXRLI1.”

[0061] As used herein, “LXR” includes all subtypes of this receptor and corresponding polynucleotides that encode such subtypes. Specifically LXR includes LXRα and LXRβ, and a ligand of LXR should be understood to include a ligand of LXRα or LXRβ.

[0062] As used herein, “ligand” includes an agonist, partial agonist or antagonist of LXR. The ligand may be selective for LXRα or LXRβ. Reference to a compound as an agonist or antagonist does not mean that that compound does not have a different biochemical effect on the target receptor under a different circumstance, e.g., in a different cell type, tissue type or disease state.

[0063] As used herein, an “isolated nucleic acid” is a nucleic acid molecule that exists in a physical form that is nonidentical to any nucleic acid molecule of identical sequence as found in nature; “isolated” does not require, although it does not prohibit, that the nucleic acid so described has itself been physically removed from its native environment. For example, a nucleic acid can be said to be “isolated” when it includes nucleotides and/or internucleoside bonds not found in nature. When instead composed of natural nucleosides in phosphodiester linkage, a nucleic acid can be said to be “isolated” when it exists at a purity not found in nature, where purity can be adjudged with respect to the presence of nucleic acids of other sequence, with respect to the presence of proteins, with respect to the presence of lipids, or with respect the presence of any other component of a biological cell, or when the nucleic acid lacks sequence that flanks an otherwise identical sequence in an organism's genome, or when the nucleic acid possesses sequence not identically present in nature. As so defined, “isolated nucleic acid” includes nucleic acids integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

[0064] A “purified nucleic acid” represents at least 10% of the total nucleic acid present in a sample or preparation. In preferred embodiments, the purified nucleic acid represents at least about 50%, at least about 75%, or at least about 95% of the total nucleic acid in a isolated nucleic acid sample or preparation. Reference to “purified nucleic acid” does not require that the nucleic acid has undergone any purification and may include, for example, chemically synthesized nucleic acid that has not been purified.

[0065] The phrases “isolated protein”, “isolated polypeptide”, “isolated peptide” and “isolated oligopeptide” refer to a protein (or respectively to a polypeptide, peptide, or oligopeptide) that is nonidentical to any protein molecule of identical amino acid sequence as found in nature; “isolated” does not require, although it does not prohibit, that the protein so described has itself been physically removed from its native environment. For example, a protein can be said to be “isolated” when it includes amino acid analogues or derivatives not found in nature, or includes linkages other than standard peptide bonds. When instead composed entirely of natural amino acids linked by peptide bonds, a protein can be said to be “isolated” when it exists at a purity not found in nature—where purity can be adjudged with respect to the presence of proteins of other sequence, with respect to the presence of non-protein compounds, such as nucleic acids, lipids, or other components of a biological cell, or when it exists in a composition not found in nature, such as in a host cell that does not naturally express that protein.

[0066] As used herein, a “purified polypeptide” (equally, a purified protein, peptide, or oligopeptide) represents at least 10% of the total protein present in a sample or preparation, as measured on a weight basis with respect to total protein in a composition. In preferred embodiments, the purified polypeptide represents at least about 50%, at least about 75%, or at least about 95% of the total protein in a sample or preparation. A “substantially purified protein” (equally, a substantially purified polypeptide, peptide, or oligopeptide) is an isolated protein, as above described, present at a concentration of at least 70%, as measured on a weight basis with respect to total protein in a composition. Reference to “purified polypeptide” does not require that the polypeptide has undergone any purification and may include, for example, chemically synthesized polypeptide that has not been purified.

[0067] As used herein, the term “microarray” and the equivalent phrase “nucleic acid microarray” refer to a substrate-bound collection of a plurality of nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. As so defined, the term “microarray” and the phrase “nucleic acid microarray” include, but are not limited to, all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999) (ISBN: 0199637768); 1999 Nature Genet. 21(suppl):1-60; Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000) (ISBN: 1881299376); and Hughes, et al., 2001 Nature Biotechnol. 19:342-7. As so defined, the term “microarray” and the phrase “nucleic acid microarray” also include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are distributably disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, inter alia, in Brenner, et al., 2000 Proc. Natl. Acad. Sci. 97:16650-7); in such case, the term “microarray” and the phrase “nucleic acid microarray” refer to the plurality of beads in aggregate.

[0068] As used herein, the term “marker” in the context of microarrays and gene expression profiles derived therefrom, refers to a gene, EST, predicted transcript or a polypeptide encoded by any of the preceding polynucleotides that is represented on a mircroarray by a hybridization probe that is complementary and hybridizable to any portion of a corresponding mRNA transcript.

[0069] As used herein, the term “geneset” refers to a plurality of genes, ESTs and predicted transcripts that are coregulated under two or more biological conditions.

[0070] As used herein, the phrase “similarly regulated” in the context of gene expression means that a measured level of gene expression of the same marker in two or more test samples indicates that the marker is up-regulated or down-regulated to a statistically significant threshold as compared to a control sample. The control sample can be any type of cell or tissue sample that serves as an appropriate baseline for determining differential gene expression. For example, the control sample can be from normal, i.e., non-diseased cells or tissue; from cells or tissue not exposed to a test compound; from cells or tissues of a different kind as compared to the test samples, e.g., a different cell type or tissues type, or a different developmental; or a pool of a plurality of samples from any of above. The statistical significance of a gene expression result can be determined using any one of a variety of different standard statistical tests that are well known in the art (see for example, U.S. Pat. No. 6,203,987 and U.S. Pat. No. 6,351,712).

[0071] As used herein, the term “antibody” refers to a polypeptide, at least a portion of which is encoded by at least one immunoglobulin gene, or fragment thereof, and that can bind specifically to a desired target molecule. The term includes naturally-occurring forms, as well as fragments and derivatives. Fragments within the scope of the term “antibody” include those produced by digestion with various proteases, those produced by chemical cleavage and/or chemical dissociation, and those produced recombinantly, so long as the fragment remains capable of specific binding to a target molecule. Among such fragments are Fab, Fab′, Fv, F(ab)′₂, and single chain Fv (scFv) fragments. Derivatives within the scope of the term include antibodies (or fragments thereof) that have been modified in sequence, but remain capable of specific binding to a target molecule, including: interspecies chimeric and humanized antibodies; antibody fusions; heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies (see, e.g., Marasco (ed.), Intracellular Antibodies: Research and Disease Applications, Springer-Verlag New York, Inc. (1998) (ISBN: 3540641513). As used herein, antibodies can be produced by any known technique, including harvest from cell culture of native B lymphocytes, harvest from culture of hybridomas, recombinant expression systems, and phage display.

[0072] As used herein, a “purified antibody preparation” is a preparation where at least 10% of the antibodies present bind to the target ligand. In preferred embodiments, antibodies binding to the target ligand represent at least about 50%, at least about 75%, or at least about 95% of the total antibodies present. Reference to “purified antibody preparation” does not require that the antibodies in the preparation have undergone any purification.

[0073] As used herein, “specific binding” refers to the ability of two molecular species concurrently present in a heterogeneous (inhomogeneous) sample to bind to one another in preference to binding to other molecular species in the sample. Typically, a specific binding interaction will discriminate over adventitious binding interactions in the reaction by at least two-fold, more typically by at least 10-fold, often at least 100-fold; when used to detect analyte, specific binding is sufficiently discriminatory when determinative of the presence of the analyte in a heterogeneous (inhomogeneous) sample. Typically, the affinity or avidity of a specific binding reaction is least about 10⁻⁷ M, with specific binding reactions of greater specificity typically having affinity or avidity of at least 10⁻⁸ M to at least about 10⁻⁹ M.

[0074] The term “antisense”, as used herein, refers to a nucleic acid molecule sufficiently complementary in sequence, and sufficiently long in that complementary sequence, as to hybridize under intracellular conditions to (i) a target mRNA transcript or (ii) the genomic DNA strand complementary to that transcribed to produce the target mRNA transcript.

[0075] The term “reverse cholesterol transport” describes the transport of cholesterol from extrahepatic tissues to the liver where it maybe catabolized and eliminated.

[0076] The term “subject”, as used herein refers to an organism and to cells or tissues derived therefrom. For example the organism may be an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is usually a mammal, and most commonly human.

DETAILED DESCRIPTION OF THE INVENTION

[0077] The present invention relates to the amino acid sequence of human LXRLI1 and to nucleotide sequences encoding this protein. SEQ ID NO 1) is a cDNA sequence containing a full open reading frame that encodes LXRLI1 (SEQ ID NO 2). Transcription of the LXRLI1 gene was found to be induced by the LXRα/β agonist compound acetylpodocarpic dimer (APD).

[0078] LXRLI1 polynucleotides encoding LXRLI1 and LXRLI1 proteins, as exemplified and enabled herein include a number of specific, substantial and credible utilities. For example, LXRLI1 encoding nucleic acids were cloned from a human source (see Example 2). Such nucleic acids can be used as hybridization probes to distinguish between cells that produce LXRLI1 transcripts from human or non-human cells (including bacteria) that do not produce such transcripts. Similarly, antibodies specific for LXRLI1 can be used to distinguish between cells that express LXRLI1 from human or non-human cells (including bacteria) that do not express LXRLI1.

[0079] Based on LXRLI1 being a LXR regulated gene whose gene product protein plays a role in cholesterol/lipid metabolism, LXRLI1 provides a target to achieve a beneficial effect in a subject. Preferably, LXRLI1 activity is modulated to achieve one or more of the following: prevent or reduce the risk of occurrence, or recurrence where the potential exist, of cholesterol gallstones, atherosclerosis, lipid storage diseases, obesity, diabetes, Alzheimer's disease, or hypercholesterolemia. Compounds that treat hypercholesterolemia are particularly important because of the cause-and-effect relationship between hypercholesterolemia and morbidity and mortality from coronary artery disease (CAD) (for a review see, Witztum, In, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, 1996, Ch. 36, pp. 875-897).

[0080] Modulation of LXRLI1 activity is preferably achieved by evoking a response at the LXR nuclear receptor protein or by altering a response evoked by a LXR nuclear receptor agonist or antagonist. Compounds modulating LXR receptor activity include agonists, antagonists, and allosteric modulators. Generally, LXR-agonists and allosteric modulators positively affecting LXRLI1 activity will be used to increase reverse cholesterol transport. It is believed that plasma HDL particles play a major role in the reverse transport process, acting as scavengers of tissue cholesterol. The evidence linking elevated serum cholesterol to coronary heart disease is overwhelming. For example, atherosclerosis is a slowly progressive disease characterized by the accumulation of cholesterol within the arterial wall. Compelling evidence supports the concept that lipids deposited in atherosclerotic lesions are derived primarily from plasma LDL; thus, LDLs have popularly become known as the “bad” cholesterol. In contrast, HDL serum levels correlate inversely with coronary heart disease—indeed, high serum levels of HDL are regarded as a negative risk factor. It is hypothesized that high levels of plasma HDL are not only protective against coronary artery disease, but may actually induce regression of atherosclerotic plaques (e.g., see Badimon, et al., 1992 Circulation 86 (Suppl. III):86-94). Thus, HDL have popularly become known as the “good” cholesterol and treatments that increase the level of RCT have a beneficial therapeutic effect on a subject.

[0081] LXRLI1 activity can also be affected by modulating LXRLI1 expression. Compounds modulating LXRLI1 expression include a cloned polynucleotide encoding LXRLI1 that can express LXRLI1 in vivo, antisense nucleic acids targeted to LXRLI1 transcripts and enzymatic nucleic acids, such as ribozymes and RNAi, targeted to LXRLI1 transcripts.

[0082] Preferably, LXRLI1 activity is modulated to achieve a therapeutic effect upon diseases in which cholesterol metabolism is in need of adjustment in a subject. For example, atherosclerosis can be treated by modulating LXRLI1 activity to achieve, for instance, increased levels of RCT and HDL. In other embodiments, the risk of developing atherosclerosis is reduced by modulating LXRLI1 activity to achieve, for example, increased levels of RCT and HDL.

LXRLI1 NUCLEIC ACID

[0083] LXRLI1 nucleic acid contain a region that encodes for a polypeptide comprising or consisting of SEQ ID NO 2 or contains comprises or consists of SEQ ID NO 1. LXRLI1 nucleic acid have a variety of uses, such as being used as a hybridization probe or PCR primer to identify the presence of LXRLI1 nucleic acid; being used as a hybridization probe or PCR primer to identify nucleic acid encoding for proteins related to LXRLI1; and/or being used for recombinant expression of LXRLI1 polypeptides.

[0084] Regions in LXRLI1 nucleic acid that do not encode for LXRLI1 amino acids or are not found in SEQ ID NO 1, if present, are preferably chosen to achieve a particular purpose. Examples of additional regions that can be used to achieve a particular purpose include capture regions that can be used as part of a sandwich assay, reporter regions that can be probed to indicate the presence of the nucleic acid, expression vector regions, and regions encoding for other polypeptides.

[0085] LXRLI1 nucleic acid also includes transcripts that are transcriptionally regulated by LXR and encode a polypeptide that has a sequence similarity of at least about 85%, preferably at least 95% with SEQ ID NO 2; and nucleic acid having a sequence similarity of at least about 85%, preferably 90% with SEQ ID NO 1. Sequence similarity for nucleic acid can be determined by FASTA. (Pearson 1990, Methods in Enzymology 183, 63-98). In one embodiment, sequence similarity is determined using FASTA search program with the following parameters: MATRIX: BLOSUM50, GAP PENALTIES: open=−12; residue=−2.

[0086] The guidance provided in the present application can be used to obtain the nucleic acid sequence encoding for LXRLI1 related proteins from different sources. Obtaining nucleic acids encoding for LXRLI1 related proteins from different sources is facilitated using sets of degenerative probes and primers and by the proper selection of hybridization conditions. Sets of degenerative probes and primers are produced taking into account the degeneracy of the genetic code. Adjusting hybridization conditions is useful for controlling probe or primer specificity to allow for hybridization to nucleic acids having similar sequences.

[0087] Techniques employed for hybridization detection and PCR cloning are well known in the art. Nucleic acid detection techniques are described, for example, in Sambrook, et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989. PCR cloning techniques are described, for example, in White, Methods in Molecular Cloning, volume 67, Humana Press, 1997.

[0088] LXRLI1 probes and primers can be used to screen nucleic acid libraries containing, for example, genomic DNA or cDNA. Such libraries are commercially available; and can be produced using techniques such as those described in Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998.

[0089] Starting with a particular amino acid sequence and the known degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be obtained. The degeneracy of the genetic code arises because almost all amino acids are encoded for by different combinations of nucleotide triplets or “codons”. The translation of a particular codon into a particular amino acid is well known in the art (see, e.g., Lewin GENES IV, p. 119, Oxford University Press, 1990). Amino acids are encoded for by codons as follows:

[0090] A=Ala=Alanine: codons GCA, GCC, GCG, GCU

[0091] C=Cys=Cysteine: codons UGC, UGU

[0092] D=Asp=Aspartic acid: codons GAC, GAU

[0093] E=Glu=Glutamic acid: codons GAA, GAG

[0094] F=Phe=Phenylalanine: codons UUC, UUU

[0095] G=Gly=Glycine: codons GGA, GGC, GGG, GGU

[0096] H=His=Histidine: codons CAC, CAU

[0097] I=Ile=Isoleucine: codons AUA, AUC, AUU

[0098] K=Lys=Lysine: codons AAA, AAG

[0099] L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU

[0100] M=Met=Methionine: codon AUG

[0101] N=Asn=Asparagine: codons AAC, AAU

[0102] P=Pro=Proline: codons CCA, CCC, CCG, CCU

[0103] Q=Gln=Glutarmine: codons CAA, CAG

[0104] R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU

[0105] S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU

[0106] T=Thr=Threonine: codons ACA, ACC, ACG, ACU

[0107] V=Val=Valine: codons GUA, GUC, GUG, GUU

[0108] W=Trp=Tryptophan: codon UGG

[0109] Y=Tyr=Tyrosine: codons UAC, UAU

[0110] Nucleic acid having a desired sequence can be synthesized using chemical and biochemical techniques. Examples of chemical techniques are described in Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, and Sambrook et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989.

[0111] Biochemical synthesis techniques involve the use of a nucleic acid template and appropriate enzymes such as DNA and/or RNA polymerases. Examples of such techniques include in vitro amplification techniques such as PCR and transcription based amplification, and in vivo nucleic acid replication. Examples of suitable techniques are provided by Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, Sambrook et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989, and U.S. Pat. No. 5,480,784.

[0112] LXRLI1 Probes

[0113] Probes for LXRLI1 contain a region that can specifically hybridize to LXRLI1 target nucleic acid under appropriate hybridization conditions and can distinguish LXRLI1 nucleic acid from non-target nucleic acids. Probes for LXRLI1 can also contain nucleic acids that are not complementary to LXRLI1 nucleic acid.

[0114] Preferably, non-complementary nucleic acid that is present has a particular purpose such as being a reporter sequence or being a capture sequence. However, additional nucleic acid need not have a particular purpose as long as the additional nucleic acid does not prevent the LXRLI1 nucleic acid from distinguishing between target and non-target.

[0115] Hybridization occurs through complementary nucleotide bases. Hybridization conditions determine whether two molecules, or regions, have sufficiently strong interactions with each other to form a stable hybrid.

[0116] The degree of interaction between two molecules that hybridize together is reflected by the Tm of the produced hybrid. The higher the Tm the stronger the interactions and the more stable the hybrid. Tm is effected by different factors well known in the art such as the degree of complementarity, the type of complementary bases present (e.g., A-T hybridization versus G-C hybridization), the presence of modified nucleic acid, and solution components (e.g., Sambrook, et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989).

[0117] Stable hybrids are formed when the Tm of a hybrid is greater than the temperature employed under a particular set of hybridization assay conditions. The degree of specificity of a probe can be varied by adjusting the hybridization stringency conditions. Detecting probe hybridization is facilitated through the use of a detectable label. Examples of detectable labels include luminescent, enzymatic, and radioactive labels.

[0118] Examples of stringency conditions are provided in Sambrook, et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989. An example of high stringency conditions is as follows: Prehybridization of filters containing DNA is carried out for 2 hours to overnight at 65° C. in buffer composed of 6×SSC, 5× Denhardt's solution, and 100 μg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hours at 65° C. in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20×10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37° C. for 1 hour in a solution containing 2×SSC, 0.1% SDS. This is followed by a wash in 0.1×SSC, 0.1% SDS at 50° C. for 45 minutes before autoradiography. Other procedures using conditions of high stringency would include, for example, either a hybridization step carried out in 5×SSC, 5× Denhardt's solution, 50% formamide at 42° C. for 12 to 48 hours or a washing step carried out in.0.2×SSPE, 0.2% SDS at 65° C. for 30 to 60 minutes.

[0119] Recombinant Expression

[0120] LXRLI1 polypeptides can be expressed from recombinant nucleic acid in a suitable host or in a test tube using a translation system. Recombinantly expressed LXRLI1 polypeptides are preferably used in assays to screen for compounds that bind to LXRLI1 and modulate the activity of the protein.

[0121] Preferably, expression is achieved in a host cell using an expression vector. An expression vector contains recombinant nucleic acid encoding for a polypeptide along with regulatory elements for proper transcription and processing. The regulatory elements that may be present include those naturally associated with the recombinant nucleic acid and exogenous regulatory elements not naturally associated with the recombinant nucleic acid. Exogenous regulatory elements such as an exogenous promoter can be useful for expressing recombinant nucleic acid in a particular host.

[0122] Generally, the regulatory elements that are present in an expression vector include a transcriptional promoter, a ribosome binding site, a terminator, and an optionally present operator. Another preferred element is a polyadenylation signal providing for processing in eukaryotic cells. Preferably, an expression vector also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses.

[0123] Expression vectors providing suitable levels of polypeptide expression in different hosts are well known in the art. Mammalian expression vectors well known in the art include, but are not restricted to, pcDNA3 (Invitrogen, Carlsbad Calif.), pSecTag2 (Invitrogen), pMClneo (Stratagene, La Jolla Calif.), pXT1 (Stratagene), pSG5 (Stratagene), pCMVLacl (Stratagene), pCI-neo (Promega), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146) and pUCTag (ATCC 37460), and. Bacterial expression vectors well known in the art include pET11a (Novagen), pBluescript SK (Stratagene, La Jolla), pQE-9 (Qiagen Inc., Valencia), lambda gt11 (Invitrogen), pcDNAII (Invitrogen), and pKK223-3 (Pharmacia). Fungal cell expression vectors well known in the art include pPICZ (Invitrogen) and pYES2 (Invitrogen), Pichia expression vector (Invitrogen). Insect cell expression vectors well known in the art include Blue Bac III (Invitrogen), pBacPAK8 (CLONTECH, Inc., Palo Alto) and PfastBacHT (Invitrogen, Carlsbad).

[0124] Recombinant host cells may be prokaryotic or eukaryotic. Examples of recombinant host cells include the following: bacteria such as E. coli; fungal cells such as yeast; mammalian cells such as human, bovine, porcine, monkey and rodent; and insect cells such as Drosophila and silkworm derived cell lines. Commercially available mammalian cell lines include L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

[0125] To enhance expression in a particular host it may be useful to modify the sequence provided in SEQ ID NO 1 to take into account codon usage of the host. Codon usage of different organisms are well known in the art (see, Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, Supplement 33 Appendix 1C).

[0126] Expression vectors may be introduced into host cells using standard techniques. Examples of such techniques include transformation, transfection, lipofection, protoplast fusion, and electroporation.

[0127] Nucleic acid encoding for a polypeptide can be expressed in a cell without the use of an expression vector employing, for example, synthetic mRNA or native mRNA. Additionally, mRNA can be translated in various cell-free systems such as wheat germ extracts and reticulocyte extracts, as well as in cell based systems, such as frog oocytes. Introduction of mRNA into cell based systems can be achieved, for example, by microinjection.

LXRLI1 POLYPEPTIDES

[0128] LXRLI1 polypeptides contain an amino acid sequence comprising or consisting of SEQ ID NO 2. LXRLI1 polypeptides have a variety of uses, such as providing a marker for LXR activity; being used as an immunogen to produce antibodies binding to LXRLI1; being used as a target to identify compounds binding to the LXRLI1; and/or being used as a target to identify compounds that alter reverse cholesterol transport.

[0129] In chimeric polypeptides containing one or more regions from LXRLI1 and one or more regions not from LXRLI1, the region(s) not from LXRLI1 can be used, for example, to achieve a particular purpose or to produce a polypeptide that can substitute for LXRLI1 or a fragment thereof. Particular purposes that can be achieved using chimeric LXRLI1 polypeptides include providing a marker for LXR activity, enhancing an immune response, and altering reverse cholesterol transport.

[0130] LXRLI1 polypeptides also include functional LXRLI1 that are induced by LXR activation and have a sequence similarity of at least about 85%, preferably at least 95% with SEQ ID NO 2 Sequence similarity for polypeptides can be deternined by BLAST (Altschul, et al., 1997 Nucleic Acids Res. 25:3389-402). In one embodiment sequence similarity is determined using BLAST search program with the following parameters:

[0131] MATRIX:BLOSUM62, PER RESIDUE GAP COST: 11, and Lambda ratio: 1.

[0132] Polypeptides can be produced using standard techniques including those involving chemical synthesis and those involving biochemical synthesis. Techniques for chemical synthesis of polypeptides are well known in the art (see e.g., Vincent, in Peptide and Protein Drug Delivery, New York, N.Y., Dekker, 1990).

[0133] Biochemical synthesis techniques for polypeptides are also well known in the art. Such techniques employ a nucleic acid template for polypeptide synthesis. The genetic code providing the sequences of nucleic acid triplets coding for particular amino acids is well known in the art (see, e.g., Lewin GENES IV, p. 119, Oxford University Press, 1990). Examples of techniques for introducing nucleic acid into a cell and expressing the nucleic acid to produce protein are provided in references such as Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, and Sambrook, et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989.

[0134] Functional LXRLI1

[0135] Functional LXRLI1 is a membrane bound protein whose expression is altered by LXR and plays a role in cholesterol metabolism, more specifically, reverse cholesterol transport. The identification of the amino acid and nucleic acid sequences of LXRLI1 provide tools for obtaining functional proteins related to LXRLI1 from other sources, for producing LXRLI1 chimeric proteins, and for producing functional derivatives of SEQ ID NO 2.

[0136] LXRLI1 polypeptides can be readily identified and obtained based on their sequence similarity to LXRLI1. Both the amino acid and nucleic acid sequences of LXRLI1 can be used to help identify and obtain LXRLI1 polypeptides. For example, SEQ ID NO 2 can be used to produce degenerative nucleic acid probes or primers for identifying and cloning nucleic acid encoding for a LXRLI1 polypeptide, and SEQ ID NO 1 or fragments thereof, can be used under conditions of moderate stringency to identify and clone nucleic acid encoding LXRLI1 polypeptides from a variety of different organisms.

[0137] The use of degenerative probes and moderate stringency conditions for cloning is well known in the art. Examples of such techniques are described by Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, and Sambrook, et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989.

[0138] Starting with LXRLI1 obtained from a particular source, derivatives can be produced that are involved in reverse cholesterol transport. Such derivatives include polypeptides with amino acid substitutions, additions and deletions. Changes to LXRLI1 to produce a derivative having essentially the same properties should be made in a manner not altering the tertiary structure.

[0139] Differences in naturally occurring amino acids are due to different R groups. An R group effects different properties of the amino acid such as physical size, charge, and hydrophobicity. Amino acids are can be divided into different groups as follows: neutral and hydrophobic (alanine, valine, leucine, isoleucine, proline, tryptophan, phenylalanine, and methionine); neutral and polar (glycine, serine, threonine, tryosine, cysteine, asparagine, and glutamine); basic (lysine, arginine, and histidine); and acidic (aspartic acid and glutamic acid).

[0140] Generally, in substituting different amino acids it is preferable to exchange amino acids having similar properties. Substituting different amino acids within a particular group, such as substituting valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in polypeptide functioning.

[0141] Changes outside of different amino acid groups can also be made. Preferably, such changes are made taking into account the position of the amino acid to be substituted in the polypeptide. For example, arginine can substitute more freely for nonpolar amino acids in the interior of a polypeptide then glutamate because of its long aliphatic side chain (See, Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, Supplement 33 Appendix 1C).

[0142] LXRLI1 Antibodies

[0143] Antibodies recognizing LXRLI1 can be produced using a polypeptide containing SEQ ID NO 2 or a fragment thereof as an immunogen. Preferably, a polypeptide used as an immunogen consists of a polypeptide of SEQ ID NO 2 or a SEQ ID NO 2 fragment at least 9 amino acids in length.

[0144] Antibodies to LXRLI1 have different uses such as being used to identify the presence of LXRLI1 and to isolate LXRLI1 polypeptides. Identifying the presence of LXRLI1 can be used, for example, to identify cells producing LXRLI1. Such identification provides an additional source of LXRLI1 and can be used to distinguish cells known to produce LXRLI1 from cells that do not produce LXRLI1. For example, antibodies to LXRLI1 can distinguish human cells expressing LXRLI1 from human cells not expressing LXRLI1 or non-human cells (including bacteria) that do not express LXRLI1. Such LXRLI1 antibodies can also be used to determine the effectiveness of LXR ligands, using techniques well known in the art, to detect and quantify changes in the protein levels of LXRLI1 in cellular extracts, and in situ immunostaining of cells and tissues.

[0145] Techniques for producing and using antibodies are well known in the art. Examples of such techniques are described in Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998; Harlow, et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; and Kohler, et al., 1975 Nature 256:495-7.

[0146] LXRLI1 Binding Assay

[0147] LXRLI1 or a fragment thereof can be used in binding studies to identify compounds binding to the protein. Such studies can be performed using different formats including competitive and non-competitive formats. Further competition studies can be carried out using additional compounds determined to bind to LXRLI1.

[0148] The particular LXRLI1 sequence involved in ligand binding can be readily identified by using labeled compounds that bind to the protein and different protein fragments. Different strategies can be employed to select fragments to be tested to narrow down the binding region. Examples of such strategies include testing consecutive fragments about 15 amino acids in length starting at the N-terminus, and testing longer length fragments. If longer length fragments are tested, a fragment binding to a compound can be subdivided to further locate the binding region. Fragments used for binding studies can be generated using recombinant nucleic acid techniques.

[0149] Preferably, binding studies are performed using LXRLI1 expressed from a recombinant nucleic acid. More preferably, recombinantly expressed LXRLI1 consists of the SEQ ID NO 2 amino acid sequence.

[0150] Binding assays can be performed using individual compounds or preparations containing different numbers of compounds. A preparation containing different numbers of compounds having the ability to bind to LXRLI1 can be divided into smaller groups of compounds that can be tested to identify the compound(s) binding to LXRLI1.

[0151] Binding assays can be performed using recombinantly produced LXRLI1 present in different environments. Such environments include, for example, cell extracts and purified cell extracts containing the LXRLI1 recombinant nucleic acid; and also include, for example, the use of a purified LXRLI1 polypeptide produced by recombinant means which is introduced into a different environment.

[0152] Functional Assays

[0153] The identification of LXRLI1 as a LXR regulated gene provides a means for screening for compounds that bind to LXRLI1 protein thereby altering reverse cholesterol transport. Assays involving a functional LXRLI1 polypeptide can be employed for different purposes such as selecting for compounds active at LXRLI1, evaluating the ability of a compound to affect reverse cholesterol transport, and mapping the activity of different LXRLI1 regions. LXRLI1 activity can be measured using different techniques such as detecting a change in the intracellular conformation of LXRLI1, detecting a change in the intracellular location of LXRLI1, or measuring the level of reverse cholesterol transport activity.

[0154] Recombinantly expressed LXRLI1 can be used to facilitate determining whether a compound is active at LXRLI1. For example, LXRLI1 can be expressed by an expression vector in a cell line and used in a co-culture growth assay, such as described in WO 99/59037, to identify compounds that bind to LXARAI1.

[0155] Techniques for measuring reverse cholesterol transport (RCT), are known in the art. In particular, Sparrow, et al. (2002 J. Biol. Chem. 277: 10021-7) report a method for performing a cholesterol efflux assay on cultured mammalian tissue culture cells using gas chromatography-mass spectrometry. Other RCT assays include, but are not limited to, measurement of efflux of radioactive cholesterol to: 1) exogenous apoA-I or HDL as described in Francis, et al. (1995 J. Clin. Invest. 96:78-87); 2) exogenous HDL subfractions or reconstituted phospholipid-apoprotein complexes as described in Kritharides, et al. (1998 Arterioscler. Throm. Vasc. Biol. 18:1589-99); and 3) endogenously formed apoE as described by Huang, et al. (2001 Arterioscier. Throm. Vasc. Biol. 21:2019-25). In addition, RCT in living humans can be determined by measurement of fecal sterol excretion (Eriksson, et al., 1999 Circulation 100:594-8).

[0156] RCT functional assays can be performed using cells expressing LXRLI1 at a high level contacted with individual compounds or preparations containing different compounds. A preparation containing different compounds where one or more compounds affect RCT in cells over producing LXRLI1 as compared to control cells containing expression vector lacking LXRLI1 coding sequence, can be divided into smaller groups of compounds to identify the compound(s) affecting LXRLI1 mediated RCT activity.

[0157] LXRLI1 and RCT functional assays can be performed using recombinantly produced LXRLI1 present in different environments. Such environments include, for example, cell extracts and purified cell extracts containing the LXRLI1 expressed from recombinant nucleic acid and an appropriate membrane for the polypeptide; and the use of a purified LXRLI1 produced by recombinant means that is introduced into a different environment suitable for measuring RCT.

MODULATING LXRLI1 EXPRESSION

[0158] LXRLI1 expression can be modulated as a means for increasing or decreasing LXRLI1 activity. Such modulation includes inhibiting LXRLI1 nucleic acid activity to reduce LXRLI1 expression or supplying LXRLI1 nucleic acid to increase LXRLI1 activity.

[0159] Inhibition of LXRLI1 Activity

[0160] LXRLI1 nucleic acid activity can be inhibited using nucleic acids recognizing LXRLI1 nucleic acid and affecting the ability of such nucleic acid to be transcribed or translated. Inhibition of LXRLI1 nucleic acid activity can be used, for example, in target validation studies.

[0161] A preferred target for inhibiting LXRLI1 translation is mRNA. The ability of mRNA encoding LXRLI1 to be translated into a protein can be effected by compounds such as anti-sense nucleic acid, RNA interference (RNAi) and enzymatic nucleic acid.

[0162] Anti-sense nucleic acid can hybridize to a region of a target mRNA. Depending on the structure of the anti-sense nucleic acid, anti-sense activity can be brought about by different mechanisms such as blocking the initiation of translation, preventing processing of mRNA, hybrid arrest, and degradation of mRNA by RNAse H activity.

[0163] RNAi also can be used to prevent protein expression of a target transcript. This method is based on the interfering properties of double-stranded RNA derived from the coding regions of gene that disrupts the synthesis of protein from transcribed RNA.

[0164] Enzymatic nucleic acid can recognize and cleave another nucleic acid molecule. Preferred enzymatic nucleic acids are ribozymes.

[0165] General structures for anti-sense nucleic acids, RNAi and ribozymes, and methods of delivering such molecules, are well known in the art. Modified and unmodified nucleic acids can be used as anti-sense molecules, RNAi and ribozymes. Different types of modifications can affect certain anti-sense activities such as the ability to be cleaved by RNAse H, and can effect nucleic acid stability. Examples of references describing different anti-sense molecules, and ribozymes, and the use of such molecules, are provided in U.S. Pat. Nos. 5,849,902; 5,859,221; 5,852,188; and 5,616,459. Examples of organisms in which RNAi has been used to inhibit expression of a target gene include: C. elegans (Tabara, et al., 1999 Cell 99:123-32; Fire, et al., 1998 Nature 391:806-11), plants (Hamilton and Baulcombe, 1999 Science 286:950-52), Drosophila (Hammond, et al., 2001 Science 293:1146-50; Misquitta and Patterson, 1999 Proc. Nat. Acad. Sci. 96:1451-56; Kennerdell and Carthew, 1998 Cell 95:1017-26), and mammalian cells (Bernstein, et al., 2001 Nature 409:363-6; Elbashir, et al., 2001 Nature 411:494-8).

[0166] Guidelines for pharmaceutical administration in general are provided in, for example, Remington's Pharmaceutical Sciences, 18^(th) Edition, supra, and Modern Phannaceutics, 2^(nd) Edition; supra. Nucleic acid-can be introduced into cells present in different environments using in vitro, in vivo, or ex vivo techniques.

[0167] Increasing LXRLI1 Expression

[0168] Nucleic acid coding for the LXRLI1 can be used, for example, to cause an increase in RCT or to create a test system (e.g., a transgenic animal) for screening for compounds affecting LXRLI1 expression. Nucleic acids can be introduced and expressed in cells present in different environments.

[0169] Guidelines for pharmaceutical administration in general are provided in, for example, Remington's Pharmaceutical Sciences, 18^(th) Edition, supra, and Modern Pharmaceutics, 2^(nd) Edition, supra. Nucleic acid can be introduced into cells present in different environments using in vitro, in vivo, or ex vivo techniques. Examples of techniques useful in gene therapy are illustrated in Gene Therapy & Molecular Biology: From Basic Mechanisms to Clinical Applications, Ed. Boulikas, Gene Therapy Press, 1998.

GENE EXPRESSION PROFILING

[0170] Comparing patterns of gene expression is a widely used means of identifying novel genes, investigating gene function and finding potential new therapeutic targets (Shiue, et al., 1997 Drug Devel. Res. 41:142-59). The study of gene expression changes has played a major role in development of our understanding of nuclear receptor proteins. With the completion of the human genome sequencing effort, it is now a realistic goal to document all gene expression changes that occur during nuclear receptor ligand activation, in particular LXR. Historically, many techniques have been used to identify and clone differentially expressed genes (Liang, et al., 1992 Science 257:967-71; Welsh, et al., 1992 Nucleic Acids Res. 20:4965-70; Tedder, et al., 1988 Proc. Natl. Acad. Sci. 85:208-12; Davis, et al., 1984 Proc. Natl. Acad. Sci. 81:2194-8; Lisitsyn, et al., Science 259:946-51 (1993); Velculescu, et al., 1995 Science 270:484-7; Diatchenko, et al., 1996 Proc. Natl. Acad. Sci. 93:6025-30; Jiang, et al., 2000 Proc. Natl. Acad. Sci. 97:12684-9; Yang, et al., 1999 Nucleic Acids Res. 27: 517-23). However, these are generally not well suited for discerning the functional significance of gene expression differences. In many cases, these differences are not unique to a particular cellular pathway and the specificity of these changes becomes apparent only after secondary characterization using labor intensive techniques (Shiue, et al., 1997 Drug Devel. Res. 41:142-59).

[0171] Recently, it has become routine to use the technique of DNA microarray hybridization to quantify the expression of many thousands of discrete mRNA sequences in a single assay known as expression profiling (van't Veer, et al., 2002 Nature 415:530-36; Hughes, et al., 2001 Nature Biotech. 19:342-7; Hughes; et al., 2000, Cell 102:109-26; Lockhart and Winzeler, 2000 Nature 405:827-36; Roberts, et al., Science 2000 287:873-80; Wang et al., 1999 Gene 229:101-8; Lockhart, et al., 1996 Nat. Biotechnology 14:1675-80; Lockhart et al., U.S. Pat. No. 6,040,138; and Schena et al., 1995 Science 270: 467-70). Many applications have been described for expression profiling, but perhaps most relevant to elucidating gene function is the development of tools used to group genes according to similarities in patterns of gene expression in expression profiling experiments.

[0172] Coexpression of genes of known function with poorly characterized or novel genes has been suggested as a method to assign function to genes for which information is not available (Eisen, et al., 1998 Proc. Natl. Acad. Sci. 95:14863-8). Using a reference database or compendium of expression profiles from Saccharomyces cerevisiae, novel open reading frames (ORFs) showed that coordinated transcriptional regulations were enriched for a given phenotype, although there was potential for false positive detections (Hughes et al., 2000 Cell 102:109-126). In human cells, coregulation of uncharacterized expressed sequence tag (EST) sequences with known genes was noted, but no evaluation of the identities and properties of these ESTs was made.

[0173] In addition, expression profiles can also be used to identify pathway-specific reporters and target genes for a particular biological pathway of interest (see for example, WO 00/58520 and WO 00/58521). Such reporter genes, and probes directed to them, can be used to measure the activity of a particular biological pathway and may be further used in the design of drugs, drug therapies or other biological agents to target a particular biological pathway. Expression profiles can also be used to determine protein activity levels of a target protein using the methods described in U.S. Pat. No. 6,324,479.

[0174] The measurement of expression profiles using microarrays also has many important applications to the monitoring of disease states and therapies (see, for example, U.S. Pat. Nos. 6,218,122 and 6,222,093), and the identification of drug targets, identification of pathways of drug action and drug design (See, for example, U.S. Pat. No. 6,303,291; U.S. Pat. No. 6,165,709; U.S. Pat. No. 6,146,830; U.S. Pat. No. 5,965,352; and U.S. Pat. No. 5,777,888). As disclosed in many of the above-cited references, the functional identity of each gene represented on a microarray need not be understood in order for the overall expression profile to have a specific and substantial utility.

[0175] For example, van't Veer, et al. (2002 Nature 415:530-536) identified “good prognosis” and “poor prognosis” expression signatures that could be used to predict the clinical outcome of breast cancer patients. The function of many of proteins encoded by the genes represented in these expression signature groups remains unknown, yet the expression level of these genes within an expression signature still has utility in predicting disease outcome.

[0176] Similarly, U.S. Pat. No. 5,777,888 discloses the utility of microarray expression profiles to evaluate the target-specificity of a candidate drug by comparison of an expression profile obtained from cells treated with the candidate drug to a database of expression profiles obtained from cells treated with known drugs. Again, the function of a gene represented in these drug evaluation expression profiles need not be known in order to obtain useful information regarding the specificity of the candidate drug.

[0177] U.S. Pat. No. 6,218,122 provides methods for monitoring the disease state of a subject and determining the effect of a therapy upon a subject through the use of expression profiles wherein the functional identity of each gene represented in the expression profile need not be known to obtain the desired information (see also U.S. Pat. No. 6,266,093).

[0178] Shoemaker, et al. (2000 Nature 409:922-7; see also copending and commonly owned U.S. patent application Ser. No. 09/724,538 filed Nov. 11, 2000), provides methods for using microarray gene expression profiles to engage in gene discover and the detection of splice variants. Thus, microarrays comprising nucleic acids probes complementary and hybridizable to one or more exon sequences of the LXRLI1 coding sequence can be used to measure the expression levels of a plurality of LXRLI1 exons to permit high-throughput detection of splice variants of the LXRLI1 nucleic acids.

[0179] Markers Useful in Monitoring LXR Activity

[0180] Polynucleotides that are complementary and hybridizable to the LXR-regulated markers listed in Table 1 can be used to select LXR pathway reporters using the methods described in WO 00/58520 and WO 00/58521. LXR pathway reporters are useful, for example, in gene expression assays to diagnose and monitor treatment of diseases related to cholesterol metabolism and to identify and classify compounds affecting LXR activity. LXR pathway reporters can also be used to identify and categorize cholesterol disease subtypes not heretofore appreciated using conventional diagnostic tests. Expression of the LXR pathway reporter genes of the present invention can be measured using any of a variety of methods well known in the art, such as Northern blots, microarrays, and RT-PCR, and the like.

[0181] Another aspect of the present invention provides a method of estimating LXR activity in a subject. The same method can also be used to detect changes in LXR activity in a sample in response to a disease state or treatment of a disease. The method comprises the steps of measuring a transcript level in a sample of mRNA or nucleic acid derived therefrom from the subject, wherein the transcript comprises a nucleic acid sequence selected from the sequence identification numbers listed in Table 3. The measured level of the selected transcript is then compared to the level of the same transcript measured in a control sample. In another embodiment, the method additionally includes the measurement of a transcript comprising a nucleotide sequence selected from the sequence identification numbers listed in Table 2. In alternative embodiment, the transcript encodes a polypeptide comprising an amino;:acid sequence selected from the group consisting of SEQ ID NO 2, SEQ ID NO 14, SEQ ID) NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ-ID NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID; NO 30, SEQ ID NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ID NO 40, SEQ ID NO 42, SEQ ID NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ID NO 50, SEQ ID NO 52, SEQ ID NO 54, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 60, SEQ ID NO 62, SEQ ID NO 64, SEQ ID NO 66, SEQ ID NO 68, SEQ ID NO 70, SEQ ID NO 72, SEQ ID NO 75, SEQ ID NO 78, SEQ ID NO 80, SEQ ID NO 83, and SEQ ID NO 96.

[0182] As would be apparent to an artisan of biological assays, a variety of different kinds of control samples may be used to practice the above-described methods for estimating LXR activity or detecting changes in LXR activity in a sample. For example, LXR activity may be estimated by reference to a control sample obtained from cells that express LXR gene at a low level due to, for example, the presence of a mutation in the LXR gene or due to inhibition of LXR expression by using RNAi. Other techniques for obtaining cells that express LXR at a low level are also well known in the art. Alternatively, the control sample may be obtained from cells that express high levels of LXR. Again, a variety of methods are well known in the art for manipulating the expression of a gene of interest. In some embodiments of the method, multiple control samples are used to produce a graph that relates the level of LXR expression in a cell sample to the level of expression of the measured transcripts. Alternatively, multiple control samples can be made by treating a series of cell samples from a subject with an increasing amount of a LXR agonist compound, such as APD, and measuring transcript levels corresponding to any of the markers listed in Tables 2 and 3.

[0183] In other embodiments, the methods described above for measuring LXR activity are used to diagnose a disease or disorder involving LXR activity in a sample by detecting an increase or decrease in the measured transcript level relative to the amount of the same transcript present in an analogous sample from a subject not having the disease or disorder or not subjected to therapy. Preferably, the disease or disorder is cholesterol gallstones, atherosclerosis, lipid storage diseases, obesity, diabetes, or hypercholesterolemia.

[0184] In another embodiment the methods of measuring LXR activity are used to screen for a compound that changes the activity of LXR, wherein the compound involves increased or decreased level of LXR activity in a sample from the subject contacted with the compound relative to the level present in an analogous sample from the subject not contacted with the compound. Preferably, the compound is a LXR ligand, more preferably an agonist.

[0185] The invention further provides gene marker sets that distinguish various cholesterol metabolic states of a biological sample and methods of use therefor. In one embodiment, the invention provides a method for determining the cholesterol metabolic state of a biological sample comprising detecting a difference in the expression of a first plurality of genes relative to a control biological sample, the first plurality of genes consisting of LXRLI1 and at least one of the genes corresponding to the markers listed in Table 1, excluding LXRLI1. In another embodiment, the first plurality of genes consists of at least two or more of the genes corresponding to the markers listed in Table 3. In yet another embodiment, the first plurality of genes consists of at least one or more of the genes corresponding to the markers listed in Table 3 and one or more of the genes corresponding to the markers listed in Table 2.

[0186] The invention further provides a method for classifying a test LXR ligand as a full LXR-ligand or as a selective LXR-ligand. The method comprising detecting a difference in the expression of a plurality of genes in a first cell sample contacted by the test LXR-ligand compared to the expression of the plurality of genes in a second cell sample contacted by a reference LXR-ligand, the plurality of genes consisting of at least five genes corresponding to markers listed in Table 1, wherein the test LXR-ligand is classified as a full activity LXR-ligand if each gene in said plurality of genes is similarly regulated in the first and second cell samples, and, the test LXR-ligand is classified as a selective activity LXR-ligand if fewer than all of the genes in the plurality of genes are similarly regulated in the first cell sample as compared to the second cell sample. Preferably, the ligand is an agonist and the plurality of genes consists of all of the genes corresponding to markers listed in Table 1. In other embodiments the plurality of genes consists of at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or all of the markers listed in Table 1. Preferable, in each case, at least one gene marker is selected from Group I genes, as defined in FIG. 2, and at least one gene marker is selected from Group II genes, as defined in FIG. 2.

EXAMPLES

[0187] Examples are provided below to further illustrate different features and advantages of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

Example 1

[0188] Identification of LXR Regulated Markers Using Microarray Expression Profiles

[0189] To identify human transcripts up or down regulated by LXR-ligand, FlexJet™ microarrays representing either 25,000 Unigene clusters were hybridized to a mixture of cRNAs prepared from samples obtained from untreated versus treated cells of various types. Microarrays, and materials and methods for preparing hybridization samples from purified RNA, hybridizing the microarrays, detecting hybridization signals, and data analysis are described in van't Veer,iet al. (2002 Nature 415:530-536) and Hughes, et al. (2001 Nature Biotechnol. 19:342-7).

[0190] Experiments were conducted comparing gene expression profiles of primary hepatocytes, primary human macrophage and THP-1 cells treated with a variety of compounds known to activate the LXR and PPAR nuclear receptor regulated pathways. Additional compound treatments were performed which are known to cause an increase, or decrease in cellular cholesterol. All cells were cultured at 37° C. in a humidified atmosphere consisting of 95% air and 5% carbon dioxide. For each cell sample, mRNA was extracted and purified using Trizol reagent (Invitrogen Corporation, Carlsbad, Calif.) followed by DNAse treatment, as described by Fu, et al. (2001 J. Biol. Chem. 276:38378-87). For the primary hepatocytes, the Trizol purification was followed by a RNasy DNAase (Promega Corp, Madison, Wis.) step per the manufacturer's instructions. Purified mRNA samples were processed for microarray hybridizations as described in van't Veer, et al. (2002 Nature 415:530-536). Specific cell types were grown and treated with compounds as described below.

[0191] THP-1 cells were obtained from ATCC (TIB-202) and were grown in Medium A (RPMI-1640 medium (Sigma Cat.#R8005) containing 10 mM HEPES buffer, 10% fetal calf serum (FCS), 1 mM sodium pyruvate, 2 mM L-Glutamine, and Antibiotic-Antimycotic Solution (Sigma Cat.#A9909, 100 U/ml Penicillin, 0.1 mg/ml Streptomycin, 0.25 mg/ml Amphotericin B)). THP-1 cells were differentiated into macrophages in 6-well tissue culture dishes at a density of 3 million cells/well by incubation in the same medium plus 100 nM phorbol 12-Myristate 13-acetate (Sigma Cat.#P8139) for three days. After differentiation into macrophages, cells were collected and, further treated as described below and in figure legends for each specific compound.

[0192] Human primary monocytes were prepared as described by Wright and Silverstein (1982 J. Exp. Med. 156:1149-64), and differentiated to macrophages by culturing for 7 days in Teflon jars in RPMI-1640 medium (VWR International, West Chester, Pa.) supplemented with 12% human serum, 100 units/ml penicillin and 100 mg/ml streptomycin sulfate). Cells were then plated in the same medium to initiate compound exposure as described below for each specific compound. At the time intervals indicated in figure legends, cell samples were collected and mRNA extracted. Extracted mRNA samples were prepared for microarray hybridizations as described in van't Veer, et al. (2002 Nature 415:530-536).

[0193] Human primary hepatocytes were received from In Vitro Technologies (Baltimore, Md.) in six well dishes and maintained in phenol red-free DMEM (high glucose) containing 10% charcoal-stripped FCS (Geminni Bio-Products, Inc., Calabasas, Calif.), 1% nonessential amino acids, 1% glutamine and 100 units/ml Penicillin G and 100 μg/ml Streptomycin sulfate. Dexamethasone (Sigma-Aldrich Corp., St. Louis, Mo.) was also added to the growth medium at 0.01 μM to maintain hepatocyte viability. Cells were then plated in the same medium to initiate compound exposure experiments using the compounds and concentrations indicated below and in the figure legends. Cell samples were collected after 24 hours of compound exposure and mRNA extracted.

[0194] Acetyl-podocarpic dimer, zaragozic acid, lovastatin and fenofibrate were synthesized at the Merck Research Laboratories (Rahway, N.J.). Glucagon was purchased from Sigma-Aldrich Corp. Acetylated low density lipoprotein (AcLDL) was purchased from Intracel Corp (Rockville Md.). Methyl-β-Cyclodextrin (CD), Cholesterol (Ch) and 22(R)-hydroxycholesterol were purchased from Sigma-Aldrich). Cells were treated with test compounds in the following fashion:

[0195] Acetyl-Podocarpic Dimer (APD) is a highly specific LXR agonist (Sparrow, et al., 2002 J. Biol. Chem. 10.1074/jbc.M1108225200). Hepatocytes were treated with APD at 0.001 μM, 0.01 μM and 0.1 μM for 24 hours, followed by a reapplication of fresh media containing compound for an additional six hours prior to extraction of total RNA. Macrophages were treated with APD at 0.1 μM for 24 hours prior to extraction of total RNA. THP-1 cells were treated with APD at 0.1 μM for 3, 6, or 20 hours prior to extraction of total RNA.

[0196] Dexamethasone is an anti-inflammatory glucocorticoid receptor ligand. For experiments involving the use of primary hepatocyte cells, dexamethasone was added to the culture medium at 0.01 μM to enhance hepatocyte viability.

[0197] Fenofibrate is a PPARa agonist (Guo, et al., 2001 Biochim. Biophys. Acta. 1533:220-32). Hepatocyte cell samples were treated with fenofibrate at 0.01 mM, 0.03 mM and 0.1 mM for 24 hours, then the medium replaced with fresh media containing fenofibrate at the indicated concentration and the cells incubated for an additional six hours prior to extraction of total RNA.

[0198] Glucagon is a glucagon receptor agonist (Houslay, et al., 1976 Biochim. Biophys. Acta. 436:495-504; Broer, et al., 1977 Endocrinology 101:236:49). Hepatocyte cell samples were treated with glucagon at 0.01 μM for 24 hours, then the medium was replaced with fresh media containing 0.01 μM glucagon and the cells incubated for an additional six hours prior to extraction of total RNA.

[0199] Lovastatin is an inhibitor of HMG-CoA reductase that reduces cholesterol and isoprenoid synthesis (Alberts, et al., 1980 Proc. Natl. Acad. Sci. 77:3957-61). THP-1 cell samples were treated with 50 μM lovastatin in DMSO for 3 hours, 6 hours and 20 hours, respectively, prior to extraction of total RNA.

[0200] Zaragozic Acid is an inhibitor of squalene synthase which results in inhibition of cholesterol synthesis, but not the synthesis of other isoprenoids (Bergstrom et al., 1993 Proc. Natl. Acad. Sci. 90:80-4). THP-1 cells were treated with 100 nM Zaragozic acid in DMSO for 3 hours 6 hours and 20 hours, respectively, prior to extraction of total RNA.

[0201] A total of 297 markers exhibited changes in the log ratio of expression of >0.2, with a P-value of <0.01 in at least two of the total of twelve experiments which were analyzed. The gene expression profiles of the 297 markers over the twelve experiments were analyzed by using a two dimensional hierarchical clustering algorithm. This cluster analysis groups genes showing the greatest similarity of regulation over all experiments (first dimension) and the experiments showing the greatest similarities in gene regulation (second dimension). For clarity, FIG. 1 displays only a section (55 markers) of the total data set. Each experiment and each marker, including gene names when known, are represented on the X- and Y-axes, respectively. Genes up-regulated in a particular experiment are colored dark gray; genes down regulated in that experiment are colored light gray; and genes showing no regulation in a particular experiment are colored black. The set of markers shown in FIG. 1 identifies genes that are transcriptionally up-regulated by compounds that activate LXR.

[0202] Table 1 presents a list of all of the markers (and corresponding nucleic acid and amino acid SEQ ID NOs) corresponding to the LXR-ligand induced transcripts identified from FIG. 1. Hereafter the markers listed in Table 1 are collectively referred to as the “LXR-regulated geneset.” Of the 55 markers within the LXR-regulated geneset, five markers represented genes known to be LXR regulated and to be involved with cholesterol and/or lipid metabolism. These five previously known LXR regulated genes are listed in Table 2.

[0203] Table 3 lists 50 markers identified in FIG. 1 that were not previously known to be regulated by LXR, but were identified as such in this microarray data set. Of these 50 markers, 32 markers corresponded to genes having some level of functional annotation. Inspection of the putative functions of the proteins encoded by the 32 gene markers in Table 3 revealed that the most prevalent shared functional characteristic of the group was that 14 of the proteins are reasonably involved with, or effect, cholesterol and/or lipid metabolism. Six of the markers listed in Table 3, including an incomplete, truncated version of LXRLI1 (reference as NM_(—)022918), encoded computationally predicted proteins whose functions have not yet been identified, and 13 markers represented ESTs that have not yet been experimentally associated to a gene sequence.

[0204] Inspection of NM_(—)022918 and predicted protein FLJ22104 sequences indicated that the predicted coding region was probably incomplete. On this basis NM_(—)022918 was selected from the set of markers listed in Table 3 and a full length cDNA clone was isolated and its nucleotide sequence determined as described in Example 2 below. TABLE 1 55 markers representing the LXR-regulated geneset and corresponding nucleotide and protein sequence reference numbers. Systematic Nucleotide Amino Acid Systematic Nucleotide Amino Acid Name Sequence Sequence Name Sequence Sequence LXRLII SEQ ID NO 1 SEQ ID NO 2 NM_000242 SEQ ID NO 57 SEQ ID NO 58 NM_005502 SEQ ID NO 3 SEQ ID NO 4 NM_016112 SEQ ID NO 59 SEQ ID NO 60 NM_004176 SEQ ID NO 5 SEQ ID NO 6 NM_017625 SEQ ID NO 61 SEQ ID NO 62 NM_005063 SEQ ID NO 7 SEQ ID NO 8 NM_013262 SEQ ID NO 63 SEQ ID NO 64 NM_004915 SEQ ID NO 9 SEQ ID NO 10 NM_002625 SEQ ID NO 65 SEQ ID NO 66 NM_005693 SEQ ID NO 11 SEQ ID NO 12 NM_001394 SEQ ID NO 67 SEQ ID NO 68 NM_001995 SEQ ID NO 13 SEQ ID NO 14 NM_002983 SEQ ID NO 69 SEQ ID NO 70 D10040 SEQ ID NO 15 SEQ ID NO 16 NM_001400 SEQ ID NO 71 SEQ ID NO 72 NM_004457 SEQ ID NO 17 SEQ ID NO 18 NM_018687 SEQ ID NO 73 NM_004458 SEQ ID NO 19 SEQ ID NO 20 NM_002659 SEQ ID NO 74 SEQ ID NO 75 NM_013402 SEQ ID NO 21 SEQ ID NO 22 AK022997 SEQ ID NO 76 AF035284 SEQ ID NO 23 SEQ ID NO 24 AK056513 SEQ ID NO 77 SEQ ID NO 78 NM_004265 SEQ ID NO 25 SEQ ID NO 26 AJ272057 SEQ ID NO 79 SEQ ID NO 80 NM_001645 SEQ ID NO 27 SEQ ID NO 28 Contig59509_RC SEQ ID NO 81 NM_000483 SEQ ID NO 29 SEQ ID NO 30 AF113007 SEQ ID NO 82 SEQ ID NO 83 NM_001360 SEQ ID NO 31 SEQ ID NO 32 Contig9810_RC SEQ ID NO 84 AB046780 SEQ ID NO 33 SEQ ID NO 34 Contig23581_RC SEQ ID NO 85 NM_003251 SEQ ID NO 35 SEQ ID NO 36 Contig30296_RC SEQ ID NO 86 D80010 SEQ ID NO 37 SEQ ID NO 38 Contig31291_RC SEQ ID NO 87 BC018999 SEQ ID NO 39 SEQ ID NO 40 Contig31874_RC SEQ ID NO 88 U06715 SEQ ID NO 41 SEQ ID NO 42 Contig33514_RC SEQ ID NO 89 NM_005542 SEQ ID NO 43 SEQ ID NO 44 Contig36419_RC SEQ ID NO 90 NM_031279 SEQ ID NO 45 SEQ ID NO 46 Contig37135_RC SEQ ID NO 91 NM_000854 SEQ ID NO 47 SEQ ID NO 48 Contig41022_RC SEQ ID NO 92 NM_013233 SEQ ID NO 49 SEQ ID NO 50 Contig43632_RC SEQ ID NO 93 NM_016276 SEQ ID NO 51 SEQ ID NO 52 Contig48156_RC SEQ ID NO 94 NM_006847 SEQ ID NO 53 SEQ ID NO 54 AF289609 SEQ ID NO 95 SEQ ID NO 96 NM_004848 SEQ ID NO 55 SEQ ID NO 56

[0205] TABLE 2 Genes listed in Table 1, that were previously known to be regulated by activated LXR. Protein Systematic Name Gene Name Description Gene Category NM_005502 ABCA1 ATP-binding cassette, sub- ATP-binding, Glycoprotein, family A (ABC1), member 1. Transmembrane, Transport, LXR Regulated: J. Biol. Cholesterol metabolism, Chem. 2000, 275:28240-45. Atherosclerosis, Disease mutation, Polymorphism NM_004176 SREBF1 Sterol regulatory element Transcription regulation, binding transcription factor 1 Activator, DNA-binding, LXR Regulated: Gene & Lipid metabolism, Development, 2000, Cholesterol metabolism, 14:2819-30. Nuclear protein, Transmembrane, Endoplasmic reticulum, Golgi stack, Alternative splicing, 3D-structure NM_005063 SCD Stearoyl-CoA desaturase Oxidoreductase, Fatty acid (delta-9-desaturase) biosynthesis, LXR Regulated: Gene & Transmembrane, Development, 2000, Endoplasmic reticulum, Iron, 14:2831-8. Hypothetical protein NM_004915 ABCG1 ATP-binding cassette, sub- ATP-binding, family G (WHITE), Transmembrane, Transport, member 1. Alternative splicing, LXR Regulated: J. Biol. Alternative initiation, Chem. 2001, 276:39438-47. Polymorphism NM_005693 NR1H3 (LXRα) Nuclear receptor subfamily 1, Receptor, Transcription group H, member 3 regulation, DNA-binding, LXR Regulated: Mol. Cell. Nuclear protein, Zinc-finger Biol. 2001, 21:7558-68.

[0206] TABLE 3 Genes listed in Table 1, that were first identified in this work as being regulated by LXR. Protein Systematic Name Gene Name Description Gene Category NM_001995 FACL1 Fatty-acid-Coenzyme A Ligase, Fatty acid ligase, long-chain 1 metabolism, Magnesium, Multigene family D10040 FACL2 Fatty acid Coenzyme A Ligase, Fatty acid ligase, long chain 2 metabolism, Magnesium, Multigene family NM_004457 FACL3 Fatty-acid-Coenzyme A Ligase, Fatty acid ligase, long-chain 3 metabolism, Magnesium, Multigene family NM_004458 FACL4 Fatty-acid Coenzyme A Ligase, Fatty acid ligase, long-chain 4 metabolism, Magnesium, Multigene family, Alternative splicing NM_013402 FADS1 Fatty acid desaturase 1 Heme, Fatty acid metabolism AF035284 FADS1 Fatty acid desaturase 1 Heme, Fatty acid metabolism NM_004265 FADS2 Fatty acid desaturase 2 Heme, Fatty acid metabolism, Hypothetical protein NM_001645 APOC1 Apolipoprotein C-I, Plasma, Lipid transport, transgenic mice have VLDL, Signal, 3D-structure, hypertriglyceridemia (2001 Lipoprotein Diabetes 50:2779-85). NM_000483 APOC2 Apolipoprotein C-II Chylomicron, VLDL, Plasma, Lipid transport, Lipid degradation, Signal, Disease mutation, Polymorphism, Hyperlipidemia, Lipoprotein NM_001360 DHCR7 7-Dehydrocholesterol Sterol biosynthesis, reductase Cholesterol biosynthesis, Oxidoreductase, NADP, Transmembrane, Endoplasmic reticulum, Disease mutation AB046780 KIAA156O Glycerol-3-phosphate Phospholipid biosynthesis, (referred to as Contig42768 acyltransferase Transferase, Acyltransferase, in FIGS. 1 and 2) Transmembrane, Mitochondrion, Transit peptide NM_003251 THRSP Thyroid hormone responsive Fatty Acid Synthesis (SPOT14 homolog, rat). Expressed in lactating mammary, adipose, and liver and activates genes encoding the enzymes of fatty acid synthesis (1998 PNAS 95:6989-94). D80010 LPIN1 Lipin 1, mouse mutation Lipodystropy, Hypothetical causes lipodystropy (2001 protein Nat. Gen. 27:121-4). BC018999 ASM3A Acid sphingomyelinase-like Hydrolase, Glycosidase, (referred to as AK000184 in phosphodiesterase. FIGS. 1 and 2) U06715 CYB561 Cytochrome b-561 is a major Electron transport, transmembrane protein of Transmembrane, Heme, catecholamine and possible cofactor for FADS neuropeptide secretory vesicles. NM_005542 INSIG1 Insulin induced gene 1 Leucine-rich repeat, Repeat, Thought to play a role in growth and differentiation of tissues involved in metabolic control. NM031279 AGXT2L1 Alanine-glyoxylate Transferase, (referred to as Contig31546 aminotransferase 2-like 1 Aminotransferase in FIGS. 1 and 2) NM_000854 GSTT2 Glutathione S-transferase Transferase, Multigene theta 2 family, 3D-structure NM_013233 STK39 Serine threonine kinase 39 Transferase, (STE20/SPS1 homolog, Serine/threonine-protein yeast) kinase, ATP-binding NM_016276 SGK2 Serum/glucocorticoid ATP-binding, Kinase, regulated kinase 2 Serine/threonine-protein kinase, Transferase, Hypothetical protein NM_006847 LILRB4 Leukocyte immunoglobulin- Signal, Receptor like receptor, subfamily B (with TM and ITIM domains), member 4 NM_004848 ICB-1 Basement membrane-induced gene NM_000242 MBL2 Mannose-binding lectin Signal, Lectin, (protein C) 2, soluble Hydroxylation, (opsonic defect) Glycoprotein, Mannose- binding, Membrane, Calcium, Collagen, Repeat, Polymorphism, 3D-structure NM_016112 PKD2L1 Polycystic kidney disease 2- like 1 NM_017625 ITLN Intelcetin NM_013262 MIR Myosin regulatory light chain interacting protein NM_002625 PFKFB1 6-phosphofructo-2- Multifunctional enzyme, kinase/fructose-2,6- Transferase, Kinase, biphosphatase 1 Hydrolase, ATP-binding, Phosphorylation, Liver, Multigene family NM_001394 DUSP4 Dual specificity phosphatase Hydrolase, Hypothetical 4 protein, Nuclear protein NM_002983 SCYA3 Small inducible cytokine A3 Cytokine, Chemotaxis, Inflammatory response, Signal NM_001400 EDG1 Endothelial differentiation, Receptor, Hypothetical sphingolipid G-protein- protein, G-protein coupled coupled receptor, 1 receptor, Transmembrane, Glycoprotein, Phosphorylation, Lipoprotein, Palmitate NM_004458 LOC55908 Hepatocellular carcinoma- associated gene TD26 NM_002659 PLAUR plasminogen activator, Receptor, Kinase, Signal, urokinase receptor Glycoprotein, GPI-anchor, Repeat, Alternative splicing LXRLI1 (This work, referred LXRLI1 LXRLI1 LXR-ligand induced, to as FLJ22104 in FIGS. 1 predicted transmembrane and 2) protein AK022997 FLJ12935 Homo sapiens cDNA Hypothetical protein (referred to as FLJ12935 tis, clone Contig40026_RC in FIGS. 1 NT2RP2004982 and 2) AK056513 FL131951 Homo sapiens cDNA Hypothetical protein (referred to as FLJ31951 fis, clone Contig52723_RC in FIGS. 1 NT2RP7007177, weakly and 2) similar to Homo sapiens multiple membrane spanning receptor TRC8 mRNA AJ272057 STRAIT11499 Hypothetical protein Hypothetical protein STRAIT11499 Contig59509_RC AF113007 DKFZP586A0522 DKFZP586A0522 protein, Hypothetical protein cDNA clone from human fetal liver Contig9810_RC ESTs Contig23581_RC ESTs Contig30296_RC ESTs Contig31291_RC ESTs Contig31874_RC ESTs Contig33514_RC ESTs Contig36419_RC ESTs Contig37135_RC ESTs Contig41022_RC ESTs Contig43632_RC ESTs Contig48156_RC ESTs AF289609 ESTs (referred to as Contig56160_RC in FIGS. 1 and 2)

Example 2

[0207] Cloning and Sequencing of LXRLI1

[0208] Microarray data indicated that mRNA NM_(—)022918 (SEQ ID NO 97), encoding the predicted protein FU22104 (SEQ ID NO 98) was induced in LXR-ligand experiments (see FIG. 1). Mouse homology to FU22104 indicated that there might be 82 amino acids more to be added to the amino terminal end of FLJ22104 ORF (mRNA NM_(—)022918). The new predicted ORF was a combination of EST BM149697 (SEQ ID NO 99) and overlapping mRNA NM_(—)022918. The new predicted ORF protein was named LXRLI1 and the encoding nucleotide region was named LXRLI1. RT-PCR primers were designed to include, not only the new 5′ extension of the open reading frame contained within BM149697, but also noncoding sequence in the genomic sequence 5′ to BM149697. This 5′ genomic sequence contained an in-frame STOP codon. The presence of this in-frame STOP codon 5′ to the LXRLI1 ORF indicates that the predicted ORF is full length and cannot be extended beyond the predicted starting methionine amino acid. The 5′ “forward” primer used to amplify and clone the entire LXRLI1 ORF was designed to have a nucleotide of 5′ CAGAGTAACCCCGCTCTCGTGAC 3′ (SEQ ID NO 100). The 3′ “reverse” primer was designed to have the nucleotide sequence of 5′ GTGTTCAACATAATTAACTCTTCA AGATTG 3′ (SEQ ID NO 101). All PCR and sequencing primers were obtained from RESGEN/Invitrogen, Huntsville, Ala.

[0209] RT-PCR

[0210] The LXRLI1 cDNA sequence was cloned using a combination of RT and PCR. 20 ng of small intestinal mRNA (Ambion, Austen, Tex.) or 400 ng of THP-1 total RNA (see above for description of THP-1 cell line) was reverse transcribed using Superscript II (Gibco/Invitrogen,, Carlsbad, Calif.) and oligod(T) primer (RESGEN/Invitrogen, Huntsville, Ala.) according to the Superscript II manufacturer's instructions. For PCR, 1 μl of the completed RT reaction was added to 40 μl of water, 5 μl of 10× buffer, 1 μl of dNTPs and 1 μl of enzyme from the Clonetech (PaloAlto, Calif.) Advantage 2 PCR kit. PCR was done in a Gene Amp PCR System 9700 (Applied Biosystems, Foster City, Calif.). After an initial 94° C. denaturation of 1 minute, 35 cycles of a 30 second denaturation at 94° C. followed by a 1 minute annealing at 65° C. and a 90 second synthesis at 68° C. The 35 cycles of PCR were followed by a 7 minute extension at 68° C. The 50 μl reaction was then chilled to 4° C. 10 ml of the resulting reaction product was run on a 1% agarose (Invitrogen, Ultra pure) gel stained with 0.3 μg/ml ethidium bromide (Fisher Biotech, Fair Lawn, N.J.). The gel was visualized and photographed on a UV light box to determined if the PCR had yielded products of the expected size, in the case of the predicted LXRLI1, ORF about 1.5 kilobases (Kb). A faint about 1.5 Kb stained DNA band was seen for the RT-PCR from small intestine. The remainder of the 50 ml PCR reactions from small intestine and THP-1 cells was purified using the QIAquik Gel extraction Kit (Qiagen, Valencia, Calif.) following the QIAquik PCR Purification Protocol provided with the kit. An about 50 μl of product obtained from the purification protocol was concentrated to about 6 μl by drying in a Speed Vac Plus (SC110A, from Savant, Holbrook, N.Y.) attached to a Universal Vacuum Sytem 400 (also from Savant) for about 30 minutes on medium heat.

[0211] Cloning of RT-PCR Products

[0212] About 4 μl of the 6 μl of purified LXRLI1 RT-PCR product was used in a cloning reaction using the reagents and instructions provided with the TOPO TA cloning kit (Invitrogen, Carlsbad, Calif.). About 2 μg of the cloning reaction was used following the manufacturer's instructions to transform TOP10 chemically competent E. coli provided with the cloning kit. After the 1 hour recovery of the cells in SOC medium (provided with the TOPO TA cloning kit), 200 μl of the mixture was plated on LB medium plates (Sambrook, et al., in Molecular Cloning, A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989) containing 100 μg/ml Ampicillin (Sigma, St. Louis, Mo.) and 80 μg/ml X-GAL (5-Bromo-4-chloro-3-indoyl B-D-galactoside, Sigma, St. Louis, Mo.). Plates were incubated overnight at 37° C. White colonies were picked from the plates into 2 ml of 2×LB medium. These liquid cultures were incubated overnight on a roller at 37° C. Plasmid DNA was extracted from these cultures using the Qiagen (Valencia, Calif.) Qiaquik Spin Miniprep kit. About 3 μl of each DNA miniprep was digested 1 hour at 37° C. with 0.5 μl of the restriction enzyme EcoRI (provided at 10 units/μl by Gibco/Invitrogen, Carlsbad, Calif.). About 10 μl of the 15 μl digestion reaction was run on a 1% Agarose gel and the DNA bands were visualized and photographed on a UV light box to determine which minipreps samples had inserts of the size predicted for a cDNA insert encoding for the predicted LXRLI1 ORF, about 1.5 Kb. Six clones having the expected 1.5 Kb inserts were identified and prepared for DNA sequencing of the putative LXRLI1 ORF.

[0213] Sequencing of RT-PCR Products from cDNA Clones

[0214] Six putative full length clones of LXRLI1 were chosen for sequencing (two clones obtained from small intestinal mRNA and four clones obtained from THP-1 total RNA). About 4 ml of each DNA miniprep (described previously above) were used in a DNA sequencing reaction with each of the following oligonucleotide primers: F 5′ GTAAAACGACGGCCAGT 3′ (SEQ ID NO 102) R 5′ GGAAACAGCTATGACCATG 3′ (SEQ ID NO 103) MB291 5′ CCAAAGCCAGGAGTCCATGAGTAG 3′ (SEQ ID NO 104) MB306 5′ TGGTCTAGTCAGGAAATTTGTGGATTC 3′ (SEQ ID NO 105) MB307 5′ GAATCCACAAATTTCCTGACTAGACCA 3′ (SEQ ID NO 106) MB314 5′ CTACTCATGGACTCCTGGCTTTG 3′ (SEQ ID NO 107) MB315 5′ GCACAACAATTCCCATGTATTTAGCG 3′ (SEQ ID NO 108) MB316 5′ CGCTAAATACATGGGAATTGTTGTGC 3′. (SEQ ID NO 109)

[0215] Sequencing reactions were composed of 4 μl of miniprep, 4 μl of primer (at 1 mM), 4 μl of water and 8 μl of BigDye Terminator Cycle Sequencing Ready Reaction (Applied Biosystems, Foster City, Calif.).

[0216] The PCR was carried out using Gene Amp PCR System 9700 (Applied Biosystems, Foster City, Calif.) using the PCR conditions in the instructions supplied with the Ready Reaction kit. Sequencing reactions were purified using the DyeEx Spin Kit (Qiagen, Valencia, Calif.) and dried for 20 minutes on low heat in a Speed Vac Plus (SC110A, from Savant, Holbrook, N.Y.) attached to a Universal Vacuum Sytem 400 (also from Savant). The reactions were resuspended in 4 μl of a 4 to 1 mixture of formamide (Sigma, St. Louis, Mo.) with 25 mM EDTA (Sigma) and 50 mg/ml dextran blue (Sigma). The reactions were then heated to 100° C. for 2 minutes and chilled on ice. The DNA was sequenced on an ABI 377 DNA Sequencer. The sequencing gel was prepared using a Long Ranger Singe1 Pack (BioWhittaker Molecular Applications, Rockland, Me.) according to the manufacturer's instructions. 2 μl of the sequencing reaction was loaded into each well of the gel. The gel was run for 3.5 hours using the 36E 2400 run module, the dye set DT (BD set Andy-Primer) and the dRHOD Matrix.

[0217] LXRLI1 clone sequences were compiled into contigs using either the small intestinal LXRLI1 clone sequences or the THP-1 LXRLI1 clone sequences as follows. One clone from both the small intestine and the THP-1 LXRLI1 clones were designated as a reference clone. The sequence of each reference LXRLI1 clone was first compared to published genomic clones from the AK000684 region (NCBI website, BlastN). When the sequence of the reference THP-1 or small intestinal LXRLI1 clone differed from the published sequence, the LXRLI1 sequence was then compared to the same region of sequence in the other sequenced clones from the same cell source to determine if the sequence difference observed was due to PCR error, or represented the consensus sequence for LXRLI1 in the small intestine or THP-1 cell line. Comparison of the consensus LXRLI1 nucleotide sequences obtained from the small intestine and THP-1 cells showed that the DNA sequence from small intestine differs by one base pair (from a G to a C at position 1435) from the sequence cloned from THP-1 cells. The final LXRLI1 cDNA sequence is set forth in SEQ ID NO 1. The predicted LXRLI1 protein from small intestine differs by one amino acid (from a Gly to an Ala at position 430) from the sequence predicted in THP-1 cells. The final LXRLI1 amino acid sequence is set forth in SEQ ID NO 2.

[0218] The nucleotide sequence of LXRLI1 cDNA (SEQ ID NO 1) was used to query the GenBank sequence database operated by the National Library of Medicine, in a BLAST (Basic Local Alignment Search Tool) search (Table 4). The search was performed using the following parameters: bl2seq, BLASTn program, non-default parameters—e 0.0001-FF. A BLAST search returns an Expect (E) value; the E value is the probability that a particular search result would have occurred by chance. Highly significant E values are greatly smaller than 1.0 (but larger than 0.0), while insignificant E values are close to 1.0.

[0219] The amino acid sequence of LXRLI1 protein (SEQ ID NO 2) was also used to query the GenBank sequence database (Table 5). The search was performed using the following parameters: bl2seq, BLASTp program, non-default parameters—e 0.0001-FF. * Amino acid sequences of the predicted protein products were compared to entries in two protein motif databases, Pfam and PROSITE. No significant protein motif matches were found. However, analyses of the LXRLI1 polypeptide sequence using two different membrane topology prediction programs, SOSUI (Hirokawa, et al., 1998 Bioinformatics 14:378-9) and TMpred (Hofmann and Stoffel, 1993 Biol. Chem. Hoppe-Seyler 374:166), suggests that the LXRLI1 protein has four (SOSUI) to seven (TMpred) transmembrane helices. These data suggest that LXRLI1 is a membrane protein.

[0220] SEQ ID NO 1 contained a full open reading frame that encoded a protein (SEQ ID NO 1) identical to the predicted FLJ22104 protein (SEQ ID NO 98), but contained an eighty-two additional amino acids at the amino terminus, an additional twenty-two amino acids, starting at amino acid 50 of SEQ ID NO 98) and an isoleucine rather than threonine at amino acid 235 of SEQ ID NO 98. TABLE 4 BLASTn results for LXRLI1-encoding nucleotide sequences. Maximum Percent Maximum Percent Novel cDNA Blast Identify over Sequence Identify over Sequence Maximum Length of Novel cDNA Polypeptide Description Window of 125 bp Window of 275 bp 100% Identity SEQ ID NO 1 SEQ ID NO 2 1. AK000684 1. 100% 1. 100% 1. 504 nucleotides 2. AK013269 2. 96.8% 2. 95.3% 2. 68 nucleotides 3. AK025757 3. 100% 3. 100% 3. 553 nucleotides

[0221] TABLE 5 BLASTp results for LXARAI1 Protein. Prosite Maximum Length of Maximum Length of Polypeptide Blast Score Blast Description Pfam Motif(s) Motif(s) 100% Identity 100% Similarity SEQ ID NO 2 1. 870, E = 0.0 1. BAB28760 1. None 1. None 1. 112 amino acids out 1. 146 amino acids out [Mus musculus] of a total of 458 of a total of 458 2. 711, E = 0.0 2. BAB15233 predicted 2. None 2. None 2. 184 amino acids out 2. 184 amino acids out protein FLJ22104 of a total of 458 of a total of 458 [Homo sapiens]

Example 3

[0222] Real Time Quantitative PCR of LXRLI1 Gene Expression

[0223] The relative expression of LXRLI1 mRNA was determined for a panel of human tissues using a quantitative real time polymerase chain reaction (PCR) based assay. Total RNA isolated from eight different human tissues was obtained from Ambion Inc. (Austin, Tex.). One hundred ng of total RNA from each tissue was subjected to a one-step reverse transcription-PCR amplification protocol following Applied Biosystems, Inc. (ABI, Foster City, Calif.) specifications as outlined in the ABI protocol manual 4310299B. The ABI human beta actin pre-developed assay reagent (PDAR #4326315E) was used to amplify the reference gene beta actin. The following LXRLI1 primer set: 57662FW 5′-GACGGTGGTACACTCTTGAGAAAA-3′ (SEQ ID NO 110) and 57662RV 5′-GAAGATGGGAAAACATTGTATAATTTAAGC-3′ (SEQ ID NO 111), designed using ABI primer express software, was used at a concentration of 300 nM. LXRLI1 primer optimization and validation of the 57662FW/57662RV primer set-target specificity was carried out prior to analysis of human tissue samples. Human beta actin amplification was detected using the actin specific 5′-VIC labeled TaqMan PDAR probes obtained from ABI. The LXRLI1 primer set described above was used to amplify a 119 base pair LXRLI1 specific amplicon that was detected by Syber Green binding and exhibited the predicted T_(m) of 74° C. All of the RT-PCT reactions were carried out in triplicate along with non-template controls using the ABI Prism 7000 sequence detection system. Critical threshold (C_(T)) values (Bustin, 2000 J. Mol. Endocrinol. 25:169-93) were obtained for each reaction, and average C_(T) values; were generated for each gene in each tissue as described in the TaqMan user manual (TaqMan Universal PCR Master Mix; Protocol, p.5; © 1998 PE Applied Biosystems).

[0224] The relative expression of LXRLI1 in each of eight tissues tested is depicted in Table 6 as a fold change in expression relative to LXRLI1 expression in kidney, as further normalized to beta-actin expression across all eight tissues. The data shown in Table 6 shows that LXRLI1 is expressed in all of the tissues examined. The highest relative level of LXELI1 expression was observed in adrenal and skeletal muscle tissue, with intermediate levels of expression in bladder, liver and testis tissue, and a low level of expression in lung, spleen and kidney tissue. TABLE 6 Expression of LXRLI1 in Human Tissue (Fold expression relative to expression level in Kidney as normalized with beta-actin expression level). Human Tissue LXRLI1 Adrenal 23 Skeletal Muscle 20 Bladder 10.8 Liver 8.6 Testis 8.5 Lung 4.7 Spleen 1.4 Kidney 1.0

Example 4

[0225] Use of LXR-Ligand Induced Markers to Classify LXR-Ligands

[0226] The 55 markers, representing the LXR-regulated geneset defined in Table 1, can also be used to classify LXR-ligands as exemplified in this example.

[0227] Microarray gene expression profiles were obtaining using RNA samples from different human cell lines exposed to LXR-agonist APD and to other treatments known to increase or decrease cellular cholesterol levels. Experimental methods were the same as those described in Example 1, except as described below.

[0228] 22(R)-hydroxycholesterol (22RHC) is a LXR-ligand that is also thought to mimic cholesterol loading via suppression of SREBP processing (Brown and Goldstein, 1999 Proc. Natl. Acad. Sci. 96:11041-8). THP-1 cell samples were treated with 10 μM 22RHC (Sigma C 9384) in 10 mM ethanol. Cells were incubated in 22RHC for 3 hours, 6 hours and 20 hours, respectively, prior to extraction of total RNA.

[0229] Acetylated Low Density Lipoprotein (AcLDL) is a composition known to increase intracellular cholesterol levels, i.e., cholesterol loading (Chinetti, et al., 2001 Nature Med. 7:53-8; Fu, et al., 2001 J. Biol. Chem. 42:38378-87). THP-1 cells were cultured with AcLDL (200 μg/ml) for 3, 6, and 20 hours prior to extraction of total RNA.

[0230] Methyl-β-cyclodextrin (CD) is an inducer of cholesterol efflux from plasma membranes (Kilsdonk, et al., 1995, J. Biol. Chem. 270:17250-6). Medium A was aspirated from THP-1 cells and replaced with RPMI-1640 containing 2.0 mM methyl-β-cyclodextrin (Sigma C 4555), 0.1% BSA, and 100 nM PMA and the cells were incubated for 1 hour. This medium was then changed back to Medium A, and cells were collected for RNA measurements after 3 hours, 6 hours, and 20 hours of additional culture time.

[0231] Cholesterol mixed with CD results in the formation of water soluble cholesterol/CD complexes which are taken up by plasma membranes at an increased rate as compared to cholesterol alone (Christian, et al., 1997 J. Lipid Res. 38:2264-72). Cholesterol/CD mixture was prepared by dissolving 24.17 mg cholesterol powder in 5 ml of 100 mM CD (assume molecular weight 1338 for CD), shaking overnight at 37° C., and then filtering the cholesterol/CD complex solution through a 0.25 μm filter. The filtered cholesterol/CD complex was then added to THP-1 cells growing in Medium A to a final concentration of 0.5 mM CD, 24 μg/ml cholesterol. The THP-1 cells were cultured in Medium A with the CD and cholesterol mixture for 3, 6, and 20 hours prior to extraction of total RNA.

[0232] Gene expression profiles were obtained using the methods of Example 1, from twenty different RNA samples obtained from cell samples treated as described in the legend to FIG. 2. Expression levels for each of the markers comprising the LXR-regulated geneset were then sorted and rank ordered (X-axis) based upon their correlation to the ABCG1 marker expression profile across the twenty experimental conditions (Y-axis) represented in FIG. 2.

[0233] The results shown in FIG. 2 demonstrate that measurement of gene expression of the LXR-regulated geneset markers can be used to monitor cholesterol and lipid metabolism, and, to classify LXR ligand compounds. Inspection of the gene expression patterns displayed in FIG. 2 shows that the LXR-regulated geneset markers can be divided into two groups, designated “Group I” and “Group II” in FIG. 2. The Group I markers contain several genes, in particular, ABCA1 (SEQ ID NO 3), ABCG1 (SEQ ID NO 9), and SREBF1 (SEQ ID NO 5) that are well known to be directly regulated by LXR at the transcriptional level. In addition, Group I markers also contain a number of genes whose protein products are known to be directly involved in reverse cholesterol transport which serves to lower cholesterol and plant sterol absorption. In contrast, Group II markers include several genes, in particular, SCD (SEQ ID NO 7), FADS1 (SEQ ID NO 21) and FADS2 (SEQ ID NO 25) that are transcriptionally regulated by SREBF1. In addition, Group II markers are enriched for genes whose protein products are involved in lipid synthesis.

[0234] The data in FIG. 2 is also organized by experimental treatments on the Y-axis to show the differences in gene expression levels of the LXR-regulated geneset in response to cell treatments that are characterized as lowering cellular cholesterol levels verses those that cause an increase in cellular cholesterol levels. Inspection of the gene expression changes observed in the Group I markers as compared to the Group II markers across the cholesterol lowering and increasing treatments reveals that the Group I markers respond in a fashion that is reciprocal to the Group II response.

[0235] In summary, the data presented in FIG. 2 demonstrate the utility of monitoring the changes in gene expression levels of the LXR-regulated geneset markers set forth in Table 1. In particular, given the functional dichotomy between the markers in Group I verses Group II, the LXR-regulated geneset markers can be used to classify LXR-ligands into those that are general, i.e., affect markers in both groups, verses those that affect primarily Group I or Group II markers. The LXR-regulated geneset markers can also be used to determine the state of cholesterol metabolism in a cell sample by comparing the gene expression level of markers in Group I to the markers in Group II. Increased levels of gene expression of Group I markers and decreased levels of gene expression of Group II markers in a cell sample being indicative of a metabolic state of low cholesterol; while increased levels of gene expression of Group II markers and decreased levels of gene expression of Group I markers in a cell sample are indicative of a metabolic state of increased cholesterol. Based upon this result, the Group I and Group II markers can also be used in gene expression assays of corresponding transcript levels to classify LXR-ligands to determine whether the ligand compound affects expression of both Group I and Group II markers, or whether the ligand is selective in its affects on Group I or Group II markers.

[0236] All patents, patent publications, and other published references mentioned herein are hereby incorporated by reference in their entireties as if each had been individually and specifically incorporated by reference herein. While preferred illustrative embodiments of the present invention are shown and described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for,purposes of illustration only and not by way of limitation. Various modifications may be made to the embodiments described herein without departing from the spirit and scope of the present invention. The present invention is limited only by the claims that follow.

1 111 1 1586 DNA Homo sapiens 1 cagagtaacc ccgctctcgt gacctttccc ctccattccg cacctccgag tgctggccgg 60 gcgagaggct ggcggctggg ctctcgcgcc cctccctgca gggctcaggc tctccccctc 120 ctgtcttctc cgcgctgttc ctcgtcatgg cggccctcag caagtccatc cctcataact 180 gctatgagat cggccacact tggcaccctt cctgccgggt ctccttcctg cagatcaccg 240 ggggcgccct ggaggagtcc ctgaagatct atgctcctct gtacttgatt gcagcaattc 300 tccggaaacg gaaattagac tattatttac acaaactact ccctgagatc ctacaatccg 360 cttcatttct aactgctaat ggggccttgt atatggcttt cttttgcatt ttaaggaaga 420 tacttggaaa attctactca tggactcctg gctttggtgc cgctctgcca gcatcttatg 480 tggccattct cattgaaaga aaaagcagga gagggctgct cacaatttat atggccaact 540 tggccacaga aacactattc agaatgggtg tagcaagagg aaccatcaca acattaagaa 600 atggagaagt ccttttgttt tgcatcacag ctgccatgta catgttcttt ttcaggtgca 660 aggatggctt gaaaggattt acattttctg cacttaggtt cattgtaggg aaggaagaaa 720 ttcccacaca ttctttttca ccagaggcag catatgcaaa agtggaacaa aagagagagc 780 aacatgagga aaaacccaga agaatgaata tgattggtct agtcaggaaa tttgtggatt 840 caatatgcaa acatggacca aggcatagat gttgcaaaca ttatgaagat aattgcatct 900 cttattgcat taaaggtttc atcagaatgt ttagcgtggg gtacttgatc cagtgctgcc 960 tccgaatccc ttctgcattt aggcatctgt ttacacagcc atctcggcta ctttctctct 1020 tctacaataa agaaaacttc cagcttggag cttttcttgg ctcttttgtt agtatataca 1080 agggtactag ttgcttcctg cgctggatca gaaacttaga tgatgaacta catgctatta 1140 tagctggatt tttggcaggt atatcaatga tgttttataa aagcacaaca atttccatgt 1200 atttagcgtc caaattggta gagacaatgt atttcaaagg cattgaagca gggaaggttc 1260 cctattttcc tcatgcagat actatcatct attccatctc tacagcaatt tgcttccagg 1320 cagctgtcat ggaagttcag actttgagac catcttactg gaagttcctt ttaagactca 1380 ccaagggcaa atttgctgtc atgaaccgaa aagtccttga tgtttttggt actgctgcat 1440 ctaaacactt tcaggatttc atccccaggt tggatccaag atacacaact gtaacaccag 1500 agttgcccac agagttttcc tgaagatgac tgtaacttat taatgtgact aaatgtttca 1560 tcttgaagag ttaattatgt tgaaca 1586 2 458 PRT Homo sapiens 2 Met Ala Ala Leu Ser Lys Ser Ile Pro His Asn Cys Tyr Glu Ile Gly 1 5 10 15 His Thr Trp His Pro Ser Cys Arg Val Ser Phe Leu Gln Ile Thr Gly 20 25 30 Gly Ala Leu Glu Glu Ser Leu Lys Ile Tyr Ala Pro Leu Tyr Leu Ile 35 40 45 Ala Ala Ile Leu Arg Lys Arg Lys Leu Asp Tyr Tyr Leu His Lys Leu 50 55 60 Leu Pro Glu Ile Leu Gln Ser Ala Ser Phe Leu Thr Ala Asn Gly Ala 65 70 75 80 Leu Tyr Met Ala Phe Phe Cys Ile Leu Arg Lys Ile Leu Gly Lys Phe 85 90 95 Tyr Ser Trp Thr Pro Gly Phe Gly Ala Ala Leu Pro Ala Ser Tyr Val 100 105 110 Ala Ile Leu Ile Glu Arg Lys Ser Arg Arg Gly Leu Leu Thr Ile Tyr 115 120 125 Met Ala Asn Leu Ala Thr Glu Thr Leu Phe Arg Met Gly Val Ala Arg 130 135 140 Gly Thr Ile Thr Thr Leu Arg Asn Gly Glu Val Leu Leu Phe Cys Ile 145 150 155 160 Thr Ala Ala Met Tyr Met Phe Phe Phe Arg Cys Lys Asp Gly Leu Lys 165 170 175 Gly Phe Thr Phe Ser Ala Leu Arg Phe Ile Val Gly Lys Glu Glu Ile 180 185 190 Pro Thr His Ser Phe Ser Pro Glu Ala Ala Tyr Ala Lys Val Glu Gln 195 200 205 Lys Arg Glu Gln His Glu Glu Lys Pro Arg Arg Met Asn Met Ile Gly 210 215 220 Leu Val Arg Lys Phe Val Asp Ser Ile Cys Lys His Gly Pro Arg His 225 230 235 240 Arg Cys Cys Lys His Tyr Glu Asp Asn Cys Ile Ser Tyr Cys Ile Lys 245 250 255 Gly Phe Ile Arg Met Phe Ser Val Gly Tyr Leu Ile Gln Cys Cys Leu 260 265 270 Arg Ile Pro Ser Ala Phe Arg His Leu Phe Thr Gln Pro Ser Arg Leu 275 280 285 Leu Ser Leu Phe Tyr Asn Lys Glu Asn Phe Gln Leu Gly Ala Phe Leu 290 295 300 Gly Ser Phe Val Ser Ile Tyr Lys Gly Thr Ser Cys Phe Leu Arg Trp 305 310 315 320 Ile Arg Asn Leu Asp Asp Glu Leu His Ala Ile Ile Ala Gly Phe Leu 325 330 335 Ala Gly Ile Ser Met Met Phe Tyr Lys Ser Thr Thr Ile Ser Met Tyr 340 345 350 Leu Ala Ser Lys Leu Val Glu Thr Met Tyr Phe Lys Gly Ile Glu Ala 355 360 365 Gly Lys Val Pro Tyr Phe Pro His Ala Asp Thr Ile Ile Tyr Ser Ile 370 375 380 Ser Thr Ala Ile Cys Phe Gln Ala Ala Val Met Glu Val Gln Thr Leu 385 390 395 400 Arg Pro Ser Tyr Trp Lys Phe Leu Leu Arg Leu Thr Lys Gly Lys Phe 405 410 415 Ala Val Met Asn Arg Lys Val Leu Asp Val Phe Gly Thr Ala Ala Ser 420 425 430 Lys His Phe Gln Asp Phe Ile Pro Arg Leu Asp Pro Arg Tyr Thr Thr 435 440 445 Val Thr Pro Glu Leu Pro Thr Glu Phe Ser 450 455 3 9497 DNA Homo sapiens misc_feature (1)..(9497) n = a,c,g, or t 3 caaacatgtc agctgttact ggaagtggcc tggcctctat ttatcttcct gatcctgatc 60 tctgttcggc tgagctaccc accctatgaa caacatgaat gccattttcc aaataaagcc 120 atgccctctg caggaacact tccttgggtt caggggatta tctgtaatgc caacaacccc 180 tgtttccgtt acccgactcc tggggaggct cccggagttg ttggaaactt taacaaatcc 240 attgtggctc gcctgttctc agatgctcgg aggcttcttt tatacagcca gaaagacacc 300 agcatgaagg acatgcgcaa agttctgaga acattacagc agatcaagaa atccagctca 360 aacttgaagc ttcaagattt cctggtggac aatgaaacct tctctgggtt cctgtatcac 420 aacctctctc tcccaaagtc tactgtggac aagatgctga gggctgatgt cattctccac 480 aaggtatttt tgcaaggcta ccagttacat ttgacaagtc tgtgcaatgg atcaaaatca 540 gaagagatga ttcaacttgg tgaccaagaa gtttctgagc tttgtggcct accaagggag 600 aaactggctg cagcagagcg agtacttcgt tccaacatgg acatcctgaa gccaatcctg 660 agaacactaa actctacatc tcccttcccg agcaaggagc tggccgaagc cacaaaaaca 720 ttgctgcata gtcttgggac tctggcccag gagctgttca gcatgagaag ctggagtgac 780 atgcgacagg aggtgatgtt tctgaccaat gtgaacagct ccagctcctc cacccaaatc 840 taccaggctg tgtctcgtat tgtctgcggg catcccgagg gaggggggct gaagatcaag 900 tctctcaact ggtatgagga caacaactac aaagccctct ttggaggcaa tggcactgag 960 gaagatgctg aaaccttcta tgacaactct acaactcctt actgcaatga tttgatgaag 1020 aatttggagt ctagtcctct ttcccgcatt atctggaaag ctctgaagcc gctgctcgtt 1080 gggaagatcc tgtatacacc tgacactcca gccacaaggc aggtcatggc tgaggtgaac 1140 aagaccttcc aggaactggc tgtgttccat gatctggaag gcatgtggga ggaactcagc 1200 cccaagatct ggaccttcat ggagaacagc caagaaatgg accttgtccg gatgctgttg 1260 gacagcaggg acaatgacca cttttgggaa cagcagttgg atggcttaga ttggacagcc 1320 caagacatcg tggcgttttt ggccaagcac ccagaggatg tccagtccag taatggttct 1380 gtgtacacct ggagagaagc tttcaacgag actaaccagg caatccggac catatctcgc 1440 ttcatggagt gtgtcaacct gaacaagcta gaacccatag caacagaagt ctggctcatc 1500 aacaagtcca tggagctgct ggatgagagg aagttctggg ctggtattgt gttcactgga 1560 attactccag gcagcattga gctgccccat catgtcaagt acaagatccg aatggacatt 1620 gacaatgtgg agaggacaaa taaaatcaag gatgggtact gggaccctgg tcctcgagct 1680 gacccctttg aggacatgcg gtacgtctgg gggggcttcg cctacttgca ggatgtggtg 1740 gagcaggcaa tcatcagggt gctgacgggc accgagaaga aaactggtgt ctatatgcaa 1800 cagatgccct atccctgtta cgttgatgac atctttctgc gggtgatgag ccggtcaatg 1860 cccctcttca tgacgctggc ctggatttac tcagtggctg tgatcatcaa gggcatcgtg 1920 tatgagaagg aggcacggct gaaagagacc atgcggatca tgggcctgga caacagcatc 1980 ctctggttta gctggttcat tagtagcctc attcctcttc ttgtgagcgc tggcctgcta 2040 gtggtcatcc tgaagttagg aaacctgctg ccctacagtg atcccagcgt ggtgtttgtc 2100 ttcctgtccg tgtttgctgt ggtgacaatc ctgcagtgct tcctgattag cacactcttc 2160 tccagagcca acctggcagc agcctgtggg ggcatcatct acttcacgct gtacctgccc 2220 tacgtcctgt gtgtggcatg gcaggactac gtgggcttca cactcaagat cttcgctagc 2280 ctgctgtctc ctgtggcttt tgggtttggc tgtgagtact ttgccctttt tgaggagcag 2340 ggcattggag tgcagtggga caacctgttt gagagtcctg tggaggaaga tggcttcaat 2400 ctcaccactt cggtctccat gatgctgttt gacaccttcc tctatggggt gatgacctgg 2460 tacattgagg ctgtctttcc aggccagtac ggaattccca ggccctggta ttttccttgc 2520 accaagtcct actggtttgg cgaggaaagt gatgagaaga gccaccctgg ttccaaccag 2580 aagagaatat cagaaatctg catggaggag gaacccaccc acttgaagct gggcgtgtcc 2640 attcagaacc tggtaaaagt ctaccgagat gggatgaagg tggctgtcga tggcctggca 2700 ctgaattttt atgagggcca gatcacctcc ttcctgggcc acaatggagc ggggaagacg 2760 accaccatgt caatcctgac cgggttgttc cccccgacct cgggcaccgc ctacatcctg 2820 ggaaaagaca ttcgctctga gatgagcacc atccggcaga acctgggggt ctgtccccag 2880 cataacgtgc tgtttgacat gctgactgtc gaagaacaca tctggttcta tgcccgcttg 2940 aaagggctct ctgagaagca cgtgaaggcg gagatggagc agatggccct ggatgttggt 3000 ttgccatcaa gcaagctgaa aagcaaaaca agccagctgt caggtggaat gcagagaaag 3060 ctatctgtgg ccttggcctt tgtcggggga tctaaggttg tcattctgga tgaacccaca 3120 gctggtgtgg acccttactc ccgcagggga atatgggagc tgctgctgaa ataccgacaa 3180 ggccgcacca ttattctctc tacacaccac atggatgaag cggacgtcct gggggacagg 3240 attgccatca tctcccatgg gaagctgtgc tgtgtgggct cctccctgtt tctgaagaac 3300 cagctgggaa caggctacta cctgaccttg gtcaagaaag atgtggaatc ctccctcagt 3360 tcctgcagaa acagtagtag cactgtgtca tacctgaaaa aggaggacag tgtttctcag 3420 agcagttctg atgctggcct gggcagcgac catgagagtg acacgctgac catcgatgtc 3480 tctgctatct ccaacctcat caggaagcat gtgtctgaag cccggctggt ggaagacata 3540 gggcatgagc tgacctatgt gctgccatat gaagctgcta aggagggagc ctttgtggaa 3600 ctctttcatg agattgatga ccggctctca gacctgggca tttctagtta tggcatctca 3660 gagacgaccc tggaagaaat attcctcaag gtggccgaag agagtggggt ggatgctgag 3720 acctcagatg gtaccttgcc agcaagacga aacaggcggg ccttcgggga caagcagagc 3780 tgtcttcgcc cgttcactga agatgatgct gctgatccaa atgattctga catagaccca 3840 gaatccagag agacagactt gctcagtggg atggatggca aagggtccta ccaggtgaaa 3900 ggctggaaac ttacacagca acagtttgtg gcccttttgt ggaagagact gctaattgcc 3960 agacggagtc ggaaaggatt ttttgctcag attgtcttgc cagctgtgtt tgtctgcatt 4020 gcccttgtgt tcagcctgat cgtgccaccc tttggcaagt accccagcct ggaacttcag 4080 ccctggatgt acaacgaaca gtacacattt gtcagcaatg atgctcctga ggacacggga 4140 accctggaac tcttaaacgc cctcaccaaa gaccctggct tcgggacccg ctgtatggaa 4200 ggaaacccaa tcccagacac gccctgccag gcaggggagg aagagtggac cactgcccca 4260 gttccccaga ccatcatgga cctcttccag aatgggaact ggacaatgca gaacccttca 4320 cctgcatgcc agtgtagcag cgacaaaatc aagaagatgc tgcctgtgtg tcccccaggg 4380 gcaggggggc tgcctcctcc acaaagaaaa caaaacactg cagatatcct tcaggacctg 4440 acaggaagaa acatttcgga ttatctggtg aagacgtatg tgcagatcat agccaaaagc 4500 ttaaagaaca agatctgggt gaatgagttt aggtatggcg gcttttccct gggtgtcagt 4560 aatactcaag cacttcctcc gagtcaagaa gttaatgatg ccaccaaaca aatgaagaaa 4620 cacctaaagc tggccaagga cagttctgca gatcgatttc tcaacagctt gggaagattt 4680 atgacaggac tggacaccag aaataatgtc aaggtgtggt tcaataacaa gggctggcat 4740 gcaatcagct ctttcctgaa tgtcatcaac aatgccattc tccgggccaa cctgcaaaag 4800 ggagagaacc ctagccatta tggaattact gctttcaatc atcccctgaa tctcaccaag 4860 cagcagctct cagaggtggc tccgatgacc acatcagtgg atgtccttgt gtccatctgt 4920 gtcatctttg caatgtcctt cgtcccagcc agctttgtcg tattcctgat ccaggagcgg 4980 gtcagcaaag caaaacacct gcagttcatc agtggagtga agcctgtcat ctactggctc 5040 tctaattttg tctgggatat gtgcaattac gttgtccctg ccacactggt cattatcatc 5100 ttcatctgct tccagcagaa gtcctatgtg tcctccacca atctgcctgt gctagccctt 5160 ctacttttgc tgtatgggtg gtcaatcaca cctctcatgt acccagcctc ctttgtgttc 5220 aagatcccca gcacagccta tgtggtgctc accagcgtga acctcttcat tggcattaat 5280 ggcagcgtgg ccacctttgt gctggagctg ttcaccgaca ataagctgaa taatatcaat 5340 gatatcctga agtccgtgtt cttgatcttc ccacattttt gcctgggacg agggctcatc 5400 gacatggtga aaaaccaggc aatggctgat gccctggaaa ggtttgggga gaatcgcttt 5460 gtgtcaccat tatcttggga cttggtggga cgaaacctct tcgccatggc cgtggaaggg 5520 gtggtgttct tcctcattac tgttctgatc cagtacagat tcttcatcag gcccagacct 5580 gtaaatgcaa agctatctcc tctgaatgat gaagatgaag atgtgaggcg ggaaagacag 5640 agaattcttg atggtggagg ccagaatgac atcttagaaa tcaaggagtt gacgaagata 5700 tatagaagga agcggaagcc tgctgttgac aggatttgcg tgggcattcc tcctggtgag 5760 tgctttgggc tcctgggagt taatggggct ggaaaatcat caactttcaa gatgttaaca 5820 ggagatacca ctgttaccag aggagatgct ttccttaaca gaaatagtat cttatcaaac 5880 atccatgaag tacatcagaa catgggctac tgccctcagt ttgatgccat cacagagctg 5940 ttgactggga gagaacacgt ggagttcttt gcccttttga gaggagtccc agagaaagaa 6000 gttggcaagg ttggtgagtg ggcgattcgg aaactgggcc tcgtgaagta tggagaaaaa 6060 tatgctggta actatagtgg aggcaacaaa cgcaagctct ctacagccat ggctttgatc 6120 ggcgggcctc ctgtggtgtt tctggatgaa cccaccacag gcatggatcc caaagcccgg 6180 cggttcttgt ggaattgtgc cctaagtgtt gtcaaggagg ggagatcagt agtgcttaca 6240 tctcatagta tggaagaatg tgaagctctt tgcactagga tggcaatcat ggtcaatgga 6300 aggttcaggt gccttggcag tgtccagcat ctaaaaaata ggtttggaga tggttataca 6360 atagttgtac gaatagcagg gtccaacccg gacctgaagc ctgtccagga tttctttgga 6420 cttgcatttc ctggaagtgt tccaaaagag aaacaccgga acatgctaca ataccagctt 6480 ccatcttcat tatcttctct ggccaggata ttcagcatcc tctcccagag caaaaagcga 6540 ctccacatag aagactactc tgtttctcag acaacacttg accaagtatt tgtgaacttt 6600 gccaaggacc aaagtgatga tgaccactta aaagacctct cattacacaa aaaccagaca 6660 gtagtggacg ttgcagttct cacatctttt ctacaggatg agaaagtgaa agaaagctat 6720 gtatgaagaa tcctgttcat acggggtggc tgaaagtaaa gaggnactag actttccttt 6780 gcaccatgtg aagtgttgtg gagaaaagag ccagaagttg atgtgggaag aagtaaactg 6840 gatactgtac tgatactatt caatgcaatg caattcaatg caatgaaaac aaaattccat 6900 tacaggggca gtgcctttgt agcctatgtc ttgtatggct ctcaagtgaa agacttgaat 6960 ttagtttttt acctatacct atgtgaaact ctattatgga acccaatgga catatgggtt 7020 tgaactcaca cttttttttt ttttttgttc ctgtgtattc tcattggggt tgcaacaata 7080 attcatcaag taatcatggc cagcgattat tgatcaaaat caaaaggtaa tgcacatcct 7140 cattcactaa gccatgccat gcccaggaga ctggtttccc ggtgacacat ccattgctgg 7200 caatgagtgt gccagagtta ttagtgccaa gtttttcaga aagtttgaag caccatggtg 7260 tgtcatgctc acttttgtga aagctgctct gctcagagtc tatcaacatt gaatatcagt 7320 tgacagaatg gtgccatgcg tggctaacat cctgctttga ttccctctga taagctgttc 7380 tggtggcagt aacatgcaac aaaaatgtgg gtgtctctag gcacgggaaa cttggttcca 7440 ttgttatatt gtcctatgct tcgagccatg ggtctacagg gtcatcctta tgagactctt 7500 aaatatactt agatcctggt aagaggcaaa gaatcaacag ccaaactgct ggggctgcaa 7560 gctgctgaag ccagggcatg ggattaaaga gattgtgcgt tcaaacctag ggaagcctgt 7620 gcccatttgt cctgactgtc tgctaacatg gtacactgca tctcaagatg tttatctgac 7680 acaagtgtat tatttctggc tttttgaatt aatctagaaa atgaaaagat ggagttgtat 7740 tttgacaaaa atgtttgtac tttttaatgt tatttggaat tttaagttct atcagtgact 7800 tctgaatcct tagaatggcc tctttgtaga accctgtggt atagaggagt atggccactg 7860 ccccactatt tttattttct tatgtaagtt tgcatatcag tcatgactag tgcctagaaa 7920 gcaatgtgat ggtcaggatc tcatgacatt atatttgagt ttctttcaga tcatttagga 7980 tactcttaat ctcacttcat caatcaaata ttttttgagt gtatgctgta gctgaaagag 8040 tatgtacgta cgtataagac tagagagata ttaagtctca gtacacttcc tgtgccatgt 8100 tattcagctc actggtttac aaatataggt tgtcttgtgg ttgtaggagc ccactgtaac 8160 aatactgggc agcctttttt ttttttttta attgcaacaa tgcaaaagcc aagaaagtat 8220 aagggtcaca agtctaaaca atgaattctt caacagggaa aacagctagc ttgaaaactt 8280 gctgaaaaac acaacttgtg tttatggcat ttagtacctt caaataattg gctttgcaga 8340 tattggatac cccattaaat ctgacagtct caaatttttc atctcttcaa tcactagtca 8400 agaaaaatat aaaaacaaca aatacttcca tatggagcat ttttcagagt tttctaaccc 8460 agtcttattt ttctagtcag taaacatttg taaaaatact gtttcactaa tacttactgt 8520 taactgtctt gagagaaaag aaaaatatga gagaactatt gtttggggaa gttcaagtga 8580 tctttcaata tcattactaa cttcttccac tttttccaaa atttgaatat taacgctaaa 8640 ggtgtaagac ttcagatttc aaattaatct ttctatattt tttaaattta cagaatatta 8700 tataacccac tgctgaaaaa gaaaaaaatg attgttttag aagttaaagt caatattgat 8760 tttaaatata agtaatgaag gcatatttcc aataactagt gatatggcat cgttgcattt 8820 tacagtatct tcaaaaatac agaatttata gaataatttc tcctcattta atatttttca 8880 aaatcaaagt tatggtttcc tcattttact aaaatcgtat tctaattctt cattatagta 8940 aatctatgag caactcctta cttcggttcc tctgatttca aggccatatt ttaaaaaatc 9000 aaaaggcact gtgaactatt ttgaagaaaa cacaacattt taatacagat tgaaaggacc 9060 tcttctgaag ctagaaacaa tctatagtta tacatcttca ttaatactgt gttacctttt 9120 aaaatagtaa ttttttacat tttcctgtgt aaacctaatt gtggtagaaa tttttaccaa 9180 ctctatactc aatcaagcaa aatttctgta tattccctgt ggaatgtacc tatgtgagtt 9240 tcagaaattc tcaaaatacg tgttcaaaaa tttctgcttt tgcatctttg ggacacctca 9300 gaaaacttat taacaactgt gaatatgaga aatacagaag aaaataataa gccctctata 9360 cataaatgcc cagcacaatt cattgttaaa aaacaaccaa acctcacact actgtatttc 9420 attatctgta ctgaaagcaa atgctttgtg actattaaat gttgcacatc attcattcaa 9480 aaaaaaaaaa aaaaaaa 9497 4 2201 PRT Homo sapiens 4 Met Pro Ser Ala Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn 1 5 10 15 Ala Asn Asn Pro Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly 20 25 30 Val Val Gly Asn Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp 35 40 45 Ala Arg Arg Leu Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp 50 55 60 Met Arg Lys Val Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser 65 70 75 80 Asn Leu Lys Leu Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly 85 90 95 Phe Leu Tyr His Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met 100 105 110 Leu Arg Ala Asp Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln 115 120 125 Leu His Leu Thr Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile 130 135 140 Gln Leu Gly Asp Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu 145 150 155 160 Lys Leu Ala Ala Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu 165 170 175 Lys Pro Ile Leu Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys 180 185 190 Glu Leu Ala Glu Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu 195 200 205 Ala Gln Glu Leu Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu 210 215 220 Val Met Phe Leu Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile 225 230 235 240 Tyr Gln Ala Val Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Gly 245 250 255 Leu Lys Ile Lys Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala 260 265 270 Leu Phe Gly Gly Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp 275 280 285 Asn Ser Thr Thr Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser 290 295 300 Ser Pro Leu Ser Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val 305 310 315 320 Gly Lys Ile Leu Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met 325 330 335 Ala Glu Val Asn Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu 340 345 350 Glu Gly Met Trp Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu 355 360 365 Asn Ser Gln Glu Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp 370 375 380 Asn Asp His Phe Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala 385 390 395 400 Gln Asp Ile Val Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser 405 410 415 Ser Asn Gly Ser Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn 420 425 430 Gln Ala Ile Arg Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn 435 440 445 Lys Leu Glu Pro Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met 450 455 460 Glu Leu Leu Asp Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly 465 470 475 480 Ile Thr Pro Gly Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile 485 490 495 Arg Met Asp Ile Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly 500 505 510 Tyr Trp Asp Pro Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr 515 520 525 Val Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile 530 535 540 Ile Arg Val Leu Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln 545 550 555 560 Gln Met Pro Tyr Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met 565 570 575 Ser Arg Ser Met Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val 580 585 590 Ala Val Ile Ile Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys 595 600 605 Glu Thr Met Arg Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser 610 615 620 Trp Phe Ile Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu 625 630 635 640 Val Val Ile Leu Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser 645 650 655 Val Val Phe Val Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln 660 665 670 Cys Phe Leu Ile Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala 675 680 685 Cys Gly Gly Ile Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys 690 695 700 Val Ala Trp Gln Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser 705 710 715 720 Leu Leu Ser Pro Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu 725 730 735 Phe Glu Glu Gln Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser 740 745 750 Pro Val Glu Glu Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met 755 760 765 Leu Phe Asp Thr Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala 770 775 780 Val Phe Pro Gly Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys 785 790 795 800 Thr Lys Ser Tyr Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro 805 810 815 Gly Ser Asn Gln Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro 820 825 830 Thr His Leu Lys Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr 835 840 845 Arg Asp Gly Met Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr 850 855 860 Glu Gly Gln Ile Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr 865 870 875 880 Thr Thr Met Ser Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr 885 890 895 Ala Tyr Ile Leu Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg 900 905 910 Gln Asn Leu Gly Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu 915 920 925 Thr Val Glu Glu His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser 930 935 940 Glu Lys His Val Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly 945 950 955 960 Leu Pro Ser Ser Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly 965 970 975 Met Gln Arg Lys Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys 980 985 990 Val Val Ile Leu Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg 995 1000 1005 Arg Gly Ile Trp Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr 1010 1015 1020 Ile Ile Leu Ser Thr His His Met Asp Glu Ala Asp Val Leu Gly 1025 1030 1035 Asp Arg Ile Ala Ile Ile Ser His Gly Lys Leu Cys Cys Val Gly 1040 1045 1050 Ser Ser Leu Phe Leu Lys Asn Gln Leu Gly Thr Gly Tyr Tyr Leu 1055 1060 1065 Thr Leu Val Lys Lys Asp Val Glu Ser Ser Leu Ser Ser Cys Arg 1070 1075 1080 Asn Ser Ser Ser Thr Val Ser Tyr Leu Lys Lys Glu Asp Ser Val 1085 1090 1095 Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly Ser Asp His Glu Ser 1100 1105 1110 Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser Asn Leu Ile Arg 1115 1120 1125 Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile Gly His Glu 1130 1135 1140 Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly Ala Phe 1145 1150 1155 Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu Gly 1160 1165 1170 Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe 1175 1180 1185 Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp 1190 1195 1200 Gly Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys 1205 1210 1215 Gln Ser Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro 1220 1225 1230 Asn Asp Ser Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu 1235 1240 1245 Ser Gly Met Asp Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys 1250 1255 1260 Leu Thr Gln Gln Gln Phe Val Ala Leu Leu Trp Lys Arg Leu Leu 1265 1270 1275 Ile Ala Arg Arg Ser Arg Lys Gly Phe Phe Ala Gln Ile Val Leu 1280 1285 1290 Pro Ala Val Phe Val Cys Ile Ala Leu Val Phe Ser Leu Ile Val 1295 1300 1305 Pro Pro Phe Gly Lys Tyr Pro Ser Leu Glu Leu Gln Pro Trp Met 1310 1315 1320 Tyr Asn Glu Gln Tyr Thr Phe Val Ser Asn Asp Ala Pro Glu Asp 1325 1330 1335 Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu Thr Lys Asp Pro Gly 1340 1345 1350 Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile Pro Asp Thr Pro 1355 1360 1365 Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro Val Pro Gln 1370 1375 1380 Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met Gln Asn 1385 1390 1395 Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys Met 1400 1405 1410 Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln 1415 1420 1425 Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg 1430 1435 1440 Asn Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala 1445 1450 1455 Lys Ser Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly 1460 1465 1470 Gly Phe Ser Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser 1475 1480 1485 Gln Glu Val Asn Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys 1490 1495 1500 Leu Ala Lys Asp Ser Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly 1505 1510 1515 Arg Phe Met Thr Gly Leu Asp Thr Arg Asn Asn Val Lys Val Trp 1520 1525 1530 Phe Asn Asn Lys Gly Trp His Ala Ile Ser Ser Phe Leu Asn Val 1535 1540 1545 Ile Asn Asn Ala Ile Leu Arg Ala Asn Leu Gln Lys Gly Glu Asn 1550 1555 1560 Pro Ser His Tyr Gly Ile Thr Ala Phe Asn His Pro Leu Asn Leu 1565 1570 1575 Thr Lys Gln Gln Leu Ser Glu Val Ala Pro Met Thr Thr Ser Val 1580 1585 1590 Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala Met Ser Phe Val 1595 1600 1605 Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg Val Ser Lys 1610 1615 1620 Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val Ile Tyr 1625 1630 1635 Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val Pro 1640 1645 1650 Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser 1655 1660 1665 Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu 1670 1675 1680 Leu Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe 1685 1690 1695 Val Phe Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val 1700 1705 1710 Asn Leu Phe Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu 1715 1720 1725 Glu Leu Phe Thr Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu 1730 1735 1740 Lys Ser Val Phe Leu Ile Phe Pro His Phe Cys Leu Gly Arg Gly 1745 1750 1755 Leu Ile Asp Met Val Lys Asn Gln Ala Met Ala Asp Ala Leu Glu 1760 1765 1770 Arg Phe Gly Glu Asn Arg Phe Val Ser Pro Leu Ser Trp Asp Leu 1775 1780 1785 Val Gly Arg Asn Leu Phe Ala Met Ala Val Glu Gly Val Val Phe 1790 1795 1800 Phe Leu Ile Thr Val Leu Ile Gln Tyr Arg Phe Phe Ile Arg Pro 1805 1810 1815 Arg Pro Val Asn Ala Lys Leu Ser Pro Leu Asn Asp Glu Asp Glu 1820 1825 1830 Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp Gly Gly Gly Gln 1835 1840 1845 Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile Tyr Arg Arg 1850 1855 1860 Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile Pro Pro 1865 1870 1875 Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys Ser 1880 1885 1890 Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly 1895 1900 1905 Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn Ile His Glu 1910 1915 1920 Val His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr 1925 1930 1935 Glu Leu Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu 1940 1945 1950 Arg Gly Val Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala 1955 1960 1965 Ile Arg Lys Leu Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly 1970 1975 1980 Asn Tyr Ser Gly Gly Asn Lys Arg Lys Leu Ser Thr Ala Met Ala 1985 1990 1995 Leu Ile Gly Gly Pro Pro Val Val Phe Leu Asp Glu Pro Thr Thr 2000 2005 2010 Gly Met Asp Pro Lys Ala Arg Arg Phe Leu Trp Asn Cys Ala Leu 2015 2020 2025 Ser Val Val Lys Glu Gly Arg Ser Val Val Leu Thr Ser His Ser 2030 2035 2040 Met Glu Glu Cys Glu Ala Leu Cys Thr Arg Met Ala Ile Met Val 2045 2050 2055 Asn Gly Arg Phe Arg Cys Leu Gly Ser Val Gln His Leu Lys Asn 2060 2065 2070 Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg Ile Ala Gly Ser 2075 2080 2085 Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly Leu Ala Phe 2090 2095 2100 Pro Gly Ser Val Pro Lys Glu Lys His Arg Asn Met Leu Gln Tyr 2105 2110 2115 Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser Ile 2120 2125 2130 Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val 2135 2140 2145 Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp 2150 2155 2160 Gln Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn 2165 2170 2175 Gln Thr Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp 2180 2185 2190 Glu Lys Val Lys Glu Ser Tyr Val 2195 2200 5 4154 DNA Homo sapiens 5 taacgaggaa cttttcgccg gcgccgggcc gcctctgagg ccagggcagg acacgaacgc 60 gcggagcggc ggcggcgact gagagccggg gccgcggcgg cgctccctag gaagggccgt 120 acgaggcggc gggcccggcg ggcctcccgg aggaggcggc tgcgccatgg acgagccacc 180 cttcagcgag gcggctttgg agcaggcgct gggcgagccg tgcgatctgg acgcggcgct 240 gctgaccgac atcgaagaca tgcttcagct tatcaacaac caagacagtg acttccctgg 300 cctatttgac ccaccctatg ctgggagtgg ggcagggggc acagaccctg ccagccccga 360 taccagctcc ccaggcagct tgtctccacc tcctgccaca ttgagctcct ctcttgaagc 420 cttcctgagc gggccgcagg cagcgccctc acccctgtcc cctccccagc ctgcacccac 480 tccattgaag atgtacccgt ccatgcccgc tttctcccct gggcctggta tcaaggaaga 540 gtcagtgcca ctgagcatcc tgcagacccc caccccacag cccctgccag gggccctcct 600 gccacagagc ttcccagccc cagccccacc gcagttcagc tccacccctg tgttaggcta 660 ccccagccct ccgggaggct tctctacagg aagccctccc gggaacaccc agcagccgct 720 gcctggcctg ccactggctt ccccgccagg ggtcccgccc gtctccttgc acacccaggt 780 ccagagtgtg gtcccccagc agctactgac agtcacagct gcccccacgg cagcccctgt 840 aacgaccact gtgacctcgc agatccagca ggtcccggtc ctgctgcagc cccacttcat 900 caaggcagac tcgctgcttc tgacagccat gaagacagac ggagccactg tgaaggcggc 960 aggtctcagt cccctggtct ctggcaccac tgtgcagaca gggcctttgc cgaccctggt 1020 gagtggcgga accatcttgg caacagtccc actggtcgta gatgcggaga agctgcctat 1080 caaccggctc gcagctggca gcaaggcccc ggcctctgcc cagagccgtg gagagaagcg 1140 cacagcccac aacgccattg agaagcgcta ccgctcctcc atcaatgaca aaatcattga 1200 gctcaaggat ctggtggtgg gcactgaggc aaagctgaat aaatctgctg tcttgcgcaa 1260 ggccatcgac tacattcgct ttctgcaaca cagcaaccag aaactcaagc aggagaacct 1320 aagtctgcgc actgctgtcc acaaaagcaa atctctgaag gatctggtgt cggcctgtgg 1380 cagtggaggg aacacagacg tgctcatgga gggcgtgaag actgaggtgg aggacacact 1440 gaccccaccc ccctcggatg ctggctcacc tttccagagc agccccttgt cccttggcag 1500 caggggcagt ggcagcggtg gcagtggcag tgactcggag cctgacagcc cagtctttga 1560 ggacagcaag gcaaagccag agcagcggcc gtctctgcac agccggggca tgctggaccg 1620 ctcccgcctg gccctgtgca cgctcgtctt cctctgcctg tcctgcaacc ccttggcctc 1680 cttgctgggg gcccgggggc ttcccagccc ctcagatacc accagcgtct accatagccc 1740 tgggcgcaac gtgctgggca ccgagagcag agatggccct ggctgggccc agtggctgct 1800 gcccccagtg gtctggctgc tcaatgggct gttggtgctc gtctccttgg tgcttctctt 1860 tgtctacggt gagccagtca cacggcccca ctcaggcccc gccgtgtact tctggaggca 1920 tcgcaagcag gctgacctgg acctggcccg gggagacttt gcccaggctg cccagcagct 1980 gtggctggcc ctgcgggcac tgggccggcc cctgcccacc tcccacctgg acctggcttg 2040 tagcctcctc tggaacctca tccgtcacct gctgcagcgt ctctgggtgg gccgctggct 2100 ggcaggccgg gcagggggcc tgcagcagga ctgtgctctg cgagtggatg ctagcgccag 2160 cgcccgagac gcagccctgg tctaccataa gctgcaccag ctgcacacca tggggaagca 2220 cacaggcggg cacctcactg ccaccaacct ggcgctgagt gccctgaacc tggcagagtg 2280 tgcaggggat gccgtgtctg tggcgacgct ggccgagatc tatgtggcgg ctgcattgag 2340 agtgaagacc agtctcccac gggccttgca ttttctgaca cgcttcttcc tgagcagtgc 2400 ccgccaggcc tgcctggcac agagtggctc agtgcctcct gccatgcagt ggctctgcca 2460 ccccgtgggc caccgtttct tcgtggatgg ggactggtcc gtgctcagta ccccatggga 2520 gagcctgtac agcttggccg ggaacccagt ggaccccctg gcccaggtga ctcagctatt 2580 ccgggaacat ctcttagagc gagcactgaa ctgtgtgacc cagcccaacc ccagccctgg 2640 gtcagctgat ggggacaagg aattctcgga tgccctcggg tacctgcagc tgctgaacag 2700 ctgttctgat gctgcggggg ctcctgccta cagcttctcc atcagttcca gcatggccac 2760 caccaccggc gtagacccgg tggccaagtg gtgggcctct ctgacagctg tggtgatcca 2820 ctggctgcgg cgggatgagg aggcggctga gcggctgtgc ccgctggtgg agcacctgcc 2880 ccgggtgctg caggagtctg agagacccct gcccagggca gctctgcact ccttcaaggc 2940 tgcccgggcc ctgctgggct gtgccaaggc agagtctggt ccagccagcc tgaccatctg 3000 tgagaaggcc agtgggtacc tgcaggacag cctggctacc acaccagcca gcagctccat 3060 tgacaaggcc gtgcagctgt tcctgtgtga cctgcttctt gtggtgcgca ccagcctgtg 3120 gcggcagcag cagcccccgg ccccggcccc agcagcccag ggcgccagca gcaggcccca 3180 ggcttccgcc cttgagctgc gtggcttcca acgggacctg agcagcctga ggcggctggc 3240 acagagcttc cggcccgcca tgcggagggt gttcctacat gaggccacgg cccggctgat 3300 ggcgggggcc agccccacac ggacacacca gctcctcgac cgcagtctga ggcggcgggc 3360 aggccccggt ggcaaaggag gcgcggtggc ggagctggag ccgcggccca cgcggcggga 3420 gcacgcggag gccttgctgc tggcctcctg ctacctgccc cccggcttcc tgtcggcgcc 3480 cgggcagcgc gtgggcatgc tggctgaggc ggcgcgcaca ctcgagaagc ttggcgatcg 3540 ccggctgctg cacgactgtc agcagatgct catgcgcctg ggcggtggga ccactgtcac 3600 ttccagctag accccgtgtc cccggcctca gcacccctgt ctctagccac tttggtcccg 3660 tgcagcttct gtcctgcgtc gaagctttga aggccgaagg cagtgcaaga gactctggcc 3720 tccacagttc gacctgcggc tgctgtgtgc cttcgcggtg gaaggcccga ggggcgcgat 3780 cttgacccta agaccggcgg ccatgatggt gctgacctct ggtggccgat cggggcactg 3840 caggggccga gccattttgg ggggcccccc tccttgctct gcaggcacct tagtggcttt 3900 tttcctcctg tgtacaggga agagaggggt acatttccct gtgctgacgg aagccaactt 3960 ggctttcccg gactgcaagc agggctctgc cccagaggcc tctctctccg tcgtgggaga 4020 gagacgtgta catagtgtag gtcagcgtgc ttagcctcct gacctgaggc tcctgtgcta 4080 ctttgccttt tgcaaacttt attttcatag attgagaagt tttgtacaga gaattaaaaa 4140 tgaaattatt tata 4154 6 1147 PRT Homo sapiens 6 Met Asp Glu Pro Pro Phe Ser Glu Ala Ala Leu Glu Gln Ala Leu Gly 1 5 10 15 Glu Pro Cys Asp Leu Asp Ala Ala Leu Leu Thr Asp Ile Glu Asp Met 20 25 30 Leu Gln Leu Ile Asn Asn Gln Asp Ser Asp Phe Pro Gly Leu Phe Asp 35 40 45 Pro Pro Tyr Ala Gly Ser Gly Ala Gly Gly Thr Asp Pro Ala Ser Pro 50 55 60 Asp Thr Ser Ser Pro Gly Ser Leu Ser Pro Pro Pro Ala Thr Leu Ser 65 70 75 80 Ser Ser Leu Glu Ala Phe Leu Ser Gly Pro Gln Ala Ala Pro Ser Pro 85 90 95 Leu Ser Pro Pro Gln Pro Ala Pro Thr Pro Leu Lys Met Tyr Pro Ser 100 105 110 Met Pro Ala Phe Ser Pro Gly Pro Gly Ile Lys Glu Glu Ser Val Pro 115 120 125 Leu Ser Ile Leu Gln Thr Pro Thr Pro Gln Pro Leu Pro Gly Ala Leu 130 135 140 Leu Pro Gln Ser Phe Pro Ala Pro Ala Pro Pro Gln Phe Ser Ser Thr 145 150 155 160 Pro Val Leu Gly Tyr Pro Ser Pro Pro Gly Gly Phe Ser Thr Gly Ser 165 170 175 Pro Pro Gly Asn Thr Gln Gln Pro Leu Pro Gly Leu Pro Leu Ala Ser 180 185 190 Pro Pro Gly Val Pro Pro Val Ser Leu His Thr Gln Val Gln Ser Val 195 200 205 Val Pro Gln Gln Leu Leu Thr Val Thr Ala Ala Pro Thr Ala Ala Pro 210 215 220 Val Thr Thr Thr Val Thr Ser Gln Ile Gln Gln Val Pro Val Leu Leu 225 230 235 240 Gln Pro His Phe Ile Lys Ala Asp Ser Leu Leu Leu Thr Ala Met Lys 245 250 255 Thr Asp Gly Ala Thr Val Lys Ala Ala Gly Leu Ser Pro Leu Val Ser 260 265 270 Gly Thr Thr Val Gln Thr Gly Pro Leu Pro Thr Leu Val Ser Gly Gly 275 280 285 Thr Ile Leu Ala Thr Val Pro Leu Val Val Asp Ala Glu Lys Leu Pro 290 295 300 Ile Asn Arg Leu Ala Ala Gly Ser Lys Ala Pro Ala Ser Ala Gln Ser 305 310 315 320 Arg Gly Glu Lys Arg Thr Ala His Asn Ala Ile Glu Lys Arg Tyr Arg 325 330 335 Ser Ser Ile Asn Asp Lys Ile Ile Glu Leu Lys Asp Leu Val Val Gly 340 345 350 Thr Glu Ala Lys Leu Asn Lys Ser Ala Val Leu Arg Lys Ala Ile Asp 355 360 365 Tyr Ile Arg Phe Leu Gln His Ser Asn Gln Lys Leu Lys Gln Glu Asn 370 375 380 Leu Ser Leu Arg Thr Ala Val His Lys Ser Lys Ser Leu Lys Asp Leu 385 390 395 400 Val Ser Ala Cys Gly Ser Gly Gly Asn Thr Asp Val Leu Met Glu Gly 405 410 415 Val Lys Thr Glu Val Glu Asp Thr Leu Thr Pro Pro Pro Ser Asp Ala 420 425 430 Gly Ser Pro Phe Gln Ser Ser Pro Leu Ser Leu Gly Ser Arg Gly Ser 435 440 445 Gly Ser Gly Gly Ser Gly Ser Asp Ser Glu Pro Asp Ser Pro Val Phe 450 455 460 Glu Asp Ser Lys Ala Lys Pro Glu Gln Arg Pro Ser Leu His Ser Arg 465 470 475 480 Gly Met Leu Asp Arg Ser Arg Leu Ala Leu Cys Thr Leu Val Phe Leu 485 490 495 Cys Leu Ser Cys Asn Pro Leu Ala Ser Leu Leu Gly Ala Arg Gly Leu 500 505 510 Pro Ser Pro Ser Asp Thr Thr Ser Val Tyr His Ser Pro Gly Arg Asn 515 520 525 Val Leu Gly Thr Glu Ser Arg Asp Gly Pro Gly Trp Ala Gln Trp Leu 530 535 540 Leu Pro Pro Val Val Trp Leu Leu Asn Gly Leu Leu Val Leu Val Ser 545 550 555 560 Leu Val Leu Leu Phe Val Tyr Gly Glu Pro Val Thr Arg Pro His Ser 565 570 575 Gly Pro Ala Val Tyr Phe Trp Arg His Arg Lys Gln Ala Asp Leu Asp 580 585 590 Leu Ala Arg Gly Asp Phe Ala Gln Ala Ala Gln Gln Leu Trp Leu Ala 595 600 605 Leu Arg Ala Leu Gly Arg Pro Leu Pro Thr Ser His Leu Asp Leu Ala 610 615 620 Cys Ser Leu Leu Trp Asn Leu Ile Arg His Leu Leu Gln Arg Leu Trp 625 630 635 640 Val Gly Arg Trp Leu Ala Gly Arg Ala Gly Gly Leu Gln Gln Asp Cys 645 650 655 Ala Leu Arg Val Asp Ala Ser Ala Ser Ala Arg Asp Ala Ala Leu Val 660 665 670 Tyr His Lys Leu His Gln Leu His Thr Met Gly Lys His Thr Gly Gly 675 680 685 His Leu Thr Ala Thr Asn Leu Ala Leu Ser Ala Leu Asn Leu Ala Glu 690 695 700 Cys Ala Gly Asp Ala Val Ser Val Ala Thr Leu Ala Glu Ile Tyr Val 705 710 715 720 Ala Ala Ala Leu Arg Val Lys Thr Ser Leu Pro Arg Ala Leu His Phe 725 730 735 Leu Thr Arg Phe Phe Leu Ser Ser Ala Arg Gln Ala Cys Leu Ala Gln 740 745 750 Ser Gly Ser Val Pro Pro Ala Met Gln Trp Leu Cys His Pro Val Gly 755 760 765 His Arg Phe Phe Val Asp Gly Asp Trp Ser Val Leu Ser Thr Pro Trp 770 775 780 Glu Ser Leu Tyr Ser Leu Ala Gly Asn Pro Val Asp Pro Leu Ala Gln 785 790 795 800 Val Thr Gln Leu Phe Arg Glu His Leu Leu Glu Arg Ala Leu Asn Cys 805 810 815 Val Thr Gln Pro Asn Pro Ser Pro Gly Ser Ala Asp Gly Asp Lys Glu 820 825 830 Phe Ser Asp Ala Leu Gly Tyr Leu Gln Leu Leu Asn Ser Cys Ser Asp 835 840 845 Ala Ala Gly Ala Pro Ala Tyr Ser Phe Ser Ile Ser Ser Ser Met Ala 850 855 860 Thr Thr Thr Gly Val Asp Pro Val Ala Lys Trp Trp Ala Ser Leu Thr 865 870 875 880 Ala Val Val Ile His Trp Leu Arg Arg Asp Glu Glu Ala Ala Glu Arg 885 890 895 Leu Cys Pro Leu Val Glu His Leu Pro Arg Val Leu Gln Glu Ser Glu 900 905 910 Arg Pro Leu Pro Arg Ala Ala Leu His Ser Phe Lys Ala Ala Arg Ala 915 920 925 Leu Leu Gly Cys Ala Lys Ala Glu Ser Gly Pro Ala Ser Leu Thr Ile 930 935 940 Cys Glu Lys Ala Ser Gly Tyr Leu Gln Asp Ser Leu Ala Thr Thr Pro 945 950 955 960 Ala Ser Ser Ser Ile Asp Lys Ala Val Gln Leu Phe Leu Cys Asp Leu 965 970 975 Leu Leu Val Val Arg Thr Ser Leu Trp Arg Gln Gln Gln Pro Pro Ala 980 985 990 Pro Ala Pro Ala Ala Gln Gly Ala Ser Ser Arg Pro Gln Ala Ser Ala 995 1000 1005 Leu Glu Leu Arg Gly Phe Gln Arg Asp Leu Ser Ser Leu Arg Arg 1010 1015 1020 Leu Ala Gln Ser Phe Arg Pro Ala Met Arg Arg Val Phe Leu His 1025 1030 1035 Glu Ala Thr Ala Arg Leu Met Ala Gly Ala Ser Pro Thr Arg Thr 1040 1045 1050 His Gln Leu Leu Asp Arg Ser Leu Arg Arg Arg Ala Gly Pro Gly 1055 1060 1065 Gly Lys Gly Gly Ala Val Ala Glu Leu Glu Pro Arg Pro Thr Arg 1070 1075 1080 Arg Glu His Ala Glu Ala Leu Leu Leu Ala Ser Cys Tyr Leu Pro 1085 1090 1095 Pro Gly Phe Leu Ser Ala Pro Gly Gln Arg Val Gly Met Leu Ala 1100 1105 1110 Glu Ala Ala Arg Thr Leu Glu Lys Leu Gly Asp Arg Arg Leu Leu 1115 1120 1125 His Asp Cys Gln Gln Met Leu Met Arg Leu Gly Gly Gly Thr Thr 1130 1135 1140 Val Thr Ser Ser 1145 7 1470 DNA Homo sapiens 7 gacggtcacc cgttgccagc tctagccttt aaattcccgg ctcggggacc tccacgcacc 60 gcggctagcg ccgacaacca gctagcgtgc aaggcgccgc ggctcagcgc gtaccggcgg 120 gtttcgaaac cgcagtcctc cggcgacccc gaactccgct ccggagcctc agccccctgg 180 aaagtgatcc cggcatcgga gagccaagat gccggcccac ttgctgcagg acgatatctc 240 tagctcctat accaccacca ccaccattac agcgcctcct ccaggggtcc tgcagaatgg 300 aggagataag ttggagacga tgcccctcta cttggaagac gacattcgcc ctgatataaa 360 agatgatata tatgacccca cctacaagga taaggaaggc ccaagcccca aggttgaata 420 tgtctggaga aacatcatcc ttatgtctct gctacacttg ggagccctgt atgggatcac 480 tttgattcct acctgcaagt tctacacctg gctttggggg gtattctact attttgtcag 540 tgccctgggc ataacagcag gagctcatcg tctgtggagc caccgctctt acaaagctcg 600 gctgccccta cggctctttc tgatcattgc caacacaatg gcattccaga atgatgtcta 660 tgaatgggct cgtgaccacc gtgcccacca caagttttca gaaacacatg ctgatcctca 720 taattcccga cgtggctttt tcttctctca cgtgggttgg ctgcttgtgc gcaaacaccc 780 agctgtcaaa gagaagggga gtacgctaga cttgtctgac ctagaagctg agaaactggt 840 gatgttccag aggaggtact acaaacctgg cttgctgatg atgtgcttca tcctgcccac 900 gcttgtgccc tggtatttct ggggtgaaac ttttcaaaac agtgtgttcg ttgccacttt 960 cttgcgatat gctgtggtgc ttaatgccac ctggctggtg aacagtgctg cccacctctt 1020 cggatatcgt ccttatgaca agaacattag cccccgggag aatatcctgg tttcacttgg 1080 agctgtgggt gagggcttcc acaactacca ccactccttt ccctatgact actctgccag 1140 tgagtaccgc tggcacatca acttcaacac attcttcatt gattggatgg ccgccctcgg 1200 tctgacctat gaccggaaga aagtctccaa ggccgccatc ttggccagga ttaaaagaac 1260 cggagatgga aactacaaga gtggctgagt ttggggtccc tcaggttcct ttttcaaaaa 1320 ccagccaggc agaggtttta atgtctgttt attaactact gaataatgct accaggatgc 1380 taaagatgat gatgttaacc cattccagta cagtattctt ttaaaattca aaagtattga 1440 aagccaaaaa aaaaaaaaaa aaaaaaaaaa 1470 8 359 PRT Homo sapiens 8 Met Pro Ala His Leu Leu Gln Asp Asp Ile Ser Ser Ser Tyr Thr Thr 1 5 10 15 Thr Thr Thr Ile Thr Ala Pro Pro Pro Gly Val Leu Gln Asn Gly Gly 20 25 30 Asp Lys Leu Glu Thr Met Pro Leu Tyr Leu Glu Asp Asp Ile Arg Pro 35 40 45 Asp Ile Lys Asp Asp Ile Tyr Asp Pro Thr Tyr Lys Asp Lys Glu Gly 50 55 60 Pro Ser Pro Lys Val Glu Tyr Val Trp Arg Asn Ile Ile Leu Met Ser 65 70 75 80 Leu Leu His Leu Gly Ala Leu Tyr Gly Ile Thr Leu Ile Pro Thr Cys 85 90 95 Lys Phe Tyr Thr Trp Leu Trp Gly Val Phe Tyr Tyr Phe Val Ser Ala 100 105 110 Leu Gly Ile Thr Ala Gly Ala His Arg Leu Trp Ser His Arg Ser Tyr 115 120 125 Lys Ala Arg Leu Pro Leu Arg Leu Phe Leu Ile Ile Ala Asn Thr Met 130 135 140 Ala Phe Gln Asn Asp Val Tyr Glu Trp Ala Arg Asp His Arg Ala His 145 150 155 160 His Lys Phe Ser Glu Thr His Ala Asp Pro His Asn Ser Arg Arg Gly 165 170 175 Phe Phe Phe Ser His Val Gly Trp Leu Leu Val Arg Lys His Pro Ala 180 185 190 Val Lys Glu Lys Gly Ser Thr Leu Asp Leu Ser Asp Leu Glu Ala Glu 195 200 205 Lys Leu Val Met Phe Gln Arg Arg Tyr Tyr Lys Pro Gly Leu Leu Met 210 215 220 Met Cys Phe Ile Leu Pro Thr Leu Val Pro Trp Tyr Phe Trp Gly Glu 225 230 235 240 Thr Phe Gln Asn Ser Val Phe Val Ala Thr Phe Leu Arg Tyr Ala Val 245 250 255 Val Leu Asn Ala Thr Trp Leu Val Asn Ser Ala Ala His Leu Phe Gly 260 265 270 Tyr Arg Pro Tyr Asp Lys Asn Ile Ser Pro Arg Glu Asn Ile Leu Val 275 280 285 Ser Leu Gly Ala Val Gly Glu Gly Phe His Asn Tyr His His Ser Phe 290 295 300 Pro Tyr Asp Tyr Ser Ala Ser Glu Tyr Arg Trp His Ile Asn Phe Asn 305 310 315 320 Thr Phe Phe Ile Asp Trp Met Ala Ala Leu Gly Leu Thr Tyr Asp Arg 325 330 335 Lys Lys Val Ser Lys Ala Ala Ile Leu Ala Arg Ile Lys Arg Thr Gly 340 345 350 Asp Gly Asn Tyr Lys Ser Gly 355 9 2930 DNA Homo sapiens 9 gaattccggt ttcttcctaa aaaatgtctg atggccgctt tctcggtcgg caccgccatg 60 aatgccagca gttactctgc agagatgacg gagcccaagt cggtgtgtgt ctcggtggat 120 gaggtggtgt ccagcaacat ggaggccact gagacggacc tgctgaatgg acatctgaaa 180 aaagtagata ataacctcac ggaagcccag cgcttctcct ccttgcctcg gagggcagct 240 gtgaacattg aattcaggga cctttcctat tcggttcctg aaggaccctg gtggaggaag 300 aaaggataca agaccctcct gaaaggaatt tccgggaagt tcaatagtgg tgagttggtg 360 gccattatgg gtccttccgg ggccgggaag tccacgctga tgaacatcct ggctggatac 420 agggagacgg gcatgaaggg ggccgtcctc atcaacggcc tgccccggga cctgcgctgc 480 ttccggaagg tgtcctgcta catcatgcag gatgacatgc tgctgccgca tctcactgtg 540 caggaggcca tgatggtgtc ggcacatctg aagcttcagg agaaggatga aggcagaagg 600 gaaatggtca aggagatact gacagcgctg ggcttgctgt cttgcgccaa cacgcggacc 660 gggagcctgt caggtggtca gcgcaagcgc ctggccatcg cgctggagct ggtgaacaac 720 cctccagtca tgttcttcga tgagcccacc agcggcctgg acagcgcctc ctgcttccag 780 gtggtctcgc tgatgaaagg gctcgctcaa gggggtcgct ccatcatttg caccatccac 840 cagcccagcg ccaaactctt cgagctgttc gaccagcttt acgtcctgag tcaaggacaa 900 tgtgtgtacc ggggaaaagt ctgcaatctt gtgccatatt tgagggattt gggtctgaac 960 tgcccaacct accacaaccc agcagatttt gtcatggagg ttgcatccgg cgagtacggt 1020 gatcagaaca gtcggctggt gagagcggtt cgggagggca tgtgtgactc agaccacaag 1080 agagacctcg ggggtgatgc cgaggtgaac ccttttcttt ggcaccgccc ctctgaagag 1140 gtaaagcaga caaaacgatt aaaggggttg agaaaggact cctcgtccat ggaaggctgc 1200 cacagcttct ctgccagctg cctcacgcag ttctgcatcc tcttcaagag gaccttcctc 1260 agcatcatga gggactcggt cctgacacac ctgcgcatca cctcgcacat tgggatcggc 1320 ctcctcattg gcctgctgta cttggggatc gggaacgaaa ccaagaaggt cttgagcaac 1380 tccggcttcc tcttcttctc catgctgttc ctcatgttcg cggccctcat gcctactgtt 1440 ctgacatttc ccctggagat gggagtcttt cttcgggaac acctgaacta ctggtacagc 1500 ctgaaggcct actacctggc caagaccatg gcagacgtgc cctttcagat catgttccca 1560 gtggcctact gcagcatcgt gtactggatg acgtcgcagc cgtccgacgc cgtgcgcttt 1620 gtgctgtttg ccgcgctggg caccatgacc tccctggtgg cacagtccct gggcctgctg 1680 atcggagccg cctccacgtc cctgcaggtg gccactttcg tgggcccagt gacagccatc 1740 ccggtgctcc tgttctcggg gttcttcgtc agcttcgaca ccatccccac gtacctacag 1800 tggatgtcct acatctccta tgtcaggtat gggttcgaag gggtcatcct ctccatctat 1860 ggcttagacc gggaagatct gcactgtgac atcgacgaga cgtgccactt ccagaagtcg 1920 gaggccatcc tgcgggagct ggacgtggaa aatgccaagc tgtacctgga cttcatcgta 1980 ctcgggattt tcttcatctc cctccgcctc attgcctatt tggtcctcag gtacaaaatc 2040 cgggcagaga ggtaaaacac ctgaatgcca ggaaacagga agattagaca ctgtggccga 2100 gggcacgtct agaatcgagg aggcaagcct gtgcccgacc gacgacacag agactcttct 2160 gatccaaccc ctagaaccgc gttgggtttg tgggtgtctc gtgctcagcc actctgccca 2220 gctgggttgg atcttctctc cattcccctt tctagcttta actaggaaga tgtaggcaga 2280 ttggtggttt tttttttttt tttaacatac agaattttaa ataccacaac tggggcagaa 2340 tttaaagctg caacacagct ggtgatgaga ggcttcctca gtccagtcgc tccttagcac 2400 caggcaccgt gggtcctgga tggggaactg caagcagcct ctcagctgat ggctgcacag 2460 tcagatgtct ggtggcagag agtccgagca tggagcgatt ccattttatg actgttgttt 2520 ttcacatttt catctttcta aggtgtgtct cttttccaat gagaagtcat ttttgcaagc 2580 caaaagtcga tcaatcgcat tcattttaag aaattatacc tttttagtac ttgctgaaga 2640 atgattcagg gtaaatcaca tactttgttt agagaggcga ggggtttaac ccgagtcacc 2700 cagctggtct catacataga cagcacttgt gaaggattga atgcaggttc caggtggagg 2760 gaagacgtgg acaccatctc cactgagcca tgcagacatt tttaaaagct atacacaaaa 2820 ttgtgagaag acattggcca actctttcaa agtctttctt tttccacgtg cttcttattt 2880 taagcgaaat atattgtttg tttcttccta aaaaaaaaaa aaaaaaaaaa 2930 10 674 PRT Homo sapiens 10 Met Ala Ala Phe Ser Val Gly Thr Ala Met Asn Ala Ser Ser Tyr Ser 1 5 10 15 Ala Glu Met Thr Glu Pro Lys Ser Val Cys Val Ser Val Asp Glu Val 20 25 30 Val Ser Ser Asn Met Glu Ala Thr Glu Thr Asp Leu Leu Asn Gly His 35 40 45 Leu Lys Lys Val Asp Asn Asn Leu Thr Glu Ala Gln Arg Phe Ser Ser 50 55 60 Leu Pro Arg Arg Ala Ala Val Asn Ile Glu Phe Arg Asp Leu Ser Tyr 65 70 75 80 Ser Val Pro Glu Gly Pro Trp Trp Arg Lys Lys Gly Tyr Lys Thr Leu 85 90 95 Leu Lys Gly Ile Ser Gly Lys Phe Asn Ser Gly Glu Leu Val Ala Ile 100 105 110 Met Gly Pro Ser Gly Ala Gly Lys Ser Thr Leu Met Asn Ile Leu Ala 115 120 125 Gly Tyr Arg Glu Thr Gly Met Lys Gly Ala Val Leu Ile Asn Gly Leu 130 135 140 Pro Arg Asp Leu Arg Cys Phe Arg Lys Val Ser Cys Tyr Ile Met Gln 145 150 155 160 Asp Asp Met Leu Leu Pro His Leu Thr Val Gln Glu Ala Met Met Val 165 170 175 Ser Ala His Leu Lys Leu Gln Glu Lys Asp Glu Gly Arg Arg Glu Met 180 185 190 Val Lys Glu Ile Leu Thr Ala Leu Gly Leu Leu Ser Cys Ala Asn Thr 195 200 205 Arg Thr Gly Ser Leu Ser Gly Gly Gln Arg Lys Arg Leu Ala Ile Ala 210 215 220 Leu Glu Leu Val Asn Asn Pro Pro Val Met Phe Phe Asp Glu Pro Thr 225 230 235 240 Ser Gly Leu Asp Ser Ala Ser Cys Phe Gln Val Val Ser Leu Met Lys 245 250 255 Gly Leu Ala Gln Gly Gly Arg Ser Ile Ile Cys Thr Ile His Gln Pro 260 265 270 Ser Ala Lys Leu Phe Glu Leu Phe Asp Gln Leu Tyr Val Leu Ser Gln 275 280 285 Gly Gln Cys Val Tyr Arg Gly Lys Val Cys Asn Leu Val Pro Tyr Leu 290 295 300 Arg Asp Leu Gly Leu Asn Cys Pro Thr Tyr His Asn Pro Ala Asp Phe 305 310 315 320 Val Met Glu Val Ala Ser Gly Glu Tyr Gly Asp Gln Asn Ser Arg Leu 325 330 335 Val Arg Ala Val Arg Glu Gly Met Cys Asp Ser Asp His Lys Arg Asp 340 345 350 Leu Gly Gly Asp Ala Glu Val Asn Pro Phe Leu Trp His Arg Pro Ser 355 360 365 Glu Glu Val Lys Gln Thr Lys Arg Leu Lys Gly Leu Arg Lys Asp Ser 370 375 380 Ser Ser Met Glu Gly Cys His Ser Phe Ser Ala Ser Cys Leu Thr Gln 385 390 395 400 Phe Cys Ile Leu Phe Lys Arg Thr Phe Leu Ser Ile Met Arg Asp Ser 405 410 415 Val Leu Thr His Leu Arg Ile Thr Ser His Ile Gly Ile Gly Leu Leu 420 425 430 Ile Gly Leu Leu Tyr Leu Gly Ile Gly Asn Glu Thr Lys Lys Val Leu 435 440 445 Ser Asn Ser Gly Phe Leu Phe Phe Ser Met Leu Phe Leu Met Phe Ala 450 455 460 Ala Leu Met Pro Thr Val Leu Thr Phe Pro Leu Glu Met Gly Val Phe 465 470 475 480 Leu Arg Glu His Leu Asn Tyr Trp Tyr Ser Leu Lys Ala Tyr Tyr Leu 485 490 495 Ala Lys Thr Met Ala Asp Val Pro Phe Gln Ile Met Phe Pro Val Ala 500 505 510 Tyr Cys Ser Ile Val Tyr Trp Met Thr Ser Gln Pro Ser Asp Ala Val 515 520 525 Arg Phe Val Leu Phe Ala Ala Leu Gly Thr Met Thr Ser Leu Val Ala 530 535 540 Gln Ser Leu Gly Leu Leu Ile Gly Ala Ala Ser Thr Ser Leu Gln Val 545 550 555 560 Ala Thr Phe Val Gly Pro Val Thr Ala Ile Pro Val Leu Leu Phe Ser 565 570 575 Gly Phe Phe Val Ser Phe Asp Thr Ile Pro Thr Tyr Leu Gln Trp Met 580 585 590 Ser Tyr Ile Ser Tyr Val Arg Tyr Gly Phe Glu Gly Val Ile Leu Ser 595 600 605 Ile Tyr Gly Leu Asp Arg Glu Asp Leu His Cys Asp Ile Asp Glu Thr 610 615 620 Cys His Phe Gln Lys Ser Glu Ala Ile Leu Arg Glu Leu Asp Val Glu 625 630 635 640 Asn Ala Lys Leu Tyr Leu Asp Phe Ile Val Leu Gly Ile Phe Phe Ile 645 650 655 Ser Leu Arg Leu Ile Ala Tyr Leu Val Leu Arg Tyr Lys Ile Arg Ala 660 665 670 Glu Arg 11 1528 DNA Homo sapiens 11 cagtgccttg gtaatgacca gggctccaga aagagatgtc cttgtggctg ggggcccctg 60 tgcctgacat tcctcctgac tctgcggtgg agctgtggaa gccaggcgca caggatgcaa 120 gcagccaggc ccagggaggc agcagctgca tcctcagaga ggaagccagg atgccccact 180 ctgctggggg tactgcaggg gtggggctgg aggctgcaga gcccacagcc ctgctcacca 240 gggcagagcc cccttcagaa cccacagaga tccgtccaca aaagcggaaa aaggggccag 300 cccccaaaat gctggggaac gagctatgca gcgtgtgtgg ggacaaggcc tcgggcttcc 360 actacaatgt tctgagctgc gagggctgca agggattctt ccgccgcagc gtcatcaagg 420 gagcgcacta catctgccac agtggcggcc actgccccat ggacacctac atgcgtcgca 480 agtgccagga gtgtcggctt cgcaaatgcc gtcaggctgg catgcgggag gagtgtgtcc 540 tgtcagaaga acagatccgc ctgaagaaac tgaagcggca agaggaggaa caggctcatg 600 ccacatcctt gccccccagg cgttcctcac ccccccaaat cctgccccag ctcagcccgg 660 aacaactggg catgatcgag aagctcgtcg ctgcccagca acagtgtaac cggcgctcct 720 tttctgaccg gcttcgagtc acgccttggc ccatggcacc agatccccat agccgggagg 780 cccgtcagca gcgctttgcc cacttcactg agctggccat cgtctctgtg caggagatag 840 ttgactttgc taaacagcta cccggcttcc tgcagctcag ccgggaggac cagattgccc 900 tgctgaagac ctctgcgatc gaggtgatgc ttctggagac atctcggagg tacaaccctg 960 ggagtgagag tatcaccttc ctcaaggatt tcagttataa ccgggaagac tttgccaaag 1020 cagggctgca agtggaattc atcaacccca tcttcgagtt ctccagggcc atgaatgagc 1080 tgcaactcaa tgatgccgag tttgccttgc tcattgctat cagcatcttc tctgcagacc 1140 ggcccaacgt gcaggaccag ctccaggtgg agaggctgca gcacacatat gtggaagccc 1200 tgcatgccta cgtctccatc caccatcccc atgaccgact gatgttccca cggatgctaa 1260 tgaaactggt gagcctccgg accctgagca gcgtccactc agagcaagtg tttgcactgc 1320 gtctgcagga caaaaagctc ccaccgctgc tctctgagat ctgggatgtg cacgaatgac 1380 tgttctgtcc ccatattttc tgttttcttg gccggatggc tgaggcctgg tggctgcctc 1440 ctagaagtgg aacagactga gaagggcaaa cattcctggg agctgggcaa ggagatcctc 1500 ccgtggcatt aaaagagagt caaagggt 1528 12 447 PRT Homo sapiens 12 Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser 1 5 10 15 Ala Val Glu Leu Trp Lys Pro Gly Ala Gln Asp Ala Ser Ser Gln Ala 20 25 30 Gln Gly Gly Ser Ser Cys Ile Leu Arg Glu Glu Ala Arg Met Pro His 35 40 45 Ser Ala Gly Gly Thr Ala Gly Val Gly Leu Glu Ala Ala Glu Pro Thr 50 55 60 Ala Leu Leu Thr Arg Ala Glu Pro Pro Ser Glu Pro Thr Glu Ile Arg 65 70 75 80 Pro Gln Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly Asn Glu 85 90 95 Leu Cys Ser Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn Val 100 105 110 Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Ile Lys 115 120 125 Gly Ala His Tyr Ile Cys His Ser Gly Gly His Cys Pro Met Asp Thr 130 135 140 Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Arg Lys Cys Arg Gln 145 150 155 160 Ala Gly Met Arg Glu Glu Cys Val Leu Ser Glu Glu Gln Ile Arg Leu 165 170 175 Lys Lys Leu Lys Arg Gln Glu Glu Glu Gln Ala His Ala Thr Ser Leu 180 185 190 Pro Pro Arg Arg Ser Ser Pro Pro Gln Ile Leu Pro Gln Leu Ser Pro 195 200 205 Glu Gln Leu Gly Met Ile Glu Lys Leu Val Ala Ala Gln Gln Gln Cys 210 215 220 Asn Arg Arg Ser Phe Ser Asp Arg Leu Arg Val Thr Pro Trp Pro Met 225 230 235 240 Ala Pro Asp Pro His Ser Arg Glu Ala Arg Gln Gln Arg Phe Ala His 245 250 255 Phe Thr Glu Leu Ala Ile Val Ser Val Gln Glu Ile Val Asp Phe Ala 260 265 270 Lys Gln Leu Pro Gly Phe Leu Gln Leu Ser Arg Glu Asp Gln Ile Ala 275 280 285 Leu Leu Lys Thr Ser Ala Ile Glu Val Met Leu Leu Glu Thr Ser Arg 290 295 300 Arg Tyr Asn Pro Gly Ser Glu Ser Ile Thr Phe Leu Lys Asp Phe Ser 305 310 315 320 Tyr Asn Arg Glu Asp Phe Ala Lys Ala Gly Leu Gln Val Glu Phe Ile 325 330 335 Asn Pro Ile Phe Glu Phe Ser Arg Ala Met Asn Glu Leu Gln Leu Asn 340 345 350 Asp Ala Glu Phe Ala Leu Leu Ile Ala Ile Ser Ile Phe Ser Ala Asp 355 360 365 Arg Pro Asn Val Gln Asp Gln Leu Gln Val Glu Arg Leu Gln His Thr 370 375 380 Tyr Val Glu Ala Leu His Ala Tyr Val Ser Ile His His Pro His Asp 385 390 395 400 Arg Leu Met Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr 405 410 415 Leu Ser Ser Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp 420 425 430 Lys Lys Leu Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu 435 440 445 13 3188 DNA Homo sapiens 13 cgggcagtga cagccggcgc ggatcgcgcg tccacggagg agaatcagct tagagaacta 60 tcaacacagg acaatgcaag cccatgagct gttccggtat tttcgaatgc cagagctggt 120 tgacttccga cagtgcgtga ctcttccgac caacacgctt atgggcttcg gagctttttc 180 cagacgactc accaccttct ggcggccacg ccacccaaaa cccctgaagc cgccatggca 240 cctctccatg cagtcagtgg aagtggcggg tagtggtggt gcacgaagat ccgcactact 300 tgacagcgac gagcccttgg tgtatttcta tgatgatgtt acaacattat acgaaggttt 360 ccagagaggg atacaggtgt caaataatgg cccttgttta ggctctcgga aaccagacca 420 accctatgaa tggctttcat ataaacaggt tgcagaattg tcggagtgca taggctcagc 480 actgatccag aagggcttca agactgcccc agatcagttc attggcatct ttgctcaaaa 540 tagacctgag tgggtgatta ttgaacaagg atgctttgct tattcgatgg tgatcgttcc 600 actttatgat acccttggaa atgaagccat cacgtacata gtcaacaaag ctgaactctc 660 tctggttttt gttgacaagc cagagaaggc caaactctta ttagagggtg tagaaaataa 720 gttaatacca ggccttaaaa tcatagttgt catggactcg tacggcagtg aactggtgga 780 acgaggccag aggtgtgggg tggaagtcac cagcatgaag gcgatggagg acctgggaag 840 agccaacaga cggaagccca agcctccagc acctgaagat cttgcagtaa tttgtttcac 900 aagtggaact acaggcaacc ccaaaggagc aatggtcact caccgaaaca tagtgagcga 960 ttgttcagct tttgtgaaag caacagagaa tacagtcaat ccttgcccag atgatacttt 1020 gatatctttc ttgcctctcg cccatatgtt tgagagagtt gtagagtgtg taatgctgtg 1080 tcatggagct aaaatcggat ttttccaagg agatatcagg ctgctcatgg atgacctcaa 1140 ggtgcttcaa cccactgtct tccccgtggt tccaagactg ctgaaccgga tgtttgaccg 1200 aattttcgga caagcaaaca ccaccgtgaa gcgatggctc ttggactttg cctccaagag 1260 gaaagaagca gacgttcgca gcggcatcat cagaaacaac agcctgtggg accggctgat 1320 cttccacaaa gtacagtcga gcctgggcgg aagagtccgg ctgatggtga caggagccgc 1380 cccggtgtct gccactgtgc tgacgttcct cagagcagcc ctgggctgtc agttttatga 1440 aggatacgga cagacagagt gcactgccgg gtgctgccta accatgcctg gagactggac 1500 cacaggccat gttggggccc cgatgccgtg caatttgata aaacttggtt ggcagttgga 1560 agaaatgaat tacatggcgt ccgagggcga gggcgaggtg tgtgtgaaag ggccaaatgt 1620 atttcagggc tacttgaagg acccagcgaa aacagcagaa gctttggaca aagacggctg 1680 gttacacaca ggggacatcg gaaaatggtt accaaatggc accttgaaaa ttatcgaccg 1740 gaaaaagcac atatttaagc tggcacaagg agaatacata gcccctgaaa agattgaaaa 1800 tatctacatg cgaagtgagc ctgttgctca ggtgtttgtc cacggagaaa gcctgcaggc 1860 atttctcatt gcaattgtgg taccagatgt tgagacatta tgttcctggg cccaaaagag 1920 aggatttgaa gggtcgtttg aggaactgtg cagaaataag gatgtcaaaa aagctatcct 1980 cgaagatatg gtgagacttg ggaaggattc tggtctgaaa ccatttgaac aggtcaaagg 2040 catcacattg caccctgaat tattttctat cgacaatggc cttctgactc caacaatgaa 2100 ggcgaaaagg ccagagctgc ggaactattt caggtcgcag atagatgacc tctattccat 2160 catcaaggtt tagtgtgaag aagaaagctc agaggaaatg gcacagttcc acaatctctt 2220 ctcctgctga tggccttcat gttgttaatt ttgaatacag caagtgtagg gaaggaagcg 2280 ttctgtgttt gacttgtcca ttcggggttc ttctcatagg aatgctagag gaaacagaac 2340 actgccttac agtcacctca gtgttcagac catgtttatg gtaatacaca cttccaaaag 2400 tagccttaaa aattgtaaag ggatactata aatgtgctaa ttatttgaga cttcctcagt 2460 ttaaaaagtg ggttttaaat cttctgtctc cctgtttttc taatcaaggg gttaggactt 2520 tgctatctct gagatgtctg ctacttcgtc gaaattctgc agctgtctgc tgctctaaag 2580 agtacagtgc tctagaggga agtgttccct ttaaaaataa gaacaactgt cctggctgga 2640 gatctcacaa gcggaccaga gatcttttta aatccctgct actgtccctt ctcacaggca 2700 ttcacagaac ccttctgatt cgaagggtta cgaaactcat gttcttctcc agtcccctgt 2760 ggtttctgtt ggagcataag gtttccagta agcgggaggg cagatccaac tcagaaccat 2820 gcagataagg agcctctggc aaatgggtgc tgcatcagaa cgcgtggatt ctctttcatg 2880 gcagatgctc ttggactcgg ttctccaggc ctgattcccc gactccatcc tttttcaggg 2940 ttatttaaaa atctgcctta gattctatag tgaagacaag catttcaaga aagagttacc 3000 tggatcagcc atgctcagct gtgacgcctg ataactgtct actttatctt cactgaacca 3060 ctcactctgt gtaaaggcca acggattttt aatgtggttt tcatatcaaa agatcatgtt 3120 gggattaact tgcctttttc cccaaaaaat aaactctcag gcaaggcatt tcttttaaag 3180 ctattccg 3188 14 699 PRT Homo sapiens 14 Met Gln Ala His Glu Leu Phe Arg Tyr Phe Arg Met Pro Glu Leu Val 1 5 10 15 Asp Phe Arg Gln Cys Val Thr Leu Pro Thr Asn Thr Leu Met Gly Phe 20 25 30 Gly Ala Phe Ser Arg Arg Leu Thr Thr Phe Trp Arg Pro Arg His Pro 35 40 45 Lys Pro Leu Lys Pro Pro Trp His Leu Ser Met Gln Ser Val Glu Val 50 55 60 Ala Gly Ser Gly Gly Ala Arg Arg Ser Ala Leu Leu Asp Ser Asp Glu 65 70 75 80 Pro Leu Val Tyr Phe Tyr Asp Asp Val Thr Thr Leu Tyr Glu Gly Phe 85 90 95 Gln Arg Gly Ile Gln Val Ser Asn Asn Gly Pro Cys Leu Gly Ser Arg 100 105 110 Lys Pro Asp Gln Pro Tyr Glu Trp Leu Ser Tyr Lys Gln Val Ala Glu 115 120 125 Leu Ser Glu Cys Ile Gly Ser Ala Leu Ile Gln Lys Gly Phe Lys Thr 130 135 140 Ala Pro Asp Gln Phe Ile Gly Ile Phe Ala Gln Asn Arg Pro Glu Trp 145 150 155 160 Val Ile Ile Glu Gln Gly Cys Phe Ala Tyr Ser Met Val Ile Val Pro 165 170 175 Leu Tyr Asp Thr Leu Gly Asn Glu Ala Ile Thr Tyr Ile Val Asn Lys 180 185 190 Ala Glu Leu Ser Leu Val Phe Val Asp Lys Pro Glu Lys Ala Lys Leu 195 200 205 Leu Leu Glu Gly Val Glu Asn Lys Leu Ile Pro Gly Leu Lys Ile Ile 210 215 220 Val Val Met Asp Ser Tyr Gly Ser Glu Leu Val Glu Arg Gly Gln Arg 225 230 235 240 Cys Gly Val Glu Val Thr Ser Met Lys Ala Met Glu Asp Leu Gly Arg 245 250 255 Ala Asn Arg Arg Lys Pro Lys Pro Pro Ala Pro Glu Asp Leu Ala Val 260 265 270 Ile Cys Phe Thr Ser Gly Thr Thr Gly Asn Pro Lys Gly Ala Met Val 275 280 285 Thr His Arg Asn Ile Val Ser Asp Cys Ser Ala Phe Val Lys Ala Thr 290 295 300 Glu Asn Thr Val Asn Pro Cys Pro Asp Asp Thr Leu Ile Ser Phe Leu 305 310 315 320 Pro Leu Ala His Met Phe Glu Arg Val Val Glu Cys Val Met Leu Cys 325 330 335 His Gly Ala Lys Ile Gly Phe Phe Gln Gly Asp Ile Arg Leu Leu Met 340 345 350 Asp Asp Leu Lys Val Leu Gln Pro Thr Val Phe Pro Val Val Pro Arg 355 360 365 Leu Leu Asn Arg Met Phe Asp Arg Ile Phe Gly Gln Ala Asn Thr Thr 370 375 380 Val Lys Arg Trp Leu Leu Asp Phe Ala Ser Lys Arg Lys Glu Ala Asp 385 390 395 400 Val Arg Ser Gly Ile Ile Arg Asn Asn Ser Leu Trp Asp Arg Leu Ile 405 410 415 Phe His Lys Val Gln Ser Ser Leu Gly Gly Arg Val Arg Leu Met Val 420 425 430 Thr Gly Ala Ala Pro Val Ser Ala Thr Val Leu Thr Phe Leu Arg Ala 435 440 445 Ala Leu Gly Cys Gln Phe Tyr Glu Gly Tyr Gly Gln Thr Glu Cys Thr 450 455 460 Ala Gly Cys Cys Leu Thr Met Pro Gly Asp Trp Thr Thr Gly His Val 465 470 475 480 Gly Ala Pro Met Pro Cys Asn Leu Ile Lys Leu Gly Trp Gln Leu Glu 485 490 495 Glu Met Asn Tyr Met Ala Ser Glu Gly Glu Gly Glu Val Cys Val Lys 500 505 510 Gly Pro Asn Val Phe Gln Gly Tyr Leu Lys Asp Pro Ala Lys Thr Ala 515 520 525 Glu Ala Leu Asp Lys Asp Gly Trp Leu His Thr Gly Asp Ile Gly Lys 530 535 540 Trp Leu Pro Asn Gly Thr Leu Lys Ile Ile Asp Arg Lys Lys His Ile 545 550 555 560 Phe Lys Leu Ala Gln Gly Glu Tyr Ile Ala Pro Glu Lys Ile Glu Asn 565 570 575 Ile Tyr Met Arg Ser Glu Pro Val Ala Gln Val Phe Val His Gly Glu 580 585 590 Ser Leu Gln Ala Phe Leu Ile Ala Ile Val Val Pro Asp Val Glu Thr 595 600 605 Leu Cys Ser Trp Ala Gln Lys Arg Gly Phe Glu Gly Ser Phe Glu Glu 610 615 620 Leu Cys Arg Asn Lys Asp Val Lys Lys Ala Ile Leu Glu Asp Met Val 625 630 635 640 Arg Leu Gly Lys Asp Ser Gly Leu Lys Pro Phe Glu Gln Val Lys Gly 645 650 655 Ile Thr Leu His Pro Glu Leu Phe Ser Ile Asp Asn Gly Leu Leu Thr 660 665 670 Pro Thr Met Lys Ala Lys Arg Pro Glu Leu Arg Asn Tyr Phe Arg Ser 675 680 685 Gln Ile Asp Asp Leu Tyr Ser Ile Ile Lys Val 690 695 15 3634 DNA Homo sapiens 15 tcaacacagg acaatgcaag cccatgagct gttccggtat tttcgaatgc cagagctggt 60 tgacttccga cagtacgtgc gtactcttcc gaccaacacg cttatgggct tcggagcttt 120 tgcagcactc accaccttct ggtacgccac gagacccaaa cccctgaagc cgccatgcga 180 cctctccatg cagtcagtgg aagtggcggg tagtggtggt gcacgaagat ccgcactact 240 tgacagcgac gagcccttgg tgtatttcta tgatgatgtc acaacattat acgaaggttt 300 ccagagggga atacaggtgt caaataatgg cccttgttta ggctctcgga aaccagacca 360 accctatgaa tggctttcat ataaacaggt tgcagaattg tcggagtgca taggctcagc 420 actgatccag aagggcttca agactgcccc agatcagttc attggcatct ttgctcaaaa 480 tagacctgag tgggtgatta ttgaacaagg atgctttgct tattcgatgg tgatcgttcc 540 actttatgat acccttggaa atgaagccat cacgtacata gtcaacaaag ctgaactctc 600 tctggttttt gttgacaagc cagagaaggc caaactctta ttagagggtg tagaaaataa 660 gttaatacca ggccttaaaa tcatagttgt catggatgcc tacggcagtg aactggtgga 720 acgaggccag aggtgtgggg tggaagtcac cagcatgaag gcgatggagg acctgggaag 780 agccaacaga cggaagccca agcctccagc acctgaagat cttgcagtaa tttgtttcac 840 aagtggaact acaggcaacc ccaaaggagc aatggtcact caccgaaaca tagtgagcga 900 ttgttcagct tttgtgaaag caacagagaa tacagtcaat ccttgcccag atgatacttt 960 gatatctttc ttgcctctcg cccatatgtt tgagagagtt gtagagtgtg taatgctgtg 1020 tcatggagct aaaatcggat ttttccaagg agatatcagg ctgctcatgg atgacctcaa 1080 ggtgcttcaa cccactgtct tccccgtggt tccaagactg ctgaaccgga tgtttgaccg 1140 aattttcgga caagcaaaca ccacgctgaa gcgatggctc ttggactttg cctccaagag 1200 gaaagaagca gagcttcgca gcggcatcat cagaaacaac agcctgtggg accggctgat 1260 cttccacaaa gtacagtcga gcctgggcgg aagagtccgg ctgatggtga caggagccgc 1320 cccggtgtct gccactgtgc tgacgttcct cagagcagcc ctgggctgtc agttttatga 1380 aggatacgga cagacagagt gcactgccgg gtgctgccta accatgcctg gagactggac 1440 cgcaggccat gttggggccc cgatgccgtg caatttgata aaacttgttg atgtggaaga 1500 aatgaattac atggctgccg agggcgaggg cgaggtgtgt gtgaaagggc caaatgtatt 1560 tcagggctac ttgaaggacc cagcgaaaac agcagaagct ttggacaaag acggctggtt 1620 acacacaggg gacattggaa aatggttacc aaatggcacc ttgaaaatta tcgaccggaa 1680 aaagcacata tttaagctgg cacaaggaga atacatagcc cctgaaaaga ttgaaaatat 1740 ctacatgcga agtgagcctg ttgctcaggt gtttgtccac ggagaaagcc tgcaggcatt 1800 tctcattgca attgtggtac cagatgttga gacattatgt tcctgggccc aaaagagagg 1860 atttgaaggg tcgtttgagg aactgtgcag aaataaggat gtcaaaaaag ctatcctcga 1920 agatatggtg agacttggga aggattctgg tctgaaacca tttgaacagg tcaaaggcat 1980 cacattgcac cctgaattat tttctatcga caatggcctt ctgactccaa caatgaaggc 2040 gaaaaggcca gagctgcgga actatttcag gtcgcagata gatgacctct attccactat 2100 caaggtttag tgtgaagaag aaagctcaga ggaaatggca cagttccaca atctcttctc 2160 ctgctgatgg ccttcatgtt gttaattttg aatacagcaa gtgtagggaa ggaagcgttc 2220 gtgtttgact tgtccattcg gggttcttct cataggaatg ctagaggaaa cagaacaccg 2280 ccttacagtc acctcatgtt gcagaccatg tttatggtaa tacacacttt ccaaaatgag 2340 ccttaaaaat tgtaaagggg atactataaa tgtgctaagt tatttgagac ttcctcagtt 2400 taaaaagtgg gttttaaatc ttctgtctcc ctgcttttct aatcaagggg ttaggacttt 2460 gctatctctg agatgtctgc tacttgctgc aaattctgca gctgtctgct gctctaaaga 2520 gtacagtgca ctagagggaa gtgttccctt taaaaataag aacaactgtc ctggctggag 2580 aatctcacaa gcggaccaga gatcttttta aatccctgct actgtccctt ctcacaggca 2640 ttcacagaac ccttctgatt cgtaagggtt acgaaactca tgttcttctc cagtcccctg 2700 tggtttctgt tggagcataa ggtttccagt aagcgggagg gcagatccaa ctcagaacca 2760 tgcagataag gagcctctgg caaatgggtg ctcatcagaa cgcgtggatt ctctttcatg 2820 gcagaatgct cttggactcg gttctccagg cctgattccc cgactccatc ctttttcagg 2880 ggttatttaa aaatctgcct tagattctat agtgaagaca agcatttcaa gaaagagtta 2940 cctggatcag ccatgctcag ctgtgacgcc tgaataactg tctactttat cttcactgaa 3000 ccactcactc tgtgtaaagg ccaacagatt tttaatgtgg ttttcatatc aaaagatcat 3060 gttgggatta acttgccttt ttccccaaaa aataaactct caggcaagca tttctttaaa 3120 gctattaagg gagtatatac ttgagtactt attgaaatgg acagtaataa gcaaatgttc 3180 ttataatgct acctgatttc tatgaaatgt gtttgacaag ccaaaattct aggatgtaga 3240 aatctggaaa gttcatttcc tgggattcac ttctccaggg attttttaaa gttaatttgg 3300 gaaattaaca gcagttcact ttattgtgag tctttgccac atttgactga attgagctgt 3360 catttgtaca tttaaagcag ctgttttggg gtctgtgaga gtacatgtat tatatacaag 3420 cacaacaggg cttgcactaa agaattgtca ttgtaataac actacttggt agcctaactt 3480 catatatgta ttcttaattg cacaaaaagt caataatttg tcaccttggg gttttgaatg 3540 tttgctttaa gtgttggcta tttctatgtt ttataaacca aaacaaaatt tccaaaaaca 3600 atgaaggaaa ccaaaataaa tatttctgca tttc 3634 16 698 PRT Homo sapiens 16 Met Gln Ala His Glu Leu Phe Arg Tyr Phe Arg Met Pro Glu Leu Val 1 5 10 15 Asp Phe Arg Gln Tyr Val Arg Thr Leu Pro Thr Asn Thr Leu Met Gly 20 25 30 Phe Gly Ala Phe Ala Ala Leu Thr Thr Phe Trp Tyr Ala Thr Arg Pro 35 40 45 Lys Pro Leu Lys Pro Pro Cys Asp Leu Ser Met Gln Ser Val Glu Val 50 55 60 Ala Gly Ser Gly Gly Ala Arg Arg Ser Ala Leu Leu Asp Ser Asp Glu 65 70 75 80 Pro Leu Val Tyr Phe Tyr Asp Asp Val Thr Thr Leu Tyr Glu Gly Phe 85 90 95 Gln Arg Gly Ile Gln Val Ser Asn Asn Gly Pro Cys Leu Gly Ser Arg 100 105 110 Lys Pro Asp Gln Pro Tyr Glu Trp Leu Ser Tyr Lys Gln Val Ala Glu 115 120 125 Leu Ser Glu Cys Ile Gly Ser Ala Leu Ile Gln Lys Gly Phe Lys Thr 130 135 140 Ala Pro Asp Gln Phe Ile Gly Ile Phe Ala Gln Asn Arg Pro Glu Trp 145 150 155 160 Val Ile Ile Glu Gln Gly Cys Phe Ala Tyr Ser Met Val Ile Val Pro 165 170 175 Leu Tyr Asp Thr Leu Gly Asn Glu Ala Ile Thr Tyr Ile Val Asn Lys 180 185 190 Ala Glu Leu Ser Leu Val Phe Val Asp Lys Pro Glu Lys Ala Lys Leu 195 200 205 Leu Leu Glu Gly Val Glu Asn Lys Leu Ile Pro Gly Leu Lys Ile Ile 210 215 220 Val Val Met Asp Ala Tyr Gly Ser Glu Leu Val Glu Arg Gly Gln Arg 225 230 235 240 Cys Gly Val Glu Val Thr Ser Met Lys Ala Met Glu Asp Leu Gly Arg 245 250 255 Ala Asn Arg Arg Lys Pro Lys Pro Pro Ala Pro Glu Asp Leu Ala Val 260 265 270 Ile Cys Phe Thr Ser Gly Thr Thr Gly Asn Pro Lys Gly Ala Met Val 275 280 285 Thr His Arg Asn Ile Val Ser Asp Cys Ser Ala Phe Val Lys Ala Thr 290 295 300 Glu Asn Thr Val Asn Pro Cys Pro Asp Asp Thr Leu Ile Ser Phe Leu 305 310 315 320 Pro Leu Ala His Met Phe Glu Arg Val Val Glu Cys Val Met Leu Cys 325 330 335 His Gly Ala Lys Ile Gly Phe Phe Gln Gly Asp Ile Arg Leu Leu Met 340 345 350 Asp Asp Leu Lys Val Leu Gln Pro Thr Val Phe Pro Val Val Pro Arg 355 360 365 Leu Leu Asn Arg Met Phe Asp Arg Ile Phe Gly Gln Ala Asn Thr Thr 370 375 380 Leu Lys Arg Trp Leu Leu Asp Phe Ala Ser Lys Arg Lys Glu Ala Glu 385 390 395 400 Leu Arg Ser Gly Ile Ile Arg Asn Asn Ser Leu Trp Asp Arg Leu Ile 405 410 415 Phe His Lys Val Gln Ser Ser Leu Gly Gly Arg Val Arg Leu Met Val 420 425 430 Thr Gly Ala Ala Pro Val Ser Ala Thr Val Leu Thr Phe Leu Arg Ala 435 440 445 Ala Leu Gly Cys Gln Phe Tyr Glu Gly Tyr Gly Gln Thr Glu Cys Thr 450 455 460 Ala Gly Cys Cys Leu Thr Met Pro Gly Asp Trp Thr Ala Gly His Val 465 470 475 480 Gly Ala Pro Met Pro Cys Asn Leu Ile Lys Leu Val Asp Val Glu Glu 485 490 495 Met Asn Tyr Met Ala Ala Glu Gly Glu Gly Glu Val Cys Val Lys Gly 500 505 510 Pro Asn Val Phe Gln Gly Tyr Leu Lys Asp Pro Ala Lys Thr Ala Glu 515 520 525 Ala Leu Asp Lys Asp Gly Trp Leu His Thr Gly Asp Ile Gly Lys Trp 530 535 540 Leu Pro Asn Gly Thr Leu Lys Ile Ile Asp Arg Lys Lys His Ile Phe 545 550 555 560 Lys Leu Ala Gln Gly Glu Tyr Ile Ala Pro Glu Lys Ile Glu Asn Ile 565 570 575 Tyr Met Arg Ser Glu Pro Val Ala Gln Val Phe Val His Gly Glu Ser 580 585 590 Leu Gln Ala Phe Leu Ile Ala Ile Val Val Pro Asp Val Glu Thr Leu 595 600 605 Cys Ser Trp Ala Gln Lys Arg Gly Phe Glu Gly Ser Phe Glu Glu Leu 610 615 620 Cys Arg Asn Lys Asp Val Lys Lys Ala Ile Leu Glu Asp Met Val Arg 625 630 635 640 Leu Gly Lys Asp Ser Gly Leu Lys Pro Phe Glu Gln Val Lys Gly Ile 645 650 655 Thr Leu His Pro Glu Leu Phe Ser Ile Asp Asn Gly Leu Leu Thr Pro 660 665 670 Thr Met Lys Ala Lys Arg Pro Glu Leu Arg Asn Tyr Phe Arg Ser Gln 675 680 685 Ile Asp Asp Leu Tyr Ser Thr Ile Lys Val 690 695 17 2905 DNA Homo sapiens 17 gaattcgttg ttgggaagga ctggggaaac agctgtaaca tttgccaccc tcagaagctg 60 ctggtcctgt gtcacaccac cttagcctct tgatcgagga agattctcgc tgaagtctgt 120 taattctact ttttgagtac ttatgaataa ccacgtgtct tcaaaaccat ctaccatgaa 180 gctaaaacat accatcaacc ctattctttt atattttata cattttctaa tatcacttta 240 tactatttta acatacattc cgttttattt tttctccgag tcaagacaag aaaaatcaaa 300 ccgaattaaa gcaaagcctg taaattcaaa acctgattct gcatacagat ctgttaatag 360 tttggatggt ttggcttcag tattataccc tggatgtgat actttagata aagtttttac 420 atatgcaaaa aacaaattta agaacaaaag actcttggga acacgtgaag ttttaaatga 480 ggaagatgaa gtacaaccaa atggaaaaat ttttaaaaag gttattcttg gacagtataa 540 ttggctttcc tatgaagatg tctttgttcg agcctttaat tttggaaatg gattacagat 600 gttgggtcag aaaccaaaga ccaacatcgc catcttctgt gagaccaggg ccgagtggat 660 gatagctgca caggcgtgtt ttatgtataa ttttcagctt gttacattat atgccactct 720 aggaggtcca gccattgttc atgcattaaa tgaaacagag gtgaccaaca tcattactag 780 taaagaactc ttacaaacaa agttgaagga tatagtttct ttggtcccac gcctgcggca 840 catcatcact gttgatggaa agccaccgac ctggtccgac ttccccaagg gcatcattgt 900 gcataccatg gctgcagtgg aggccctggg agccaaggcc agcatggaaa accaacctca 960 tagcaaacca ttgccctcag atattgcagt aatcatgtac acaagtggat ccacaggact 1020 tccaaaggga gtcatgatct cacatagtaa cattattgct ggtataactg ggatggcaga 1080 aaggattcca gaactaggag aggaagatgt ctacattgga tatttgcctc tggcccatgt 1140 tctagaatta agtgctgagc ttgtctgtct ttctcacgga tgccgcattg gttactcttc 1200 accacagact ttagcagatc agtcttcaaa aattaaaaaa ggaagcaaag gggatacatc 1260 catgttgaaa ccaacactga tggcagcagt tccggaaatc atggatcgga tctacaaaaa 1320 tgtcatgaat aaagtcagtg aaatgagtag ttttcaacgt aatctgttta ttctggccta 1380 taattacaaa atggaacaga tttcaaaagg acgtaatact ccactgtgcg acagctttgt 1440 tttccggaaa gttcgaagct tgctaggggg aaatattcgt ctcctgttgt gtggtggcgc 1500 tccactttct gcaaccacgc agcgattcat gaacatctgt ttctgctgtc ctgttggtca 1560 gggatacggg ctcactgaat ctgctggggc tggaacaatt tccgaagtgt gggactacaa 1620 tactggcaga gtgggagcac cattagtttg ctgtgaaatc aaattaaaaa actgggagga 1680 aggtggatac tttaatactg ataagccaca ccccaggggt gaaattctta ttgggggcca 1740 aagtgtgaca atggggtact acaaaaatga agcaaaaaca aaagctgatt tctctgaaga 1800 tgaaaatgga caaaggtggc tctgtactgg ggatattgga gagtttgaac ccgatggatg 1860 cttaaagatt attgatcgta aaaaggacct tgtaaaacta caggcagggg aatatgtttc 1920 tcttgggaaa gtagaggcag ctttgaagaa tcttccacta gtagataaca tttgtgcata 1980 tgcaaacagt tatcattctt atgtcattgg atttgttgtg ccaaatcaaa aggaactaac 2040 tgaactagct cgaaagaaag gacttaaagg gacttgggag gagctgtgta acagttgtga 2100 aatggaaaat gaggtactta aagtgctttc cgaagctgct atttcagcaa gtctggaaaa 2160 gtttgaaatt ccagtaaaaa ttcgtttgag tcctgaaccg tggacccctg aaactggtct 2220 ggtgacagat gccttcaagc tgaaacgcaa agagcttaaa acacattacc aggcggacat 2280 tgagcgaatg tatggaagaa aataattatt ctcttctggc atcagtttgc tacagtgagc 2340 tcacatcaaa taggaaaata cttgaaatgc atgtctcaag ctgcaaggca aactccattc 2400 ctcatattaa actattactt ctcatgacgt caccattttt aactgacagg attagtaaaa 2460 cattaagaca gcaaacttgt gtctgtctct tctttcattt tccccgccac caacttactt 2520 taccacctat gactgtactt gtcagtatga gaatttttct gaatcatatt ggggaagcag 2580 tgattttaaa acctcaagtt tttaaacatg atttatatgt tctgtataat gttcagtttg 2640 taacttttta aaagtttgga tgtatagagg gataaatagg aaatataaga attggttatt 2700 tgggggcttt tttacttact gtatttaaaa atacaagggt attgatatga aattatgtaa 2760 atttcaaatg cttatgaatc aaatcattgt tgaacaaaag atttgttgct gtgtaattat 2820 tgtcttgtat gcatttgaga gaaataaata tacccatact tatgttttaa gaagttgaga 2880 tcttgtgaaa aaaaaaaaaa aaaaa 2905 18 720 PRT Homo sapiens 18 Met Asn Asn His Val Ser Ser Lys Pro Ser Thr Met Lys Leu Lys His 1 5 10 15 Thr Ile Asn Pro Ile Leu Leu Tyr Phe Ile His Phe Leu Ile Ser Leu 20 25 30 Tyr Thr Ile Leu Thr Tyr Ile Pro Phe Tyr Phe Phe Ser Glu Ser Arg 35 40 45 Gln Glu Lys Ser Asn Arg Ile Lys Ala Lys Pro Val Asn Ser Lys Pro 50 55 60 Asp Ser Ala Tyr Arg Ser Val Asn Ser Leu Asp Gly Leu Ala Ser Val 65 70 75 80 Leu Tyr Pro Gly Cys Asp Thr Leu Asp Lys Val Phe Thr Tyr Ala Lys 85 90 95 Asn Lys Phe Lys Asn Lys Arg Leu Leu Gly Thr Arg Glu Val Leu Asn 100 105 110 Glu Glu Asp Glu Val Gln Pro Asn Gly Lys Ile Phe Lys Lys Val Ile 115 120 125 Leu Gly Gln Tyr Asn Trp Leu Ser Tyr Glu Asp Val Phe Val Arg Ala 130 135 140 Phe Asn Phe Gly Asn Gly Leu Gln Met Leu Gly Gln Lys Pro Lys Thr 145 150 155 160 Asn Ile Ala Ile Phe Cys Glu Thr Arg Ala Glu Trp Met Ile Ala Ala 165 170 175 Gln Ala Cys Phe Met Tyr Asn Phe Gln Leu Val Thr Leu Tyr Ala Thr 180 185 190 Leu Gly Gly Pro Ala Ile Val His Ala Leu Asn Glu Thr Glu Val Thr 195 200 205 Asn Ile Ile Thr Ser Lys Glu Leu Leu Gln Thr Lys Leu Lys Asp Ile 210 215 220 Val Ser Leu Val Pro Arg Leu Arg His Ile Ile Thr Val Asp Gly Lys 225 230 235 240 Pro Pro Thr Trp Ser Asp Phe Pro Lys Gly Ile Ile Val His Thr Met 245 250 255 Ala Ala Val Glu Ala Leu Gly Ala Lys Ala Ser Met Glu Asn Gln Pro 260 265 270 His Ser Lys Pro Leu Pro Ser Asp Ile Ala Val Ile Met Tyr Thr Ser 275 280 285 Gly Ser Thr Gly Leu Pro Lys Gly Val Met Ile Ser His Ser Asn Ile 290 295 300 Ile Ala Gly Ile Thr Gly Met Ala Glu Arg Ile Pro Glu Leu Gly Glu 305 310 315 320 Glu Asp Val Tyr Ile Gly Tyr Leu Pro Leu Ala His Val Leu Glu Leu 325 330 335 Ser Ala Glu Leu Val Cys Leu Ser His Gly Cys Arg Ile Gly Tyr Ser 340 345 350 Ser Pro Gln Thr Leu Ala Asp Gln Ser Ser Lys Ile Lys Lys Gly Ser 355 360 365 Lys Gly Asp Thr Ser Met Leu Lys Pro Thr Leu Met Ala Ala Val Pro 370 375 380 Glu Ile Met Asp Arg Ile Tyr Lys Asn Val Met Asn Lys Val Ser Glu 385 390 395 400 Met Ser Ser Phe Gln Arg Asn Leu Phe Ile Leu Ala Tyr Asn Tyr Lys 405 410 415 Met Glu Gln Ile Ser Lys Gly Arg Asn Thr Pro Leu Cys Asp Ser Phe 420 425 430 Val Phe Arg Lys Val Arg Ser Leu Leu Gly Gly Asn Ile Arg Leu Leu 435 440 445 Leu Cys Gly Gly Ala Pro Leu Ser Ala Thr Thr Gln Arg Phe Met Asn 450 455 460 Ile Cys Phe Cys Cys Pro Val Gly Gln Gly Tyr Gly Leu Thr Glu Ser 465 470 475 480 Ala Gly Ala Gly Thr Ile Ser Glu Val Trp Asp Tyr Asn Thr Gly Arg 485 490 495 Val Gly Ala Pro Leu Val Cys Cys Glu Ile Lys Leu Lys Asn Trp Glu 500 505 510 Glu Gly Gly Tyr Phe Asn Thr Asp Lys Pro His Pro Arg Gly Glu Ile 515 520 525 Leu Ile Gly Gly Gln Ser Val Thr Met Gly Tyr Tyr Lys Asn Glu Ala 530 535 540 Lys Thr Lys Ala Asp Phe Ser Glu Asp Glu Asn Gly Gln Arg Trp Leu 545 550 555 560 Cys Thr Gly Asp Ile Gly Glu Phe Glu Pro Asp Gly Cys Leu Lys Ile 565 570 575 Ile Asp Arg Lys Lys Asp Leu Val Lys Leu Gln Ala Gly Glu Tyr Val 580 585 590 Ser Leu Gly Lys Val Glu Ala Ala Leu Lys Asn Leu Pro Leu Val Asp 595 600 605 Asn Ile Cys Ala Tyr Ala Asn Ser Tyr His Ser Tyr Val Ile Gly Phe 610 615 620 Val Val Pro Asn Gln Lys Glu Leu Thr Glu Leu Ala Arg Lys Lys Gly 625 630 635 640 Leu Lys Gly Thr Trp Glu Glu Leu Cys Asn Ser Cys Glu Met Glu Asn 645 650 655 Glu Val Leu Lys Val Leu Ser Glu Ala Ala Ile Ser Ala Ser Leu Glu 660 665 670 Lys Phe Glu Ile Pro Val Lys Ile Arg Leu Ser Pro Glu Pro Trp Thr 675 680 685 Pro Glu Thr Gly Leu Val Thr Asp Ala Phe Lys Leu Lys Arg Lys Glu 690 695 700 Leu Lys Thr His Tyr Gln Ala Asp Ile Glu Arg Met Tyr Gly Arg Lys 705 710 715 720 19 5043 DNA Homo sapiens 19 cgggattcgg ctggctctgc cacaccaccg cgcgcccccg ctccgcccgc ccctccgggc 60 gcgtcttttc cgggctcgcg ctgagtcccg cctccgccgg ctgtccgggt gcgcgcgcgc 120 cgctgcggct ttttctctgg cctccgccgc gcgctcctcc tcgtcccagc gctagcgggc 180 acgcggttcc tttttgcgag ctttccgagt gccaggcgcc ggccggctgc gaagacgcgg 240 tgggccgccc ctccgattga aatcacagaa gatattcgtg ttcttcttaa gagaaaaaga 300 ggacatttaa aaacgctatg gcaaagagaa taaaagctaa gcccacttca gacaaacctg 360 gaagtccata tcgctctgtc acacacttcg actcactagc tgtaatagac atccctggag 420 cagatactct ggataaatta tttgaccatg ctgtatccaa gtttgggaag aaggacagcc 480 ttgggaccag ggaaatccta agtgaagaaa atgaaatgca gccaaatgga aaagttttta 540 agaagttaat tcttgggaat tataaatgga tgaactatct tgaagtgaat cgcagagtga 600 ataactttgg tagtggactc actgcactgg gactaaaacc aaagaacacc attgccatct 660 tctgtgagac cagggccgaa tggatgattg cagcacagac ctgctttaag tacaactttc 720 ctcttgtgac tttatatgcc acacttggca aagaagcagt agttcatggg ctaaatgaat 780 ctgaggcttc ctatctgatt accagtgttg aacttctgga aagtaaactt aagactgcat 840 tgttagatat cagttgtgtt aaacatatca tttatgtgga caataaggct atcaataaag 900 cagagtaccc tgaaggattt gagattcaca gcatgcaatc agtagaagag ttgggatcta 960 acccagaaaa cttgggcatt cctccaagta gaccaacgcc ttcagacatg gccattgtta 1020 tgtatactag tggttctact ggccgaccta agggagtgat gatgcatcat agcaatttga 1080 tagctggaat gacaggccag tgtgaaagaa tacctggact gggaccgaag gacacatata 1140 ttggctactt gcctttggct catgtgctag aactgacagc agagatatct tgctttacct 1200 atggctgcag gattggatat tcttctccgc ttacactctc tgaccagtcc agcaaaatta 1260 aaaaaggaag caaaggagac tgtactgtac tgaagcccac acttatggct gctgttccgg 1320 aaatcatgga tagaatttat aagaatgtta tgagcaaagt ccaagagatg aattatattc 1380 agaaaactct gttcaagata gggtatgatt acaaattgga acagatcaaa aagggatatg 1440 atgcacctct ttgcaatctg ttactgttta aaaaggtcaa ggccctgctg ggagggaatg 1500 tccgcatgat gctgtctgga ggggccccgc tatctcctca gacacaccga ttcatgaatg 1560 tctgcttctg ctgcccaatt ggccagggtt atggactgac agaatcatgt ggtgctggga 1620 cagttactga agtaactgac tatactactg gcagagttgg agcacctctt atttgctgtg 1680 aaattaagct aaaagactgg caagaaggcg gttatacaat taatgacaag ccaaacccca 1740 gaggtgaaat cgtaattggt ggacagaaca tctccatggg atattttaaa aatgaagaga 1800 aaacagcaga agattattct gtggatgaaa atggacaaag gtggttttgc actggtgata 1860 ttggagaatt ccatcccgat ggatgtttac agattataga tcgtaagaaa gatctagtga 1920 agttacaagc aggagagtat gtatctcttg ggaaagtaga agctgcactg aagaattgtc 1980 cacttattga caacatctgt gcttttgcca aaagtgatca gtcctatgtg atcagttttg 2040 tggttcctaa ccagaaaagg ttgacacttt tggcacaaca gaaaggggta gaaggaactt 2100 gggttgatat ctgcaataat cctgctatgg aagctgaaat actgaaagaa attcgagaag 2160 ctgcaaatgc catgaaattg gagcgatttg aaattccaat caaggttcga ttaagcccag 2220 agccatggac ccctgaaact ggtttggtaa ctgatgcttt caaactgaaa aggaaggagc 2280 tgaggaacca ttacctcaaa gacattgaac gaatgtatgg gggcaaataa aatgttgttg 2340 tcttattgac agttgtgcag gaggtagcct ggtggttttc aacctctaga attttaagcc 2400 tttgttgaac tgttagaatg taaggtatat cattctaaag atagagtaaa aagaaaacaa 2460 aaccaaaagt tattaaaatt gttgtccggt ttactttaac ttagttttgc atagttctag 2520 tgcagctgaa attgaaaagt tatttccctt tagctgtgtt attatagagc agaaattctg 2580 tttttaaaaa ttagcctaag atatacttgt ttttgtaaag aaaaatattt aatgttgaac 2640 aaaataaatt ggagttggag tagaatgtag tttgaggaaa tttgcagctt ccaatgcctc 2700 ttgtcttcct atttcagaag tttaaatatt aagcatgaca gaaaatatgt attaacacta 2760 ctcaaagcaa aagtgctgca gggctttaaa attctcttcc aaccatttat cttgaaggaa 2820 aaattcaata gtaatataat acacaaaatc aaataatacc ttagaaggta ttaagattat 2880 aattgttgca taggttagat atagagtcat tgtaatgttg tgaataatta cagtgcctaa 2940 aataagaata gaacaacata tacaacacca aaaaatatct agtaatatat ttaaagggaa 3000 attgagctgc tttttttgaa actttgagat ctaaaaataa ctgtaattat ttgaatgact 3060 aagaggaaag tacatttttt gaaatgctga aaattgcctt tctgtgttta ttcaaactga 3120 aaagctgaga ccaagagcaa ggaaggtaaa aagttaacag gcaaacattt tctcttagaa 3180 aaggtgataa aatcataagt atttggaatt agaacccttg cacagcactg aacctgggaa 3240 agagatttaa actctgaatt tatctttgat aacagggatt gattttaaaa tgtacatgta 3300 ttaaattaca tttgtaattt aaggtctgtt tgctgttgct gattttattc ttgatcagta 3360 gtttgcattt cagaaagcct ttcattttgc tttaagttta gcaaagcggg gttataatga 3420 atgacttccc caatatcttg cttgaactta cagtgattaa cttggatgag ttttgggaag 3480 ttaaagggaa gaaaacactg ttatcatttt ttcctgtttg ggaagagctt agaaactgga 3540 aatactagat ttgggagaag ggcagagtta cttgataagg gacttgatgt ttgtgcagta 3600 acttgggagt gtggtttctt tttgaatctt taattaaaac ctgggattat atatccctga 3660 taaatattca cacttgaacc atagttactg taaaatgcaa aaaatcttaa tactgttatt 3720 ctttgcactt tttcttaatc attttttata tatatgcata tatatatgtg tgtgtgtgtg 3780 ttgcttatgt tgttttgtac agatgtgggc caccattgca acaaaataca ttctttttgc 3840 tctaaaatat ttatgaagaa aatacttaaa tgttatgtat atggtggtaa taagggaaaa 3900 atcaagtatt ataaacaaga atgaaggttt ttgtaaagat ttctgttcag cgttttgcaa 3960 ggtaaaattt taggcaagtt ttccctgaag ttatgtgtat gtgagtattc tcattcttcc 4020 caacttgcct ttgaagagtg aaataccatt attatcaagt agactactgt tcagctttta 4080 ttccttccct ggttgtttat cccttaggaa tgagtttctt agactttccc aatatgtgat 4140 tttttttccc atttagaatg gtgattttaa atgtgtgagt gcatgtacta tcttatctca 4200 gatatttgca cccccaatct gcccccaact cccaaaagct agaacactgc caactgatct 4260 gttataggtc ctttagaaac acataattaa cacttaaggt tgggtgctgc taattctttg 4320 caaaaatcca aatattgtta agggaccagg gagatgccac taccccttga ttttccatct 4380 aaaaatatac atgtttatgt aaacaaatct ttccatatcc atagtgactt ttcaagtatt 4440 taagcctaaa gattttgatc tcacattttt atacctgttt aaattgctca cagttattac 4500 atacacatca gccatcaact aaagttgtac tttaaaaatt tactacaata tgtacatttc 4560 taagtcaaac acttgtgact tttgctttaa ttccatgaat gttcctgcct ccttgatatt 4620 tgtatttatt ctttttttct ctagagtaga ggtataattg tgtgatattt cagaaataca 4680 gataaatgat tcaaaaagtc acagttaagg agaatcatgt ttctttgatc atgaataact 4740 gattagtaag tcttgcctat attttcctga tagcatatga caaatgtttc taaggtaaca 4800 agatgagaac agataaagat tgtgtggtgt tttggatttg gagagaaata ttttaatttt 4860 taaatgcagt tacaaattat aatgtattca tatttgtact ttctgttaaa atgcatgatt 4920 gcagaattgt ttagattttg tgtttattct tgatgaaaag ctttgtttgt tcttgttttt 4980 aagtttgcac tcaaatctta agaaataaat ccacccatgt tatcaaaaaa aaaaaaaaaa 5040 aaa 5043 20 670 PRT Homo sapiens 20 Met Ala Lys Arg Ile Lys Ala Lys Pro Thr Ser Asp Lys Pro Gly Ser 1 5 10 15 Pro Tyr Arg Ser Val Thr His Phe Asp Ser Leu Ala Val Ile Asp Ile 20 25 30 Pro Gly Ala Asp Thr Leu Asp Lys Leu Phe Asp His Ala Val Ser Lys 35 40 45 Phe Gly Lys Lys Asp Ser Leu Gly Thr Arg Glu Ile Leu Ser Glu Glu 50 55 60 Asn Glu Met Gln Pro Asn Gly Lys Val Phe Lys Lys Leu Ile Leu Gly 65 70 75 80 Asn Tyr Lys Trp Met Asn Tyr Leu Glu Val Asn Arg Arg Val Asn Asn 85 90 95 Phe Gly Ser Gly Leu Thr Ala Leu Gly Leu Lys Pro Lys Asn Thr Ile 100 105 110 Ala Ile Phe Cys Glu Thr Arg Ala Glu Trp Met Ile Ala Ala Gln Thr 115 120 125 Cys Phe Lys Tyr Asn Phe Pro Leu Val Thr Leu Tyr Ala Thr Leu Gly 130 135 140 Lys Glu Ala Val Val His Gly Leu Asn Glu Ser Glu Ala Ser Tyr Leu 145 150 155 160 Ile Thr Ser Val Glu Leu Leu Glu Ser Lys Leu Lys Thr Ala Leu Leu 165 170 175 Asp Ile Ser Cys Val Lys His Ile Ile Tyr Val Asp Asn Lys Ala Ile 180 185 190 Asn Lys Ala Glu Tyr Pro Glu Gly Phe Glu Ile His Ser Met Gln Ser 195 200 205 Val Glu Glu Leu Gly Ser Asn Pro Glu Asn Leu Gly Ile Pro Pro Ser 210 215 220 Arg Pro Thr Pro Ser Asp Met Ala Ile Val Met Tyr Thr Ser Gly Ser 225 230 235 240 Thr Gly Arg Pro Lys Gly Val Met Met His His Ser Asn Leu Ile Ala 245 250 255 Gly Met Thr Gly Gln Cys Glu Arg Ile Pro Gly Leu Gly Pro Lys Asp 260 265 270 Thr Tyr Ile Gly Tyr Leu Pro Leu Ala His Val Leu Glu Leu Thr Ala 275 280 285 Glu Ile Ser Cys Phe Thr Tyr Gly Cys Arg Ile Gly Tyr Ser Ser Pro 290 295 300 Leu Thr Leu Ser Asp Gln Ser Ser Lys Ile Lys Lys Gly Ser Lys Gly 305 310 315 320 Asp Cys Thr Val Leu Lys Pro Thr Leu Met Ala Ala Val Pro Glu Ile 325 330 335 Met Asp Arg Ile Tyr Lys Asn Val Met Ser Lys Val Gln Glu Met Asn 340 345 350 Tyr Ile Gln Lys Thr Leu Phe Lys Ile Gly Tyr Asp Tyr Lys Leu Glu 355 360 365 Gln Ile Lys Lys Gly Tyr Asp Ala Pro Leu Cys Asn Leu Leu Leu Phe 370 375 380 Lys Lys Val Lys Ala Leu Leu Gly Gly Asn Val Arg Met Met Leu Ser 385 390 395 400 Gly Gly Ala Pro Leu Ser Pro Gln Thr His Arg Phe Met Asn Val Cys 405 410 415 Phe Cys Cys Pro Ile Gly Gln Gly Tyr Gly Leu Thr Glu Ser Cys Gly 420 425 430 Ala Gly Thr Val Thr Glu Val Thr Asp Tyr Thr Thr Gly Arg Val Gly 435 440 445 Ala Pro Leu Ile Cys Cys Glu Ile Lys Leu Lys Asp Trp Gln Glu Gly 450 455 460 Gly Tyr Thr Ile Asn Asp Lys Pro Asn Pro Arg Gly Glu Ile Val Ile 465 470 475 480 Gly Gly Gln Asn Ile Ser Met Gly Tyr Phe Lys Asn Glu Glu Lys Thr 485 490 495 Ala Glu Asp Tyr Ser Val Asp Glu Asn Gly Gln Arg Trp Phe Cys Thr 500 505 510 Gly Asp Ile Gly Glu Phe His Pro Asp Gly Cys Leu Gln Ile Ile Asp 515 520 525 Arg Lys Lys Asp Leu Val Lys Leu Gln Ala Gly Glu Tyr Val Ser Leu 530 535 540 Gly Lys Val Glu Ala Ala Leu Lys Asn Cys Pro Leu Ile Asp Asn Ile 545 550 555 560 Cys Ala Phe Ala Lys Ser Asp Gln Ser Tyr Val Ile Ser Phe Val Val 565 570 575 Pro Asn Gln Lys Arg Leu Thr Leu Leu Ala Gln Gln Lys Gly Val Glu 580 585 590 Gly Thr Trp Val Asp Ile Cys Asn Asn Pro Ala Met Glu Ala Glu Ile 595 600 605 Leu Lys Glu Ile Arg Glu Ala Ala Asn Ala Met Lys Leu Glu Arg Phe 610 615 620 Glu Ile Pro Ile Lys Val Arg Leu Ser Pro Glu Pro Trp Thr Pro Glu 625 630 635 640 Thr Gly Leu Val Thr Asp Ala Phe Lys Leu Lys Arg Lys Glu Leu Arg 645 650 655 Asn His Tyr Leu Lys Asp Ile Glu Arg Met Tyr Gly Gly Lys 660 665 670 21 4213 DNA Homo sapiens 21 tccactcctg gagcccgcgg accccgagca cgcgcctgac agcccctgct ggcccggcgc 60 gcggcgtcgc caggccagct atggcccccg acccggtggc cgccgagacc gcggctcagg 120 gacctacccc gcgctacttc acctgggacg aggtggccca gcgctcaggg tgcgaggagc 180 ggtggctagt gatcgaccgt aaggtgtaca acatcagcga gttcacccgc cggcatccag 240 ggggctcccg ggtcatcagc cactacgccg ggcaggatgc cacggatccc tttgtggcct 300 tccacatcaa caagggcctt gtgaagaagt atatgaactc tctcctgatt ggagaactgt 360 ctccagagca gcccagcttt gagcccacca agaataaaga gctgacagat gagttccggg 420 agctgcgggc cacagtggag cggatggggc tcatgaaggc caaccatgtc ttcttcctgc 480 tgtacctgct gcacatcttg ctgctggatg gtgcagcctg gctcaccctt tgggtctttg 540 ggacgtcctt tttgcccttc ctcctctgtg cggtgctgct cagtgcagtt caggcccagg 600 ctggctggct gcagcatgac tttgggcacc tgtcggtctt cagcacctca aagtggaacc 660 atctgctaca tcattttgtg attggccacc tgaagggggc ccccgccagt tggtggaacc 720 acatgcactt ccagcaccat gccaagccca actgcttccg caaagaccca gacatcaaca 780 tgcatccctt cttctttgcc ttggggaaga tcctctctgt ggagcttggg aaacagaaga 840 aaaaatatat gccgtacaac caccagcaca aatacttctt cctaattggg cccccagcct 900 tgctgcctct ctacttccag tggtatattt tctattttgt tatccagcga aagaagtggg 960 tggacttggc ctggatgatt accttctacg tccgcttctt cctcacttat gtgccactat 1020 tggggctgaa agccttcctg ggccttttct tcatagtcag gttcctggaa agcaactggt 1080 ttgtgtgggt gacacagatg aaccatattc ccatgcacat tgatcatgac cggaacatgg 1140 actgggtttc cacccagctc caggccacat gcaatgtcca caagtctgcc ttcaatgact 1200 ggttcagtgg acacctcaac ttccagattg agcaccatct ttttcccacg atgcctcgac 1260 acaattacca caaagtggct cccctggtgc agtccttgtg tgccaagcat ggcatagagt 1320 accagtccaa gcccctgctg tcagccttcg ccgacatcat ccactcacta aaggagtcag 1380 ggcagctctg gctagatgcc tatcttcacc aataacaaca gccaccctgc ccagtctgga 1440 agaagaggag gaagactctg gagccaaggc agaggggagc ttgagggaca atgccactat 1500 agtttaatac tcagaggggg ttgggtttgg ggacataaag cctctgactc aaactcctcc 1560 cttttatctt ctagccacag ttctaagacc caaagtgggg ggtggacaca gaagtcccta 1620 ggagggaagg agctgttggg gcaggggtgt aaattatttc ctttttctag tttggcacat 1680 gcaggtagtt ggtgaacaga gagaaccagg agggtaacag aagaggaggg acctactgaa 1740 cccagagtca ggaagagatt taacactaaa attccactca tgccgggcgt ggtggcacgc 1800 gcctgtaatc ccagctaccc aggaggctga ggcaggagaa tcgcttgaac cggggaggtg 1860 gaggttgcag tgagctgaga tcacgccatt gtactccagc ctgggcgaca gagcaagact 1920 ccatttcaaa aaaaaaaaaa aaatccactc atataaaagg tgagctcagc tcactggtcc 1980 atttctcagt ggcttctcca tcctcatttg caaacctcag agggataagg cagttgaacc 2040 tgatgagcaa gaattataac agcaaggaaa cattaatgct tagaattctg agatccagca 2100 caactcagtc tgtgggagct cagctcgctg cccagggata ggtatgacct atgtctgcct 2160 taggctgctg ggagatgcca ttctccagtt tcagaagcag gcagggcaaa ggtcaagact 2220 gtggtattgg ggtcttttgg ctctgaagga tcctggaacc actgattttg gtttattccc 2280 tccagggtct aaagagaaca agaggtgcta gctcttacca aaacagatgg tagagagagt 2340 tgctggctat ttaaaaagct ctttcatctt ttaattcacc tcttcttttc acctctttaa 2400 ccactcctca ggaacagaac acttctagga ctgggggtct tttagctcca taagcaagtg 2460 agcagatggg acaagttagt cttttctccc tagaaacaaa ggggatgccc agtggtttcc 2520 ctttgcttcc caacctaaaa tttcaagttt aataaaatag caattagcag aagtgaccaa 2580 attgggagat aattatcagt catgaggaaa gacacagatt tcggtcataa agaatgtaag 2640 ggctataagt agaaactttc tataacctaa atgatgttat agaattattt ttgagcagga 2700 gcagaaagat taaatatgat cacttcatac ttctaaatca gaaataggaa gattaaaacc 2760 acagaacagt ttgtgatttc tattgctgta gctaggtatc ttactctgtc cactcttgtt 2820 caagtatcta actcttctgg aaaccaaata ggctttagaa gagattatcc tatattccta 2880 tcagtataat actaaaatgt aactttttaa tcatctggtt tttaaaagat aaacagttta 2940 gcccatctct ccagagagca aacataggaa tatgactcag gagcctccta gggcttatca 3000 tcagccctca cacccgcttc cccctccaac ccacagcctt tgcttccagg tggcaggatt 3060 actactttgc ctcttcagca gcatctactc taggcatatt gatcatttta gacactggga 3120 gaagagaacc tcaaactagg aggaaaagac agagcctcca cttagttttg ggaggggatg 3180 gcagacagtc aaggagatga gcgtcctaag gcatgttggg atagggtcag atgcaccacc 3240 catggagagg tttgtcaaca caaagacatg gaaggttaga ggtttgtcaa caaaaagaca 3300 tggaaggtta ggtttgtcaa cacaaagaca tggaagatta gaggtttgtc aacacaaaga 3360 cacaggaaga atgggctgca gaagatttag atgttttcca tttgggcaca ttttacttag 3420 ctggagaact aggtttaaaa cagcctgggt aggaaaatta gaagcaagct ggatgcagtg 3480 gctcatgcct gtaatcccaa cacttttggg aggtccaggc aggaggatca cttgggccca 3540 ggaggtcaag cctgcagcga gctgagatca caccactgca ctccagcctg gggtgataga 3600 acaagaccct gtctcaaaaa aaaaaaaaaa caacaaaaac ttagaattga ggagttgtac 3660 ctccattggc ttcctcactc caaaataggt gctgatcctt cctattccta ttctttgcca 3720 ccttttgggt gtggtgtcac cagcctgttt agccaagtag ctttgggcat aggctgccca 3780 atctgagcaa acaccagtga ggctctattg agccaagacc aagtcctcaa agcacctgaa 3840 ccactgtggc cttctcagcc tacagcagtg tggtctctta catggccaca aagggacaca 3900 cagtgacaaa aggctcggaa tgttacaatg gtaaaatgag tgatctcaaa tccactgaca 3960 gatataaaat aggcttagag aggaaaagct gcctctggtc aagtagatca tggcagcatg 4020 aattccaact cactttttta caactccaac ttctatgttt atctttgtta ctttcacttt 4080 tttacaacct ggccagaggc attttttaaa tcaggcccaa tatcagtatt ctttttgtgt 4140 gtgccaattt tgttatcaca tccctatgaa gttgaaaaat aaagttaatt ttgaccaaaa 4200 aaaaaaaaaa aag 4213 22 444 PRT Homo sapiens 22 Met Ala Pro Asp Pro Val Ala Ala Glu Thr Ala Ala Gln Gly Pro Thr 1 5 10 15 Pro Arg Tyr Phe Thr Trp Asp Glu Val Ala Gln Arg Ser Gly Cys Glu 20 25 30 Glu Arg Trp Leu Val Ile Asp Arg Lys Val Tyr Asn Ile Ser Glu Phe 35 40 45 Thr Arg Arg His Pro Gly Gly Ser Arg Val Ile Ser His Tyr Ala Gly 50 55 60 Gln Asp Ala Thr Asp Pro Phe Val Ala Phe His Ile Asn Lys Gly Leu 65 70 75 80 Val Lys Lys Tyr Met Asn Ser Leu Leu Ile Gly Glu Leu Ser Pro Glu 85 90 95 Gln Pro Ser Phe Glu Pro Thr Lys Asn Lys Glu Leu Thr Asp Glu Phe 100 105 110 Arg Glu Leu Arg Ala Thr Val Glu Arg Met Gly Leu Met Lys Ala Asn 115 120 125 His Val Phe Phe Leu Leu Tyr Leu Leu His Ile Leu Leu Leu Asp Gly 130 135 140 Ala Ala Trp Leu Thr Leu Trp Val Phe Gly Thr Ser Phe Leu Pro Phe 145 150 155 160 Leu Leu Cys Ala Val Leu Leu Ser Ala Val Gln Ala Gln Ala Gly Trp 165 170 175 Leu Gln His Asp Phe Gly His Leu Ser Val Phe Ser Thr Ser Lys Trp 180 185 190 Asn His Leu Leu His His Phe Val Ile Gly His Leu Lys Gly Ala Pro 195 200 205 Ala Ser Trp Trp Asn His Met His Phe Gln His His Ala Lys Pro Asn 210 215 220 Cys Phe Arg Lys Asp Pro Asp Ile Asn Met His Pro Phe Phe Phe Ala 225 230 235 240 Leu Gly Lys Ile Leu Ser Val Glu Leu Gly Lys Gln Lys Lys Lys Tyr 245 250 255 Met Pro Tyr Asn His Gln His Lys Tyr Phe Phe Leu Ile Gly Pro Pro 260 265 270 Ala Leu Leu Pro Leu Tyr Phe Gln Trp Tyr Ile Phe Tyr Phe Val Ile 275 280 285 Gln Arg Lys Lys Trp Val Asp Leu Ala Trp Met Ile Thr Phe Tyr Val 290 295 300 Arg Phe Phe Leu Thr Tyr Val Pro Leu Leu Gly Leu Lys Ala Phe Leu 305 310 315 320 Gly Leu Phe Phe Ile Val Arg Phe Leu Glu Ser Asn Trp Phe Val Trp 325 330 335 Val Thr Gln Met Asn His Ile Pro Met His Ile Asp His Asp Arg Asn 340 345 350 Met Asp Trp Val Ser Thr Gln Leu Gln Ala Thr Cys Asn Val His Lys 355 360 365 Ser Ala Phe Asn Asp Trp Phe Ser Gly His Leu Asn Phe Gln Ile Glu 370 375 380 His His Leu Phe Pro Thr Met Pro Arg His Asn Tyr His Lys Val Ala 385 390 395 400 Pro Leu Val Gln Ser Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Ser 405 410 415 Lys Pro Leu Leu Ser Ala Phe Ala Asp Ile Ile His Ser Leu Lys Glu 420 425 430 Ser Gly Gln Leu Trp Leu Asp Ala Tyr Leu His Gln 435 440 23 1275 DNA Homo sapiens 23 tgtactttaa cccgttttaa agtacgtttg ccattctcag ggcaactgga ttgactcgga 60 gctctaggct tatcatcgcc ttaaaccggt tccccttcca cccacgcttt gctttccagt 120 ggcaggatac tactttgcct cttcgcagca tctactctag catatgatca tttagacact 180 gggaaaagaa cctcaaacta ggaggaaaag acagagcctc cacttagttt tgggagggga 240 tggcagacag tcaaggagat gagcgtccta aggcatgttg ggatagggtc agatgcacca 300 cccatggaga ggtttgtcaa cacaaagaca tggaaggtta gaggtttgtc aacaaaaaga 360 catggaaggt taggtttgtc aacacaaaga catggaagat tagaggtttg tcaacacaaa 420 gacacaggaa gaatgggctg cagaagattt agatgttttc catttgggca cattttactt 480 agctggagaa ctaggtttaa aacagcctgg gtaggaaaat tagaagcaag ctggatgcag 540 tggctcatgc ctgtaatccc aacacttttg ggaggtccag gcaggaggat cacttgggcc 600 caggaggtca agcctgcagc gagctgagat cacaccactg cactccagcc tggggtgata 660 gaacaagacc ctgtctcaaa aaaaaaaaaa acaacaaaaa cttagaattg aggagttgta 720 cctccattgg cttcctcact ccaaaatagg tgctgatcct tcctattcct attctttgcc 780 accttttggg tgtggtgtca ccagcctgtt tagccaagta gctttgggca taggctgccc 840 aatctgagca aacaccagtg aggctctatt gagccaagac caagtcctca aagcacctga 900 accactgtgg ccttctcagc ctacagcagt gtggtctctt acatggccac aaagggacac 960 acagtgacaa aaggctcgga atgttacaat ggtaaaatga gtgatctcaa atccactgac 1020 agatataaaa taggcttaga gaggaaaagc tgcctctggt caagtagatc atggcagcat 1080 gaattccaac tcactttttt acaactccaa cttctatgtt tatctttgtt actttcactt 1140 ttttacaacc tggccagagg cattttttaa atcaggccca atatcagtat tctttttgtg 1200 tgtgccaatt ttgttatcac atccctatga agttgaaaaa taaagttaat tttgaccaaa 1260 agaaaaaaaa aaaaa 1275 24 122 PRT Homo sapiens 24 Met Ser Val Leu Arg His Val Gly Ile Gly Ser Asp Ala Pro Pro Met 1 5 10 15 Glu Arg Phe Val Asn Thr Lys Thr Trp Lys Val Arg Gly Leu Ser Thr 20 25 30 Lys Arg His Gly Arg Leu Gly Leu Ser Thr Gln Arg His Gly Arg Leu 35 40 45 Glu Val Cys Gln His Lys Asp Thr Gly Arg Met Gly Cys Arg Arg Phe 50 55 60 Arg Cys Phe Pro Phe Gly His Ile Leu Leu Ser Trp Arg Thr Arg Phe 65 70 75 80 Lys Thr Ala Trp Val Gly Lys Leu Glu Ala Ser Trp Met Gln Trp Leu 85 90 95 Met Pro Val Ile Pro Thr Leu Leu Gly Gly Pro Gly Arg Arg Ile Thr 100 105 110 Trp Ala Gln Glu Val Lys Pro Ala Ala Ser 115 120 25 3016 DNA Homo sapiens 25 ttagactggc agcatgggga agggagggaa ccagggcgag ggggccgccg agcgcgaggt 60 gtcggtgccc accttcagct gggaggagat tcagaagcat aacctgcgca ccgacaggtg 120 gctggtcatt gaccgcaagg tttacaacat caccaaatgg tccatccagc acccgggggg 180 ccagcgggtc atcgggcact acgctggaga agatgcaacg gatgccttcc gcgccttcca 240 ccctgacctg gaattcgtgg gcaagttctt gaaacccctg ctgattggtg aactggcccc 300 ggaggagccc agccaggacc acggcaagaa ctcaaagatc actgaggact tccgggccct 360 gaggaagacg gctgaggaca tgaacctgtt caagaccaac cacgtgttct tcctcctcct 420 cctggcccac atcatcgccc tggagagcat tgcatggttc actgtctttt actttggcaa 480 tggctggatt cctaccctca tcacggcctt tgtccttgct acctctcagg cccaagctgg 540 atggctgcaa catgattatg gccacctgtc tgtctacaga aaacccaagt ggaaccacct 600 tgtccacaaa ttcgtcattg gccacttaaa gggtgcctct gccaactggt ggaatcatcg 660 ccacttccag caccacgcca agcctaacat cttccacaag gatcccgatg tgaacatgct 720 gcacgtgttt gttctgggcg aatggcagcc catcgagtac ggcaagaaga agctgaaata 780 cctgccctac aatcaccagc acgaatactt cttcctgatt gggccgccgc tgctcatccc 840 catgtatttc cagtaccaga ttatcatgac catgatcgtc cataagaact gggtggacct 900 ggcctgggcc gtcagctact acatccggtt cttcatcacc tacatccctt tctacggcat 960 cctgggagcc ctccttttcc tcaacttcat caggttcctg gagagccact ggtttgtgtg 1020 ggtcacacag atgaatcaca tcgtcatgga gattgaccag gaggcctacc gtgactggtt 1080 cagtagccag ctgacagcca cctgcaacgt ggagcagtcc ttcttcaacg actggttcag 1140 tggacacctt aacttccaga ttgagcacca cctcttcccc accatgcccc ggcacaactt 1200 acacaagatc gccccgctgg tgaagtctct atgtgccaag catggcattg aataccagga 1260 gaagccgcta ctgagggccc tgctggacat catcaggtcc ctgaagaagt ctgggaagct 1320 gtggctggac gcctaccttc acaaatgaag ccacagcccc cgggacactg tggggaaggg 1380 gtgcaggtgg ggtgatggcc agaggaatga tgggcttttg ttctgagggg tgtccgagag 1440 gctggtgtat gcactgctca cggaccccat gttggatctt tctccctttc tcctctcctt 1500 tttctcttca catctccccc atagcaccct gccctcatgg gacctgccct ccctcagccg 1560 tcagccatca gccatggccc tcccagtgcc tcctagcccc ttcttccaag gagcagagag 1620 gtggccaccg ggggtggctc tgtcctacct ccactctctg cccctaaaga tgggaggaga 1680 ccagcggtcc atgggtctgg cctgtgagtc tccccttgca gcctggtcac taggcatcac 1740 ccccgctttg gttcttcaga tgctcttggg gttcataggg gcaggtccta gtcgggcagg 1800 gcccctgacc ctcccggcct ggcttcactc tccctgacgg ctgccattgg tccacccttt 1860 catagagagg cctgctttgt tacaaagctc gggtctccct cctgcagctc ggttaagtac 1920 ccgaggcctc tcttaagatg tccagggccc caggcccgcg ggcacagcca gcccaaacct 1980 tgggccctgg aagagtcctc caccccatca ctagagtgct ctgaccctgg gctttcacgg 2040 gccccattcc accgcctccc caacttgagc ctgtgacctt gggaccaaag ggggagtccc 2100 tcgtctcttg tgactcagca gaggcagtgg ccacgttcag ggaggggccg gctggcctgg 2160 aggctcagcc caccctccag cttttcctca gggtgtcctg aggtccaaga ttctggagca 2220 atctgaccct tctccaaagg ctctgttatc agctgggcag tgccagccaa tccctggcca 2280 tttggcccca ggggacgtgg gccctgcagg ctgcaggagg gcactggagc tgggaggtct 2340 cgtcccagcc ctccccatct cggggctgct gtgtggacgg cgctgcctca ggcactctcc 2400 tgtctgaacc tgcccttact gtgtttaacc tgttgctcca ggatgcattc tgataggagg 2460 gggcggcagg gctgggcctt gtgacaatct gcctttcacc acatggcctt gcctcggtgg 2520 ccctgactgt cagggagggc cagggaggca gagcgggagg gagtctcagg aggaggcttg 2580 ccctgagggg ctggggaggg ggtacctcat gaggaccagg gtggagcttg agaagaggag 2640 gaggtggggg cttggaggtg cttggtagct gaggggacgg gcaagtgaga ggggagggag 2700 ggaagtcctg ggaggatcct gagctgctgt tgcagtctaa cccactaatc agttcttaga 2760 ttcaggggaa gggcaggcac caacaactca gaatgggggc tttcggggag ggcgcctagt 2820 ccccccagct ctaagcagcc aggagggacc tgcatctaag catctgggtt gccatggcaa 2880 tggcatgccc cccagctact gtatgccccc gacccccgca gaggcagaat gaacccatag 2940 ggagctgatc gtaatgttta tcatgttact tccccacccc tacatttttt gaaataaaat 3000 aaggaatttt aaaaaa 3016 26 444 PRT Homo sapiens 26 Met Gly Lys Gly Gly Asn Gln Gly Glu Gly Ala Ala Glu Arg Glu Val 1 5 10 15 Ser Val Pro Thr Phe Ser Trp Glu Glu Ile Gln Lys His Asn Leu Arg 20 25 30 Thr Asp Arg Trp Leu Val Ile Asp Arg Lys Val Tyr Asn Ile Thr Lys 35 40 45 Trp Ser Ile Gln His Pro Gly Gly Gln Arg Val Ile Gly His Tyr Ala 50 55 60 Gly Glu Asp Ala Thr Asp Ala Phe Arg Ala Phe His Pro Asp Leu Glu 65 70 75 80 Phe Val Gly Lys Phe Leu Lys Pro Leu Leu Ile Gly Glu Leu Ala Pro 85 90 95 Glu Glu Pro Ser Gln Asp His Gly Lys Asn Ser Lys Ile Thr Glu Asp 100 105 110 Phe Arg Ala Leu Arg Lys Thr Ala Glu Asp Met Asn Leu Phe Lys Thr 115 120 125 Asn His Val Phe Phe Leu Leu Leu Leu Ala His Ile Ile Ala Leu Glu 130 135 140 Ser Ile Ala Trp Phe Thr Val Phe Tyr Phe Gly Asn Gly Trp Ile Pro 145 150 155 160 Thr Leu Ile Thr Ala Phe Val Leu Ala Thr Ser Gln Ala Gln Ala Gly 165 170 175 Trp Leu Gln His Asp Tyr Gly His Leu Ser Val Tyr Arg Lys Pro Lys 180 185 190 Trp Asn His Leu Val His Lys Phe Val Ile Gly His Leu Lys Gly Ala 195 200 205 Ser Ala Asn Trp Trp Asn His Arg His Phe Gln His His Ala Lys Pro 210 215 220 Asn Ile Phe His Lys Asp Pro Asp Val Asn Met Leu His Val Phe Val 225 230 235 240 Leu Gly Glu Trp Gln Pro Ile Glu Tyr Gly Lys Lys Lys Leu Lys Tyr 245 250 255 Leu Pro Tyr Asn His Gln His Glu Tyr Phe Phe Leu Ile Gly Pro Pro 260 265 270 Leu Leu Ile Pro Met Tyr Phe Gln Tyr Gln Ile Ile Met Thr Met Ile 275 280 285 Val His Lys Asn Trp Val Asp Leu Ala Trp Ala Val Ser Tyr Tyr Ile 290 295 300 Arg Phe Phe Ile Thr Tyr Ile Pro Phe Tyr Gly Ile Leu Gly Ala Leu 305 310 315 320 Leu Phe Leu Asn Phe Ile Arg Phe Leu Glu Ser His Trp Phe Val Trp 325 330 335 Val Thr Gln Met Asn His Ile Val Met Glu Ile Asp Gln Glu Ala Tyr 340 345 350 Arg Asp Trp Phe Ser Ser Gln Leu Thr Ala Thr Cys Asn Val Glu Gln 355 360 365 Ser Phe Phe Asn Asp Trp Phe Ser Gly His Leu Asn Phe Gln Ile Glu 370 375 380 His His Leu Phe Pro Thr Met Pro Arg His Asn Leu His Lys Ile Ala 385 390 395 400 Pro Leu Val Lys Ser Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Glu 405 410 415 Lys Pro Leu Leu Arg Ala Leu Leu Asp Ile Ile Arg Ser Leu Lys Lys 420 425 430 Ser Gly Lys Leu Trp Leu Asp Ala Tyr Leu His Lys 435 440 27 417 DNA Homo sapiens 27 acctcccaac caagccctcc agcaaggatt caggagtgcc cctcgggcct cgccatgagg 60 ctcttcctgt cgctcccggt cctggtggtg gttctgtcga tcgtcttgga aggcccagcc 120 ccagcccagg ggaccccaga cgtctccagt gccttggata agctgaagga gtttggaaac 180 acactggagg acaaggctcg ggaactcatc agccgcatca aacagagtga actttctgcc 240 aagatgcggg agtggttttc agagacattt cagaaagtga aggagaaact caagattgac 300 tcatgaggac ctgaagggtg acatccagga ggggcctctg aaatttccca caccccagcg 360 cctgtgctga ggactcccgc catgtggccc caggtgccac caataaaaat cctaccg 417 28 83 PRT Homo sapiens 28 Met Arg Leu Phe Leu Ser Leu Pro Val Leu Val Val Val Leu Ser Ile 1 5 10 15 Val Leu Glu Gly Pro Ala Pro Ala Gln Gly Thr Pro Asp Val Ser Ser 20 25 30 Ala Leu Asp Lys Leu Lys Glu Phe Gly Asn Thr Leu Glu Asp Lys Ala 35 40 45 Arg Glu Leu Ile Ser Arg Ile Lys Gln Ser Glu Leu Ser Ala Lys Met 50 55 60 Arg Glu Trp Phe Ser Glu Thr Phe Gln Lys Val Lys Glu Lys Leu Lys 65 70 75 80 Ile Asp Ser 29 503 DNA Homo sapiens 29 gtgcccgtcc ggagctggtg aggacagcct gccagagtct ggtctctgga cactatgggc 60 acacgactcc tcccagctct gtttcttgtc ctcctggtat tgggatttga ggtccagggg 120 acccaacagc cccagcaaga tgagatgcct agcccgacct tcctcaccca ggtgaaggaa 180 tctctctcca gttactggga gtcagcaaag acagccgccc agaacctgta cgagaagaca 240 tacctgcccg ctgtagatga gaaactcagg gacttgtaca gcaaaagcac agcagccatg 300 agcacttaga caggcatttt tactgaccaa gttctttctg tgctgaaggg agaggagtaa 360 cagccagaca cagccagact ggacaagggg agagtcccct actcccctga tcccccaggt 420 tcagactgag ctcccccttc ccagtagctc ttgcatcctc ctcccaactc tagcctgaat 480 tcttttcaat aaaaaataca att 503 30 84 PRT Homo sapiens 30 Met Gly Thr Arg Leu Leu Pro Ala Leu Phe Leu Val Leu Leu Val Leu 1 5 10 15 Gly Phe Glu Val Gln Gly Thr Gln Gln Pro Gln Gln Asp Glu Met Pro 20 25 30 Ser Pro Thr Phe Leu Thr Gln Val Lys Glu Ser Leu Ser Ser Tyr Trp 35 40 45 Glu Ser Ala Lys Thr Ala Ala Gln Asn Leu Tyr Glu Lys Thr Tyr Leu 50 55 60 Pro Ala Val Asp Glu Lys Leu Arg Asp Leu Tyr Ser Lys Ser Thr Ala 65 70 75 80 Ala Met Ser Thr 31 2597 DNA Homo sapiens 31 gagcagcgcg cgcaagcagg ccaggggaag gtgggcgcag gtgaggggcc gaggtgtgcg 60 caggacttta gccggttgag aaggatcaag caggcatttg gagcacaggt gtctagaaac 120 ttttaagggg ccggttcaag aaggaaaagt tcccttctgc tgtgaaacta tttggcaaga 180 ggctggaggg cccaatggct gcaaaattgc aacccaacat tcccaaagcc aagagtctag 240 atggcgtcac caatgacaga accgcatctc aagggcagtg gggccgtgcc tgggaggtgg 300 actggttttc actggcgagc gtcatcttcc tactgctgtt cgcccccttc atcgtctact 360 acttcatcat ggcttgtgac cagtacagct gcgccctgac cggccctgtg gtggacatcg 420 tcaccggaca tgctcggctc tcggacatct gggccaagac tccacctata acgaggaaag 480 ccgcccagct ctataccttg tgggtcacct tccaggtgct tctgtacacg tctctccctg 540 acttctgcca taagtttcta cccggctacg taggaggcat ccaggagggg gccgtgactc 600 ctgcaggggt tgtgaacaag tatcagatca acggcctgca agcctggctc ctcacgcacc 660 tgctctggtt tgcaaacgct catctcctgt cctggttctc gcccaccatc atcttcgaca 720 actggatccc actgctgtgg tgcgccaaca tccttggcta tgccgtctcc accttcgcca 780 tggtcaaggg ctacttcttc cccaccagcg ccagagactg caaattcaca ggcaatttct 840 tttacaacta catgatgggc atcgagttta accctcggat cgggaagtgg tttgacttca 900 agctgttctt caatgggcgc cccgggatcg tcgcctggac cctcatcaac ctgtccttcg 960 cagcgaagca gcgggagctc cacagccatg tgaccaatgc catggtcctg gtcaacgtcc 1020 tgcaggccat ctacgtgatt gacttcttct ggaacgaaac ctggtacctg aagaccattg 1080 acatctgcca tgaccacttc gggtggtacc tgggctgggg cgactgtgtc tggctgcctt 1140 atctttacac gctgcagggt ctgtacttgg tgtaccaccc cgtgcagctg tccaccccgc 1200 acgccgtggg cgtcctgctg ctgggcctgg tgggctacta catcttccgg gtggccaacc 1260 accagaagga cctgttccgc cgcacggatg ggcgctgcct catctggggc aggaagccca 1320 aggtcatcga gtgctcctac acatccgccg acgggcagag gcaccacagc aagctgctgg 1380 tgtcgggctt ctggggcgtg gcccgccact tcaactacgt cggcgacctg atgggcagcc 1440 tggcctactg cctggcctgt ggcggtggcc acctgctgcc ctacttctac atcatctaca 1500 tggccatcct gctgacccac cgctgcctcc gggacgagca ccgctgcgcc agcaagtacg 1560 gccgggactg ggagcgctac accgccgcag tgccttaccg cctgctgcct ggaatcttct 1620 aagggcacgc cctagggaga agccctgtgg ggctgtcaag agcgtgttct gccaggtcca 1680 tgggggctgg catcccagct ccaactcgag gagcctcagt ttcctcatct gtaaactgga 1740 gagagcccag cacttggcag gtgtccagta cctaatcacg ctctgttcct tgcttttgcc 1800 ttcaagggaa ttccgagtgt ccagcactgc cgtattgcca gcacagacgg attttctcta 1860 atcagtgtcc ctgggcagga ggatgaccca gtcaccttta ctagtccttt ggagacaatt 1920 tacctgtatt aggagcccag gccacgctac actctgccca cactggtgag caggaggtct 1980 tcccacgccc tgtcattagg ctgcatttac tcttgctaaa taaaagtggg agtggggcgt 2040 gcgcgttatc catgtattgc ctttcagctc tagatccccc tcccctgcct gctctgcagt 2100 cgtgggtggg gcccgtgcgc cgtttctcct tggtagcgtg cacggtgttg aactgggaca 2160 ctggggagaa aggggctttc atgtcgtttc cttcctgctc ctgctgcaca gctgccagga 2220 gtgctctgcc tggagtctgc agacctcaga gaggtcccag cactggctgt ggctttcagg 2280 tgtaggcagg tgggctctgc ttcccgattc cctgtgagcg cccaccctct cgaaagaatt 2340 ttctgtcttg ccctgtgact gtgcagactc tggctcgagc aacccgggga acttcaccct 2400 caggggcctc tccacacctt ctccagcgag gaggtctcag tcccagcctc gggagggcac 2460 ctccttttct gtgctttctt ccctgaggca ttcttcctca tccctagggt gttgtgtaga 2520 actcttttta aactctatgc tccgagtaga gttcatcttt atattaaact tcccctgttc 2580 aaaaaaaaaa aaaaaaa 2597 32 475 PRT Homo sapiens 32 Met Ala Ala Lys Leu Gln Pro Asn Ile Pro Lys Ala Lys Ser Leu Asp 1 5 10 15 Gly Val Thr Asn Asp Arg Thr Ala Ser Gln Gly Gln Trp Gly Arg Ala 20 25 30 Trp Glu Val Asp Trp Phe Ser Leu Ala Ser Val Ile Phe Leu Leu Leu 35 40 45 Phe Ala Pro Phe Ile Val Tyr Tyr Phe Ile Met Ala Cys Asp Gln Tyr 50 55 60 Ser Cys Ala Leu Thr Gly Pro Val Val Asp Ile Val Thr Gly His Ala 65 70 75 80 Arg Leu Ser Asp Ile Trp Ala Lys Thr Pro Pro Ile Thr Arg Lys Ala 85 90 95 Ala Gln Leu Tyr Thr Leu Trp Val Thr Phe Gln Val Leu Leu Tyr Thr 100 105 110 Ser Leu Pro Asp Phe Cys His Lys Phe Leu Pro Gly Tyr Val Gly Gly 115 120 125 Ile Gln Glu Gly Ala Val Thr Pro Ala Gly Val Val Asn Lys Tyr Gln 130 135 140 Ile Asn Gly Leu Gln Ala Trp Leu Leu Thr His Leu Leu Trp Phe Ala 145 150 155 160 Asn Ala His Leu Leu Ser Trp Phe Ser Pro Thr Ile Ile Phe Asp Asn 165 170 175 Trp Ile Pro Leu Leu Trp Cys Ala Asn Ile Leu Gly Tyr Ala Val Ser 180 185 190 Thr Phe Ala Met Val Lys Gly Tyr Phe Phe Pro Thr Ser Ala Arg Asp 195 200 205 Cys Lys Phe Thr Gly Asn Phe Phe Tyr Asn Tyr Met Met Gly Ile Glu 210 215 220 Phe Asn Pro Arg Ile Gly Lys Trp Phe Asp Phe Lys Leu Phe Phe Asn 225 230 235 240 Gly Arg Pro Gly Ile Val Ala Trp Thr Leu Ile Asn Leu Ser Phe Ala 245 250 255 Ala Lys Gln Arg Glu Leu His Ser His Val Thr Asn Ala Met Val Leu 260 265 270 Val Asn Val Leu Gln Ala Ile Tyr Val Ile Asp Phe Phe Trp Asn Glu 275 280 285 Thr Trp Tyr Leu Lys Thr Ile Asp Ile Cys His Asp His Phe Gly Trp 290 295 300 Tyr Leu Gly Trp Gly Asp Cys Val Trp Leu Pro Tyr Leu Tyr Thr Leu 305 310 315 320 Gln Gly Leu Tyr Leu Val Tyr His Pro Val Gln Leu Ser Thr Pro His 325 330 335 Ala Val Gly Val Leu Leu Leu Gly Leu Val Gly Tyr Tyr Ile Phe Arg 340 345 350 Val Ala Asn His Gln Lys Asp Leu Phe Arg Arg Thr Asp Gly Arg Cys 355 360 365 Leu Ile Trp Gly Arg Lys Pro Lys Val Ile Glu Cys Ser Tyr Thr Ser 370 375 380 Ala Asp Gly Gln Arg His His Ser Lys Leu Leu Val Ser Gly Phe Trp 385 390 395 400 Gly Val Ala Arg His Phe Asn Tyr Val Gly Asp Leu Met Gly Ser Leu 405 410 415 Ala Tyr Cys Leu Ala Cys Gly Gly Gly His Leu Leu Pro Tyr Phe Tyr 420 425 430 Ile Ile Tyr Met Ala Ile Leu Leu Thr His Arg Cys Leu Arg Asp Glu 435 440 445 His Arg Cys Ala Ser Lys Tyr Gly Arg Asp Trp Glu Arg Tyr Thr Ala 450 455 460 Ala Val Pro Tyr Arg Leu Leu Pro Gly Ile Phe 465 470 475 33 5674 DNA Homo sapiens 33 aaaaagaaag ctaaaaggat tcttcaagaa atggttgcca ctgtctcacc ggcaatgatc 60 agactgactg ggtgggtgct gctaaaactg ttcaacagct tcttttggaa cattcaaatt 120 cacaaaggtc aacttgagat ggttaaagct gcaactgaga cgaatttgcc gcttctgttt 180 ctaccagttc atagatccca tattgactat ctgctgctca ctttcattct cttctgccat 240 aacatcaaag caccatacat tgcttcaggc aataatctca acatcccaat cttcagtacc 300 ttgatccata agcttggggg cttcttcata cgacgaaggc tcgatgaaac accagatgga 360 cggaaagatg ttctctatag agctttgctc catgggcata tagttgaatt acttcgacag 420 cagcaattct tggagatctt cctggaaggc acacgttcta ggagtggaaa aacctcttgt 480 gctcgggcag gacttttgtc agttgtggta gatactctgt ctaccaatgt catcccagac 540 atcttgataa tacctgttgg aatctcctat gatcgcatta tcgaaggtca ctacaatggt 600 gaacaactgg gcaaacctaa gaagaatgag agcctgtgga gtgtagcaag aggtgttatt 660 agaatgttac gaaaaaacta tggttgtgtc cgagtggatt ttgcacagcc attttcctta 720 aaggaatatt tagaaagcca aagtcagaaa ccggtgtctg ctctactttc cctggagcaa 780 gcgttgttac cagctatact tccttcaaga cccagtgatg ctgctgatga aggtagagac 840 acgtccatta atgagtccag aaatgcaaca gatgaatccc tacgaaggag gttgattgca 900 aatctggctg agcatattct attcactgct agcaagtcct gtgccattat gtccacacac 960 attgtggctt gcctgctcct ctacagacac aggcagggaa ttgatctctc cacattggtc 1020 gaagacttct ttgtgatgaa agaggaagtc ctggctcgtg attttgacct ggggttctca 1080 ggaaattcag aagatgtagt aatgcatgcc atacagctgc tgggaaattg tgtcacaatc 1140 acccacacta gcaggaacga tgagtttttt atcaccccca gcacaactgt cccatcagtc 1200 ttcgaactca acttctacag caatggggta cttcatgtct ttatcatgga ggccatcata 1260 gcttgcagcc tttatgcagt tctgaacaag aggggactgg ggggtcccac tagcacccca 1320 cctaacctga tcagccagga gcagctggtg cggaaggcgg ccagcctgtg ctaccttctc 1380 tccaatgaag gcaccatctc actgccttgc cagacatttt accaagtctg ccatgaaaca 1440 gtaggaaagt ttatccagta tggcattctt acagtggcag agcacgatga ccaggaagat 1500 atcagtccta gtcttgctga gcagcagtgg gacaagaagc ttcctgaacc tttgtcttgg 1560 agaagtgatg aagaagatga agacagtgac tttggggagg aacagcgaga ttgctacctg 1620 aaggtgagcc aatccaagga gcaccagcag tttatcacct tcttacagag actccttggg 1680 cctttgctgg aggcctacag ctctgctgcc atctttgttc acaacttcag tggtcctgtt 1740 ccagaacctg agtatctgca aaagttgcac aaatacctaa taaccagaac agaaagaaat 1800 gttgcagtat atgctgagag tgccacatat tgtcttgtga agaatgctgt gaaaatgttt 1860 aaggatattg gggttttcaa ggagaccaaa caaaagagag tgtctgtttt agaactgagc 1920 agcacttttc tacctcaatg caaccgacaa aaacttctag aatatattct gagttttgtg 1980 gtgctgtagg taacgtgtgg cactgctggc aaatgaaggt catgagatga gttccttgta 2040 ggtaccagct tctggctcaa gagttgaagg tgccgtcgca gggtcaggcc tgccctgtcc 2100 cgaggtgatc tcctggaaga caagtgcctt ctccctccat ggatctgtga tcttcccagc 2160 tctgcatcaa cacagcagcc tgcagataac acttgggggg acctcagcct ctattcgcaa 2220 ctcataatcc gtagactaca agatgaaatc tcaataaatt atttttgagt ttattaaaga 2280 ttgacatttt aagtacaacg tttaaggact aattactgtg atggacacag aaatgtagct 2340 gtgttctgga actgaatctt acatggtata cttagtgctg ctgggtaatt tgttggtata 2400 ttatctggtt agtggttaat gcttccttta aaaataattg agtcatccat tcactctttt 2460 tcagttttat ctgtcaatag tagctacatt tttaatggga gcacctttta tcccaaagtg 2520 ctttataaat tgagtggact gatatatatc acacccaggt atcactgtgc tgtcctttgc 2580 tgtcagattt agaaatgttt ttaagagcta tgtgaaaaca gacaatatta gtttaggtcg 2640 ggaactgaga tattgtaatc aaatagttaa catcaggaag ttaatttggc tggcaaaatt 2700 ctagggaaac ttggccagaa aactggtgtt gaaggctttt gctcatataa acaagtgcca 2760 ttgagtttca aatgaccagc aaatatattt agaacccttc ctgttttatg tctgtacctc 2820 gtccacccct caggtaatac ctgcctctca caggtacagc tgtttcttgg aaatcctcca 2880 accaaatagc agttttccta acttgattag cttgagctga cagactgtta gaatacagtt 2940 ctctggccac agctgatgag ggctttctgt actgcacaca gattgtgtac tgcaccccag 3000 tccaggtgac tggtacccac tcgagttgtg ccgtgcacaa cctgtccagt atatgcatgt 3060 ggtggcccta ctgactggta atggttagag gcatttatgg atttttagct ttgaggaaaa 3120 accatgactt ttaacaaatt tttatgggtt atatgcctaa acccttatgc cacatagtgg 3180 taaataatta tgaaaaatgg tctgttcata attggtaggt gccttttgtg agcagggagc 3240 ataattattg gtttattatg gtaattatgg tgattttttt aaatatcatg taatgttaaa 3300 acgttttcta acagtttact gttgcttatc tccaagatat tatggaatta agaatttttc 3360 cagatgagtg ttacatagat tctttgaatt tagtataaaa gtactgagaa ttaagtttgt 3420 acttccataa gcttggattt taaacactga tagtatctca tgagtaatgt gtgttttggg 3480 agagggaggg atgctgattg atatttcaca ttgtatgaaa taccatgttt gaaactcata 3540 gcaataatgc tatgctgttg tgatccctct caagttctgc atttaaaata tattttttct 3600 ttataggaat tgatgtatac catgaagtca ttgtcagttg tagtagctct gatgttgaat 3660 gagatatcat gttttagcat tccattttac tgactagggt agaagaacac ttttcttggc 3720 tacatttgga ggatacccag ggagtcttgg gtgttcctta tctggggaag caaacatttc 3780 actagtctct ttttttcatc ctttaaattg taaattaagg attactcaag ctcaccatta 3840 ttcaagattg ggactcgctt cccagtcgac actctgccct gcctgtcatt gctgcaaaga 3900 gctgctgctt tgccaaccta agcaaagaaa atacggcttc tcttgcatta ttttcccttt 3960 tggttggttt gttttctaga agtacgttca gatgctttgg ggaatgcaat gtatgatttg 4020 ctagctctct caccacttaa ctcactgtga ggataaatat gcatgctttt tgtaattaac 4080 tggtgctttg aaaatctttt ttaagggaga aaaatctcaa ccaaagttat gctcatccag 4140 acaagctgac ctttgagtta atttcagcac aactcattct tcagtgcctc atgactgaaa 4200 acaaaaaaca aaaaaacgaa agcatcttca caatgaagct tccagatagc accgttttgc 4260 taaaagatac attctcattg ttttccaaca gtgatggctt ccacataagg ttaaacaaac 4320 taggtgcttg taaataattt attacagttt actctatcgc atttctgtaa catgaaatgc 4380 atgcccttct tcaggggaag actgtggtca agttaaaaaa aaaaaacaat attaaacaac 4440 atgaaactgc agtctgtttt tgaaaatgag aatgtcctaa gtgattcaga agagaggagg 4500 gaagttgtgc actctgaaaa tgcatgaaaa acaaaggcaa aaactagtgg gaaatgtgta 4560 gaactgttaa ctgagacggc ttcgagtctt ccttctggaa tctgttaaat ttcacaaagt 4620 catgagggta aatggagaaa atatttctgg gattacaatg aatgtaagcc caaattgtgg 4680 aattgccagt aacctggatg gggaaaagca tttcccatag cactccatgt aatatgagtg 4740 ctctgtgaga tgttcatcag tgttttatag aaatggtgtt gctgggaaac caagtttgca 4800 cctggaaact tacaatgcac tttagcgcag taagggcttg gcatccggta gtgaaaaact 4860 gtctaaccca gcattgccca aactattttg acaccaggac ctttttctcc tttgggatac 4920 ttatgaacct ctcactaatg tcctgtggag aacattttgg gaaacactat gttagatagt 4980 tctttaagga gacaaaacgg taatgaacag atagcactgg ggcagaatat gcatgcattt 5040 tgtaacgtcc agtgtggcgt tgaatagatg tgtatttcct cccctgcaga aaataagcac 5100 agaaaattat aatgtaggtg atcggagctc tttcctttga tagagagaac agccccaatg 5160 atcctggctt tttcactgaa cgtatcagaa tacatggatg aattggggta aataaggttt 5220 taattcagat ctagaagaaa gtattgtacg tttgaatgca gatttttatc cacagatagt 5280 tgtagtgttt agacatgaca ggacctatcg ttgaggtttc taagacttac tatgggctgt 5340 aaacctgttt tttaaaacta ttttagaaac ctgagacttg ccgtctggca ttttagttta 5400 atacaaacta atgattgcat ttgaaagaga ttcttgacct tatttctaaa cgtctagagc 5460 tctgaaatgt cttgatggaa ggtattaaac tatttgcctg ttgtacaaag aaatgttaag 5520 actcgtgaaa agaattacta taaggtactg tgaaataact gcgattttgt gagcaaaaca 5580 tacttggaaa tgctgattga tttttatgct tgttagtgta ttgcaagaaa cacagaaaat 5640 gtagttttgt tttaataaac caaaaattga acat 5674 34 662 PRT Homo sapiens 34 Lys Lys Lys Ala Lys Arg Ile Leu Gln Glu Met Val Ala Thr Val Ser 1 5 10 15 Pro Ala Met Ile Arg Leu Thr Gly Trp Val Leu Leu Lys Leu Phe Asn 20 25 30 Ser Phe Phe Trp Asn Ile Gln Ile His Lys Gly Gln Leu Glu Met Val 35 40 45 Lys Ala Ala Thr Glu Thr Asn Leu Pro Leu Leu Phe Leu Pro Val His 50 55 60 Arg Ser His Ile Asp Tyr Leu Leu Leu Thr Phe Ile Leu Phe Cys His 65 70 75 80 Asn Ile Lys Ala Pro Tyr Ile Ala Ser Gly Asn Asn Leu Asn Ile Pro 85 90 95 Ile Phe Ser Thr Leu Ile His Lys Leu Gly Gly Phe Phe Ile Arg Arg 100 105 110 Arg Leu Asp Glu Thr Pro Asp Gly Arg Lys Asp Val Leu Tyr Arg Ala 115 120 125 Leu Leu His Gly His Ile Val Glu Leu Leu Arg Gln Gln Gln Phe Leu 130 135 140 Glu Ile Phe Leu Glu Gly Thr Arg Ser Arg Ser Gly Lys Thr Ser Cys 145 150 155 160 Ala Arg Ala Gly Leu Leu Ser Val Val Val Asp Thr Leu Ser Thr Asn 165 170 175 Val Ile Pro Asp Ile Leu Ile Ile Pro Val Gly Ile Ser Tyr Asp Arg 180 185 190 Ile Ile Glu Gly His Tyr Asn Gly Glu Gln Leu Gly Lys Pro Lys Lys 195 200 205 Asn Glu Ser Leu Trp Ser Val Ala Arg Gly Val Ile Arg Met Leu Arg 210 215 220 Lys Asn Tyr Gly Cys Val Arg Val Asp Phe Ala Gln Pro Phe Ser Leu 225 230 235 240 Lys Glu Tyr Leu Glu Ser Gln Ser Gln Lys Pro Val Ser Ala Leu Leu 245 250 255 Ser Leu Glu Gln Ala Leu Leu Pro Ala Ile Leu Pro Ser Arg Pro Ser 260 265 270 Asp Ala Ala Asp Glu Gly Arg Asp Thr Ser Ile Asn Glu Ser Arg Asn 275 280 285 Ala Thr Asp Glu Ser Leu Arg Arg Arg Leu Ile Ala Asn Leu Ala Glu 290 295 300 His Ile Leu Phe Thr Ala Ser Lys Ser Cys Ala Ile Met Ser Thr His 305 310 315 320 Ile Val Ala Cys Leu Leu Leu Tyr Arg His Arg Gln Gly Ile Asp Leu 325 330 335 Ser Thr Leu Val Glu Asp Phe Phe Val Met Lys Glu Glu Val Leu Ala 340 345 350 Arg Asp Phe Asp Leu Gly Phe Ser Gly Asn Ser Glu Asp Val Val Met 355 360 365 His Ala Ile Gln Leu Leu Gly Asn Cys Val Thr Ile Thr His Thr Ser 370 375 380 Arg Asn Asp Glu Phe Phe Ile Thr Pro Ser Thr Thr Val Pro Ser Val 385 390 395 400 Phe Glu Leu Asn Phe Tyr Ser Asn Gly Val Leu His Val Phe Ile Met 405 410 415 Glu Ala Ile Ile Ala Cys Ser Leu Tyr Ala Val Leu Asn Lys Arg Gly 420 425 430 Leu Gly Gly Pro Thr Ser Thr Pro Pro Asn Leu Ile Ser Gln Glu Gln 435 440 445 Leu Val Arg Lys Ala Ala Ser Leu Cys Tyr Leu Leu Ser Asn Glu Gly 450 455 460 Thr Ile Ser Leu Pro Cys Gln Thr Phe Tyr Gln Val Cys His Glu Thr 465 470 475 480 Val Gly Lys Phe Ile Gln Tyr Gly Ile Leu Thr Val Ala Glu His Asp 485 490 495 Asp Gln Glu Asp Ile Ser Pro Ser Leu Ala Glu Gln Gln Trp Asp Lys 500 505 510 Lys Leu Pro Glu Pro Leu Ser Trp Arg Ser Asp Glu Glu Asp Glu Asp 515 520 525 Ser Asp Phe Gly Glu Glu Gln Arg Asp Cys Tyr Leu Lys Val Ser Gln 530 535 540 Ser Lys Glu His Gln Gln Phe Ile Thr Phe Leu Gln Arg Leu Leu Gly 545 550 555 560 Pro Leu Leu Glu Ala Tyr Ser Ser Ala Ala Ile Phe Val His Asn Phe 565 570 575 Ser Gly Pro Val Pro Glu Pro Glu Tyr Leu Gln Lys Leu His Lys Tyr 580 585 590 Leu Ile Thr Arg Thr Glu Arg Asn Val Ala Val Tyr Ala Glu Ser Ala 595 600 605 Thr Tyr Cys Leu Val Lys Asn Ala Val Lys Met Phe Lys Asp Ile Gly 610 615 620 Val Phe Lys Glu Thr Lys Gln Lys Arg Val Ser Val Leu Glu Leu Ser 625 630 635 640 Ser Thr Phe Leu Pro Gln Cys Asn Arg Gln Lys Leu Leu Glu Tyr Ile 645 650 655 Leu Ser Phe Val Val Leu 660 35 441 DNA Homo sapiens 35 atgcaggtgc taaccaagcg ttaccccaag aactgcctgc tgaccgtcat ggaccggtat 60 gcagccgagg tgcacaacat ggagcaggtg gtgatgatcc ccagccttct gcgggacgtg 120 cagctgagtg ggcctggggg ccaggcccag gctgaggccc ctgatctcta cacctacttc 180 accatgctca aggccatctg tgtggatgtg gaccatgggc tgctgccgcg ggaggagtgg 240 caggccaagg tggcaggcag cgaagagaat ggaaccgcag agacagagga agtcgaggac 300 gagagtgcct caggagagct ggacctggaa gcccagttcc acctgcactt ctccagcctc 360 catcacatcc tcatgcacct caccgagaaa gcccaggagg tgacaaggaa ataccaggaa 420 atgacgggac aagtttggta g 441 36 146 PRT Homo sapiens 36 Met Gln Val Leu Thr Lys Arg Tyr Pro Lys Asn Cys Leu Leu Thr Val 1 5 10 15 Met Asp Arg Tyr Ala Ala Glu Val His Asn Met Glu Gln Val Val Met 20 25 30 Ile Pro Ser Leu Leu Arg Asp Val Gln Leu Ser Gly Pro Gly Gly Gln 35 40 45 Ala Gln Ala Glu Ala Pro Asp Leu Tyr Thr Tyr Phe Thr Met Leu Lys 50 55 60 Ala Ile Cys Val Asp Val Asp His Gly Leu Leu Pro Arg Glu Glu Trp 65 70 75 80 Gln Ala Lys Val Ala Gly Ser Glu Glu Asn Gly Thr Ala Glu Thr Glu 85 90 95 Glu Val Glu Asp Glu Ser Ala Ser Gly Glu Leu Asp Leu Glu Ala Gln 100 105 110 Phe His Leu His Phe Ser Ser Leu His His Ile Leu Met His Leu Thr 115 120 125 Glu Lys Ala Gln Glu Val Thr Arg Lys Tyr Gln Glu Met Thr Gly Gln 130 135 140 Val Trp 145 37 5307 DNA Homo sapiens 37 ccacgcgcgg cgccgctcgg tgcagaccat gaattacgtg gggcagttag ccggccaggt 60 gtttgtcacc gtgaaggagc tctacaaggg gctgaatccc gccacactct cagggtgcat 120 tgacatcatt gtcatccgcc agcccaatgg aaacctccaa tgctcccctt tccacgtccg 180 ctttgggaag atgggggtcc tgcgctcccg agagaaagtg gttgacatag aaatcaatgg 240 ggaatctgtg gatttgcata tgaaattggg agataatgga gaagcatttt ttgttcaaga 300 aacagataat gatcaggaag ttatccctat gcacctggcc acctccccca tcctgtcaga 360 aggagcttcg agaatggaat gccagctgaa aaggggctct gtggacagga tgagaggcct 420 ggaccccagc acgccagccc aagtgatcgc tcccagcgag acgccgtcaa gcagctctgt 480 agtaaagaag agaagaaaaa ggaggagaaa gtcacagctg gacagcctga agagagatga 540 caacatgaac acatctgagg atgaggacat gttccccatc gagatgagct cggatgaggc 600 catggagctg ctggagagca gcagaactct tcctaatgat atacctccat tccaagatga 660 tattcctgag gaaaacctct ccctggctgt gatttaccct cagtcagcct cataccctaa 720 ttcggataga gagtggtcac ccactcccag tccttccggt tcccgacctt caacacctaa 780 aagtgattca gaattggtca gcaagtccac ggaaaggaca gggcagaaga acccagaaat 840 gctttggctg tggggagagc tgccgcaggc tgctaagtct tcttctccac acaagatgaa 900 agagtccagc ccattgagca gtagaaaaat ttgtgataaa agtcactttc aggccattca 960 cagcgaatct tcagacactt ttagtgacca atcgccaact ctggtcggtg gggcactttt 1020 ggaccagaac aagcctcaga cagaaatgca gtttgtgaat gaagaagacc tggagacctt 1080 aggagcagca gcgccactct tgcccatgat cgaggagctc aaacccccct ctgccagtgt 1140 agtccagaca gcaaacaaga cggattctcc ttccaggaaa agagataaac gaagccgaca 1200 tcttggtgct gacggcgtct acttggatga cctcacagac atggatcctg aagtggcggc 1260 cctgtatttt cccaaaaacg gagatccttc cggactcgca aaacatgcaa gcgacaacgg 1320 agcccggtca gccaaccagt ccccgcagtc ggtgggcagc tcgggcgtgg acagtggcgt 1380 ggagagcacc tcggacgggc tgagggacct cccttccatc gccatctccc tctgcggggg 1440 cctcagcgac caccgggaga tcacgaaaga tgcattcctg gagcaagctg tgtcatatca 1500 acagtttgtg gacaaccccg ctattatcga tgaccccaat ctcgtggtaa agattgggag 1560 taaatattat aactggacaa cagcagcacc cctcctcctg gcaatgcagg ccttccagaa 1620 acctttgcca aaggccactg tggaatctat catgagggat aaaatgccca aaaagggagg 1680 aagatggtgg ttttcatgga ggggaagaaa caccacaatc aaggaggaaa gtaagccaga 1740 gcagtgcttg gctggcaagg cccatagcac cggagagcaa ccgccgcagc tcagcttggc 1800 caccagggta aagcatgaat catcctccag tgatgaggag cgcgcagctg ccaagccatc 1860 aaacgcaggc cacctccctc ttctgcctaa tgtcagctac aagaagactc tccggctgac 1920 ttccgagcag cttaaaagct tgaagttgaa gaatggcccc aacgacgtgg ttttcagtgt 1980 caccacgcag taccaaggca cgtgccgctg tgagggcacc atctatctgt ggaactggga 2040 tgataaagtc atcatttctg atattgatgg gacaattacc agatcagata ctcttggcca 2100 cattttgccc acccttggga aggattggac ccatcagggc atcgctaagc tgtaccataa 2160 agtgagccag aatggatata aatttctcta ctgttctgcc cgtgccatcg ggatggcgga 2220 catgacgcgg ggctacctgc actgggtcaa cgagaggggc acggtgctgc cccaggggcc 2280 cctgctgctg agtcccagca gcctcttctc tgccctgcac agagaagtga ttgaaaagaa 2340 gccagaaaag tttaaagtcc agtgtttgac agacatcaaa aacctgtttt tccccaacac 2400 agaacccttt tatgctgctt ttggaaaccg accagctgat gtgtattcat acaagcaagt 2460 aggagtgtct ttgaatagaa tatttaccgt caaccctaaa ggagagctgg tacaggaaca 2520 tgcaaagacc aacatctctt cgtatgtgag actctgtgaa gtagtcgacc acgttttccc 2580 gttgctgaaa agaagccatt cttcagactt tccctgttcg gataccttca gtaacttcac 2640 cttttggaga gagccactgc caccttttga aaaccaggac attcattctg cctcagcgta 2700 aaatgtccca agcagcctct tgccagcagt gcagagcctg gttgtcaccc attaaaggat 2760 aggtctcccc ggagtgcaca gctccacctg ggagcctggc gcgtcatcat tggcctgaca 2820 gcagagagaa ttgagaagca tttctcccct gccccacccc ggggctgaca tttctaagca 2880 agataggaag ggagcacttt ctaggctagg agttgggtgc atttgtaccg tgaaaagcat 2940 tcctcagttg tggcttaatg ccagttacga cgctgccttt ccggcctgct ccagcaagta 3000 gctactggtt cacgtgcagt ttggggctgt gaaacctagg cagaaggcgg ctgtctgagg 3060 gctgtccccg cctaggacag ggtcaatcga ggaatgccag atgtgcacgg tttttggcaa 3120 agtagggggc acatttccat tatagcaatg ttagtgccac caccttctga acacagtggg 3180 gagggctgtg aaggctcatg tgacctggat ctgaggtctc tgatagaaat ctggacgcca 3240 ccgggtccag gcctggcctc agacttggcc ttgtggatgg gccccttaca gtatttgctg 3300 actagtctca tttttaggtg ataagttttt ctttaattcc tttggttaaa gatagtctat 3360 ttcattggca tatctccccc cagtttttgt ggctcaaggc tggaatattt atgccttaat 3420 atatctatgg cagacattta agaatgcgct ttatctagct catggtaact ttgcaacgcc 3480 ttagattaaa atgacagtaa atattactaa ggcagtattt tgaatgagtt tgacactgcc 3540 ggcttccttc catccagcga ggtggtgctg acagtgtgga cttgagcaca cttatgccaa 3600 atgataatga tactgacttc tgttgggagc tctccaaaga aactggttgg ttttaagaaa 3660 atagtttcaa gaagttcaac tatattcttt tagatattat gtattgtttt actctgatta 3720 ggttactgtg ataggcattt attcatattc tttctatacc actgtcatta atatattaaa 3780 aagatgtatg tgttagacta tcgaaagggc cttattctct ctttctcata gactgacctt 3840 cttttggaat ttctgagtca tttattttcc ttagcttttt ccactcaaat taagggcaag 3900 cgaaaaagta ataatttggc attctttaag cctacagaat gtgattcttt cacttgttta 3960 ttacactggc tcgtggacag aacaatttga aaagtgaaag aattattttg gtaaaagatt 4020 ttgctttact tttcgaagca ttattttttt aaagagtgtt ttactccaac gattgaaaca 4080 ttttcctatt taaatttcat cgttagaatc acaggaggca aaaaatggaa cggttgaatg 4140 aaattttact ctttctgtga aagaaaatcc acagagttgt tgcctccgtt gtagttggtg 4200 ggccccgtta gcattggatg cctttgccaa atggttcatg tggacacaca aaggcaaaca 4260 gatctgccat cgatcgcaga tttctgtaga aacacggatg tgcatgtgca gattcccttt 4320 tgcaggtatt aaaaataatt aaaaatagtc ctgcctgagg ttgcagtgag ccgagcttgc 4380 actactgcac tccagcctgg gtgacagagt aagactccat gtcaaaaaaa aaaaaaaaaa 4440 aaaaaagtcc tgccttaact aactcctctg cgcttgttca ctagtaacct aaagaggcta 4500 tattcattct ttatgcaatg agggtatttt tgagtgaatt ttaactgctc tgaactaagt 4560 ataagctcat gggcctgcaa aggttcagac ggtttctcct ttgcacccag gaggaacttt 4620 ggctgcgaga atggggggat gtatccctca tgcagttggc atccaggcag ccctctgcag 4680 cagcacaccc tgcaggcgga gttttcagag gatgcaattt tggatcccga attttgatgt 4740 accttaaact tccacatcac tgcaccctga aacagagcat gctttccaga aagtcacact 4800 ctcagatctg tgtcaagttc aatgtgagcc ctggcaaggc tggcatatta acacctgcct 4860 tctggcttct gaaagtgaga tttgtatatg ggctgcactc acgcatatac gagttggttt 4920 atctttgtgt acatgactat aacccagtga tgctgaggtc atgtgctgga atgctgtatt 4980 tggaccacac atttcaaagt tgccctatgg aaatgaatcc tacttagtga caagtcatca 5040 aatgtttgtc acatgtgatg aagacaaata tgtatacctg gcatagagaa aaatatatac 5100 ctggtacatt ggagaaaaat aattacactt tcaaagagaa ttccctttgc aattttatgt 5160 ttggatcacc actgtaagca cactttattt gcatttgatc tgtatttgta tatgctgatg 5220 caatgataaa aatcactgta atacttcatt gtgttgtact ggatgcaaag ctagaaaata 5280 ttgcaataaa tgagaccgat gaaagac 5307 38 899 PRT Homo sapiens 38 His Ala Arg Arg Arg Ser Val Gln Thr Met Asn Tyr Val Gly Gln Leu 1 5 10 15 Ala Gly Gln Val Phe Val Thr Val Lys Glu Leu Tyr Lys Gly Leu Asn 20 25 30 Pro Ala Thr Leu Ser Gly Cys Ile Asp Ile Ile Val Ile Arg Gln Pro 35 40 45 Asn Gly Asn Leu Gln Cys Ser Pro Phe His Val Arg Phe Gly Lys Met 50 55 60 Gly Val Leu Arg Ser Arg Glu Lys Val Val Asp Ile Glu Ile Asn Gly 65 70 75 80 Glu Ser Val Asp Leu His Met Lys Leu Gly Asp Asn Gly Glu Ala Phe 85 90 95 Phe Val Gln Glu Thr Asp Asn Asp Gln Glu Val Ile Pro Met His Leu 100 105 110 Ala Thr Ser Pro Ile Leu Ser Glu Gly Ala Ser Arg Met Glu Cys Gln 115 120 125 Leu Lys Arg Gly Ser Val Asp Arg Met Arg Gly Leu Asp Pro Ser Thr 130 135 140 Pro Ala Gln Val Ile Ala Pro Ser Glu Thr Pro Ser Ser Ser Ser Val 145 150 155 160 Val Lys Lys Arg Arg Lys Arg Arg Arg Lys Ser Gln Leu Asp Ser Leu 165 170 175 Lys Arg Asp Asp Asn Met Asn Thr Ser Glu Asp Glu Asp Met Phe Pro 180 185 190 Ile Glu Met Ser Ser Asp Glu Ala Met Glu Leu Leu Glu Ser Ser Arg 195 200 205 Thr Leu Pro Asn Asp Ile Pro Pro Phe Gln Asp Asp Ile Pro Glu Glu 210 215 220 Asn Leu Ser Leu Ala Val Ile Tyr Pro Gln Ser Ala Ser Tyr Pro Asn 225 230 235 240 Ser Asp Arg Glu Trp Ser Pro Thr Pro Ser Pro Ser Gly Ser Arg Pro 245 250 255 Ser Thr Pro Lys Ser Asp Ser Glu Leu Val Ser Lys Ser Thr Glu Arg 260 265 270 Thr Gly Gln Lys Asn Pro Glu Met Leu Trp Leu Trp Gly Glu Leu Pro 275 280 285 Gln Ala Ala Lys Ser Ser Ser Pro His Lys Met Lys Glu Ser Ser Pro 290 295 300 Leu Ser Ser Arg Lys Ile Cys Asp Lys Ser His Phe Gln Ala Ile His 305 310 315 320 Ser Glu Ser Ser Asp Thr Phe Ser Asp Gln Ser Pro Thr Leu Val Gly 325 330 335 Gly Ala Leu Leu Asp Gln Asn Lys Pro Gln Thr Glu Met Gln Phe Val 340 345 350 Asn Glu Glu Asp Leu Glu Thr Leu Gly Ala Ala Ala Pro Leu Leu Pro 355 360 365 Met Ile Glu Glu Leu Lys Pro Pro Ser Ala Ser Val Val Gln Thr Ala 370 375 380 Asn Lys Thr Asp Ser Pro Ser Arg Lys Arg Asp Lys Arg Ser Arg His 385 390 395 400 Leu Gly Ala Asp Gly Val Tyr Leu Asp Asp Leu Thr Asp Met Asp Pro 405 410 415 Glu Val Ala Ala Leu Tyr Phe Pro Lys Asn Gly Asp Pro Ser Gly Leu 420 425 430 Ala Lys His Ala Ser Asp Asn Gly Ala Arg Ser Ala Asn Gln Ser Pro 435 440 445 Gln Ser Val Gly Ser Ser Gly Val Asp Ser Gly Val Glu Ser Thr Ser 450 455 460 Asp Gly Leu Arg Asp Leu Pro Ser Ile Ala Ile Ser Leu Cys Gly Gly 465 470 475 480 Leu Ser Asp His Arg Glu Ile Thr Lys Asp Ala Phe Leu Glu Gln Ala 485 490 495 Val Ser Tyr Gln Gln Phe Val Asp Asn Pro Ala Ile Ile Asp Asp Pro 500 505 510 Asn Leu Val Val Lys Ile Gly Ser Lys Tyr Tyr Asn Trp Thr Thr Ala 515 520 525 Ala Pro Leu Leu Leu Ala Met Gln Ala Phe Gln Lys Pro Leu Pro Lys 530 535 540 Ala Thr Val Glu Ser Ile Met Arg Asp Lys Met Pro Lys Lys Gly Gly 545 550 555 560 Arg Trp Trp Phe Ser Trp Arg Gly Arg Asn Thr Thr Ile Lys Glu Glu 565 570 575 Ser Lys Pro Glu Gln Cys Leu Ala Gly Lys Ala His Ser Thr Gly Glu 580 585 590 Gln Pro Pro Gln Leu Ser Leu Ala Thr Arg Val Lys His Glu Ser Ser 595 600 605 Ser Ser Asp Glu Glu Arg Ala Ala Ala Lys Pro Ser Asn Ala Gly His 610 615 620 Leu Pro Leu Leu Pro Asn Val Ser Tyr Lys Lys Thr Leu Arg Leu Thr 625 630 635 640 Ser Glu Gln Leu Lys Ser Leu Lys Leu Lys Asn Gly Pro Asn Asp Val 645 650 655 Val Phe Ser Val Thr Thr Gln Tyr Gln Gly Thr Cys Arg Cys Glu Gly 660 665 670 Thr Ile Tyr Leu Trp Asn Trp Asp Asp Lys Val Ile Ile Ser Asp Ile 675 680 685 Asp Gly Thr Ile Thr Arg Ser Asp Thr Leu Gly His Ile Leu Pro Thr 690 695 700 Leu Gly Lys Asp Trp Thr His Gln Gly Ile Ala Lys Leu Tyr His Lys 705 710 715 720 Val Ser Gln Asn Gly Tyr Lys Phe Leu Tyr Cys Ser Ala Arg Ala Ile 725 730 735 Gly Met Ala Asp Met Thr Arg Gly Tyr Leu His Trp Val Asn Glu Arg 740 745 750 Gly Thr Val Leu Pro Gln Gly Pro Leu Leu Leu Ser Pro Ser Ser Leu 755 760 765 Phe Ser Ala Leu His Arg Glu Val Ile Glu Lys Lys Pro Glu Lys Phe 770 775 780 Lys Val Gln Cys Leu Thr Asp Ile Lys Asn Leu Phe Phe Pro Asn Thr 785 790 795 800 Glu Pro Phe Tyr Ala Ala Phe Gly Asn Arg Pro Ala Asp Val Tyr Ser 805 810 815 Tyr Lys Gln Val Gly Val Ser Leu Asn Arg Ile Phe Thr Val Asn Pro 820 825 830 Lys Gly Glu Leu Val Gln Glu His Ala Lys Thr Asn Ile Ser Ser Tyr 835 840 845 Val Arg Leu Cys Glu Val Val Asp His Val Phe Pro Leu Leu Lys Arg 850 855 860 Ser His Ser Ser Asp Phe Pro Cys Ser Asp Thr Phe Ser Asn Phe Thr 865 870 875 880 Phe Trp Arg Glu Pro Leu Pro Pro Phe Glu Asn Gln Asp Ile His Ser 885 890 895 Ala Ser Ala 39 1768 DNA Homo sapiens 39 ggcacgaggc tcaggcctga cggtccgagt ggagctgcgg gacagcccga acctccaggt 60 cagccccgcg gccctccatg gcgctggtgc gcgcactcgt ctgctgcctg ctgactgcct 120 ggcactgccg ctccggcctc gggctgcccg tggcgcccgc aggcggcagg aatcctcctc 180 cggcgatagg acagttttgg catgtgactg acttacactt agaccctact taccacatca 240 cagatgacca cacaaaagtg tgtgcttcat ctaaaggtgc aaatgcctcc aaccctggcc 300 cttttggaga tgttctgtgt gattctccat atcaacttat tttgtcagca tttgatttta 360 ttaaaaattc tggacaagaa gcatctttca tgatatggac aggggatagc ccacctcatg 420 ttcctgtacc tgaactctca acagacactg ttataaatgt gatcactaat atgacaacca 480 ccatccagag tctctttcca aatctccagg ttttccctgc gctgggtaat catgactatt 540 ggccacagga tcaactgcct gtagtcacca gtaaagtgta caatgcagta gcaaacctct 600 ggaaaccatg gctagatgaa gaagctatta gtactttaag gaaaggtggt ttttattcac 660 agaaagttac aactaatcca aaccttagga tcatcagtct aaacacaaac ttgtactacg 720 gcccaaatat aatgacactg aacaagactg acccagccaa ccagtttgaa tggctagaaa 780 gtacattgaa caactctcag cagaataagg agaaggtgta tatcatagca catgttccag 840 tggggtatct gccatcttca cagaacatca cagcaatgag agaatactat aatgagaaat 900 tgatagatat ttttcaaaaa tacagtgatg tcattgcagg acaattttat ggacacactc 960 acagagacag cattatggtt ctttcagata aaaaaggaag tccagtaaat tctttgtttg 1020 tggctcctgc tgttacacca gtgaagagtg ttttagaaaa acagaccaac aatcctggta 1080 tcagactgtt tcagtatgat cctcgtgatt ataaattatt ggatatgttg cagtattact 1140 tgaatctgac agaggcgaat ctaaagggag agtccatctg gaagctggag tatatcctga 1200 cccagaccta cgacattgaa gatttgcagc cggaaagttt atatggatta gctaaacaat 1260 ttacaatcct agacagtaag cagtttataa aatactacaa ttacttcttt gtgagttatg 1320 acagcagtgt aacatgtgat aagacatgta aggcctttca gatttgtgca attatgaatc 1380 ttgataatat ttcctatgca gattgcctca aacagcttta tataaagcac aattactagt 1440 atttcacagt ttttgctaat agaaaatgct gattctgatt ctgagatcaa tttgtgggaa 1500 ttttacataa atctttgtta attactgagt gggcaagtag acttcctgtc tttgctttct 1560 tttttttttc tttttgatgc cttaatgtag atatctttat cattctgaat tgtattatat 1620 atttaaagtg ctcattaata gaatgatgga tgtaaattgg atgtaaatat tcagtttata 1680 taattatatc taatttgtac ccttgttgaa attgtcattt atacaataaa gcgaattctt 1740 tatctctaaa aaaaaaaaaa aaaaaaaa 1768 40 453 PRT Homo sapiens 40 Met Ala Leu Val Arg Ala Leu Val Cys Cys Leu Leu Thr Ala Trp His 1 5 10 15 Cys Arg Ser Gly Leu Gly Leu Pro Val Ala Pro Ala Gly Gly Arg Asn 20 25 30 Pro Pro Pro Ala Ile Gly Gln Phe Trp His Val Thr Asp Leu His Leu 35 40 45 Asp Pro Thr Tyr His Ile Thr Asp Asp His Thr Lys Val Cys Ala Ser 50 55 60 Ser Lys Gly Ala Asn Ala Ser Asn Pro Gly Pro Phe Gly Asp Val Leu 65 70 75 80 Cys Asp Ser Pro Tyr Gln Leu Ile Leu Ser Ala Phe Asp Phe Ile Lys 85 90 95 Asn Ser Gly Gln Glu Ala Ser Phe Met Ile Trp Thr Gly Asp Ser Pro 100 105 110 Pro His Val Pro Val Pro Glu Leu Ser Thr Asp Thr Val Ile Asn Val 115 120 125 Ile Thr Asn Met Thr Thr Thr Ile Gln Ser Leu Phe Pro Asn Leu Gln 130 135 140 Val Phe Pro Ala Leu Gly Asn His Asp Tyr Trp Pro Gln Asp Gln Leu 145 150 155 160 Pro Val Val Thr Ser Lys Val Tyr Asn Ala Val Ala Asn Leu Trp Lys 165 170 175 Pro Trp Leu Asp Glu Glu Ala Ile Ser Thr Leu Arg Lys Gly Gly Phe 180 185 190 Tyr Ser Gln Lys Val Thr Thr Asn Pro Asn Leu Arg Ile Ile Ser Leu 195 200 205 Asn Thr Asn Leu Tyr Tyr Gly Pro Asn Ile Met Thr Leu Asn Lys Thr 210 215 220 Asp Pro Ala Asn Gln Phe Glu Trp Leu Glu Ser Thr Leu Asn Asn Ser 225 230 235 240 Gln Gln Asn Lys Glu Lys Val Tyr Ile Ile Ala His Val Pro Val Gly 245 250 255 Tyr Leu Pro Ser Ser Gln Asn Ile Thr Ala Met Arg Glu Tyr Tyr Asn 260 265 270 Glu Lys Leu Ile Asp Ile Phe Gln Lys Tyr Ser Asp Val Ile Ala Gly 275 280 285 Gln Phe Tyr Gly His Thr His Arg Asp Ser Ile Met Val Leu Ser Asp 290 295 300 Lys Lys Gly Ser Pro Val Asn Ser Leu Phe Val Ala Pro Ala Val Thr 305 310 315 320 Pro Val Lys Ser Val Leu Glu Lys Gln Thr Asn Asn Pro Gly Ile Arg 325 330 335 Leu Phe Gln Tyr Asp Pro Arg Asp Tyr Lys Leu Leu Asp Met Leu Gln 340 345 350 Tyr Tyr Leu Asn Leu Thr Glu Ala Asn Leu Lys Gly Glu Ser Ile Trp 355 360 365 Lys Leu Glu Tyr Ile Leu Thr Gln Thr Tyr Asp Ile Glu Asp Leu Gln 370 375 380 Pro Glu Ser Leu Tyr Gly Leu Ala Lys Gln Phe Thr Ile Leu Asp Ser 385 390 395 400 Lys Gln Phe Ile Lys Tyr Tyr Asn Tyr Phe Phe Val Ser Tyr Asp Ser 405 410 415 Ser Val Thr Cys Asp Lys Thr Cys Lys Ala Phe Gln Ile Cys Ala Ile 420 425 430 Met Asn Leu Asp Asn Ile Ser Tyr Ala Asp Cys Leu Lys Gln Leu Tyr 435 440 445 Ile Lys His Asn Tyr 450 41 2643 DNA Homo sapiens 41 cgcatctcag gcgcagtctc taggggctgt gcgcatccta gggggggaca tgtgcatctc 60 aggggggctg ctcgcatctg gggggtgctg tgtgcatctc gggggggctg tgcatctagc 120 ggggtggctg tgtccgcatc tggagggggc tgtgcgcaac ccgggggggg tgttgcgcgc 180 atctagcagg ggcggctgtg cgcatttcgg gggggggctg tgcatatctg gggggaccgt 240 gcttatctct gggggcggct gtgcgcatct tgaggggtgt gtacatctcg gggggcctgt 300 gcgcatcttg gggggctgtg tgcatccgcg ggggctgtgc gcatctcggg tgctgtgcgc 360 tgctcctctg agctctgctc tttcttgcag cgtttgcctc agccatggag ggcggggccg 420 cggcagccac ccccacagca ctgccttact acgtggcctt ctcccagctg ctgggcctga 480 ccttggtggc catgaccggc gcgtggctcg ggctgtaccg aggcggcatt gcctgggaga 540 gcgacctgca gttcaacgcg caccccctct gcatggtcat aggcctgatc ttcctgcagg 600 gaaatgccct gctggtttac cgtgtcttca ggaacgaagc taaacgcacc accaaggtcc 660 tgcacgggct gctgcacatc tttgcgctcg tcatcgccct ggttggcttg gtggcggtgt 720 tcgactacca caggaagaag ggctacgctg acctgtacag cctacacagc tggtgcggga 780 tccttgtctt tgtcctgtac tttgtgcagt ggctggtggg cttcagcttc ttcctgttcc 840 ccggagcttc attctccctg cggagccgct accgcccaca gcacatcttc tttggtgcta 900 ccatcttcct ccttcccgtg ggcaccgccc tgctgggcct gaaggaggca ctgctgttca 960 acctcggggg caagtatagc gcatttgagc ccgagggtgt cctggccaac gtgctgggcc 1020 tgctgctggc ctgcttcggt ggggcggtgc tctacatctt gacccgggcc gactggaagc 1080 ggccttccca ggcggaagag caggccctct ccatggactt caagacgctg aggcagggag 1140 atagccccgg ctcccagtga tgcgcccggc cggccctggg ggttcgcggg gtgtcttctt 1200 gcctgcccct gctgaggcgt cttcaggact gcaggctccg gagagtggct ctggcagcag 1260 gcgggcgggt gggtgcaggg ggatccgttt gatgcgtcgt ttctggggca ggtctccgcc 1320 tcctctgctt ctcgtttctc cgctgctata gaccagttca ttgtgtgtgg ctcccgtgtc 1380 tctgttgccc ccttcagtgc agaaggcttt gggtagactt cgggtgttcg gtcctggtcg 1440 cagagcacag atctttaaag aagcgttaga gaggtaggtt ctaccctctt ggtagtagat 1500 gcctggggca aggcccaggg gaaactgggg gggcctcagg gacaggcctg gaaaggccac 1560 gatggcctgc tgaattcaaa caaggagtcc ctccagcctg aataacacgt ggcacaaatg 1620 ggcccggcct ttggcagagg agcaagtgat atgatgtgta aagtatgttg gtggtgaaag 1680 caaggttccc caggagaggg gagggactgg cccctgggaa gctctgagat gaggctgtgg 1740 cccagctgta gtcctgacct tactcttctt taaaaccctt tagccctagg atggctttgg 1800 tgggagaggg gatagaagcc catgacttca gacagacttt ctcttggcag atgcaggcag 1860 gcctcctccc aggctgctcc agacatgggg gttggggatg gggggtacct tgcagcccct 1920 tcctgctggg gctccctcct tgtagcaccc ccttgcggct cagctctggt ttcctctccc 1980 aggctcaccc aggctctgct caggctggga ggcagagggc acaaacctta taatttttta 2040 aatgaaaaac cgctgctgct ggctgtggct agagccccct ggggctgctg gagctgctgc 2100 ctctgttctg gaggacgagc cttctcctta tctgctgccc atctttccag gaagtcagga 2160 tggagtcaga caactaacga tcatcccccg tggtgtctgc acatcactcc agccccataa 2220 agagtgtcat gttagctgag tcaccatttg gcttcggcct ggaaatagtg tgttagaaca 2280 ctgatcgtgt gcgaggccag gagatcaaga ccatcctgac taacaaacac agtgaaaccc 2340 cgtctctacg gaattccctg tattagtcta tatggttctc caagaaactg aatgaatcca 2400 ttggagaagc ggtggataac tagccagaca aaatttgaga atacataaac aacgcattcc 2460 gcaggaaaca tacagaggat gccttttctg tgattgggtg ggattttttc cctttttatg 2520 tggatatagt agttacttgt gacaagaata attttggaat aatttctatt aatatcaact 2580 ctgaagctaa ttgtacataa tctcgagatt gtgtttgttc ataataaaag tgaagtgaat 2640 ctg 2643 42 247 PRT Homo sapiens 42 Ala Ala Ala Ala Thr Pro Thr Ala Leu Pro Tyr Tyr Val Ala Phe Ser 1 5 10 15 Gln Leu Leu Gly Leu Thr Leu Val Ala Met Thr Gly Ala Trp Leu Gly 20 25 30 Leu Tyr Arg Gly Gly Ile Ala Trp Glu Ser Asp Leu Gln Phe Asn Ala 35 40 45 His Pro Leu Cys Met Val Ile Gly Leu Ile Phe Leu Gln Gly Asn Ala 50 55 60 Leu Leu Val Tyr Arg Val Phe Arg Asn Glu Ala Lys Arg Thr Thr Lys 65 70 75 80 Val Leu His Gly Leu Leu His Ile Phe Ala Leu Val Ile Ala Leu Val 85 90 95 Gly Leu Val Ala Val Phe Asp Tyr His Arg Lys Lys Gly Tyr Ala Asp 100 105 110 Leu Tyr Ser Leu His Ser Trp Cys Gly Ile Leu Val Phe Val Leu Tyr 115 120 125 Phe Val Gln Trp Leu Val Gly Phe Ser Phe Phe Leu Phe Pro Gly Ala 130 135 140 Ser Phe Ser Leu Arg Ser Arg Tyr Arg Pro Gln His Ile Phe Phe Gly 145 150 155 160 Ala Thr Ile Phe Leu Leu Pro Val Gly Thr Ala Leu Leu Gly Leu Lys 165 170 175 Glu Ala Leu Leu Phe Asn Leu Gly Gly Lys Tyr Ser Ala Phe Glu Pro 180 185 190 Glu Gly Val Leu Ala Asn Val Leu Gly Leu Leu Leu Ala Cys Phe Gly 195 200 205 Gly Ala Val Leu Tyr Ile Leu Thr Arg Ala Asp Trp Lys Arg Pro Ser 210 215 220 Gln Ala Glu Glu Gln Ala Leu Ser Met Asp Phe Lys Thr Leu Arg Gln 225 230 235 240 Gly Asp Ser Pro Gly Ser Gln 245 43 2587 DNA Homo sapiens 43 aggcgctgcg gccgtcccgg gccgtgactc ctcctttccc ccgccccgcc tccgttcgga 60 gagccggcgg gcgggcgcct ctcggccagg tacgcggccg gctgggatag gggtcgcggg 120 cgggctttgg tcgcgcagca gccggtcctc cccggaggta ggcgggcgcg ggccctgttg 180 ggtctttggg acgcgggtcc cgctggggcc ggggatgctc ctctctgtga gcgcggtccc 240 gtccccccct gtccccgggc gggcgcacgg gggtctaacc ttggggggcg gcgctcccgc 300 ctgtcccggg tgccggggtt cgcgtcccgc ggggccttcc tcgctctttg tctcttctga 360 gtgaacttga tgaccccctt cttccaggaa gcgcctcttg gacgcgtgtg accgatgccc 420 agattgcacg accacttctg gagctgctcc tgtgcgcaca gcgcgaggcg ccgaggcccc 480 ccgcgagcca gcaccgcggg gctgccgccc aaggttgggg agatgatcaa cgtttccgtg 540 tccgggccct ccctgctggc ggcccacggt gccccggacg ctgaccccgc gcccaggggc 600 cgcagtgctg cgatgagcgg ccccgagccc ggcagcccct accccaacac ctggcatcat 660 cgcctgttgc agaggagcct cgtgctcttc tcggttgggg tggtcctaac cctggtgctc 720 aacctgctgc agatccagag gaatgtcact ctcttccccg aggaggtgat cgccaccatc 780 ttttcctccg cctggtgggt ccctccctgc tgcgggacag cagctgctgt tgttggccta 840 ctgtacccct gtatcgacag tcacctcgga gaaccccaca aatttaagag agaatgggcc 900 agtgtcatgc gctgcatagc aggttttggt ggcattaacc acgccagtgc taaattggat 960 tttgccaata atgtccagct gtccttgact ttagcagccc tatctttggg cctttggtgg 1020 acatttgatc gttccagaag tggccttggg ctggggatca ccatagcttt tctagctacg 1080 ctgatcacgc agtttctcgt gtataatggt gtctatcagt atacgtcccc agatttcctc 1140 tatattcgtt cttggctccc ttgtatattt ttctcaggag gcgtcacggt ggggaacata 1200 ggacgacagt tagctatggg tgttcctgaa aagccccata gtgattgagt cttcaaaacc 1260 accgattctg agagcaagga agattttgga agaaaatctg actgtggatt atgacaaaga 1320 ttatcttttt tcttaagtaa tctatttaga tcgggctgac tgtacaaatg actcctggaa 1380 aaaactcgtc acctatctag aaaagtcaag aatagggagg tggagaatga tgacttaccc 1440 tgaagtcttc ccttgctacc cacactggcg cctgtctgtg ccctggagca ttctgcccag 1500 cctacgtggg ttcagtcagg tgccaccttc ccaagtattc gatttcattc atgtgattaa 1560 aacaagttgc catatttcaa agccttgagc taagactcaa ttaccaaccc gcagttttgt 1620 gtcagtgccc aaaggaggga ggttgatggt gcttaacaaa catgaagtat ggtgtaatag 1680 gaataatatt tatccaaaag atttttaaaa atagggctgt gtttaaagaa ggaatcaaaa 1740 caagaaaagc agcagtgatt atagagaggt cacactctaa gtggggtcgc ggcgtggcca 1800 cgcttcacgg tcacgctcgt ccgtcctgca gtggcgtgtt tacatggtca cacgtgtgtg 1860 tatcaccagt gggtcaactg cttgtcattc ctcccgcggc agtgttgtgt agacaatctt 1920 actgagcaaa aggcaatgaa aagtcttggg ctcccacact gcgatatatt ggaattccca 1980 cctcagttta tgaagtttat ttcgaaatcc atagtcatct aagaatgaat acctgtctgc 2040 catgtatttc aatcttagtg agccaaaatt gtttgtttgt tactacagaa tagagatgac 2100 tgttttttgg cacagcccta tggaatttgc aatctgtgat tgccttgtaa aaaggagagt 2160 gcatatggca ctgcattaaa cgtgtggtgt ttctagtcaa tgatattggt gagcacaatg 2220 tattcattta atggcataga ccataccaga cctaatttgc aagtattggg tcttcaaact 2280 tcaagtgcaa tgtattatga aaaccaatct gagccttgta tctcttaaat atttattcct 2340 tctaacgtgt gagatgtccc gagagaaggg ttctccattc atttcagtgc tgcctggagg 2400 aaactcggca atgatttctt cagttgtgaa gttcctttcg ggttacaacc tccactggaa 2460 ccctcaacct tcgaaatact ccagttttgg gggttggggc catttactta taaatttacc 2520 gccgggtttt tggaatctac atgtcttggg ggcgggctca aattcttcga aagtggttgg 2580 attaaaa 2587 44 277 PRT Homo sapiens 44 Met Pro Arg Leu His Asp His Phe Trp Ser Cys Ser Cys Ala His Ser 1 5 10 15 Ala Arg Arg Arg Gly Pro Pro Arg Ala Ser Thr Ala Gly Leu Pro Pro 20 25 30 Lys Val Gly Glu Met Ile Asn Val Ser Val Ser Gly Pro Ser Leu Leu 35 40 45 Ala Ala His Gly Ala Pro Asp Ala Asp Pro Ala Pro Arg Gly Arg Ser 50 55 60 Ala Ala Met Ser Gly Pro Glu Pro Gly Ser Pro Tyr Pro Asn Thr Trp 65 70 75 80 His His Arg Leu Leu Gln Arg Ser Leu Val Leu Phe Ser Val Gly Val 85 90 95 Val Leu Thr Leu Val Leu Asn Leu Leu Gln Ile Gln Arg Asn Val Thr 100 105 110 Leu Phe Pro Glu Glu Val Ile Ala Thr Ile Phe Ser Ser Ala Trp Trp 115 120 125 Val Pro Pro Cys Cys Gly Thr Ala Ala Ala Val Val Gly Leu Leu Tyr 130 135 140 Pro Cys Ile Asp Ser His Leu Gly Glu Pro His Lys Phe Lys Arg Glu 145 150 155 160 Trp Ala Ser Val Met Arg Cys Ile Ala Gly Phe Gly Gly Ile Asn His 165 170 175 Ala Ser Ala Lys Leu Asp Phe Ala Asn Asn Val Gln Leu Ser Leu Thr 180 185 190 Leu Ala Ala Leu Ser Leu Gly Leu Trp Trp Thr Phe Asp Arg Ser Arg 195 200 205 Ser Gly Leu Gly Leu Gly Ile Thr Ile Ala Phe Leu Ala Thr Leu Ile 210 215 220 Thr Gln Phe Leu Val Tyr Asn Gly Val Tyr Gln Tyr Thr Ser Pro Asp 225 230 235 240 Phe Leu Tyr Ile Arg Ser Trp Leu Pro Cys Ile Phe Phe Ser Gly Gly 245 250 255 Val Thr Val Gly Asn Ile Gly Arg Gln Leu Ala Met Gly Val Pro Glu 260 265 270 Lys Pro His Ser Asp 275 45 2027 DNA Homo sapiens misc_feature (1)..(2027) n = a,c,g, or t 45 gggataacgg gaggaaggcc ggccggggcc ncanaggagt cccaggctcg cgtaggaggc 60 gcgcagacct tgcaccttgc accttcgcag cgccctgcac cccgccacca tgtgcgagct 120 gtacagtaag cgggacactc tggggctgag gaagaagcac atcgggccct catgcaaagt 180 tttctttgca tcggatccca tcaaaatagt gagagcccag aggcagtaca tgtttgatga 240 gaacggtgaa cagtacttgg actgcatcaa caatgttgcc catggagtgg tcaaagctgc 300 cctgaaacag atggaactgc taaatacaaa ttctcgattc ctccacgaca acattgttga 360 gtatgccaaa cgcctttcag caactctgcc ggagaaactc tctgtttgtt attttacaaa 420 ttcaggatcc gaagccaacg acttagcctt acgcctggct cggcagttca gaggccacca 480 ggatgtgatc actcttgacc atgcttacca tggtcaccta tcatccttaa ttgagattag 540 cccatataag tttcagaaag gaaaagatgt caaaaaagaa tttgtacatg tggcaccaac 600 tccagatact tacagaggaa aatatagaga agaccatgca gactcagcca gtgcttatgc 660 agatgaagtg aagaaaatca ttgaagatgc tcataacagt ggaaggaaga ttgctgcctt 720 tattgctgaa tccatgcaga gttgtggcgg acaaataatt cctccagcag gctacttcca 780 gaaagtggca gaatatgtac acggtgcagg gggtgtgttt atagctgatg aagttcaagt 840 gggctttggc agagttggga aacatttctg gagcttccag atgtatggtg aagactttgt 900 tccagacatc gtcacaatgg gaaaaccgat gggcaacggc cacccggtgg catgtgtggt 960 aacaaccaaa gaaattgcag aagccttcag cagctctggg atggaatatt ttaatacgta 1020 tggaggaaat ccagtatctt gtgctgttgg tttggctgtc ctggatataa ttgaaaatga 1080 agaccttcaa ggaaatgcca agagagtagg gaattatctc actgagttac tgaaaaaaca 1140 gaaggctaaa cacactttga taggagatat taggggcatt ggccttttta ttggaattga 1200 tttagtgaag gaccatctga aaaggacccc tgccacagct gaagctcagc acatcatcta 1260 caagatgaaa gaaaaacgag tgcttctcag tgccgatgga cctcatagaa atgtacttaa 1320 aataaaacca cctatgtgct tcactgaaga agatgcaaag ttcatggtgg accaacttga 1380 taggattcta acagttttag aagaagctat gggaaccaaa accgaaagtg tgacctctga 1440 gaatactcca tgcaaaacaa agatgctgaa agaagcccac atagaactgc ttagggacag 1500 caccactgac tccaaagaaa atcccagcag aaagagaaat ggaatgtgca cggatacaca 1560 ttcactgctc agtaagaggc tcaagacatg actgatttgc attttaaagc aagatgcgat 1620 gtccagagtt acagagaatg agtagatgtg tctcatcggt taatagctct attatacctc 1680 taaaggtgga attgtcagtt tagattcata aatgaaaagg taaatgagta atcagaataa 1740 accaagtgat aatcaaacca tgtcaagatt attagttcag actctagcct gttaattttc 1800 ttagttgatt tctgaagcta cctgatttat tctattaaat tgtaagcttg caaactcaaa 1860 ataaattggc agatttacct ctcatgtttt aatgtgtcaa attagagagc aaagtataac 1920 aggtgccttc acttttgaga cttagtgcct taaaatatgt attctataat gatttcatat 1980 ataaaagtat atttattgac tgtaataaaa taaaatatga tgtaaac 2027 46 493 PRT Homo sapiens 46 Met Cys Glu Leu Tyr Ser Lys Arg Asp Thr Leu Gly Leu Arg Lys Lys 1 5 10 15 His Ile Gly Pro Ser Cys Lys Val Phe Phe Ala Ser Asp Pro Ile Lys 20 25 30 Ile Val Arg Ala Gln Arg Gln Tyr Met Phe Asp Glu Asn Gly Glu Gln 35 40 45 Tyr Leu Asp Cys Ile Asn Asn Val Ala His Gly Val Val Lys Ala Ala 50 55 60 Leu Lys Gln Met Glu Leu Leu Asn Thr Asn Ser Arg Phe Leu His Asp 65 70 75 80 Asn Ile Val Glu Tyr Ala Lys Arg Leu Ser Ala Thr Leu Pro Glu Lys 85 90 95 Leu Ser Val Cys Tyr Phe Thr Asn Ser Gly Ser Glu Ala Asn Asp Leu 100 105 110 Ala Leu Arg Leu Ala Arg Gln Phe Arg Gly His Gln Asp Val Ile Thr 115 120 125 Leu Asp His Ala Tyr His Gly His Leu Ser Ser Leu Ile Glu Ile Ser 130 135 140 Pro Tyr Lys Phe Gln Lys Gly Lys Asp Val Lys Lys Glu Phe Val His 145 150 155 160 Val Ala Pro Thr Pro Asp Thr Tyr Arg Gly Lys Tyr Arg Glu Asp His 165 170 175 Ala Asp Ser Ala Ser Ala Tyr Ala Asp Glu Val Lys Lys Ile Ile Glu 180 185 190 Asp Ala His Asn Ser Gly Arg Lys Ile Ala Ala Phe Ile Ala Glu Ser 195 200 205 Met Gln Ser Cys Gly Gly Gln Ile Ile Pro Pro Ala Gly Tyr Phe Gln 210 215 220 Lys Val Ala Glu Tyr Val His Gly Ala Gly Gly Val Phe Ile Ala Asp 225 230 235 240 Glu Val Gln Val Gly Phe Gly Arg Val Gly Lys His Phe Trp Ser Phe 245 250 255 Gln Met Tyr Gly Glu Asp Phe Val Pro Asp Ile Val Thr Met Gly Lys 260 265 270 Pro Met Gly Asn Gly His Pro Val Ala Cys Val Val Thr Thr Lys Glu 275 280 285 Ile Ala Glu Ala Phe Ser Ser Ser Gly Met Glu Tyr Phe Asn Thr Tyr 290 295 300 Gly Gly Asn Pro Val Ser Cys Ala Val Gly Leu Ala Val Leu Asp Ile 305 310 315 320 Ile Glu Asn Glu Asp Leu Gln Gly Asn Ala Lys Arg Val Gly Asn Tyr 325 330 335 Leu Thr Glu Leu Leu Lys Lys Gln Lys Ala Lys His Thr Leu Ile Gly 340 345 350 Asp Ile Arg Gly Ile Gly Leu Phe Ile Gly Ile Asp Leu Val Lys Asp 355 360 365 His Leu Lys Arg Thr Pro Ala Thr Ala Glu Ala Gln His Ile Ile Tyr 370 375 380 Lys Met Lys Glu Lys Arg Val Leu Leu Ser Ala Asp Gly Pro His Arg 385 390 395 400 Asn Val Leu Lys Ile Lys Pro Pro Met Cys Phe Thr Glu Glu Asp Ala 405 410 415 Lys Phe Met Val Asp Gln Leu Asp Arg Ile Leu Thr Val Leu Glu Glu 420 425 430 Ala Met Gly Thr Lys Thr Glu Ser Val Thr Ser Glu Asn Thr Pro Cys 435 440 445 Lys Thr Lys Met Leu Lys Glu Ala His Ile Glu Leu Leu Arg Asp Ser 450 455 460 Thr Thr Asp Ser Lys Glu Asn Pro Ser Arg Lys Arg Asn Gly Met Cys 465 470 475 480 Thr Asp Thr His Ser Leu Leu Ser Lys Arg Leu Lys Thr 485 490 47 1100 DNA Homo sapiens 47 cagctgctgc ccacaccgcg tcgacgcctt cactgccatc cccgctgtcc ttgccgcccc 60 cgccatgggc ctagagctgt ttcttgacct ggtgtcccag cccagccgcg ccgtctacat 120 cttcgccaag aagaatggca tccccttaga gctgcgcacc gtggatttgg tcaaagggca 180 gcacaagagc aaggagttct tgcagatcaa cagcctgggg aaactgccga cgctcaagga 240 tggtgatttc atcttgaccg aaagctcggc catcctgatt tacctgagct gtaagtacca 300 gacgccggac cactggtatc catctgacct gcaggctcgt gcccgtgttc atgagtacct 360 gggctggcat gccgactgca tccgtggcac ctttggtata cccctgtggg tccaggtgtt 420 ggggccactc attggggtcc aggtgcccga ggagaaggtg gaacgcaaca ggactgccat 480 ggaccaggcc ctgcaatggc tggaggacaa gttcctgggg gacaggccct tcctcgctgg 540 ccagcaggtg acactggctg atctcatggc cctggaggag ctgatgcagc cggtggctct 600 cggctacgaa ctgtttgagg gacggccacg actggcagca tggcgtggac gagtggaggc 660 tttcctgggt gctgagctat gccaggaggc ccacagcatc atcttgagca tcctggaaca 720 ggcggccaag aaaaccctcc caacaccctc accagaggcc tatcaggcta tgctgcttcg 780 aatcgccagg atcccctgaa gggtctggga tgggggccag gagattagca acaaggattc 840 attctgttac ttacttgccc ctttttatct ttccctcttg ccccagtccc ttctctccag 900 cttcatgtga agctctgcac agacaagaca ctcagtgtcc ttggcagtgc tgctactcct 960 caggtgcagc atacataacc agtaagagac taaatctgca atatataaag agctcctaca 1020 aatcagtaac atgaagaaca ctcaaaaatt ggcaaatgtc atcagtgttt taaacagaat 1080 aaagattcca aacactttga 1100 48 244 PRT Homo sapiens 48 Met Gly Leu Glu Leu Phe Leu Asp Leu Val Ser Gln Pro Ser Arg Ala 1 5 10 15 Val Tyr Ile Phe Ala Lys Lys Asn Gly Ile Pro Leu Glu Leu Arg Thr 20 25 30 Val Asp Leu Val Lys Gly Gln His Lys Ser Lys Glu Phe Leu Gln Ile 35 40 45 Asn Ser Leu Gly Lys Leu Pro Thr Leu Lys Asp Gly Asp Phe Ile Leu 50 55 60 Thr Glu Ser Ser Ala Ile Leu Ile Tyr Leu Ser Cys Lys Tyr Gln Thr 65 70 75 80 Pro Asp His Trp Tyr Pro Ser Asp Leu Gln Ala Arg Ala Arg Val His 85 90 95 Glu Tyr Leu Gly Trp His Ala Asp Cys Ile Arg Gly Thr Phe Gly Ile 100 105 110 Pro Leu Trp Val Gln Val Leu Gly Pro Leu Ile Gly Val Gln Val Pro 115 120 125 Glu Glu Lys Val Glu Arg Asn Arg Thr Ala Met Asp Gln Ala Leu Gln 130 135 140 Trp Leu Glu Asp Lys Phe Leu Gly Asp Arg Pro Phe Leu Ala Gly Gln 145 150 155 160 Gln Val Thr Leu Ala Asp Leu Met Ala Leu Glu Glu Leu Met Gln Pro 165 170 175 Val Ala Leu Gly Tyr Glu Leu Phe Glu Gly Arg Pro Arg Leu Ala Ala 180 185 190 Trp Arg Gly Arg Val Glu Ala Phe Leu Gly Ala Glu Leu Cys Gln Glu 195 200 205 Ala His Ser Ile Ile Leu Ser Ile Leu Glu Gln Ala Ala Lys Lys Thr 210 215 220 Leu Pro Thr Pro Ser Pro Glu Ala Tyr Gln Ala Met Leu Leu Arg Ile 225 230 235 240 Ala Arg Ile Pro 49 3293 DNA Homo sapiens 49 cgctccctcc cctcctagct ggcttcggcg gggacggcgg cggcggcggc ggcggcggcg 60 gcgggcgggg agggcgtgcg ccggccgaga ggtgtcggcg gcgaggcaaa ggaagtttca 120 agtggaaggt cgtccgtcgg ccggcgcgtc ctcctgctct cctccgcagc atcatggcgg 180 agccgagcgg ctcgcccgtg cacgtccagc ttccccagca ggcggccccg gtgacagcgg 240 cggcggcggc ggccccggcg gccgcgacag cagcgccggc cccggcagct cccgcggccc 300 cggccccggc cccggccccg gccccggcgg cacaggctgt cggctggccc atctgcaggg 360 acgcgtacga gctgcaggag gttatcggca gtggagctac tgctgtggtt caggcagccc 420 tatgcaaacc caggcaagaa cgtgtagcaa taaaacggat caacttggaa aaatgccaga 480 ccagtatgga tgaactatta aaagaaattc aagccatgag tcagtgcagc catcccaacg 540 tagtgaccta ttacacctct tttgtggtca aagatgaact ttggctggtc atgaaattac 600 taagtggagg ttcaatgttg gatatcataa aatacattgt caaccgagga gaacacaaga 660 atggagttct ggaagaggca ataatagcaa caattcttaa agaggttttg gaaggcttag 720 actatctaca cagaaacggt cagattcaca gggatttgaa agctggtaat attcttctgg 780 gtgaggatgg ttcagtacaa atagcagatt ttggggtaag tgcgttccta gcaacagggg 840 gtgatgttac ccgaaataaa gtaagaaaaa cattcgttgg caccccatgt tggatggctc 900 ctgaagtcat ggaacaggtg agaggctatg acttcaaggc tgacatgtgg agttttggaa 960 taactgccat tgaattagca acaggagcag cgccttatca caaatatcct cccatgaaag 1020 tgttaatgtt gactttgcaa aatgatccac ccactttgga aacaggggta gaggataaag 1080 aaatgatgaa aaagtacggc aagtccttta gaaaattact ttcactgtgt cttcagaaag 1140 atccttccaa aaggcccaca gcagcagaac ttttaaaatg caaattcttc cagaaagcca 1200 agaacagaga gtacctgatt gagaagctgc ttacaagaac accagacata gcccaaagag 1260 ccaaaaaggt aagaagagtt cctgggtcaa gtggtcacct tcataaaacc gaagacgggg 1320 actgggagtg gagtgacgac gagatggatg agaagagcga agaagggaaa gcagcttttt 1380 ctcaggaaaa gtcacgaaga gtaaaagaag aaaatccaga gattgcagtg agtgccagca 1440 ccatccccga acaaatacag tccctctctg tgcacgactc tcagggccca cccaatgcta 1500 atgaagacta cagagaagct tcttcttgtg ccgtgaacct cgttttgaga ttaagaaact 1560 ccagaaagga acttaatgac atacgatttg agtttactcc aggaagagat acagcagatg 1620 gtgtatctca ggagctcttc tctgctggct tggtggatgg tcacgatgta gttatagtgg 1680 ctgctaattt acagaagatt gtagatgatc ccaaagcttt aaaaacattg acatttaagt 1740 tggcttctgg ctgtgatggg tcggagattc ctgatgaagt gaagctgatt gggtttgctc 1800 agttgagtgt cagctgatgt atgtcccttg atgtcaccct gatctgtcat gccccaccgc 1860 cacccctact cccttcaacc ctccctcttt ctgcccattt cctcccaccc cctcactccc 1920 atttcctagc aaaatcagaa gattgtgaag aggccggctt caacaaaatg ggataaaaaa 1980 ataatttttt aaaacttaca acactccgag ttctgcttta ttctctagca atccacagta 2040 caagaacaag caaatgccac agctgcacga ctgttgctca tttttccaaa agctatttaa 2100 tattcttagc aatcaatttg gatatccctt aagtgaaaag aatctgaaat acactcaggt 2160 ggtcttattt attggcaaca aaaggaattt tctatccaga agcctatttc tcctttcatt 2220 gttgttattt ctgttataat actttaaatt gtacatctga caatactgcc tcttttatgt 2280 tgtatttaga aattaatata cttataaaat taagatttat tagccaaact tgaattctag 2340 ttttaaaact gactgtgaat tttatttttc atatatttat gcattacaca ccttagctat 2400 aagaaaaaaa gggttttgat tatatgcttc ttgcagttaa tctcgttatt taaacaaaaa 2460 gttttgggtc tgtctttgga gtatttgtaa cttctaaatt ttgaaatgac tgaattagga 2520 atttggatgc ttattctttt agtctgtttg cctaaaaacc aatttacaat ctgactgtct 2580 cttgggagag ggaggtgcct tgcaaacttt cacattaaga atgtgcctga ggctgcttta 2640 ctctggaata gtctcagatc taaaatttcc tctatataag gtggcatatg ttaagttttg 2700 cttcattgga ccgtttagaa tgctatgtaa aatgttgcca ttctgttaga ttgctaacta 2760 tatacccatc tctgatttgg ctctccttaa gtgataggat ttgttattct aaaggtgata 2820 aacttgaaaa tatcagaatc tgagttttac ttgaaatttt gcagaatacc caggtggagt 2880 gaaaattgga agggttttgt gcaatgacta aaaggtaaaa cgctgttaag gttcaagaat 2940 caatactttc aacccaagta gccccctgct tgactgtata ttatggaact agtaaacctt 3000 aggattttga aaattggagt ctaatctttc aaggaggtgg gctcccagga tggtaccatt 3060 gctctttcct agctaaccct agatatggca gctctttaat gtacttcaaa aagcaaatat 3120 atattactaa ggaaaaaaag ttatttataa ttgccttgtc ataattgtta aggtgttcta 3180 gagccatttg catacaattt aatgtaattt cattccattc tattgtttac acaacgatta 3240 ctcgaagatg actgcaaagg taaaaggaaa ataaaagtgt attgcacaat gag 3293 50 547 PRT Homo sapiens 50 Met Ala Glu Pro Ser Gly Ser Pro Val His Val Gln Leu Pro Gln Gln 1 5 10 15 Ala Ala Pro Val Thr Ala Ala Ala Ala Ala Ala Pro Ala Ala Ala Thr 20 25 30 Ala Ala Pro Ala Pro Ala Ala Pro Ala Ala Pro Ala Pro Ala Pro Ala 35 40 45 Pro Ala Pro Ala Ala Gln Ala Val Gly Trp Pro Ile Cys Arg Asp Ala 50 55 60 Tyr Glu Leu Gln Glu Val Ile Gly Ser Gly Ala Thr Ala Val Val Gln 65 70 75 80 Ala Ala Leu Cys Lys Pro Arg Gln Glu Arg Val Ala Ile Lys Arg Ile 85 90 95 Asn Leu Glu Lys Cys Gln Thr Ser Met Asp Glu Leu Leu Lys Glu Ile 100 105 110 Gln Ala Met Ser Gln Cys Ser His Pro Asn Val Val Thr Tyr Tyr Thr 115 120 125 Ser Phe Val Val Lys Asp Glu Leu Trp Leu Val Met Lys Leu Leu Ser 130 135 140 Gly Gly Ser Met Leu Asp Ile Ile Lys Tyr Ile Val Asn Arg Gly Glu 145 150 155 160 His Lys Asn Gly Val Leu Glu Glu Ala Ile Ile Ala Thr Ile Leu Lys 165 170 175 Glu Val Leu Glu Gly Leu Asp Tyr Leu His Arg Asn Gly Gln Ile His 180 185 190 Arg Asp Leu Lys Ala Gly Asn Ile Leu Leu Gly Glu Asp Gly Ser Val 195 200 205 Gln Ile Ala Asp Phe Gly Val Ser Ala Phe Leu Ala Thr Gly Gly Asp 210 215 220 Val Thr Arg Asn Lys Val Arg Lys Thr Phe Val Gly Thr Pro Cys Trp 225 230 235 240 Met Ala Pro Glu Val Met Glu Gln Val Arg Gly Tyr Asp Phe Lys Ala 245 250 255 Asp Met Trp Ser Phe Gly Ile Thr Ala Ile Glu Leu Ala Thr Gly Ala 260 265 270 Ala Pro Tyr His Lys Tyr Pro Pro Met Lys Val Leu Met Leu Thr Leu 275 280 285 Gln Asn Asp Pro Pro Thr Leu Glu Thr Gly Val Glu Asp Lys Glu Met 290 295 300 Met Lys Lys Tyr Gly Lys Ser Phe Arg Lys Leu Leu Ser Leu Cys Leu 305 310 315 320 Gln Lys Asp Pro Ser Lys Arg Pro Thr Ala Ala Glu Leu Leu Lys Cys 325 330 335 Lys Phe Phe Gln Lys Ala Lys Asn Arg Glu Tyr Leu Ile Glu Lys Leu 340 345 350 Leu Thr Arg Thr Pro Asp Ile Ala Gln Arg Ala Lys Lys Val Arg Arg 355 360 365 Val Pro Gly Ser Ser Gly His Leu His Lys Thr Glu Asp Gly Asp Trp 370 375 380 Glu Trp Ser Asp Asp Glu Met Asp Glu Lys Ser Glu Glu Gly Lys Ala 385 390 395 400 Ala Phe Ser Gln Glu Lys Ser Arg Arg Val Lys Glu Glu Asn Pro Glu 405 410 415 Ile Ala Val Ser Ala Ser Thr Ile Pro Glu Gln Ile Gln Ser Leu Ser 420 425 430 Val His Asp Ser Gln Gly Pro Pro Asn Ala Asn Glu Asp Tyr Arg Glu 435 440 445 Ala Ser Ser Cys Ala Val Asn Leu Val Leu Arg Leu Arg Asn Ser Arg 450 455 460 Lys Glu Leu Asn Asp Ile Arg Phe Glu Phe Thr Pro Gly Arg Asp Thr 465 470 475 480 Ala Asp Gly Val Ser Gln Glu Leu Phe Ser Ala Gly Leu Val Asp Gly 485 490 495 His Asp Val Val Ile Val Ala Ala Asn Leu Gln Lys Ile Val Asp Asp 500 505 510 Pro Lys Ala Leu Lys Thr Leu Thr Phe Lys Leu Ala Ser Gly Cys Asp 515 520 525 Gly Ser Glu Ile Pro Asp Glu Val Lys Leu Ile Gly Phe Ala Gln Leu 530 535 540 Ser Val Ser 545 51 1812 DNA Homo sapiens 51 gaagagggca gagccgtgca tggggctgct ccccaggacc tgagcaggaa cctggagttt 60 tcagagctgc ctgatcattg ctacagaatg aactctagcc cagctgggac cccaagtcca 120 cagccctcca gggccaatgg gaacatcaac ctggggcctt cagccaaccc aaatgcccag 180 cccacggact tcgacttcct caaagtcatc ggcaaaggga actacgggaa ggtcctactg 240 gccaagcgca agtctgatgg ggcgttctat gcagtgaagg tactacagaa aaagtccatc 300 ttaaagaaga aagagcagag ccacatcatg gcagagcgca gtgtgcttct gaagaacgtg 360 cggcacccct tcctcgtggg cctgcgctac tccttccaga cacctgagaa gctctacttc 420 gtgctcgact atgtcaacgg gggagagctc ttcttccacc tgcagcggga gcgccggttc 480 ctggagcccc gggccaggtt ctacgctgct gaggtggcca gcgccattgg ctacctgcac 540 tccctcaaca tcatttacag ggatctgaaa ccagagaaca ttctcttgga ctgccaggga 600 cacgtggtgc tgacggattt tggcctctgc aaggaaggtg tagagcctga agacaccaca 660 tccacattct gtggtacccc tgagtacttg gcacctgaag tgcttcggaa agagccttat 720 gatcgagcag tggactggtg gtgcttgggg gcagtcctct acgagatgct ccatggcctg 780 ccgcccttct acagccaaga tgtatcccag atgtatgaga acattctgca ccagccgcta 840 cagatccccg gaggccggac agtggccgcc tgtgacctcc tgcaaagcct tctccacaag 900 gaccagaggc agcggctggg ctccaaagca gactttcttg agattaagaa ccatgtattc 960 ttcagcccca taaactggga tgacctgtac cacaagaggc taactccacc cttcaaccca 1020 aatgtgacag gacctgctga cttgaagcat tttgacccag agttcaccca ggaagctgtg 1080 tccaagtcca ttggctgtac ccctgacact gtggccagca gctctggggc ctcaagtgca 1140 ttcctgggat tttcttatgc gccagaggat gatgacatct tggattgcta gaagagaagg 1200 acctgtgaaa ctactgaggc cagctggtat tagtaaggaa ttaccttcag ctgctaggaa 1260 gagcgactca aactaacaat ggcttcaacg agaagcaggt ttattttttc cagcacataa 1320 aagaaaaata atgtttcgga gtccaggact ggcaggacag gtcatcagat actcagaggc 1380 tgtatctctg ccctgccaac cttgacaaat ggcttccaat gttaggtttg ctacaagatg 1440 gttactggag ctctagctgc ctattttgtg tttagggaag ggaaaatgga ggaaagggga 1500 gaagagcaaa gggcgctttt aaagagcttt cccaaaagct ccccccaatg acttttgctt 1560 ccatctcact aaccacccac ccctacctgg aatggaggct gggaaatgtg gcttatttgc 1620 tgggtacgtg actatcccta ataacaaagg ggttttgacc ctaagacatt aggggagaat 1680 gttgggtagg cagccagccc tcttttacca tagggcctcc tggtgtttgg attttgatct 1740 caatgtgtaa aatgacagag atgtaacaag ctcatagggt atcaatatct cttattgttc 1800 tatgttgaaa aa 1812 52 367 PRT Homo sapiens 52 Met Asn Ser Ser Pro Ala Gly Thr Pro Ser Pro Gln Pro Ser Arg Ala 1 5 10 15 Asn Gly Asn Ile Asn Leu Gly Pro Ser Ala Asn Pro Asn Ala Gln Pro 20 25 30 Thr Asp Phe Asp Phe Leu Lys Val Ile Gly Lys Gly Asn Tyr Gly Lys 35 40 45 Val Leu Leu Ala Lys Arg Lys Ser Asp Gly Ala Phe Tyr Ala Val Lys 50 55 60 Val Leu Gln Lys Lys Ser Ile Leu Lys Lys Lys Glu Gln Ser His Ile 65 70 75 80 Met Ala Glu Arg Ser Val Leu Leu Lys Asn Val Arg His Pro Phe Leu 85 90 95 Val Gly Leu Arg Tyr Ser Phe Gln Thr Pro Glu Lys Leu Tyr Phe Val 100 105 110 Leu Asp Tyr Val Asn Gly Gly Glu Leu Phe Phe His Leu Gln Arg Glu 115 120 125 Arg Arg Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala Glu Val Ala 130 135 140 Ser Ala Ile Gly Tyr Leu His Ser Leu Asn Ile Ile Tyr Arg Asp Leu 145 150 155 160 Lys Pro Glu Asn Ile Leu Leu Asp Cys Gln Gly His Val Val Leu Thr 165 170 175 Asp Phe Gly Leu Cys Lys Glu Gly Val Glu Pro Glu Asp Thr Thr Ser 180 185 190 Thr Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu Arg Lys 195 200 205 Glu Pro Tyr Asp Arg Ala Val Asp Trp Trp Cys Leu Gly Ala Val Leu 210 215 220 Tyr Glu Met Leu His Gly Leu Pro Pro Phe Tyr Ser Gln Asp Val Ser 225 230 235 240 Gln Met Tyr Glu Asn Ile Leu His Gln Pro Leu Gln Ile Pro Gly Gly 245 250 255 Arg Thr Val Ala Ala Cys Asp Leu Leu Gln Ser Leu Leu His Lys Asp 260 265 270 Gln Arg Gln Arg Leu Gly Ser Lys Ala Asp Phe Leu Glu Ile Lys Asn 275 280 285 His Val Phe Phe Ser Pro Ile Asn Trp Asp Asp Leu Tyr His Lys Arg 290 295 300 Leu Thr Pro Pro Phe Asn Pro Asn Val Thr Gly Pro Ala Asp Leu Lys 305 310 315 320 His Phe Asp Pro Glu Phe Thr Gln Glu Ala Val Ser Lys Ser Ile Gly 325 330 335 Cys Thr Pro Asp Thr Val Ala Ser Ser Ser Gly Ala Ser Ser Ala Phe 340 345 350 Leu Gly Phe Ser Tyr Ala Pro Glu Asp Asp Asp Ile Leu Asp Cys 355 360 365 53 1603 DNA Homo sapiens 53 tgagatgaga gctgccgaca gttgggggtc aagggaggag acgccatgat ccccaccttc 60 acggctctgc tctgcctcgg gctgagtctg ggccccagga cccacatgca ggcagggccc 120 ctccccaaac ccaccctctg ggctgagcca ggctctgtga tcagctgggg gaactctgtg 180 accatctggt gtcaggggac cctggaggct cgggagtacc gtctggataa agaggaaagc 240 ccagcaccct gggacagaca gaacccactg gagcccaaga acaaggccag attctccatc 300 ccatccatga cagaggacta tgcagggaga taccgctgtt actatcgcag ccctgtaggc 360 tggtcacagc ccagtgaccc cctggagctg gtgatgacag gagcctacag taaacccacc 420 ctttcagccc tgccgagtcc tcttgtgacc tcaggaaaga gcgtgaccct gctgtgtcag 480 tcacggagcc caatggacac tttccttctg atcaaggagc gggcagccca tcccctactg 540 catctgagat cagagcacgg agctcagcag caccaggctg aattccccat gagtcctgtg 600 acctcagtgc acggggggac ctacaggtgc ttcagctcac acggcttctc ccactacctg 660 ctgtcacacc ccagtgaccc cctggagctc atagtctcag gatccttgga gggtcccagg 720 ccctcaccca caaggtccgt ctcaacagct gcaggccctg aggaccagcc cctcatgcct 780 acagggtcag tcccccacag tggtctgaga aggcactggg aggtactgat cggggtcttg 840 gtggtctcca tcctgcttct ctccctcctc ctcttcctcc tcctccaaca ctggcgtcag 900 ggaaaacaca ggacattggc ccagagacag gctgatttcc aacgtcctcc aggggctgcc 960 gagccagagc ccaaggacgg gggcctacag aggaggtcca gcccagctgc tgacgtccag 1020 ggagaaaact tctgtgctgc cgtgaagaac acacagcctg aggacggggt ggaaatggac 1080 actcggcaga gcccacacga tgaagacccc caggcagtga cgtatgccaa ggtgaaacac 1140 tccagaccta ggagagaaat ggcctctcct ccctccccac tgtctgggga attcctggac 1200 acaaaggaca gacaggcaga agaggacaga cagatggaca ctgaggctgc tgcatctgaa 1260 gccccccagg atgtgaccta cgcccagctg cacagcttta ccctcagaca gaaggcaact 1320 gagcctcctc catcccagga aggggcctct ccagctgagc ccagtgtcta tgccactctg 1380 gccatccact aatccagggg ggacccagac cccacaagcc atggagactc aggaccccag 1440 aaggcatgga agctgcctcc agtagacatc actgaacccc agccagccca gacccctgac 1500 acagaccact agaagattcc gggaacgttg ggagtcacct gattctgcaa agataaataa 1560 tatccctgca ttatcaaaat aaagtagcag acctctcaat tca 1603 54 448 PRT Homo sapiens 54 Met Ile Pro Thr Phe Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Met Gln Ala Gly Pro Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Asn Ser Val Thr Ile Trp 35 40 45 Cys Gln Gly Thr Leu Glu Ala Arg Glu Tyr Arg Leu Asp Lys Glu Glu 50 55 60 Ser Pro Ala Pro Trp Asp Arg Gln Asn Pro Leu Glu Pro Lys Asn Lys 65 70 75 80 Ala Arg Phe Ser Ile Pro Ser Met Thr Glu Asp Tyr Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Arg Ser Pro Val Gly Trp Ser Gln Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Met Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala 115 120 125 Leu Pro Ser Pro Leu Val Thr Ser Gly Lys Ser Val Thr Leu Leu Cys 130 135 140 Gln Ser Arg Ser Pro Met Asp Thr Phe Leu Leu Ile Lys Glu Arg Ala 145 150 155 160 Ala His Pro Leu Leu His Leu Arg Ser Glu His Gly Ala Gln Gln His 165 170 175 Gln Ala Glu Phe Pro Met Ser Pro Val Thr Ser Val His Gly Gly Thr 180 185 190 Tyr Arg Cys Phe Ser Ser His Gly Phe Ser His Tyr Leu Leu Ser His 195 200 205 Pro Ser Asp Pro Leu Glu Leu Ile Val Ser Gly Ser Leu Glu Gly Pro 210 215 220 Arg Pro Ser Pro Thr Arg Ser Val Ser Thr Ala Ala Gly Pro Glu Asp 225 230 235 240 Gln Pro Leu Met Pro Thr Gly Ser Val Pro His Ser Gly Leu Arg Arg 245 250 255 His Trp Glu Val Leu Ile Gly Val Leu Val Val Ser Ile Leu Leu Leu 260 265 270 Ser Leu Leu Leu Phe Leu Leu Leu Gln His Trp Arg Gln Gly Lys His 275 280 285 Arg Thr Leu Ala Gln Arg Gln Ala Asp Phe Gln Arg Pro Pro Gly Ala 290 295 300 Ala Glu Pro Glu Pro Lys Asp Gly Gly Leu Gln Arg Arg Ser Ser Pro 305 310 315 320 Ala Ala Asp Val Gln Gly Glu Asn Phe Cys Ala Ala Val Lys Asn Thr 325 330 335 Gln Pro Glu Asp Gly Val Glu Met Asp Thr Arg Gln Ser Pro His Asp 340 345 350 Glu Asp Pro Gln Ala Val Thr Tyr Ala Lys Val Lys His Ser Arg Pro 355 360 365 Arg Arg Glu Met Ala Ser Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu 370 375 380 Asp Thr Lys Asp Arg Gln Ala Glu Glu Asp Arg Gln Met Asp Thr Glu 385 390 395 400 Ala Ala Ala Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Gln Leu His 405 410 415 Ser Phe Thr Leu Arg Gln Lys Ala Thr Glu Pro Pro Pro Ser Gln Glu 420 425 430 Gly Ala Ser Pro Ala Glu Pro Ser Val Tyr Ala Thr Leu Ala Ile His 435 440 445 55 2366 DNA Homo sapiens 55 gaccacgcgt atcgatgtcg acccacagga ttgtcacaga gggcagggtg gtgactgagg 60 accagctcct catgcttgag gctgtggtga tgcacctcgg gatccgctct gcccgctgtg 120 tcctgggcat ggagggtcag caggtcatcc tgcacctgcc cctatcccag aaggggccct 180 tctggacatg ggagcctagt gcccctcgaa ctctgctcca ggtcctacag gatccagccc 240 tgaaagacct cgtcctcacc tgccccaccc tgccctggca ttccctgatc ctgcggcccc 300 agtatgagat ccaagccatc atgcacatgc gcaggaccat tgtcaagatc ccttctaccc 360 tggaggtcga cgtggaggac gtcaccgcct cctcccggca cgtccacttt atcaaaccgc 420 tgctgctgag cgaggtcctg gcctgggaag gccctttccc cctgtccatg gagatcctgg 480 aggttcctga gggccgcccc atcttcctca gcccgtgggt gggctccttg caaaaaggcc 540 agaggctttg cgtctatggc ctagcctcac caccctggcg ggtcctggcc tcaagcaagg 600 gccgcaaggt gcccaggcac ttcctggtgt cagggggcta ccaaggcaag ctgcggcggc 660 ggccaaggga gttccccacg gcctatgacc tcctaggtgc tttccagcca ggccggccac 720 tccgggtggt ggccacaaag gactgtgagg gcgagaggga ggagaatccc gagttcacgt 780 ccctggctgt gggtgaccgg ctggaggtgc tggggcctgg ccaggcccat ggggcccagg 840 gcagtgacgt ggatgtcttg gtttgtcagc ggctgagtga ccaggctggg gaagatgagg 900 aggaagagtg caaagaggag gcagagaccc agagcgggtc ctgctgccct tccacttccc 960 tggcagtttc gtggaggaga tgagtgacag ccggcgctac agcctggcag atctgactgc 1020 ccagttttca atgccttgtg aggtcaaggt ggtggccaag gacaccagcc accccaatga 1080 ccctcagaac ctccttcctg ggcctgcggc tggaggagaa gatcacagag ccattcttgg 1140 tggtgagcct ggactctgag ctgggatgtg ctttgagatc cctccccgga ggctggacct 1200 gactgtcgtg gaggccaagg ggcagccaga cttgccagag gggtctctcc ccatagccac 1260 agtggaggaa gctggaacag acacctttta ttattgtctt cggaagttac cagcctgtga 1320 gatccaagcc cccccaccca ggccccctaa aaatcagggc ctcagcaagc agaggagaca 1380 cagcagtgag ggaggcgtca agtcttctca agtcttagga ttgcagcaac acgttcggct 1440 gcccaaaccc aaggcgaaga ccttgccaga gttcatcaag gatggctcca gtacgtacag 1500 caagattcct gcccacagga agggccacag gcccgctaag ccccaaaggc aggatctaga 1560 tgatgatgaa catgattatg aagaaatact tgagcaattt cagaaaacca tctaagtgct 1620 ggaggaacca cgcttcctaa ctgctgcttc tcagggaatc cgacaccagc caaccatttt 1680 aagcctctaa aagacctcgg gcaagtctca cagaaactga gctgcagacg gggagtagct 1740 ttgtggaaac tgatttgatg gacactgcac cagcttcctt caggttctag attcttgcta 1800 cttagggcgg gctggtttgg acctaacatc tcgcacgtga ctccctcagc ctcagagcct 1860 tgggatgcag agcagctggc agggttcctc tcaatcctgc aaccccagct gtcccaccgg 1920 tggatgcaga ggggaatccg aggccatcaa ccttggtgac agcagcgcag tgccaatgct 1980 gatcacactg catgggagat tttgttaacg tctgccaccc ccactctcac ccccaagctc 2040 taagcccccg ggaggcctgg actgtcttcc tcatctctgt agcaccaagc ctgatagatc 2100 tgtatatggt aaacaggggt ttaaccacat gtggttaaca tggattaatg tgggaatttg 2160 gcttcaagaa cacaacctta ggaccttggg ccccaaaagc tggtggtgaa atgagaggag 2220 ccaatttaag aagaccctta tggagacctg aggctgcaga aactggtagg tttcatcagg 2280 tggttaaagt cgtcaaagtt gtaagtgact aaccaagatt atttcatttt aaaaccacag 2340 aataaaaatg acacctgagc ttctcc 2366 56 284 PRT Homo sapiens 56 Met Glu Gly Gln Gln Val Ile Leu His Leu Pro Leu Ser Gln Lys Gly 1 5 10 15 Pro Phe Trp Thr Trp Glu Pro Ser Ala Pro Arg Thr Leu Leu Gln Val 20 25 30 Leu Gln Asp Pro Ala Leu Lys Asp Leu Val Leu Thr Cys Pro Thr Leu 35 40 45 Pro Trp His Ser Leu Ile Leu Arg Pro Gln Tyr Glu Ile Gln Ala Ile 50 55 60 Met His Met Arg Arg Thr Ile Val Lys Ile Pro Ser Thr Leu Glu Val 65 70 75 80 Asp Val Glu Asp Val Thr Ala Ser Ser Arg His Val His Phe Ile Lys 85 90 95 Pro Leu Leu Leu Ser Glu Val Leu Ala Trp Glu Gly Pro Phe Pro Leu 100 105 110 Ser Met Glu Ile Leu Glu Val Pro Glu Gly Arg Pro Ile Phe Leu Ser 115 120 125 Pro Trp Val Gly Ser Leu Gln Lys Gly Gln Arg Leu Cys Val Tyr Gly 130 135 140 Leu Ala Ser Pro Pro Trp Arg Val Leu Ala Ser Ser Lys Gly Arg Lys 145 150 155 160 Val Pro Arg His Phe Leu Val Ser Gly Gly Tyr Gln Gly Lys Leu Arg 165 170 175 Arg Arg Pro Arg Glu Phe Pro Thr Ala Tyr Asp Leu Leu Gly Ala Phe 180 185 190 Gln Pro Gly Arg Pro Leu Arg Val Val Ala Thr Lys Asp Cys Glu Gly 195 200 205 Glu Arg Glu Glu Asn Pro Glu Phe Thr Ser Leu Ala Val Gly Asp Arg 210 215 220 Leu Glu Val Leu Gly Pro Gly Gln Ala His Gly Ala Gln Gly Ser Asp 225 230 235 240 Val Asp Val Leu Val Cys Gln Arg Leu Ser Asp Gln Ala Gly Glu Asp 245 250 255 Glu Glu Glu Glu Cys Lys Glu Glu Ala Glu Thr Gln Ser Gly Ser Cys 260 265 270 Cys Pro Ser Thr Ser Leu Ala Val Ser Trp Arg Arg 275 280 57 3605 DNA Homo sapiens 57 ggtaaatatg tgttcattaa ctgagattaa ccttccctga gttttctcac accaaggtga 60 ggaccatgtc cctgtttcca tcactccctc tccttctcct gagtatggtg gcagcgtctt 120 actcagaaac tgtgacctgt gaggatgccc aaaagacctg ccctgcagtg attgcctgta 180 gctctccagg catcaacggc ttcccaggca aagatgggcg tgatggcacc aagggagaaa 240 agggggaacc aggccaaggg ctcagaggct tacagggccc ccctggaaag ttggggcctc 300 caggaaatcc agggccttct gggtcaccag gaccaaaggg ccaaaaagga gaccctggaa 360 aaagtccgga tggtgatagt agcctggctg cctcagaaag aaaagctctg caaacagaaa 420 tggcacgtat caaaaagtgg ctgaccttct ctctgggcaa acaagttggg aacaagttct 480 tcctgaccaa tggtgaaata atgacctttg aaaaagtgaa ggccttgtgt gtcaagttcc 540 aggcctctgt ggccaccccc aggaatgctg cagagaatgg agccattcag aatctcatca 600 aggaggaagc cttcctgggc atcactgatg agaagacaga agggcagttt gtggatctga 660 caggaaatag actgacctac acaaactgga acgagggtga acccaacaat gctggttctg 720 atgaagattg tgtattgcta ctgaaaaatg gccagtggaa tgacgtcccc tgctccacct 780 cccatctggc cgtctgtgag ttccctatct gaagggtcat atcactcagg ccctccttgt 840 ctttttactg caacccacag gcccacagta tgcttgaaaa gataaattat atcaatttcc 900 tcatatccag tattgttcct tttgtgggca atcactaaaa atgatcacta acagcaccaa 960 caaagcaata atagtagtag tagtagttag cagcagcagt agtagtcatg ctaattatat 1020 aatattttta atatatacta tgaggcccta tcttttgcat cctacattaa ttatctagtt 1080 taattaatct gtaatgcttt cgatagtgtt aacttgctgc agtatgaaaa taagacggat 1140 ttatttttcc atttacaaca aacacctgtg ctctgttgag ccttcctttc tgtttgggta 1200 gagggctccc ctaatgacat caccacagtt taataccaca gctttttacc aagtttcagg 1260 tattaagaaa atctattttg taactttctc tatgaactct gttttctttc taatgagata 1320 ttaaaccatg taaagaacat aaataacaaa tctcaagcaa acagcttcac aaattctcac 1380 acacatacat acctatatac tcactttcta gattaagata tgggacattt ttgactccct 1440 agaagccccg ttataactcc tcctagtact aactcctagg aaaatactat tctgacctcc 1500 atgactgcac agtaatttcg tctgtttata aacattgtat agttggaatc atattgtgtg 1560 taatgttgta tgtcttgctt actcagaatt aagtctgtga gattcattca tgtcatgtgt 1620 acaaaagttt catccttttc attgccatgt agggttccct tatattaata ttcctcagtt 1680 catccattct attgttaata ggcacttaag tggcttccaa tttttggcca tgaggaagag 1740 aacccacgaa cattcctgga cttgtctttt ggtggacatg gtgcactaat ttcactacct 1800 atccaggagt ggaactggta gaggatgagg aaagcatgta ttcagcttta gtagatatta 1860 ccagttttcc taagtgattg tatgaattta tgctcctacc ggcaatgtgt ggcagtccta 1920 gatgctctat gtgcttgtaa aaagtcaatg ttttcagttc tcttgatttt cattattcct 1980 gtggatgtaa agtgatattt ccccatggtt ttaatctgta tttccccaac atgtaataag 2040 gttgaacact tttttatatg cttattgggc acttgggtat cttcttctgt gaagtacccg 2100 ttcacatttt tgtattttgt ttaaattagt tagccaatat ttttcttact gatttttaag 2160 ttatttttac attctgaata tgtccttttt aatgtgtatt acaaatattt tgctagtttt 2220 tgacttgctc ctaatgttga attttgatga acaaaatttc ctaattttga gaaagtctta 2280 tttattcata ttttctttca aaattagtgc tttttgtgtc atgtttaaga aatttttgcc 2340 catcccaaaa tcataagata tttttcatga ttttgaaacc atgaagagat ttttcatgat 2400 tttgaaatca tgaagatatt tttccatttt tttctaatag ttttattaat aaacattcta 2460 tctattcctg gtagaataga tatccacttg agacagcact atgtaggaaa gaccattttt 2520 cctccactga actagggtgg tgcatttttg taagttaggt aactgtatgt gtgtgtgtct 2580 gtttctgggc tgtctattct agtctatttg ttgatgcttg tgtcaaacag tacactatct 2640 taattattgt acatttatag ttgtaactgt agtccagctt tgttcttctt caagtcaaga 2700 tttccatata aatattagaa acagtttctc aatttctaca aaatcctgat gaggtttcta 2760 ctgggaccac attgagtcta tcaatcaact tatgcagaac tggcaactta ctactgaatc 2820 tctaatcaat gttcatcatg tatcgcttca tttaactagg atttctctaa cttaattgct 2880 atgttttgag atttttagtt taaaaacctt gtatatcttg ttttggtggt tttagtgatt 2940 ttaataatat attttaaata ttttttcttt tctattgttg tacacagaaa tacagttaag 3000 ttttgtgtgt agtcttacga tgtttagtaa cctcaataag tttatttctt aaatctagta 3060 atttgtagat tcctctggat tttgtatatg catagtcatg taagctgaaa atatggcaat 3120 acttgcttct tcccaattgc tttacctttt ttcttacctt attgcactgg ttagcaaccc 3180 caatacagag accaccagag caggtataga ctcctgaaag acaatataat gaagtgctcc 3240 agtcaggcct atctaaactg gattcacagc tctgtcactt aattgctaca tgatctagag 3300 ccagttactt tgtgtttcag ccatgtattt gcagctgaga gaaaataatc attcttattt 3360 catgaaaatt gtggggatga tgaaataagt taacaccttt aaagtgtgta gtaaagtatc 3420 aggatactat attttaggtc ttaatacaca cagttatgcc gctagataca tgctttttaa 3480 tgagataatg tgatattata cataacacat atcgattttt aaaaattaaa tcaaccttgc 3540 tttgatggaa taaactccat ttagtcacaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3600 aaaaa 3605 58 248 PRT Homo sapiens 58 Met Ser Leu Phe Pro Ser Leu Pro Leu Leu Leu Leu Ser Met Val Ala 1 5 10 15 Ala Ser Tyr Ser Glu Thr Val Thr Cys Glu Asp Ala Gln Lys Thr Cys 20 25 30 Pro Ala Val Ile Ala Cys Ser Ser Pro Gly Ile Asn Gly Phe Pro Gly 35 40 45 Lys Asp Gly Arg Asp Gly Thr Lys Gly Glu Lys Gly Glu Pro Gly Gln 50 55 60 Gly Leu Arg Gly Leu Gln Gly Pro Pro Gly Lys Leu Gly Pro Pro Gly 65 70 75 80 Asn Pro Gly Pro Ser Gly Ser Pro Gly Pro Lys Gly Gln Lys Gly Asp 85 90 95 Pro Gly Lys Ser Pro Asp Gly Asp Ser Ser Leu Ala Ala Ser Glu Arg 100 105 110 Lys Ala Leu Gln Thr Glu Met Ala Arg Ile Lys Lys Trp Leu Thr Phe 115 120 125 Ser Leu Gly Lys Gln Val Gly Asn Lys Phe Phe Leu Thr Asn Gly Glu 130 135 140 Ile Met Thr Phe Glu Lys Val Lys Ala Leu Cys Val Lys Phe Gln Ala 145 150 155 160 Ser Val Ala Thr Pro Arg Asn Ala Ala Glu Asn Gly Ala Ile Gln Asn 165 170 175 Leu Ile Lys Glu Glu Ala Phe Leu Gly Ile Thr Asp Glu Lys Thr Glu 180 185 190 Gly Gln Phe Val Asp Leu Thr Gly Asn Arg Leu Thr Tyr Thr Asn Trp 195 200 205 Asn Glu Gly Glu Pro Asn Asn Ala Gly Ser Asp Glu Asp Cys Val Leu 210 215 220 Leu Leu Lys Asn Gly Gln Trp Asn Asp Val Pro Cys Ser Thr Ser His 225 230 235 240 Leu Ala Val Cys Glu Phe Pro Ile 245 59 3044 DNA Homo sapiens 59 cagcatcgcc ttttcctccc gtttctcctt ccactcccag ctccacatcc tcctcctatt 60 ctcccctctc ccctcttcaa acccccacct tccagttccc tcacctcccc tttcggctgg 120 tcccctgggg cttgcagcaa gagggagaga gagctcctga caggattgat ggtccttccc 180 caccctgtcc tctcatccgc tccctcccca gcaggcacag acatccccct acaaaaggca 240 ggagcccagg ctgtgtggaa acagctgctc tcagacgcct ttccatttgc tctctgctgg 300 ctaggctggg ctgtgcctct gctccctctt cctctagctg agagtgggca cctggggtac 360 cgggcccccc cacctcattc cccatgaatg ctgtgggaag tcctgagggg caggagctgc 420 acaagctggg gagtggagcc tgggacaacc ccgcctacag tggtccccct tccccacacg 480 ggacgctgag agtctgcacc atctccagca cggggcctct ccagccccaa cccaagaagc 540 ctgaagatga accccaggag acggcataca ggacccaggt gtccagctgc tgcctccata 600 tctgtcaagg catcagagga ctttggggaa caaccctgac tgagaacaca gctgagaacc 660 gggaacttta tatcaagacc accctgaggg agctgttggt atatattgtg ttcctggtgg 720 acatctgtct actgacctat ggaatgacaa gctccagtgc ttattactac accaaagtga 780 tgtctgagct cttcttacat actccatcag acactggagt ctcctttcag gccatcagca 840 gcatggcgga cttctgggat tttgcccagg gcccactact ggacagtttg tattggacca 900 aatggtacaa caaccagagc ctgggccatg gctcccactc cttcatctac tatgagaaca 960 tgctgctggg ggttccgagg ctgcggcagc taaaggtccg caatgactcc tgtgtggtgc 1020 atgaagactt ccgggaggac attctgagct gctatgatgt ctactctcca gacaaagaag 1080 aacaactccc ctttgggccc ttcaatggca cagcgtggac ataccactcg caggatgagt 1140 tggggggctt ctcccactgg ggcaggctca caagctacag cggaggtggc tactacctgg 1200 accttccagg atcccgacag ggtagtgcag aggctctccg ggcccttcag gaggggctgt 1260 ggctggacag gggcactcga gtggtgttca tcgacttctc agtctacaat gccaatatca 1320 atcttttctg tgtcctgagg ctggtggtgg agtttccagc tacaggaggt gccatcccat 1380 cctggcaaat ccgcacagtc aagctgatcc gctatgtcag caactgggac ttctttatcg 1440 ttggctgtga ggtcatcttc tgcgtcttca tcttctacta tgtggtggaa gagatcctgg 1500 agctccacat tcaccggctt cgctacctca gcagcatctg gaacatactg gacctggtga 1560 tcatcttgct ctccattgtg gctgtgggct tccacatatt ccgaaccctc gaggtgaatc 1620 ggctcatggg gaagctcctg cagcagccaa acacgtatgc agactttgag ttcctcgcct 1680 tctggcagac acagtacaac aacatgaatg ctgtcaacct cttcttcgcc tggatcaaga 1740 tattcaagta catcagcttc aacaaaacca tgacccagct ctcctccacg ctggcccgct 1800 gtgccaagga catcctgggc ttcgccgtca tgttcttcat tgttttcttc gcctatgccc 1860 aactcggcta cctgcttttc gggacccaag tggaaaactt tagcactttc atcaagtgca 1920 ttttcactca gttccggata atcctcgggg actttgacta caatgctatc gacaatgcca 1980 accgcatcct gggccctgcc tactttgtca cctatgtctt cttcgtcttc ttcgtgctcc 2040 tgaacatgtt cctggccatc atcaatgaca catattcaga ggtcaaggag gagctggctg 2100 gacagaagga tgagctgcaa ctttctgacc tcctgaaaca gggctacaac aagaccctac 2160 taagactgcg tctgaggaag gagagggttt cggatgtgca gaaggtcctg cagggtgggg 2220 agcaggagat ccagtttgag gatttcacca acaccttaag ggaactggga cacgcagagc 2280 atgaaatcac tgagctcacg gccaccttca ccaagtttga cagagatggg aatcgtattc 2340 tggatgagaa ggaacaggaa aaaatgcgac aggacctgga ggaagagagg gtggccctca 2400 acactgagat tgagaaacta ggccgatcta ttgtgagcag cccacaaggc aaatcgggtc 2460 cagaggctgc cagagcagga ggctgggttt caggagaaga attctacatg ctcacaagga 2520 gagttctgca gctggagact gtcctggaag gagtagtgtc ccagattgat gctgtaggct 2580 caaagctgaa aatgctggag aggaaggggt ggctggctcc ctccccaggc gtgaaggaac 2640 aagctatttg gaagcacccg cagccagccc cagctgtgac cccagacccc tggggagtcc 2700 agggtgggca ggagagtgag gttccctata aaagagaaga ggaagcctta gaggagagga 2760 gactctcccg tggtgagatt ccaacgttgc agaggagtta agtgtgaggc actcccggag 2820 caaagtctat gaaggatctt ctgcaagagg ctgcctcctg gtccactgaa cctggaaact 2880 gagtgggctt taaccaggag ataaaaatgg agcctgaagg gaatcaggca aggaaatgaa 2940 ctcaggattc agagatcttt gaattaatat gtggtgggtt ctgacattat tcttccataa 3000 gaccatgtgg gtttccatgg tggctatcaa taaaactcct tagt 3044 60 805 PRT Homo sapiens 60 Met Asn Ala Val Gly Ser Pro Glu Gly Gln Glu Leu His Lys Leu Gly 1 5 10 15 Ser Gly Ala Trp Asp Asn Pro Ala Tyr Ser Gly Pro Pro Ser Pro His 20 25 30 Gly Thr Leu Arg Val Cys Thr Ile Ser Ser Thr Gly Pro Leu Gln Pro 35 40 45 Gln Pro Lys Lys Pro Glu Asp Glu Pro Gln Glu Thr Ala Tyr Arg Thr 50 55 60 Gln Val Ser Ser Cys Cys Leu His Ile Cys Gln Gly Ile Arg Gly Leu 65 70 75 80 Trp Gly Thr Thr Leu Thr Glu Asn Thr Ala Glu Asn Arg Glu Leu Tyr 85 90 95 Ile Lys Thr Thr Leu Arg Glu Leu Leu Val Tyr Ile Val Phe Leu Val 100 105 110 Asp Ile Cys Leu Leu Thr Tyr Gly Met Thr Ser Ser Ser Ala Tyr Tyr 115 120 125 Tyr Thr Lys Val Met Ser Glu Leu Phe Leu His Thr Pro Ser Asp Thr 130 135 140 Gly Val Ser Phe Gln Ala Ile Ser Ser Met Ala Asp Phe Trp Asp Phe 145 150 155 160 Ala Gln Gly Pro Leu Leu Asp Ser Leu Tyr Trp Thr Lys Trp Tyr Asn 165 170 175 Asn Gln Ser Leu Gly His Gly Ser His Ser Phe Ile Tyr Tyr Glu Asn 180 185 190 Met Leu Leu Gly Val Pro Arg Leu Arg Gln Leu Lys Val Arg Asn Asp 195 200 205 Ser Cys Val Val His Glu Asp Phe Arg Glu Asp Ile Leu Ser Cys Tyr 210 215 220 Asp Val Tyr Ser Pro Asp Lys Glu Glu Gln Leu Pro Phe Gly Pro Phe 225 230 235 240 Asn Gly Thr Ala Trp Thr Tyr His Ser Gln Asp Glu Leu Gly Gly Phe 245 250 255 Ser His Trp Gly Arg Leu Thr Ser Tyr Ser Gly Gly Gly Tyr Tyr Leu 260 265 270 Asp Leu Pro Gly Ser Arg Gln Gly Ser Ala Glu Ala Leu Arg Ala Leu 275 280 285 Gln Glu Gly Leu Trp Leu Asp Arg Gly Thr Arg Val Val Phe Ile Asp 290 295 300 Phe Ser Val Tyr Asn Ala Asn Ile Asn Leu Phe Cys Val Leu Arg Leu 305 310 315 320 Val Val Glu Phe Pro Ala Thr Gly Gly Ala Ile Pro Ser Trp Gln Ile 325 330 335 Arg Thr Val Lys Leu Ile Arg Tyr Val Ser Asn Trp Asp Phe Phe Ile 340 345 350 Val Gly Cys Glu Val Ile Phe Cys Val Phe Ile Phe Tyr Tyr Val Val 355 360 365 Glu Glu Ile Leu Glu Leu His Ile His Arg Leu Arg Tyr Leu Ser Ser 370 375 380 Ile Trp Asn Ile Leu Asp Leu Val Ile Ile Leu Leu Ser Ile Val Ala 385 390 395 400 Val Gly Phe His Ile Phe Arg Thr Leu Glu Val Asn Arg Leu Met Gly 405 410 415 Lys Leu Leu Gln Gln Pro Asn Thr Tyr Ala Asp Phe Glu Phe Leu Ala 420 425 430 Phe Trp Gln Thr Gln Tyr Asn Asn Met Asn Ala Val Asn Leu Phe Phe 435 440 445 Ala Trp Ile Lys Ile Phe Lys Tyr Ile Ser Phe Asn Lys Thr Met Thr 450 455 460 Gln Leu Ser Ser Thr Leu Ala Arg Cys Ala Lys Asp Ile Leu Gly Phe 465 470 475 480 Ala Val Met Phe Phe Ile Val Phe Phe Ala Tyr Ala Gln Leu Gly Tyr 485 490 495 Leu Leu Phe Gly Thr Gln Val Glu Asn Phe Ser Thr Phe Ile Lys Cys 500 505 510 Ile Phe Thr Gln Phe Arg Ile Ile Leu Gly Asp Phe Asp Tyr Asn Ala 515 520 525 Ile Asp Asn Ala Asn Arg Ile Leu Gly Pro Ala Tyr Phe Val Thr Tyr 530 535 540 Val Phe Phe Val Phe Phe Val Leu Leu Asn Met Phe Leu Ala Ile Ile 545 550 555 560 Asn Asp Thr Tyr Ser Glu Val Lys Glu Glu Leu Ala Gly Gln Lys Asp 565 570 575 Glu Leu Gln Leu Ser Asp Leu Leu Lys Gln Gly Tyr Asn Lys Thr Leu 580 585 590 Leu Arg Leu Arg Leu Arg Lys Glu Arg Val Ser Asp Val Gln Lys Val 595 600 605 Leu Gln Gly Gly Glu Gln Glu Ile Gln Phe Glu Asp Phe Thr Asn Thr 610 615 620 Leu Arg Glu Leu Gly His Ala Glu His Glu Ile Thr Glu Leu Thr Ala 625 630 635 640 Thr Phe Thr Lys Phe Asp Arg Asp Gly Asn Arg Ile Leu Asp Glu Lys 645 650 655 Glu Gln Glu Lys Met Arg Gln Asp Leu Glu Glu Glu Arg Val Ala Leu 660 665 670 Asn Thr Glu Ile Glu Lys Leu Gly Arg Ser Ile Val Ser Ser Pro Gln 675 680 685 Gly Lys Ser Gly Pro Glu Ala Ala Arg Ala Gly Gly Trp Val Ser Gly 690 695 700 Glu Glu Phe Tyr Met Leu Thr Arg Arg Val Leu Gln Leu Glu Thr Val 705 710 715 720 Leu Glu Gly Val Val Ser Gln Ile Asp Ala Val Gly Ser Lys Leu Lys 725 730 735 Met Leu Glu Arg Lys Gly Trp Leu Ala Pro Ser Pro Gly Val Lys Glu 740 745 750 Gln Ala Ile Trp Lys His Pro Gln Pro Ala Pro Ala Val Thr Pro Asp 755 760 765 Pro Trp Gly Val Gln Gly Gly Gln Glu Ser Glu Val Pro Tyr Lys Arg 770 775 780 Glu Glu Glu Ala Leu Glu Glu Arg Arg Leu Ser Arg Gly Glu Ile Pro 785 790 795 800 Thr Leu Gln Arg Ser 805 61 1146 DNA Homo sapiens 61 agggagggag tgaaggagct ctctgtaccc aaggaaagtg cagctgagac tcagacaaga 60 ttacaatgaa ccaactcagc ttcctgctgt ttctcatagc gaccaccaga ggatggagta 120 cagatgaggc taatacttac ttcaaggaat ggacctgttc ttcgtctcca tctctgccca 180 gaagctgcaa ggaaatcaaa gacgaatgtc ctagtgcatt tgatggcctg tattttctcc 240 gcactgagaa tggtgttatc taccagacct tctgtgacat gacctctggg ggtggcggct 300 ggaccctggt ggccagcgtg catgagaatg acatgcgtgg gaagtgcacg gtgggcgatc 360 gctggtccag tcagcagggc agcaaagcag actacccaga gggggacggc aactgggcca 420 actacaacac ctttggatct gcagaggcgg ccacgagcga tgactacaag aaccctggct 480 actacgacat ccaggccaag gacctgggca tctggcacgt gcccaataag tcccccatgc 540 agcactggag aaacagctcc ctgctgaggt accgcacgga cactggcttc ctccagacac 600 tgggacataa tctgtttggc atctaccaga aatatccagt gaaatatgga gaaggaaagt 660 gttggactga caacggcccg gtgatccctg tggtctatga ttttggcgac gcccagaaaa 720 cagcatctta ttactcaccc tatggccagc gggaattcac tgcgggattt gttcagttca 780 gggtatttaa taacgagaga gcagccaacg ccttgtgtgc tggaatgagg gtcaccggat 840 gtaacactga gcaccactgc attggtggag gaggatactt tccagaggcc agtccccagc 900 agtgtggaga tttttctggt tttgattgga gtggatatgg aactcatgtt ggttacagca 960 gcagccgtga gataactgag gcagctgtgc ttctattcta tcgttgagag ttttgtggga 1020 gggaacccag acctctcctc ccaaccatga gatcccaagg atggagaaca acttacccag 1080 tagctagaat gttaatggca gaagagaaaa caataaatca tattgactca aaaaaaaaaa 1140 aaaaaa 1146 62 313 PRT Homo sapiens 62 Met Asn Gln Leu Ser Phe Leu Leu Phe Leu Ile Ala Thr Thr Arg Gly 1 5 10 15 Trp Ser Thr Asp Glu Ala Asn Thr Tyr Phe Lys Glu Trp Thr Cys Ser 20 25 30 Ser Ser Pro Ser Leu Pro Arg Ser Cys Lys Glu Ile Lys Asp Glu Cys 35 40 45 Pro Ser Ala Phe Asp Gly Leu Tyr Phe Leu Arg Thr Glu Asn Gly Val 50 55 60 Ile Tyr Gln Thr Phe Cys Asp Met Thr Ser Gly Gly Gly Gly Trp Thr 65 70 75 80 Leu Val Ala Ser Val His Glu Asn Asp Met Arg Gly Lys Cys Thr Val 85 90 95 Gly Asp Arg Trp Ser Ser Gln Gln Gly Ser Lys Ala Asp Tyr Pro Glu 100 105 110 Gly Asp Gly Asn Trp Ala Asn Tyr Asn Thr Phe Gly Ser Ala Glu Ala 115 120 125 Ala Thr Ser Asp Asp Tyr Lys Asn Pro Gly Tyr Tyr Asp Ile Gln Ala 130 135 140 Lys Asp Leu Gly Ile Trp His Val Pro Asn Lys Ser Pro Met Gln His 145 150 155 160 Trp Arg Asn Ser Ser Leu Leu Arg Tyr Arg Thr Asp Thr Gly Phe Leu 165 170 175 Gln Thr Leu Gly His Asn Leu Phe Gly Ile Tyr Gln Lys Tyr Pro Val 180 185 190 Lys Tyr Gly Glu Gly Lys Cys Trp Thr Asp Asn Gly Pro Val Ile Pro 195 200 205 Val Val Tyr Asp Phe Gly Asp Ala Gln Lys Thr Ala Ser Tyr Tyr Ser 210 215 220 Pro Tyr Gly Gln Arg Glu Phe Thr Ala Gly Phe Val Gln Phe Arg Val 225 230 235 240 Phe Asn Asn Glu Arg Ala Ala Asn Ala Leu Cys Ala Gly Met Arg Val 245 250 255 Thr Gly Cys Asn Thr Glu His His Cys Ile Gly Gly Gly Gly Tyr Phe 260 265 270 Pro Glu Ala Ser Pro Gln Gln Cys Gly Asp Phe Ser Gly Phe Asp Trp 275 280 285 Ser Gly Tyr Gly Thr His Val Gly Tyr Ser Ser Ser Arg Glu Ile Thr 290 295 300 Glu Ala Ala Val Leu Leu Phe Tyr Arg 305 310 63 1635 DNA Homo sapiens 63 gggggtggcg gggacgcgag tggcggccgc ggggccccgg acaagggtcc gcagagctgc 60 agccttcgag ggccagccct ctccgagtcc ggggctgggt cccaccagtg acaaggcggc 120 agccccgcgc acaccaaaga gaaagcggct gtggcggcag cggcagcccc agccatgctg 180 tgttatgtga cgaggccgga cgcggtgctg atggaggtgg aggtggaggc gaaagccaac 240 ggcgaggact gcctcaacca ggtgtgcagg cgactgggaa tcatagaagt tgactatttt 300 ggactgcaat ttacgggtag caaaggtgaa agtttatggc taaacctgag aaaccggatc 360 tcccagcaga tggatgggct agccccttac aggcttaaac ttagagtcaa gttcttcgtg 420 gagcctcatc tcatcttaca ggagcagact aggcatatct ttttcttgca catcaaggag 480 gccctcttgg caggccacct cttgtgttcc ccagagcagg cagtggaact cagtgccctc 540 ctggcccaga ccaagtttgg agactacaac cagaacactg ccaagtataa ctatgaggag 600 ctctgtgcca aggagctctc ctctgccacc ttgaacagca ttgttgcaaa acataaggag 660 ttggagggga ccagccaggc ttcagctgaa taccaagttt tgcagattgt gtcggcaatg 720 gaaaactatg gcatagaatg gcattctgtg cgggatagcg aagggcagag actgctcatt 780 ggggttggac ctgaaggaat ctcaatttgt aaagatgact ttagcccaat taataggata 840 gcttatcctg tggtgcagat ggccacccag tcaggaaaga atgtatattt gacggtcacc 900 aaggaatctg ggaacagcat cgtgctcttg tttaaaatga tcagcaccag ggcggccagc 960 gggctctacc gagcgataac agagacgcac gcattctaca ggtgtgacac agtgaccagc 1020 gccgtgatga tgcagtatag ccgtgacttg aagggccact tggcatctct gtttctgaat 1080 gaaaacatta accttggcaa gaaatatgtc tttgatatta aaagaacatc aaaggaggtg 1140 tatgaccatg ccaggagggc tctgtacaat gctggcgttg tggacctcgt ttcaagaagc 1200 aaccagagcc cttcacactc gcctctgaag tcctcagaaa gcagcatgaa ctgcagcagc 1260 tgcgagggcc tcagctgcca gcagacccgg gtgctgcagg agaagctacg caagctgaag 1320 gaagccatgc tgtgcatggt gtgctgcgag gaggagatca actccacctt ctgtccctgt 1380 ggccacactg tgtgctgtga gagctgcgcc gcccagctac agtcatgtcc cgtctgcagg 1440 tcgcgtgtgg agcatgtcca gcacgtctat ctgccaacgc acaccagtct tctcaatctg 1500 actgtaatct aatctgttgt gcttttgttg gacttggcat gtttccatga actgcactat 1560 tataaactat taaaatgata gatgttggag aaagtaatta ttccaacacc catctgccca 1620 tgcgatgtta aaaaa 1635 64 445 PRT Homo sapiens 64 Met Leu Cys Tyr Val Thr Arg Pro Asp Ala Val Leu Met Glu Val Glu 1 5 10 15 Val Glu Ala Lys Ala Asn Gly Glu Asp Cys Leu Asn Gln Val Cys Arg 20 25 30 Arg Leu Gly Ile Ile Glu Val Asp Tyr Phe Gly Leu Gln Phe Thr Gly 35 40 45 Ser Lys Gly Glu Ser Leu Trp Leu Asn Leu Arg Asn Arg Ile Ser Gln 50 55 60 Gln Met Asp Gly Leu Ala Pro Tyr Arg Leu Lys Leu Arg Val Lys Phe 65 70 75 80 Phe Val Glu Pro His Leu Ile Leu Gln Glu Gln Thr Arg His Ile Phe 85 90 95 Phe Leu His Ile Lys Glu Ala Leu Leu Ala Gly His Leu Leu Cys Ser 100 105 110 Pro Glu Gln Ala Val Glu Leu Ser Ala Leu Leu Ala Gln Thr Lys Phe 115 120 125 Gly Asp Tyr Asn Gln Asn Thr Ala Lys Tyr Asn Tyr Glu Glu Leu Cys 130 135 140 Ala Lys Glu Leu Ser Ser Ala Thr Leu Asn Ser Ile Val Ala Lys His 145 150 155 160 Lys Glu Leu Glu Gly Thr Ser Gln Ala Ser Ala Glu Tyr Gln Val Leu 165 170 175 Gln Ile Val Ser Ala Met Glu Asn Tyr Gly Ile Glu Trp His Ser Val 180 185 190 Arg Asp Ser Glu Gly Gln Arg Leu Leu Ile Gly Val Gly Pro Glu Gly 195 200 205 Ile Ser Ile Cys Lys Asp Asp Phe Ser Pro Ile Asn Arg Ile Ala Tyr 210 215 220 Pro Val Val Gln Met Ala Thr Gln Ser Gly Lys Asn Val Tyr Leu Thr 225 230 235 240 Val Thr Lys Glu Ser Gly Asn Ser Ile Val Leu Leu Phe Lys Met Ile 245 250 255 Ser Thr Arg Ala Ala Ser Gly Leu Tyr Arg Ala Ile Thr Glu Thr His 260 265 270 Ala Phe Tyr Arg Cys Asp Thr Val Thr Ser Ala Val Met Met Gln Tyr 275 280 285 Ser Arg Asp Leu Lys Gly His Leu Ala Ser Leu Phe Leu Asn Glu Asn 290 295 300 Ile Asn Leu Gly Lys Lys Tyr Val Phe Asp Ile Lys Arg Thr Ser Lys 305 310 315 320 Glu Val Tyr Asp His Ala Arg Arg Ala Leu Tyr Asn Ala Gly Val Val 325 330 335 Asp Leu Val Ser Arg Ser Asn Gln Ser Pro Ser His Ser Pro Leu Lys 340 345 350 Ser Ser Glu Ser Ser Met Asn Cys Ser Ser Cys Glu Gly Leu Ser Cys 355 360 365 Gln Gln Thr Arg Val Leu Gln Glu Lys Leu Arg Lys Leu Lys Glu Ala 370 375 380 Met Leu Cys Met Val Cys Cys Glu Glu Glu Ile Asn Ser Thr Phe Cys 385 390 395 400 Pro Cys Gly His Thr Val Cys Cys Glu Ser Cys Ala Ala Gln Leu Gln 405 410 415 Ser Cys Pro Val Cys Arg Ser Arg Val Glu His Val Gln His Val Tyr 420 425 430 Leu Pro Thr His Thr Ser Leu Leu Asn Leu Thr Val Ile 435 440 445 65 1741 DNA Homo sapiens 65 gaattccgga caggtagtaa gataggaagt gaggccaggt accttgtggg cagtgatgtc 60 attcggtgcg actcctaaga tgtctccaga gatgggagag ctcacccaaa ccaggttgca 120 gaagatctgg attccacaca gcagcggcag cagcaggctg caacggagaa ggggctcatc 180 cataccccag tttaccaatt cccccacaat ggtgatcatg gtgggtttac cagctcgagg 240 caagacctat atctccacaa agctcacacg atatctcaac tggataggaa caccaactaa 300 agtgtttaat ttaggccagt atcgacgaga ggcagtgagc tacaagaact atgaattctt 360 tcttccagac aacatggaag ccctgcaaat caggaagcag tgcgccctgg cagccctgaa 420 ggatgttcac aactatctca gccatgagga aggtcatgtt gcggtttttg atgccaccaa 480 cactaccaga gaacgacggt cactgatcct gcagtttgca aaagaacatg gttacaaggt 540 gtttttcatt gagtccattt gtaatgaccc tggcataatt gcagaaaaca tcaggcaagt 600 gaaacttggc agccctgatt atatagactg tgaccgggaa aaggttctgg aagactttct 660 aaagagaatt gagtgctatg aggtcaacta ccaacccttg gatgaggaac tggacagcca 720 cctgtcctac atcaagatct tcgacgtggg cacacgctac atggtgaacc gagtgcagga 780 tcacatccag agccgcacag tctactacct catgaatatc catgtcacac ctcgctccat 840 ctacctttgc cgacatggcg agagtgaact caacatcaga ggccgcatcg gaggtgactc 900 tggcctctca gttcgcggca agcagtatgc ctatgccctg gccaacttca ttcagtccca 960 gggcatcagc tccctgaagg tgtggaccag tcgcatgaag aggaccatcc agacagctga 1020 ggccctgggt gtcccctatg agcagtggaa ggccctgaat gagattgatg cgggtgtctg 1080 tgaggagatg acctatgaag aaatccagga acattaccct gaagaatttg cactgcgaga 1140 ccaagataaa tatcgctacc gctatcccaa gggagagtcc tatgaggatc tggttcagcg 1200 tctggagcca gtgataatgg agctagaacg acaggagaat gtactggtga tctgccacca 1260 ggctgtcatg cggtgcctcc tggcctattt cctggataaa agttcagatg agcttccata 1320 tctcaagtgc cctctgcaca cagtgctcaa actcactcct gtggcttatg gctgcaaagt 1380 ggaatccatc tacctgaatg tggaggccgt gaacacacac cgggagaagc ctgagaatgt 1440 ggacatcacc cgggaacctg aggaagccct ggatactgtc ccagcccact actgagccct 1500 ttccaagaag tcaaactgcc tgtgtcctca tcgccttcca cctttaggaa atgctatctt 1560 tgctcttctc ctactctgcc ttggcctcac tgaggcaccc cacttccagt gaagaagtcc 1620 tccgcaactc ccaaacaagc ctcgcttgct ggccgcaacc aaggagctat ctagctctgg 1680 aggaaacttt ctttcttaat tcctattctc tgacgaataa agacttactg cctacaagag 1740 g 1741 66 471 PRT Homo sapiens 66 Met Ser Pro Glu Met Gly Glu Leu Thr Gln Thr Arg Leu Gln Lys Ile 1 5 10 15 Trp Ile Pro His Ser Ser Gly Ser Ser Arg Leu Gln Arg Arg Arg Gly 20 25 30 Ser Ser Ile Pro Gln Phe Thr Asn Ser Pro Thr Met Val Ile Met Val 35 40 45 Gly Leu Pro Ala Arg Gly Lys Thr Tyr Ile Ser Thr Lys Leu Thr Arg 50 55 60 Tyr Leu Asn Trp Ile Gly Thr Pro Thr Lys Val Phe Asn Leu Gly Gln 65 70 75 80 Tyr Arg Arg Glu Ala Val Ser Tyr Lys Asn Tyr Glu Phe Phe Leu Pro 85 90 95 Asp Asn Met Glu Ala Leu Gln Ile Arg Lys Gln Cys Ala Leu Ala Ala 100 105 110 Leu Lys Asp Val His Asn Tyr Leu Ser His Glu Glu Gly His Val Ala 115 120 125 Val Phe Asp Ala Thr Asn Thr Thr Arg Glu Arg Arg Ser Leu Ile Leu 130 135 140 Gln Phe Ala Lys Glu His Gly Tyr Lys Val Phe Phe Ile Glu Ser Ile 145 150 155 160 Cys Asn Asp Pro Gly Ile Ile Ala Glu Asn Ile Arg Gln Val Lys Leu 165 170 175 Gly Ser Pro Asp Tyr Ile Asp Cys Asp Arg Glu Lys Val Leu Glu Asp 180 185 190 Phe Leu Lys Arg Ile Glu Cys Tyr Glu Val Asn Tyr Gln Pro Leu Asp 195 200 205 Glu Glu Leu Asp Ser His Leu Ser Tyr Ile Lys Ile Phe Asp Val Gly 210 215 220 Thr Arg Tyr Met Val Asn Arg Val Gln Asp His Ile Gln Ser Arg Thr 225 230 235 240 Val Tyr Tyr Leu Met Asn Ile His Val Thr Pro Arg Ser Ile Tyr Leu 245 250 255 Cys Arg His Gly Glu Ser Glu Leu Asn Ile Arg Gly Arg Ile Gly Gly 260 265 270 Asp Ser Gly Leu Ser Val Arg Gly Lys Gln Tyr Ala Tyr Ala Leu Ala 275 280 285 Asn Phe Ile Gln Ser Gln Gly Ile Ser Ser Leu Lys Val Trp Thr Ser 290 295 300 Arg Met Lys Arg Thr Ile Gln Thr Ala Glu Ala Leu Gly Val Pro Tyr 305 310 315 320 Glu Gln Trp Lys Ala Leu Asn Glu Ile Asp Ala Gly Val Cys Glu Glu 325 330 335 Met Thr Tyr Glu Glu Ile Gln Glu His Tyr Pro Glu Glu Phe Ala Leu 340 345 350 Arg Asp Gln Asp Lys Tyr Arg Tyr Arg Tyr Pro Lys Gly Glu Ser Tyr 355 360 365 Glu Asp Leu Val Gln Arg Leu Glu Pro Val Ile Met Glu Leu Glu Arg 370 375 380 Gln Glu Asn Val Leu Val Ile Cys His Gln Ala Val Met Arg Cys Leu 385 390 395 400 Leu Ala Tyr Phe Leu Asp Lys Ser Ser Asp Glu Leu Pro Tyr Leu Lys 405 410 415 Cys Pro Leu His Thr Val Leu Lys Leu Thr Pro Val Ala Tyr Gly Cys 420 425 430 Lys Val Glu Ser Ile Tyr Leu Asn Val Glu Ala Val Asn Thr His Arg 435 440 445 Glu Lys Pro Glu Asn Val Asp Ile Thr Arg Glu Pro Glu Glu Ala Leu 450 455 460 Asp Thr Val Pro Ala His Tyr 465 470 67 2234 DNA Homo sapiens 67 ccccctccgc tctgctgcgc cgcccggctg ggccccgagg ccgctccgac tgctatgtga 60 ccgcgaggct gcgggaggaa ggggacaggg aagaagaggc tctcccgcgg gagcccttga 120 ggaccaagtt tgcggccact tctgcaggcg tcccttctta gctctcgcct gcccctttct 180 gcagcctagg cggcccaggt tctcttctct tcctcgcgcg cccagccgcc tcggttcccg 240 gcgaccatgg tgacgatgga ggagctgcgg gagatggact gcagtgtgct caaaaggctg 300 atgaaccggg acgagaatgg cggcggcgcg ggcggcagcg gcagccacgg caccctgggg 360 ctgccgagcg gcggcaagtg cctgctgctg gactgcagac cgttcctggc gcacagcgcg 420 ggctacatcc taggttcggt caacgtgcgc tgtaacacca tcgtgcggcg gcgggctaag 480 ggctccgtga gcctggagca gatcctgccc gccgaggagg aggtacgcgc ccgcttgcgc 540 tccggcctct actcggcggt catcgtctac gacgagcgca gcccgcgcgc cgagagcctc 600 cgcgaggaca gcaccgtgtc gctggtggtg caggcgctgc gccgcaacgc cgagcgcacc 660 gacatctgcc tgctcaaagg cggctatgag aggttttcct ccgagtaccc agaattctgt 720 tctaaaacca aggccctggc agccatccca cccccggttc cccccagcgc cacagagccc 780 ttggacctgg gctgcagctc ctgtgggacc ccactacacg accagggggg tcctgtggag 840 atccttccct tcctctacct cggcagtgcc taccatgctg cccggagaga catgctggac 900 gccctgggca tcacggctct gttgaatgtc tcctcggact gcccaaacca ctttgaagga 960 cactatcagt acaagtgcat cccagtggaa gataaccaca aggccgacat cagctcctgg 1020 ttcatggaag ccatagagta catcgatgcc gtgaaggact gccgtgggcg cgtgctggtg 1080 cactgccagg cgggcatctc gcggtcggcc accatctgcc tggcctacct gatgatgaag 1140 aaacgggtga ggctggagga ggccttcgag ttcgttaagc agcgccgcag catcatctcg 1200 cccaacttca gcttcatggg gcagctgctg cagttcgagt cccaggtgct ggccacgtcc 1260 tgtgctgcgg aggctgctag cccctcggga cccctgcggg agcggggcaa gacccccgcc 1320 acccccacct cgcagttcgt cttcagcttt ccggtctccg tgggcgtgca ctcggccccc 1380 agcagcctgc cctacctgca cagccccatc accacctctc ccagctgtta gagccgccct 1440 gggggcccca gaaccagagc tggctcccag caagggtagg acgggccgca tgcggcagaa 1500 agttgggact gagcagctgg gagcaggcga ccgagctcct tccccatcat ttctccttgg 1560 ccaacgacga ggccagccag aatggcaata aggactccga atacataata aaagcaaaca 1620 gaacactcca acttagagca ataaccggtg ccgcagcagc cagggaagac cttggtttgg 1680 tttatgtgtc agtttcactt ttccgataga aatttcttac ctcatttttt taagcagtaa 1740 ggcttgaagt gatgaaaccc acagatccta gcaaatgtgc ccaaccagct ttactaaagg 1800 gggaggaagg gagggcaaag ggatgagaag acaagtttcc cagaagtgcc tggttctggg 1860 tacttgtccc tttgttgtcg ttgttgtagt taaaggaatt tcatttttaa aagaaatctt 1920 cgaaggtgtg gttttcattt ctcagtcacc aacagatgaa taattatgct taataataaa 1980 gtatttatta agactttctt cagagtatga aagtacaaaa agtctagtta cagtggattt 2040 agaatatatt tatgttgatg tcaaacagct gagcaccgta gcatgcagat gtcaaggcag 2100 ttaggaagta aatggtgtct tgtagatatg tgcaaggtag catgatgagc aacttgagtt 2160 tgttgccact gagaagcagg cgggttgggt gggaggagga agaaagggaa gaattaggtt 2220 tgaattgctt ttta 2234 68 394 PRT Homo sapiens 68 Met Val Thr Met Glu Glu Leu Arg Glu Met Asp Cys Ser Val Leu Lys 1 5 10 15 Arg Leu Met Asn Arg Asp Glu Asn Gly Gly Gly Ala Gly Gly Ser Gly 20 25 30 Ser His Gly Thr Leu Gly Leu Pro Ser Gly Gly Lys Cys Leu Leu Leu 35 40 45 Asp Cys Arg Pro Phe Leu Ala His Ser Ala Gly Tyr Ile Leu Gly Ser 50 55 60 Val Asn Val Arg Cys Asn Thr Ile Val Arg Arg Arg Ala Lys Gly Ser 65 70 75 80 Val Ser Leu Glu Gln Ile Leu Pro Ala Glu Glu Glu Val Arg Ala Arg 85 90 95 Leu Arg Ser Gly Leu Tyr Ser Ala Val Ile Val Tyr Asp Glu Arg Ser 100 105 110 Pro Arg Ala Glu Ser Leu Arg Glu Asp Ser Thr Val Ser Leu Val Val 115 120 125 Gln Ala Leu Arg Arg Asn Ala Glu Arg Thr Asp Ile Cys Leu Leu Lys 130 135 140 Gly Gly Tyr Glu Arg Phe Ser Ser Glu Tyr Pro Glu Phe Cys Ser Lys 145 150 155 160 Thr Lys Ala Leu Ala Ala Ile Pro Pro Pro Val Pro Pro Ser Ala Thr 165 170 175 Glu Pro Leu Asp Leu Gly Cys Ser Ser Cys Gly Thr Pro Leu His Asp 180 185 190 Gln Gly Gly Pro Val Glu Ile Leu Pro Phe Leu Tyr Leu Gly Ser Ala 195 200 205 Tyr His Ala Ala Arg Arg Asp Met Leu Asp Ala Leu Gly Ile Thr Ala 210 215 220 Leu Leu Asn Val Ser Ser Asp Cys Pro Asn His Phe Glu Gly His Tyr 225 230 235 240 Gln Tyr Lys Cys Ile Pro Val Glu Asp Asn His Lys Ala Asp Ile Ser 245 250 255 Ser Trp Phe Met Glu Ala Ile Glu Tyr Ile Asp Ala Val Lys Asp Cys 260 265 270 Arg Gly Arg Val Leu Val His Cys Gln Ala Gly Ile Ser Arg Ser Ala 275 280 285 Thr Ile Cys Leu Ala Tyr Leu Met Met Lys Lys Arg Val Arg Leu Glu 290 295 300 Glu Ala Phe Glu Phe Val Lys Gln Arg Arg Ser Ile Ile Ser Pro Asn 305 310 315 320 Phe Ser Phe Met Gly Gln Leu Leu Gln Phe Glu Ser Gln Val Leu Ala 325 330 335 Thr Ser Cys Ala Ala Glu Ala Ala Ser Pro Ser Gly Pro Leu Arg Glu 340 345 350 Arg Gly Lys Thr Pro Ala Thr Pro Thr Ser Gln Phe Val Phe Ser Phe 355 360 365 Pro Val Ser Val Gly Val His Ser Ala Pro Ser Ser Leu Pro Tyr Leu 370 375 380 His Ser Pro Ile Thr Thr Ser Pro Ser Cys 385 390 69 776 DNA Homo sapiens 69 aaggacacgg gcagcagaca gtggtcagtc ctttcttggc tctgctgaca ctcgagccca 60 cattccgtca cctgctcaga atcatgcagg tctccactgc tgcccttgct gtcctcctct 120 gcaccatggc tctctgcaac cagttctctg catcacttgc tgctgacacg ccgaccgcct 180 gctgcttcag ctacacctcc cggcagattc cacagaattt catagctgac tactttgaga 240 cgagcagcca gtgctccaag cccggtgtca tcttcctaac caagcgaagc cggcaggtct 300 gtgctgaccc cagtgaggag tgggtccaga aatatgtcag cgacctagag ctgagtgcct 360 gaggggtcca gaagcttcga ggcccagcga cctcggtggg ccagtgggga ggagcaggag 420 cctgagcctt gggaaacatg cgtgtgacct ccacagctac ctcttctatg gactggttgt 480 tgccaaacag ccacactgtg ggactcttct taacttaaat tttaatttat ttatactatt 540 tagtttttgt aatttatttt cgatttcaca gtgtgtttgt gattgtttgc tctgagagtt 600 cccctgtccc ctcccccttc cctcacaccg cgtctggtga caaccgagtg gctgtcatca 660 gcctgtgtag gcagtcatgg caccaaagcc accagactga caaatgtgta tcggatgctt 720 ttgttcaggg ctgtgatcgg cctggggaaa taataaagca cgctctttta aaaggt 776 70 92 PRT Homo sapiens 70 Met Gln Val Ser Thr Ala Ala Leu Ala Val Leu Leu Cys Thr Met Ala 1 5 10 15 Leu Cys Asn Gln Phe Ser Ala Ser Leu Ala Ala Asp Thr Pro Thr Ala 20 25 30 Cys Cys Phe Ser Tyr Thr Ser Arg Gln Ile Pro Gln Asn Phe Ile Ala 35 40 45 Asp Tyr Phe Glu Thr Ser Ser Gln Cys Ser Lys Pro Gly Val Ile Phe 50 55 60 Leu Thr Lys Arg Ser Arg Gln Val Cys Ala Asp Pro Ser Glu Glu Trp 65 70 75 80 Val Gln Lys Tyr Val Ser Asp Leu Glu Leu Ser Ala 85 90 71 2753 DNA Homo sapiens 71 gtcgggggca gcagcaagat gcgaagcgag ccgtacagat cccgggctct ccgaacgcaa 60 cttcgccctg cttgagcgag gctgcggttt ccgaggccct ctccagccaa ggaaaagcta 120 cacaaaaagc ctggatcact catcgaacca cccctgaagc cagtgaaggc tctctcgcct 180 cgccctctag cgttcgtctg gagtagcgcc accccggctt cctggggaca cagggttggc 240 accatggggc ccaccagcgt cccgctggtc aaggcccacc gcagctcggt ctctgactac 300 gtcaactatg atatcatcgt ccggcattac aactacacgg gaaagctgaa tatcagcgcg 360 gacaaggaga acagcattaa actgacctcg gtggtgttca ttctcatctg ctgctttatc 420 atcctggaga acatctttgt cttgctgacc atttggaaaa ccaagaaatt ccaccgaccc 480 atgtactatt ttattggcaa tctggccctc tcagacctgt tggcaggagt agcctacaca 540 gctaacctgc tcttgtctgg ggccaccacc tacaagctca ctcccgccca gtggtttctg 600 cgggaaggga gtatgtttgt ggccctgtca gcctccgtgt tcagtctcct cgccatcgcc 660 attgagcgct atatcacaat gctgaaaatg aaactccaca acgggagcaa taacttccgc 720 ctcttcctgc taatcagcgc ctgctgggtc atctccctca tcctgggtgg cctgcctatc 780 atgggctgga actgcatcag tgcgctgtcc agctgctcca ccgtgctgcc gctctaccac 840 aagcactata tcctcttctg caccacggtc ttcactctgc ttctgctctc catcgtcatt 900 ctgtactgca gaatctactc cttggtcagg actcggagcc gccgcctgac gttccgcaag 960 aacatttcca aggccagccg cagctctgag aagtcgctgg cgctgctcaa gaccgtaatt 1020 atcgtcctga gcgtcttcat cgcctgctgg gcaccgctct tcatcctgct cctgctggat 1080 gtgggctgca aggtgaagac ctgtgacatc ctcttcagag cggagtactt cctggtgtta 1140 gctgtgctca actccggcac caaccccatc atttacactc tgaccaacaa ggagatgcgt 1200 cgggccttca tccggatcat gtcctgctgc aagtgcccga gcggagactc tgctggcaaa 1260 ttcaagcgac ccatcatcgc cggcatggaa ttcagccgca gcaaatcgga caattcctcc 1320 cacccccaga aagacgaagg ggacaaccca gagaccatta tgtcttctgg aaacgtcaac 1380 tcttcttcct agaactggaa gctgtccacc caccggaagc gctctttact tggtcgctgg 1440 ccaccccagt gtttggaaaa aaatctctgg gcttcgactg ctgccaggga ggagctgctg 1500 caagccagag ggaggaaggg ggagaatacg aacagcctgg tggtgtcggg tgttggtggg 1560 tagagttagt tcctgtgaac aatgcactgg gaagggtgga gatcaggtcc cggcctggaa 1620 tatatattct acccccctgg agctttgatt ttgcactgag ccaaaggtct agcattgtca 1680 agctcctaaa gggttcattt ggcccctcct caaagactaa tgtccccatg tgaaagcgtc 1740 tctttgtctg gagctttgag gagatgtttt ccttcacttt agtttcaaac ccaagtgagt 1800 gtgtgcactt ctgcttcttt agggatgccc tgtacatccc acaccccacc ctcccttccc 1860 ttcatacccc tcctcaacgt tcttttactt tatactttaa ctacctgaga gttatcagag 1920 ctggggttgt ggaatgatcg atcatctata gcaaataggc tatgttgagt acgtaggctg 1980 tgggaagatg aagatggttt ggaggtgtaa aacaatgtcc ttcgctgagg ccaaagtttc 2040 catgtaagcg ggatccgttt tttggaattt ggttgaagtc actttgattt ctttaaaaaa 2100 catcttttca atgaaatgtg ttaccatttc atatccattg aagccgaaat ctgcataagg 2160 aagcccactt tatctaaatg atattagcca ggatccttgg tgtcctagga gaaacagaca 2220 agcaaaacaa agtgaaaacc gaatggatta acttttgcaa accaagggag atttcttagc 2280 aaatgagtct aacaaatatg acatccgtct ttcccacttt tgttgatgtt tatttcagaa 2340 tcttgtgtga ttcatttcaa gcaacaacat gttgtatttt gttgtgttaa aagtactttt 2400 cttgattttt gaatgtattt gtttcaggaa gaagtcattt tatggatttt tctaacccgt 2460 gttaactttt ctagaatcca ccctcttgtg cccttaagca ttactttaac tggtagggaa 2520 cgccagaact tttaagtcca gctattcatt agatagtaat tgaagatatg tataaatatt 2580 acaaagaata aaaatatatt actgtctctt tagtatggtt ttcagtgcaa ttaaaccgag 2640 agatgtcttg tttttttaaa aagaatagta tttaataggt ttctgacttt tgtggatcat 2700 tttgcacata gctttatcaa cttttaaaca ttaataaact gattttttta aag 2753 72 382 PRT Homo sapiens 72 Met Gly Pro Thr Ser Val Pro Leu Val Lys Ala His Arg Ser Ser Val 1 5 10 15 Ser Asp Tyr Val Asn Tyr Asp Ile Ile Val Arg His Tyr Asn Tyr Thr 20 25 30 Gly Lys Leu Asn Ile Ser Ala Asp Lys Glu Asn Ser Ile Lys Leu Thr 35 40 45 Ser Val Val Phe Ile Leu Ile Cys Cys Phe Ile Ile Leu Glu Asn Ile 50 55 60 Phe Val Leu Leu Thr Ile Trp Lys Thr Lys Lys Phe His Arg Pro Met 65 70 75 80 Tyr Tyr Phe Ile Gly Asn Leu Ala Leu Ser Asp Leu Leu Ala Gly Val 85 90 95 Ala Tyr Thr Ala Asn Leu Leu Leu Ser Gly Ala Thr Thr Tyr Lys Leu 100 105 110 Thr Pro Ala Gln Trp Phe Leu Arg Glu Gly Ser Met Phe Val Ala Leu 115 120 125 Ser Ala Ser Val Phe Ser Leu Leu Ala Ile Ala Ile Glu Arg Tyr Ile 130 135 140 Thr Met Leu Lys Met Lys Leu His Asn Gly Ser Asn Asn Phe Arg Leu 145 150 155 160 Phe Leu Leu Ile Ser Ala Cys Trp Val Ile Ser Leu Ile Leu Gly Gly 165 170 175 Leu Pro Ile Met Gly Trp Asn Cys Ile Ser Ala Leu Ser Ser Cys Ser 180 185 190 Thr Val Leu Pro Leu Tyr His Lys His Tyr Ile Leu Phe Cys Thr Thr 195 200 205 Val Phe Thr Leu Leu Leu Leu Ser Ile Val Ile Leu Tyr Cys Arg Ile 210 215 220 Tyr Ser Leu Val Arg Thr Arg Ser Arg Arg Leu Thr Phe Arg Lys Asn 225 230 235 240 Ile Ser Lys Ala Ser Arg Ser Ser Glu Lys Ser Leu Ala Leu Leu Lys 245 250 255 Thr Val Ile Ile Val Leu Ser Val Phe Ile Ala Cys Trp Ala Pro Leu 260 265 270 Phe Ile Leu Leu Leu Leu Asp Val Gly Cys Lys Val Lys Thr Cys Asp 275 280 285 Ile Leu Phe Arg Ala Glu Tyr Phe Leu Val Leu Ala Val Leu Asn Ser 290 295 300 Gly Thr Asn Pro Ile Ile Tyr Thr Leu Thr Asn Lys Glu Met Arg Arg 305 310 315 320 Ala Phe Ile Arg Ile Met Ser Cys Cys Lys Cys Pro Ser Gly Asp Ser 325 330 335 Ala Gly Lys Phe Lys Arg Pro Ile Ile Ala Gly Met Glu Phe Ser Arg 340 345 350 Ser Lys Ser Asp Asn Ser Ser His Pro Gln Lys Asp Glu Gly Asp Asn 355 360 365 Pro Glu Thr Ile Met Ser Ser Gly Asn Val Asn Ser Ser Ser 370 375 380 73 1022 DNA Homo sapiens 73 acatacatcg ggtgtgagca cggaatagct gggcggcggc tggtccacag acactgggag 60 acagaagggg ccggtcccca ggcgcccgtg ctgcagcagt gggatccact ggggagaggc 120 tggagaccac cggtgtgaag gcctcgcggg taaattcact gcagctggac ttgccaaaga 180 tgacctggga gagtggattc atgagggacc catgggggat gccctacccc ccttccctgg 240 ggcacagcca ctgaccggca gagcctggct ggggtcctcg cctgtcatgt actgcactcg 300 cacggcaagg ttgcgcacgg agccctggcg gctgctgaag ttgaggctgt gcagatggag 360 gaggatattc tgcagctgca ggcagaggcc acagctgagg tgctggggga ggtggcccag 420 gcacagaagg tgctacggga cagcgtgcag cggctagaag tccagctgag gagcgcctgg 480 ctgggccctg cctaccgaga atttgaggtc ttaaaggctc acgctgacaa gcagagccac 540 atcctatggg ccctcacagg ccacgtgcag cggcagaggc gggagatggt ggcacagcag 600 catcggctgc gacagatcca ggagagactc cacacagcgg cgctcccagc ctgaatctgc 660 ctggatggaa ctgaggacca atcatgctgc aaggaacact tccacgcccc gtgaggcccc 720 tgtgcaggga ggagctgcct gttcactggg atcagccagg gcgccgggcc ccacttctga 780 gcacagagca gagacagacg caggcgggga caaaggcaga ggatgtagcc ccattgggga 840 ggggtggagg aaggacatgt accctttcat gcctacacac ccctcattaa agcagagtcg 900 tggcatctca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagggccaa aaaaaaaaaa aaaaaaaaaa 1020 aa 1022 74 1743 DNA Homo sapiens 74 cagtatccct cctgacaaaa ctaacaaaaa tcctgttagc caaataatca gccacattca 60 tatttaccgt caaagttttt atcctcattt tacagcagtg gagagcgatt gccccgggtc 120 ccacgttagg aagagagaga actgggattt gcacccaggc aatctgggga cagagctgtg 180 atcacaactc catgagtcag ggccgagcca gccccttcac caccagccgg ccgcgccccg 240 ggaaggaagt ttgtggcgga ggaggttcgt acgggaggag ggggaggcgc ccacgcatct 300 ggggctgact cgctctttcg caaaacgtct gggaggagtc cctggggcca caaaactgcc 360 tccttcctga ggccagaagg agagaagacg tgcagggacc ccgcgcacag gagctgccct 420 cgcgacatgg gtcacccgcc gctgctgccg ctgctgctgc tgctccacac ctgcgtccca 480 gcctcttggg gcctgcggtg catgcagtgt aagaccaacg gggattgccg tgtggaagag 540 tgcgccctgg gacaggacct ctgcaggacc acgatcgtgc gcttgtggga agaaggagaa 600 gagctggagc tggtggagaa aagctgtacc cactcagaga agaccaacag gaccctgagc 660 tatcggactg gcttgaagat caccagcctt accgaggttg tgtgtgggtt agacttgtgc 720 aaccagggca actctggccg ggctgtcacc tattcccgaa gccgttacct cgaatgcatt 780 tcctgtggct catcagacat gagctgtgag aggggccggc accagagcct gcagtgccgc 840 agccctgaag aacagtgcct ggatgtggtg acccactgga tccaggaagg tgaagaaggg 900 cgtccaaagg atgaccgcca cctccgtggc tgtggctacc ttcccggctg cccgggctcc 960 aatggtttcc acaacaacga caccttccac ttcctgaaat gctgcaacac caccaaatgc 1020 aacgagggcc caatcctgga gcttgaaaat ctgccgcaga atggccgcca gtgttacagc 1080 tgcaagggga acagcaccca tggatgctcc tctgaagaga ctttcctcat tgactgccga 1140 ggccccatga atcaatgtct ggtagccacc ggcactcacg aaccgaaaaa ccaaagctat 1200 atggtaagag gctgtgcaac cgcctcaatg tgccaacatg cccacctggg tgacgccttc 1260 agcatgaacc acattgatgt ctcctgctgt actaaaagtg gctgtaacca cccagacctg 1320 gatgtccagt accgcagtgg ggctgctcct cagcctggcc ctgcccatct cagcctcacc 1380 atcaccctgc taatgactgc cagactgtgg ggaggcactc tcctctggac ctaaacctga 1440 aatccccctc tctgccctgg ctggatccgg gggacccctt tgcccttccc tcggctccca 1500 gccctacaga cttgctgtgt gacctcaggc cagtgtgccg acctctctgg gcctcagttt 1560 tcccagctat gaaaacagct atctcacaaa gttgtgtgaa gcagaagaga aaagctggag 1620 gaaggccgtg ggcaatggga gagctcttgt tattattaat attgttgccg ctgttgtgtt 1680 gttgttatta attaatattc atattattta ttttatactt acataaagat tttgtaccag 1740 tgg 1743 75 335 PRT Homo sapiens 75 Met Gly His Pro Pro Leu Leu Pro Leu Leu Leu Leu Leu His Thr Cys 1 5 10 15 Val Pro Ala Ser Trp Gly Leu Arg Cys Met Gln Cys Lys Thr Asn Gly 20 25 30 Asp Cys Arg Val Glu Glu Cys Ala Leu Gly Gln Asp Leu Cys Arg Thr 35 40 45 Thr Ile Val Arg Leu Trp Glu Glu Gly Glu Glu Leu Glu Leu Val Glu 50 55 60 Lys Ser Cys Thr His Ser Glu Lys Thr Asn Arg Thr Leu Ser Tyr Arg 65 70 75 80 Thr Gly Leu Lys Ile Thr Ser Leu Thr Glu Val Val Cys Gly Leu Asp 85 90 95 Leu Cys Asn Gln Gly Asn Ser Gly Arg Ala Val Thr Tyr Ser Arg Ser 100 105 110 Arg Tyr Leu Glu Cys Ile Ser Cys Gly Ser Ser Asp Met Ser Cys Glu 115 120 125 Arg Gly Arg His Gln Ser Leu Gln Cys Arg Ser Pro Glu Glu Gln Cys 130 135 140 Leu Asp Val Val Thr His Trp Ile Gln Glu Gly Glu Glu Gly Arg Pro 145 150 155 160 Lys Asp Asp Arg His Leu Arg Gly Cys Gly Tyr Leu Pro Gly Cys Pro 165 170 175 Gly Ser Asn Gly Phe His Asn Asn Asp Thr Phe His Phe Leu Lys Cys 180 185 190 Cys Asn Thr Thr Lys Cys Asn Glu Gly Pro Ile Leu Glu Leu Glu Asn 195 200 205 Leu Pro Gln Asn Gly Arg Gln Cys Tyr Ser Cys Lys Gly Asn Ser Thr 210 215 220 His Gly Cys Ser Ser Glu Glu Thr Phe Leu Ile Asp Cys Arg Gly Pro 225 230 235 240 Met Asn Gln Cys Leu Val Ala Thr Gly Thr His Glu Pro Lys Asn Gln 245 250 255 Ser Tyr Met Val Arg Gly Cys Ala Thr Ala Ser Met Cys Gln His Ala 260 265 270 His Leu Gly Asp Ala Phe Ser Met Asn His Ile Asp Val Ser Cys Cys 275 280 285 Thr Lys Ser Gly Cys Asn His Pro Asp Leu Asp Val Gln Tyr Arg Ser 290 295 300 Gly Ala Ala Pro Gln Pro Gly Pro Ala His Leu Ser Leu Thr Ile Thr 305 310 315 320 Leu Leu Met Thr Ala Arg Leu Trp Gly Gly Thr Leu Leu Trp Thr 325 330 335 76 2776 DNA Homo sapiens 76 ttgttggttg aaatgtaagt cttttcctaa agttttaatc agaggtagcc atcactaaga 60 cttaagccac ctgtggttct cttaagtttc actgaagcca gaagaaggaa attaccacaa 120 cttgtattat actaattatc ttcattatta acgatcatat tagagccact gacatgtccc 180 aaattatatt aaaataaaaa cctgcattgc tctgacatga agctcaattc aatgtaataa 240 acaaattagg tattaaacgt tataatttaa aaaacttcta cgatatcacc agaaatcctg 300 gtgaaattta attttttccc ttttttaggt cagtggccgg tgggatagat ttttctaaac 360 tttttcctgc tatgattttg aaggcaaata catagagcac agttcagtaa aagagtttcc 420 aagccttttc actggagcat ttacattttg attctgttgt catttgaaat agaacatctg 480 cagggagata atgagcttaa gttacaattg actttggaaa aaataacaga cttttgtgtt 540 tcctcaatca tgtagtcaat agggaattct ccagttatgt gaacaatcac agtcttttaa 600 gacaatactt agatctaaat gcaaaatcta gcatgcagag gctttttaag gattttagac 660 tgtctccaaa gaacttggct cgagatggat tacacagatt tacaaatgca gttttcaact 720 gtgacatcaa actgatctta tctcatttca tgttactcaa ctgtgcccgt aggaccccaa 780 gaggtggaat attttgtcta cattatttta aacatctata gatatgtgtg gatgtgtgaa 840 taatgcctaa atttctcatc ttttaactag tttgttttta tcatacagac acagcctgtt 900 cataagacca gctttagaca acttagaact caatgctctg aagattcagg gaggccaaca 960 tagaaaaaga tcttccaaaa tatggggtgg tccaacccat ctcatccctc tctagctgga 1020 aaactataga gaaagggctg tgactgcctt gaccactgcc tggcacaatg taggcactcg 1080 gtatttgttg gatgaataag tggctgaatc agtgaataga caaaaaacat ggattttgcc 1140 ttctgaaaat ctcacaaatt ttaccagctt atattatact gattgtcact atgatttcta 1200 agtttcatgg ttagaaccat attttgagtc tatataaaaa ctttttagat gtatgaattt 1260 gaaatttcat taattacttt aaaggcttca aagatttgag gacatttgaa cagtggataa 1320 ggaacaatgt ttggggatac agagttttta tgctgagttg aactcaacct ttctagttct 1380 ttatacaagc ttcctgaatt atctggcagg aatgattcaa acataaaacc ccatttttaa 1440 attttataaa agatattttc atttttatat aaaaagatca tcaggcatat tatccccttt 1500 gatatttatt aacaaccatt ctctaagaaa ttcataataa ttggagacac catccctaaa 1560 tctcttccta ttttcaaaag atcatttatc ctttcatatt tgattcctgg aatacactaa 1620 gctgaagttt aatcacatac ttactcagat gtttccatgt gtttattcat ttaacaaata 1680 cttattgtgt acctagtgca tgctaggttc tggaaatgca acagcaaaca agacagacac 1740 aatccctctt ggaggttact gtgagaaact ctccaacatt tactctagca ataactagag 1800 agtttactgt ccattgggtc ctcttcacac ctgatagaaa aaataaaatt cctcacccca 1860 tggaagtcat gaaatactcc ctgcacagat ttgtgtgagc ttgcttttct aaaaccactg 1920 ctcaaaaatg ctgcttagtt tatctataaa ccacggttat accccagtga ggtaggtaag 1980 taatttattc ataactaaca tttatgcagc tctattttct agccactgtg ctgagtgctt 2040 ttatggacta tctcaccaaa tcccttcaac aactctattc agtaggttcc attttataga 2100 tacaaaaact gaagcacaga tatattatgt gacttgtcca aggtcacaca gctagcaggt 2160 ggaactggga tttgaaccca tgcaatctga cacaagagtt catgtgtcta atcattatct 2220 gtggtttggg ggacaccatt acattaaaat gaatgagtca ctaagtgagt cactgtacat 2280 aaaatacttg gaaattgtaa agtaatatac aaaagatatt aacaaagtat tattcatggt 2340 aaacaaatca catcagtagc aaacacaggg tgggaactca atcttatgtt atagcttact 2400 cttaagaaga atatgtgaag ccaggaacat ggttaaaggt acagaccaga aaatttctga 2460 catgtgataa atatttcagt gacttttcag atttatttct tgttagccgc tgtgtctatt 2520 tggtgctaca aaaactgaaa gaaacaaaat ccctgatgta agggcttata ataaatacac 2580 agtttggaga tgaactaagg atattttaca tttacgggaa aggattggac aatagtatca 2640 ttttctcacc atttgcatgt acatcatgtc tttccaattg ttttcattat ttttctgaaa 2700 gagctgcaaa attgtgcagt ggttcaacct gaccaaagtg gtattatgct gctgggaagt 2760 aaaagtatta gacacc 2776 77 3362 DNA Homo sapiens 77 agactccctg tctttgcggt ttgggagatg atgagaaacc acagaattgc tagtagttta 60 tgtggagatc aggtcttctc caagaaaaaa aaaaagaaaa aaaaaaacaa catggctgca 120 aaggagaaac tggaggcagt gttaaatgtg gccctgaggg tgccaagcat catgctgttg 180 gatgtcctgt acagatggga tgtcagctcc tttttccagc agatccaaag aagtagcctt 240 agtaataacc ctcttttcca gtataagtat ttggctctta atatgcatta tgtaggttat 300 atcttaagtg tggtgctgct aacattgccc aggcagcatc tggttcagct ttatctatat 360 tttttgactg ctctgctcct ctatgctgga catcaaattt ccagggacta tgttcggagt 420 gaactggagt ttgcctatga gggaccaatg tatttagaac ctctctctat gaatcggttt 480 accacagcct taataggtca gttggtggtg tgtactttat gctcctgtgt catgaaaaca 540 aagcagattt ggctgttttc agctcacatg cttcctctgc tagcacgact ctgccttgtt 600 cctttggaga caattgttat catcaataaa tttgctatga tttttactgg attggaagtt 660 ctctattttc ttgggtctaa tcttttggta ccttataacc ttgctaaatc tgcatacaga 720 gaattggttc aggtagtgga ggtatatggc cttctcgcct tgggaatgtc cctgtggaat 780 caactggtag tccctgttct tttcatggtt ttctggctcg tcttatttgc tcttcagatt 840 tactcctatt tcagtactcg agatcagcct gcatcacgtg agaggcttct tttccttttt 900 ctgacaagta ttgcggaatg ctgcagcact ccttactctc ttttgggttt ggtcttcacg 960 gtttcttttg ttgccttggg tgttctcaca ctctgcaagt tttacttgca gggttatcga 1020 gctttcatga atgatcctgc catgaatcgg ggcatgacag aaggagtaac gctgttaatc 1080 ctggcagtgc agactgggct gatagaactg caggttgttc atcgggcatt cttgctcagt 1140 attatccttt tcattgtcgt agcttctatc ctacagtcta tgttagaaat tgcagatcct 1200 attgttttgg cactgggagc atctagagac aagagcttgt ggaaacactt ccgtgctgta 1260 agcctttgtt tatttttatt ggtattccct gcttatatgg cttatatgat ttgccagttt 1320 ttccacatgg atttttggct tcttatcatt atttccagca gcattcttac ctctcttcag 1380 gttctgggaa cactttttat ttatgtctta tttatggttg aggaattcag aaaagagcca 1440 gtggaaaaca tggatgatgt catctactat gtgaatggca cttaccgcct gctggagttt 1500 cttgtggccc tctgtgtggt ggcctatggc gtctcagaga ccatctttgg agaatggaca 1560 gtgatgggct caatgatcat cttcattcat tcctactata acgtgtggct tcgggcccag 1620 ctggggtgga agagctttct tctccgcagg gatgctgtga ataagattaa atcgttaccc 1680 attgctacga aagagcagct tgagaaacac aatgatattt gtgccatctg ttatcaggac 1740 atgaaatctg ctgtgatcac gccttgcagt cattttttcc atgcaggctg tcttaagaaa 1800 tggctgtatg tccaggagac ctgccctctg tgccactgcc atctgaaaaa ctcctcccag 1860 cttccaggat taggaactga gccagttcta cagcctcatg ctggagctga gcaaaacgtc 1920 atgtttcagg aaggtactga acccccaggc caggagcata ctccagggac caggatacag 1980 gaaggttcca gggacaataa tgagtacatt gccagacgac cagataacca ggaaggggct 2040 tttgacccca aagaatatcc tcacagtgcg aaagatgaag cacatcctgt tgaatcagcc 2100 tagaggagaa gcagcaggaa tgatgctttg atactctgga ggagaagtta actcaagatg 2160 gaattcatgt tctgatttga ggaatgaaaa tgagatgatc aggcaggaaa ctgacattcc 2220 aaggatctaa tccaggaagt actctcagtg gggaccacct gctttcatcc cctgacattg 2280 tgggagaaat tttgcaatgt atgctaatca aaatgtattt atatgttctc tgctgatgtt 2340 ttatagaggt ttgtgaagaa aattcaacct cagcaacttc agaaactgcc cctgatacgt 2400 gtgagagaga aataaaatca gattttgagt gttgaaggga ctgaggaagt gaggataaag 2460 agcatgagga cagcatggaa agaaggaggc agaagtggaa ctgaactttc actctccatg 2520 ggacagatca atctcattat caagtctgaa tagcaaccag ccctctcctc caccccgttt 2580 ctcctcagtt aattggagct cagtcaggtg attattgagt cttgtacagc actgaaatga 2640 aatcaaagat gaagaagcat tgattgtatt cgaagattga agcacgctca tactttgtat 2700 gtgctttagg gaaggggtgg gtgggcactt gggccttgcg ggtgcattca tgtaatctga 2760 gactcttgaa ctttatgacg gagtcttcaa tattttgatg tatatgaaac ttttgttaaa 2820 tatgttgtat acttcgctgg ctgtgtgaag taaactaaaa ctctgatgaa cactttggag 2880 tctgctttag tgaaggagac caaagtggga agggctttag ggcactgata gaggccctgg 2940 gtgtactttt caatcctgtg taatgtttaa ttcttgcaac tgaatcaaaa cagtgttaaa 3000 ttatggcaat atttgcactt tgggaatgag tacataactg tatgatcaca ctctgcaaat 3060 gccactttta aagctgttaa tagactttgc accttttctt tgacaaggat gtgtcatatt 3120 taaattttta cattcatcat ggctacaggt agaactgggg aggggggaat gtaatttttt 3180 atgggaattt tgatatgaaa agaaactagt catttattta tacaataggc ttggctcaaa 3240 aagtgttttt cagacctcgg tattcctaat gtgggatgtg actttatttt atttttagta 3300 gcaaatttgg atgtagactg acagacatag ctgaatgtct taataaattt aaatttgaag 3360 at 3362 78 691 PRT Homo sapiens 78 Met Met Arg Asn His Arg Ile Ala Ser Ser Leu Cys Gly Asp Gln Val 1 5 10 15 Phe Ser Lys Lys Lys Lys Lys Lys Lys Lys Asn Asn Met Ala Ala Lys 20 25 30 Glu Lys Leu Glu Ala Val Leu Asn Val Ala Leu Arg Val Pro Ser Ile 35 40 45 Met Leu Leu Asp Val Leu Tyr Arg Trp Asp Val Ser Ser Phe Phe Gln 50 55 60 Gln Ile Gln Arg Ser Ser Leu Ser Asn Asn Pro Leu Phe Gln Tyr Lys 65 70 75 80 Tyr Leu Ala Leu Asn Met His Tyr Val Gly Tyr Ile Leu Ser Val Val 85 90 95 Leu Leu Thr Leu Pro Arg Gln His Leu Val Gln Leu Tyr Leu Tyr Phe 100 105 110 Leu Thr Ala Leu Leu Leu Tyr Ala Gly His Gln Ile Ser Arg Asp Tyr 115 120 125 Val Arg Ser Glu Leu Glu Phe Ala Tyr Glu Gly Pro Met Tyr Leu Glu 130 135 140 Pro Leu Ser Met Asn Arg Phe Thr Thr Ala Leu Ile Gly Gln Leu Val 145 150 155 160 Val Cys Thr Leu Cys Ser Cys Val Met Lys Thr Lys Gln Ile Trp Leu 165 170 175 Phe Ser Ala His Met Leu Pro Leu Leu Ala Arg Leu Cys Leu Val Pro 180 185 190 Leu Glu Thr Ile Val Ile Ile Asn Lys Phe Ala Met Ile Phe Thr Gly 195 200 205 Leu Glu Val Leu Tyr Phe Leu Gly Ser Asn Leu Leu Val Pro Tyr Asn 210 215 220 Leu Ala Lys Ser Ala Tyr Arg Glu Leu Val Gln Val Val Glu Val Tyr 225 230 235 240 Gly Leu Leu Ala Leu Gly Met Ser Leu Trp Asn Gln Leu Val Val Pro 245 250 255 Val Leu Phe Met Val Phe Trp Leu Val Leu Phe Ala Leu Gln Ile Tyr 260 265 270 Ser Tyr Phe Ser Thr Arg Asp Gln Pro Ala Ser Arg Glu Arg Leu Leu 275 280 285 Phe Leu Phe Leu Thr Ser Ile Ala Glu Cys Cys Ser Thr Pro Tyr Ser 290 295 300 Leu Leu Gly Leu Val Phe Thr Val Ser Phe Val Ala Leu Gly Val Leu 305 310 315 320 Thr Leu Cys Lys Phe Tyr Leu Gln Gly Tyr Arg Ala Phe Met Asn Asp 325 330 335 Pro Ala Met Asn Arg Gly Met Thr Glu Gly Val Thr Leu Leu Ile Leu 340 345 350 Ala Val Gln Thr Gly Leu Ile Glu Leu Gln Val Val His Arg Ala Phe 355 360 365 Leu Leu Ser Ile Ile Leu Phe Ile Val Val Ala Ser Ile Leu Gln Ser 370 375 380 Met Leu Glu Ile Ala Asp Pro Ile Val Leu Ala Leu Gly Ala Ser Arg 385 390 395 400 Asp Lys Ser Leu Trp Lys His Phe Arg Ala Val Ser Leu Cys Leu Phe 405 410 415 Leu Leu Val Phe Pro Ala Tyr Met Ala Tyr Met Ile Cys Gln Phe Phe 420 425 430 His Met Asp Phe Trp Leu Leu Ile Ile Ile Ser Ser Ser Ile Leu Thr 435 440 445 Ser Leu Gln Val Leu Gly Thr Leu Phe Ile Tyr Val Leu Phe Met Val 450 455 460 Glu Glu Phe Arg Lys Glu Pro Val Glu Asn Met Asp Asp Val Ile Tyr 465 470 475 480 Tyr Val Asn Gly Thr Tyr Arg Leu Leu Glu Phe Leu Val Ala Leu Cys 485 490 495 Val Val Ala Tyr Gly Val Ser Glu Thr Ile Phe Gly Glu Trp Thr Val 500 505 510 Met Gly Ser Met Ile Ile Phe Ile His Ser Tyr Tyr Asn Val Trp Leu 515 520 525 Arg Ala Gln Leu Gly Trp Lys Ser Phe Leu Leu Arg Arg Asp Ala Val 530 535 540 Asn Lys Ile Lys Ser Leu Pro Ile Ala Thr Lys Glu Gln Leu Glu Lys 545 550 555 560 His Asn Asp Ile Cys Ala Ile Cys Tyr Gln Asp Met Lys Ser Ala Val 565 570 575 Ile Thr Pro Cys Ser His Phe Phe His Ala Gly Cys Leu Lys Lys Trp 580 585 590 Leu Tyr Val Gln Glu Thr Cys Pro Leu Cys His Cys His Leu Lys Asn 595 600 605 Ser Ser Gln Leu Pro Gly Leu Gly Thr Glu Pro Val Leu Gln Pro His 610 615 620 Ala Gly Ala Glu Gln Asn Val Met Phe Gln Glu Gly Thr Glu Pro Pro 625 630 635 640 Gly Gln Glu His Thr Pro Gly Thr Arg Ile Gln Glu Gly Ser Arg Asp 645 650 655 Asn Asn Glu Tyr Ile Ala Arg Arg Pro Asp Asn Gln Glu Gly Ala Phe 660 665 670 Asp Pro Lys Glu Tyr Pro His Ser Ala Lys Asp Glu Ala His Pro Val 675 680 685 Glu Ser Ala 690 79 1956 DNA Homo sapiens 79 ggtggccctg agcgccggcg acacctttcc tggactataa attgagcacc tgggatgggt 60 agggggccaa cgcagtcacc gccgtccgca gtcacagtcc agccactgac cgcagcagcg 120 cccttgcgta gcagccgctt gcagcgagaa cactgaattg ccaacgagca ggagagtctc 180 aaggcgcaag aggaggccag ggctcgaccc acagagcacc ctcagccatc gcgagtttcc 240 gggcgccaaa gccaggagaa gccgcccatc ccgcagggcc ggtctgccag cgagacgaga 300 gttggcgagg gcggaggagt gccgggaatc ccgccacacc ggctatagcc aggcccccag 360 cgcgggcctt ggagagcgcg tgaaggcggg catccccttg acccggccga ccatccccgt 420 gcccctgcgt ccctgcgctc caacgtccgc gcggccacca tgatgcaaat ctgcgacacc 480 tacaaccaga agcactcgct ctttaacgcc atgaatcgct tcattggcgc cgtgaacaac 540 atggaccaga cggtgatggt gcccagcttg ctgcgcgacg tgcccctggc tgaccccggg 600 ttagacaacg atgttggcgt ggaggtaggc ggcagtggcg gctgcctgga ggagcgcacg 660 cccccagtcc ccgactcggg aagcgccaat ggcagctttt tcgcgccctc tcgggacatg 720 tacagccact acgtgcttct caagtccatc cgcaacgaca tcgagtgggg ggtcctgcac 780 cagccgcctc caccggctgg gagcgaggag ggcagtgcct ggaagtccaa ggacatcctg 840 gtggacctgg gccacttgga gggtgcggac gccggcgaag aagacctgga acagcagttc 900 cactaccacc tgcgcgggct gcacactgtg ctctcgaaac tcacgcgcaa agccaacatc 960 ctcactaaca gatacaagca ggagatcggc ttcggcaatt ggggccactg aggcgtggcg 1020 cccgtggctg cccagcacct tcttcgaccc atctcaccct ctctcattcc tcaaagcttt 1080 tttttttttt cctggctggg gggcgggaag ggcagactgc aaactggggg gctgcgtacg 1140 tgcaggaggc gcggtggggc tgcgtggagg agggggccac gtgtgagaga gaagaaaatg 1200 gtggccggag atgggagggc ccaaggaacc tcctgggagg gggcctgcat tctatgttgg 1260 tgggaatggg actgggctga cgccctgcat tcagcctgtg cctttcctgg ggtttctttt 1320 ctgttctttt cggaggagag ggcccgagaa ggggccatac cagggcgcgg cgctgggttg 1380 ccacacttgg gaaagcagcc cggagctggg tgctggggaa ggcggggcgc gtagcctccc 1440 gccgccctgc ggttgggccg gtggaggccc aggcgttgct aggattgcat cagttttcct 1500 gtttgcacta tttctttttg taacattggc cctgtgtgaa gtatttcgaa tctcctcctt 1560 gctctgaaac ttcagcgatt ccattgtgat aagcgcacaa acagcactgt ctgtcggtaa 1620 tcggtactac tttattaatg attttctgtt acactgtata gtagtcctat ggcaccccca 1680 ccccatccct ttcgtgccac tcccgtcccc acccccaccc cagtgtgtat aagctggcat 1740 ttcgccagct tgtacgtagc ttgccactca gtgaaaataa taacattatt atgagaaagt 1800 ggacttaacc gaaatggaac caactgacat tctatcgtgt tgtacataga atgatgaagg 1860 gttccactgt tgttgtatgt cttaaattta tttaaaactt tttttaatcc agatgtagac 1920 tatattctaa aaaataaaaa agcaaatgtg tcaact 1956 80 183 PRT Homo sapiens 80 Met Met Gln Ile Cys Asp Thr Tyr Asn Gln Lys His Ser Leu Phe Asn 1 5 10 15 Ala Met Asn Arg Phe Ile Gly Ala Val Asn Asn Met Asp Gln Thr Val 20 25 30 Met Val Pro Ser Leu Leu Arg Asp Val Pro Leu Ala Asp Pro Gly Leu 35 40 45 Asp Asn Asp Val Gly Val Glu Val Gly Gly Ser Gly Gly Cys Leu Glu 50 55 60 Glu Arg Thr Pro Pro Val Pro Asp Ser Gly Ser Ala Asn Gly Ser Phe 65 70 75 80 Phe Ala Pro Ser Arg Asp Met Tyr Ser His Tyr Val Leu Leu Lys Ser 85 90 95 Ile Arg Asn Asp Ile Glu Trp Gly Val Leu His Gln Pro Pro Pro Pro 100 105 110 Ala Gly Ser Glu Glu Gly Ser Ala Trp Lys Ser Lys Asp Ile Leu Val 115 120 125 Asp Leu Gly His Leu Glu Gly Ala Asp Ala Gly Glu Glu Asp Leu Glu 130 135 140 Gln Gln Phe His Tyr His Leu Arg Gly Leu His Thr Val Leu Ser Lys 145 150 155 160 Leu Thr Arg Lys Ala Asn Ile Leu Thr Asn Arg Tyr Lys Gln Glu Ile 165 170 175 Gly Phe Gly Asn Trp Gly His 180 81 427 DNA Homo sapiens 81 gagtgttctc cccagtgact gcccaatctt tagtgtgttt tgctgactcc tggcgctctg 60 gcttttccat aagaggcgtt tttgcacgat tgcagacagg aataaaaatg agctctgcct 120 actgggccgt cctggttagc aaggtctaca ccacctcaaa ggcagctatg gactaagagc 180 ccacaaagaa tctcgggtta tgagggaggg gctggccgtg gagacggcta aagcgcctca 240 tttgtcttcc cagcagggaa gcgatgggac ctcggcgggc agggaacgcg atctccaccc 300 gtctggaaaa ctctctgagt tctggagcac tgttcgcggc cggactgagt ggcatgtccg 360 cattttcccc attccagggt agggcagact gaggtaggag agcagagccc cgaggccgac 420 tccccgg 427 82 2365 DNA Homo sapiens 82 catcctgaca tttcccttgt acctgctgaa ctttctgggc ttgtggagct ggatatgcaa 60 aaaatggttc ccctacttct tggtgaggtt cactgtgata tacaacgaac agatggcaag 120 caagaagcgg gagctcttca gtaacctgca ggagtttgcg ggcccctccg ggaaactctc 180 cctgctggaa gtgggctgtg gcacgggggc caacttcaag ttctacccac ctgggtgcag 240 ggtgacctgt attgacccca accccaactt tgagaagttt ttgatcaaga gcattgcaga 300 gaaccgacac ctgcagtttg agcgctttgt ggtagctgcc ggggagaaca tgcaccaggt 360 ggctgatggc tctgtggatg tggtggtctg caccctggtg ctgtgctctg tgaagaacca 420 ggagcggatt ctccgcgagg tgtgcagagt gctgagaccg ggaggggctt tctatttcat 480 ggagcatgtg gcagctgagt gttcgacttg gaattacttc tggcaacaag tcctggatcc 540 tgcctggcac cttctgtttg atgggtgcaa cctgaccaga gagagctgga aggccctgga 600 gcgggccagc ttctctaagc tgaagctgca gcacatccag gccccactgt cctgggagtt 660 ggtgcgccct catatctatg gatatgctgt gaaatagtgt gagctggcag ttaagagctg 720 aatggctcaa agaatttaaa gcttcagttt tacatttaaa atgctaagtg ggagaagaga 780 aacctttttt ttggggggcg gtttttttgg tttgttgttg gttttttttt ttttttggcg 840 ggaagaaaga gttttgctct tgttgcccag gctggagtgc agtgacgtga tctccgctca 900 ctgcaacctc cacctcgcgg gtttaagcga ttcttctgcc tcagcctccc tagtagctgg 960 gattacaggt gcccaccacc atgcccagct aatttgtatt tttagttgag acagggtttc 1020 actacgttgg ccaggctggt cttgaactcc tgatctcagg caatccaccc gcctcagcct 1080 cccaaagtgc tgggatgaca ggcgtgagca accgcaccca gcttaaggtt tttttgtttt 1140 gttttgagac ggagttttcg ctcttgttgc ccaggctgga gtgcaatgct gtgatctcag 1200 cttaccacaa cctccacctc ccgggttcaa gtgattcacc tgcctcagcc tcctgagtag 1260 ctggtattac aggcatgcgt caccacgccg gctaattttg tacttttagt agagatggtg 1320 tttccccacg ttggtcagtc tggtctcaaa ttcctgacct caggtgatct gcctgcctcg 1380 gcctcccaaa gtgctgtgat tacagacgtc agccaccatg cctggcctga aacctttttt 1440 aggtaaagtt gaattccatc cttaaaagtt tctgttatat cctatttagc cattttctat 1500 tgtctcccaa agaattcaca tcaaaaaaac agctttgaac tcccccttca aaggaaacag 1560 tcgactttca taattagcat ctaccattat ccccaaatct tattttattc attgacttga 1620 aattttttcc aattgctttt tttttttttt tttaaggtta agagcagagg tttactaggc 1680 caaagaaaga gaatagctct ctgttgcaga gaggggtcct ggagaaatgg gttaccccag 1740 ttgtcttatt taaatggtta cccatcagat tttaatttta tcttctcttt gagagcttgg 1800 taataagaag cacttaaatc actccaaaga agactttaaa aagggagcag tgaaaaggtc 1860 ttaataattt attgattgaa ttaagaaata ctagctaatt aagaatctga gtctaaacag 1920 cacagatttt ttctttctgc ttttaaattg tgttttaaaa aaagagacag ggggctgggc 1980 gtggtggctc acgcctgtaa tcctagcact ttgggaggcc gaggcgggtg gatcacgagg 2040 taggagttaa agaccagcct ggccaacatg gcaaaaccct actaaagata caaaaaaaaa 2100 aaaaaaaaaa aaaaaagtat atacacctaa caagagagcc ccaaaatgta tgaagcaaaa 2160 actgacagaa ctgaagggac aaatagacaa ttcaatagta atatttggag acttcaatat 2220 cccactttca ataatgaata ggacaactaa gcaaaagatt aacaagaaca ctgaagacct 2280 gaaaagcact ataaacaaaa ctataagcta actagacaga acacacatct acagaacaaa 2340 aactccaacc aaaaaaaaaa aaaaa 2365 83 194 PRT Homo sapiens 83 Met Ala Ser Lys Lys Arg Glu Leu Phe Ser Asn Leu Gln Glu Phe Ala 1 5 10 15 Gly Pro Ser Gly Lys Leu Ser Leu Leu Glu Val Gly Cys Gly Thr Gly 20 25 30 Ala Asn Phe Lys Phe Tyr Pro Pro Gly Cys Arg Val Thr Cys Ile Asp 35 40 45 Pro Asn Pro Asn Phe Glu Lys Phe Leu Ile Lys Ser Ile Ala Glu Asn 50 55 60 Arg His Leu Gln Phe Glu Arg Phe Val Val Ala Ala Gly Glu Asn Met 65 70 75 80 His Gln Val Ala Asp Gly Ser Val Asp Val Val Val Cys Thr Leu Val 85 90 95 Leu Cys Ser Val Lys Asn Gln Glu Arg Ile Leu Arg Glu Val Cys Arg 100 105 110 Val Leu Arg Pro Gly Gly Ala Phe Tyr Phe Met Glu His Val Ala Ala 115 120 125 Glu Cys Ser Thr Trp Asn Tyr Phe Trp Gln Gln Val Leu Asp Pro Ala 130 135 140 Trp His Leu Leu Phe Asp Gly Cys Asn Leu Thr Arg Glu Ser Trp Lys 145 150 155 160 Ala Leu Glu Arg Ala Ser Phe Ser Lys Leu Lys Leu Gln His Ile Gln 165 170 175 Ala Pro Leu Ser Trp Glu Leu Val Arg Pro His Ile Tyr Gly Tyr Ala 180 185 190 Val Lys 84 345 DNA Homo sapiens 84 ctgtgccttt taaggcagag ggagatccct atggcgttag tcttcccagg ccttaaaggg 60 cccttgtctt cactcacaaa cctcttatct cttcttctcc ttcctctaca ttttaaaggg 120 ggagagggaa aagtaaccgg gagacaaatt gagccacata ttttcagaca cttgttacca 180 tattttaaaa tctggcttca catacacaga gtctttgcta tgcaccatgt actgttctaa 240 gcttcttaaa aatagaatct caattattat tttgcaggca atactctatg cattcattag 300 ctaggacaac aatgcatttg cagtagtgag atttcgttaa aaaat 345 85 348 DNA Homo sapiens 85 aatacaatat tagtaacagt tctatcaata tgctaaaagc tttacctcct cctactcctt 60 catttttaat caaaatagga ccttccctga aggattgggt tatgagtaca atgaatttat 120 gttggtctag taggcaatat tatgatttaa aagcatttct caatggccaa gtagataagg 180 aattatatga aattctacaa ataccaagag gtatttcagt ggtttacaaa tattgtctac 240 cttctgtatg cataaaatgt catagattgg tgccagtgaa cacacacacg tatctcaggt 300 gaggattggc ctcagagaaa ttactggtac attctagaag acaaaaat 348 86 384 DNA Homo sapiens 86 aagagtccca aatgtgaagt gtccattttc ctataaaatc aggacatgtt acccttccag 60 tatggatatg aaatatcaac atgtgtccca ctgttcagag ttttattggg gctccattac 120 ctagtcatga ttgattgatt gattgattgc ccaggtggtt gaactcagtc tccaggttga 180 ccgatactgt atgacgcaga tgccctaccc cagatcacat ggttagtctt tctggcatgg 240 ccagcgttca cccggtgact ctcagttatg gtcgctaagc tactagataa aaggattagg 300 cccttattca aactggttga atgcttgtca actgtcacca gagtccatcc acagaataaa 360 tagaaatata agaggcaaac agac 384 87 440 DNA Homo sapiens 87 cgtgcctggc taatttttgc agttttagta gaggcagggt ttcaccacct tggccaggct 60 ggtcttgaac tcctgacctc atgatccacc caccttgtcc tctcaaaatg cttacaggca 120 tgaaccactg tgaccggcca ggtctttttt ttttttaaag agtctatcct aggcttggta 180 cagatggcgc ctgtggtaaa tctgtgttaa catggtggta gaccatggag aatgggtaga 240 tggagcttct agactccaaa acaacaaaac cacagtgtga gtacactgtc ccattaggtt 300 gactgaagtc tgagtacatt ttctggcctg cgtgccgtga cttatccaac ctgtgaactg 360 attgtgatct gcttggtaac ttggtttggt gtaaactgct cttaaccctt tgctgatgaa 420 gaaaataatc atataagtgg 440 88 400 DNA Homo sapiens 88 gccactggac atttgcagag atgatcatat ttacttccct cctcccacca ctcttcctct 60 cagtttcctt tttactttat ttttttctcc ctttcctggt aaaagtatta gtatgtttaa 120 catagtgtta ggtggcagat aggctgggaa gagctagtat tgtaaaggaa cactgatgtg 180 tactggagcc tactagctct caatccattg ccccagactt ggggagagag agcacattct 240 ctatccagag aaataagaat atgcagttta tggttgtcct gtggacatta actgactgtg 300 aaggtaaggt atatccaaag gcagtgatat gcaggtgata gattcaccag gagatgatat 360 gtgacttttc ttgtatttta aagctctgct tcttttttag 400 89 344 DNA Homo sapiens 89 ctagcaccac tccaaattgc tgcttcaaaa gaggtcagtc agcccctttc ccttactcct 60 caaccatgac ctggtctgtc tggaaagagg atgagataca tggaccaata catcctattt 120 aaaagggagc ttgctttctc actagggact ttagactgcc tgacacacag gaaatgacta 180 gaaaatctga ccagtggagc ataactcatt gctaaaatgg caggtttgga cggctgcagg 240 atgggagagc aggcttcctg aagaggcagg aaggggcagc tggatgggaa aacagtgact 300 tttgagtttt tccttttaga gtatggtgac gtaggccgtt tatt 344 90 500 DNA Homo sapiens 90 accaagtttg attcaagcac attggttagt ggaataaagc aagctgtgct gttatatagt 60 tgttggtctt tcaaatgcct cagaaccaga ataagacaaa tgagggccag agtagaggtt 120 gctagagagc tgtgtatatt gttaggtact gatttggatg acagtgattg ctataagcat 180 ttacaatact tcgtagttta gccacagttg tcccagatag ctgcccacag ctttaaaaca 240 tttttagggt gtctgttgcc accctagtcg ttgacactgc atggagatta tttctgtgac 300 agcagtcttc accagtgtta aggaggctgg gagttgactc tgtttccata accatctaat 360 taaatcaagt gcccataatg gaatttgaat aactgcctaa ctttgatatt taaacagaaa 420 ctttgaggaa aaacaagtct ctttttgtaa atatattcta cttgttaaga aaaaataaag 480 tagatcatga tgttcatctg 500 91 476 DNA Homo sapiens 91 gatcagtgtg tgctggtgat tttattgcct tttcctctta attcaatccc actctttccc 60 ttcctcaagt cttgttcacc cagcctcctg ccccaggaat cacggggaag aagtctggga 120 gaccacagaa aaaacaccaa tgacactgag ctattagaga tcaaaactgg gtcaggaaga 180 gttcatgtta agctttcaca tgtgctaaga acgctgaaag atacacactg atttccatct 240 taatagtgcc ggataattga caaatttggg acaagatgag ggagaggtca aaatccccct 300 aacttcccaa agcaaaaaaa caggagtata atgatcagaa acgtaatagt agtgtcagaa 360 gcacacaatc agctgtggac ggtgaaacat ataatggttc tatctgttct gagattgtaa 420 aagcacaatt attttcatca ggataaaaaa taaaaatgaa aaactatgct gttgaa 476 92 439 DNA Homo sapiens 92 tcttcagcct ggctcttgag ctattgctgt attaatttta aatagggtgt gatagcataa 60 gctgatggaa gcctgcagag atctcacttt gaaatggtga tacattacat gggaaaagat 120 tagagaggtg ttttatactg cacatcggtg aggcctaata agaaagtaga atagacgtaa 180 accattgttt tcatcatcct ttaagacagg gatttcaaac tcaagaacca ggcagctacc 240 tatttaaatg agtcaagtgg gccctaatgt aagacaatgt gatgggtaag gattgattct 300 gagggaacag gagcaggcat gccctctcta acagaggccg tcagttctgc tgtacctgaa 360 atgtgggccc attgttgctg gcgattccac acttacatct aaaatttcct gattttttaa 420 gaatgacaat aactaattt 439 93 520 DNA Homo sapiens 93 agagagtcag tgagggtgtt agaggtagct gaaggagtgg aagggagtta gctagttgaa 60 ggaacactgg aggactgtcg gggatttggg ggattaagta aaaggtttat aaggagaggg 120 tggaaagagt ggttgatggc tgatattctg atcatttata ctagctactc agtctctact 180 ttttctagaa gtccccagta accaaagccc aacacatttg gtatcgttga ttccttccat 240 tgtttgcttt gctttgggtt gcctaaggct gtggttatct ctgagccacc taaattctca 300 ccctcagctg aaatcactac tgtctcttca tggctctcag tatatttcaa tccttcttca 360 ggaactggag cttttgagaa taaggcaact ttaggattga ccctaggaca gaagctctgc 420 tctcaggatc cttgtatgct cctgaatatg aattccatag tatgatattt ggagctcccc 480 agatccttgt aggcatatgt gtgtgtgtgt atttgaggcc 520 94 557 DNA Homo sapiens 94 gcatgcactg tctcagccaa cccgctccac tacccggcag tacacattcg cacccctact 60 tcacagagga agaaacctgg aaccagaggg ggcgtgcctg ccaagctcac acagcaggaa 120 ctgagccaga aacgcagatt gggctggctc tgaagccaag cctcttctta cttcacccgg 180 ctgggctcct catttttacg ggtaacagtg aggctgggaa ggggaacaca gaccaggaag 240 ctcggtgagt gatggcagaa cgatgcctgc aggcatggaa ctttttccgt tatcacccag 300 gcctgattca ctggcctggc ggagatgctt ctaaggcatg gtcgggggag agggccaaca 360 actgtccctc cttgagcacc agccccaccc aagcaagcag acatttatct tttgggtctg 420 tcctctctgt tgccttttta cagccaactt ttctagacct gttttgcttt tgtaacttga 480 agatatttat tctgggtttt gtagcatttt tattaatatg gtgacttttt aaaataaaaa 540 caaacaaacg ttgtcct 557 95 2160 DNA Homo sapiens 95 gcgtctgcca gccggcttgg ctagcgcgcg gcggccgtgg ctaaggctgc tacgaagcga 60 gcttgggagg agcagcggcc tgcggggcag aggagcatcc cgtctaccag gtcccaagcg 120 gccgtggccc gcgggtcatg gccaaaggag aaggcgccga gagcggctcc gcggcggggc 180 tgctacccac cagcatcctc caaagcactg aacgcccggc ccaggtgaag aaagaaccga 240 aaaagaagaa acaacagttg tctgtttgca acaagctttg ctatgcactt gggggagccc 300 cctaccaggt gacgggctgt gccctgggtt tcttccttca gatctaccta ttggatgtgg 360 ctcaggtggg ccctttctct gcctccatca tcctgtttgt gggccgagcc tgggatgcca 420 tcacagaccc cctggtgggc ctctgcatca gcaaatcccc ctggacctgc ctgggtcgcc 480 ttatgccctg gatcatcttc tccacgcccc tggccgtcat tgcctacttc ctcatctggt 540 tcgtgcccga cttcccacac ggccagacct attggtacct gcttttctat tgcctctttg 600 aaacaatggt cacgtgtttc catgttccct actcggctct caccatgttc atcagcaccg 660 agcagactga gcgggattct gccaccgcct atcggatgac tgtggaagtg ctgggcacag 720 tgctgggcac ggcgatccag ggacaaatcg tgggccaagc agacacgcct tgtttccagg 780 acctcaatag ctctacagta gcttcacaaa gtgccaacca tacacatggc accacctcac 840 acagggaaac gcaaaaggca tacctgctgg cagcgggggt cattgtctgt atctatataa 900 tctgtgctgt catcctgatc ctgggcgtgc gggagcagag agaaccctat gaagcccagc 960 agtctgagcc aatcgcctac ttccggggcc tacggctggt catgagccac ggcccataca 1020 tcaaacttat tactggcttc ctcttcacct ccttggcttt catgctggtg gaggggaact 1080 ttgtcttgtt ttgcacctac accttgggct tccgcaatga attccagaat ctactcctgg 1140 ccatcatgct ctcggccact ttaaccattc ccatctggca gtggttcttg acccggtttg 1200 gcaagaagac agctgtatat gttgggatct catcagcagt gccatttctc atcttggtgg 1260 ccctcatgga gagtaacctc atcattacat atgcggtagc tgtggcagct ggcatcagtg 1320 tggcagctgc cttcttacta ccctggtcca tgctgcctga tgtcattgac gacttccatc 1380 tgaagcagcc ccacttccat ggaaccgagc ccatcttctt ctccttctat gtcttcttca 1440 ccaagtttgc ctctggagtg tcactgggca tttctaccct cagtctggac tttgcagggt 1500 accagacccg tggctgctcg cagccggaac gtgtcaagtt tacactgaac atgctcgtga 1560 ccatggctcc catagttctc atcctgctgg gcctgctgct cttcaaaatg taccccattg 1620 atgaggagag gcggcggcag aataagaagg ccctgcaggc actgagggac gaggccagca 1680 gctctggctg ctcagaaaca gactccacag agctggctag catcctctag ggcccgccac 1740 gttgcccgaa gccaccatgc agaaggccac agaagggatc aggacctgtc tgccggcttg 1800 ctgagcagct ggactgcagg tgctaggaag ggaactgaag actcaaggag gtggcccagg 1860 acacttgctg tgctcactgt ggggccggct gctctgtggc ctcctgcctc ccctctgcct 1920 gcctgtgggg ccaagccctg gggctgccac tgtgaatatg ccaaggactg atcgggccta 1980 gcccggaaca ctaatgtaga aacctttttt ttacagagcc taattaataa cttaatgact 2040 gtgtacatag caatgtgtgt gtatgtatat gtctgtgagc tattaatgtt attaattttc 2100 ataaaagctg gaaagcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160 96 530 PRT Homo sapiens 96 Met Ala Lys Gly Glu Gly Ala Glu Ser Gly Ser Ala Ala Gly Leu Leu 1 5 10 15 Pro Thr Ser Ile Leu Gln Ser Thr Glu Arg Pro Ala Gln Val Lys Lys 20 25 30 Glu Pro Lys Lys Lys Lys Gln Gln Leu Ser Val Cys Asn Lys Leu Cys 35 40 45 Tyr Ala Leu Gly Gly Ala Pro Tyr Gln Val Thr Gly Cys Ala Leu Gly 50 55 60 Phe Phe Leu Gln Ile Tyr Leu Leu Asp Val Ala Gln Val Gly Pro Phe 65 70 75 80 Ser Ala Ser Ile Ile Leu Phe Val Gly Arg Ala Trp Asp Ala Ile Thr 85 90 95 Asp Pro Leu Val Gly Leu Cys Ile Ser Lys Ser Pro Trp Thr Cys Leu 100 105 110 Gly Arg Leu Met Pro Trp Ile Ile Phe Ser Thr Pro Leu Ala Val Ile 115 120 125 Ala Tyr Phe Leu Ile Trp Phe Val Pro Asp Phe Pro His Gly Gln Thr 130 135 140 Tyr Trp Tyr Leu Leu Phe Tyr Cys Leu Phe Glu Thr Met Val Thr Cys 145 150 155 160 Phe His Val Pro Tyr Ser Ala Leu Thr Met Phe Ile Ser Thr Glu Gln 165 170 175 Thr Glu Arg Asp Ser Ala Thr Ala Tyr Arg Met Thr Val Glu Val Leu 180 185 190 Gly Thr Val Leu Gly Thr Ala Ile Gln Gly Gln Ile Val Gly Gln Ala 195 200 205 Asp Thr Pro Cys Phe Gln Asp Leu Asn Ser Ser Thr Val Ala Ser Gln 210 215 220 Ser Ala Asn His Thr His Gly Thr Thr Ser His Arg Glu Thr Gln Lys 225 230 235 240 Ala Tyr Leu Leu Ala Ala Gly Val Ile Val Cys Ile Tyr Ile Ile Cys 245 250 255 Ala Val Ile Leu Ile Leu Gly Val Arg Glu Gln Arg Glu Pro Tyr Glu 260 265 270 Ala Gln Gln Ser Glu Pro Ile Ala Tyr Phe Arg Gly Leu Arg Leu Val 275 280 285 Met Ser His Gly Pro Tyr Ile Lys Leu Ile Thr Gly Phe Leu Phe Thr 290 295 300 Ser Leu Ala Phe Met Leu Val Glu Gly Asn Phe Val Leu Phe Cys Thr 305 310 315 320 Tyr Thr Leu Gly Phe Arg Asn Glu Phe Gln Asn Leu Leu Leu Ala Ile 325 330 335 Met Leu Ser Ala Thr Leu Thr Ile Pro Ile Trp Gln Trp Phe Leu Thr 340 345 350 Arg Phe Gly Lys Lys Thr Ala Val Tyr Val Gly Ile Ser Ser Ala Val 355 360 365 Pro Phe Leu Ile Leu Val Ala Leu Met Glu Ser Asn Leu Ile Ile Thr 370 375 380 Tyr Ala Val Ala Val Ala Ala Gly Ile Ser Val Ala Ala Ala Phe Leu 385 390 395 400 Leu Pro Trp Ser Met Leu Pro Asp Val Ile Asp Asp Phe His Leu Lys 405 410 415 Gln Pro His Phe His Gly Thr Glu Pro Ile Phe Phe Ser Phe Tyr Val 420 425 430 Phe Phe Thr Lys Phe Ala Ser Gly Val Ser Leu Gly Ile Ser Thr Leu 435 440 445 Ser Leu Asp Phe Ala Gly Tyr Gln Thr Arg Gly Cys Ser Gln Pro Glu 450 455 460 Arg Val Lys Phe Thr Leu Asn Met Leu Val Thr Met Ala Pro Ile Val 465 470 475 480 Leu Ile Leu Leu Gly Leu Leu Leu Phe Lys Met Tyr Pro Ile Asp Glu 485 490 495 Glu Arg Arg Arg Gln Asn Lys Lys Ala Leu Gln Ala Leu Arg Asp Glu 500 505 510 Ala Ser Ser Ser Gly Cys Ser Glu Thr Asp Ser Thr Glu Leu Ala Ser 515 520 525 Ile Leu 530 97 2952 DNA Homo sapiens 97 acaaactact ccctgagatc ctacaatccg cttcatttct aactgctaat ggggccttgt 60 atatggcttt cttttgcatt ttaaggaaga tacttggaaa attctactca tggactcctg 120 gctttggtgc cgctctgcca gcatcttatg tggccattct cattgaaaga aaaagcagga 180 gagggctgct cacaatttat atggccaact tggtcctttt gttttgcatc acagctgcca 240 tgtacatgtt ctttttcagg tgcaaggatg gcttgaaagg atttacattt tctgcactta 300 ggttcattgt agggaaggaa gaaattccca cacattcttt ttcaccagag gcagcatatg 360 caaaagtgga acaaaagaga gagcaacatg aggaaaaacc cagaagaatg aatatgattg 420 gtctagtcag gaaatttgtg gattcaatat gcaaacatgg accaaggcat agatgttgca 480 aacattatga agataattgc atctcttatt gcattaaagg tttcatcaga atgtttagcg 540 tggggtactt gatccagtgc tgcctccgaa tcccttctgc atttaggcat ctgtttacac 600 agccatctcg gctactttct ctcttctaca ataaagaaaa cttccagctt ggagcttttc 660 ttggctcttt tgttagtata tacaagggta ctagttgctt cctgcgctgg atcagaaact 720 tagatgatga actacatgct attatagctg gatttttggc aggtacatca atgatgtttt 780 ataaaagcac aacaatttcc atgtatttag cgtccaaatt ggtagagaca atgtatttca 840 aaggcattga agcagggaag gttccctatt ttcctcatgc agatactatc atctattcca 900 tctctacagc aatttgcttc caggcagctg tcatggaagt tcagactttg agaccatctt 960 actggaagtt ccttttaaga ctcaccaagg gcaaatttgc tgtcatgaac cgaaaagtcc 1020 ttgatgtttt tggtactggt gcatctaaac actttcagga tttcatcccc aggttggatc 1080 caagatacac aactgtaaca ccagagttgc ccacagagtt ttcctgaaga tgactgtaac 1140 ttattaatgt gactaaatgt ttcatcttga agagttaatt atgttgaaca caaaggaggg 1200 ggcccaagct cgaacttcag tgttatttca gttagagata ctcttttcat ttgttttgtt 1260 tttcttatga atcagaaatt cagaagcttt ttaggaagat gttgcttaat aattaagctt 1320 cctccatagc cagaataaga ttctggatca ctgtagtgac tgacattata tattattgat 1380 caaattatgt ccacaagcaa tattatataa tctacgtaga agtgtaataa caaacaagag 1440 tacacttaaa attactttaa aagatgtctt tagttcattc caatataatt cttgattaaa 1500 attaggatta tttctacatt ttaggattta caaaggatca cgggtacatg ggtttggtct 1560 atatattttt ttaaagtttt gaattggtat ctgtagtagt ggaatgttat agatttgaag 1620 taactctcca cggacagtgc tgctttcgtg tagagcaatt taattggaga agtggccatt 1680 cttacttcag ggatgcaaag atgggtctca taccatttgg ataaatgtcg tggtatccat 1740 gctttttttc aactaataac atcatctctc ttcatgacca gttaattggg ctatttggca 1800 gcccagtgaa cctatgtact aatggcaagt taggggcaaa tggaaatgga cacatccgtt 1860 aaagttgaaa tgtatgtttt aatctttcac agaagtatta cacttgaata tttaaaaaca 1920 aaacttttaa acttcctata ggtttatgat gtttgttttc atttatatgg acataatcct 1980 tcatagctca gtttatatgc cattgttgta ttagaaggga tcaaaatcct atggaacaaa 2040 gtagtcttgg caagttggca gtttgtgtcc tctcagctgt ttaacttatg taatggatgt 2100 tttgcacctg aaaacactat aaaaatccag tggttgttta aaaagtccat ttgtcactaa 2160 ttccattcag gttctccaac cttcttcttg aatatcattg tcaccattta tactgttaga 2220 ataaagaggt gacaccataa agtcctgctg ataatgagag tagttcagga cagctgtgat 2280 tgaaatatgg tcgctattta cagtttttca gggaaaagtt atacttttct atgttaataa 2340 agagctgaag tggtctacag ttaatgtgac atgtagggat gatgatattt ttaaaataca 2400 ttttgttgct aaaaagttgt taggccagtg caaattatgc agtagaactt gtgttgcaaa 2460 aggaattata acccatactt taaaaatgct taatccctca tattcaattt catcaagcct 2520 tgtatacttc tgcttaaatg taattcaatc cttggttgtt atggcaaaca gaaacccaac 2580 aaaaagacag actctggtac tatggtaaca gagccacttt atcatttggt caaaatttga 2640 cattatgatt agctttgtag aactgacctg tttatttggc aatgctgtta aaggatcatt 2700 tcggtttcag acttcaaagt tgattaataa atttaatctt aactttttat tcactggaat 2760 caaaacgatg gttggtactg tgtttactgt ttaaaatgaa gtactaaagc cctgagaact 2820 gcacctcatt ttctttatcc agaaattgtg cttatatatt ttcctgtcag gtttaaaaag 2880 atgttttaat tcataaatta ttgttttcat tgacattaaa ggactgtgat attgaaaaaa 2940 aaaaaaaaaa aa 2952 98 354 PRT Homo sapiens 98 Met Ala Phe Phe Cys Ile Leu Arg Lys Ile Leu Gly Lys Phe Tyr Ser 1 5 10 15 Trp Thr Pro Gly Phe Gly Ala Ala Leu Pro Ala Ser Tyr Val Ala Ile 20 25 30 Leu Ile Glu Arg Lys Ser Arg Arg Gly Leu Leu Thr Ile Tyr Met Ala 35 40 45 Asn Leu Val Leu Leu Phe Cys Ile Thr Ala Ala Met Tyr Met Phe Phe 50 55 60 Phe Arg Cys Lys Asp Gly Leu Lys Gly Phe Thr Phe Ser Ala Leu Arg 65 70 75 80 Phe Ile Val Gly Lys Glu Glu Ile Pro Thr His Ser Phe Ser Pro Glu 85 90 95 Ala Ala Tyr Ala Lys Val Glu Gln Lys Arg Glu Gln His Glu Glu Lys 100 105 110 Pro Arg Arg Met Asn Met Ile Gly Leu Val Arg Lys Phe Val Asp Ser 115 120 125 Ile Cys Lys His Gly Pro Arg His Arg Cys Cys Lys His Tyr Glu Asp 130 135 140 Asn Cys Ile Ser Tyr Cys Ile Lys Gly Phe Ile Arg Met Phe Ser Val 145 150 155 160 Gly Tyr Leu Ile Gln Cys Cys Leu Arg Ile Pro Ser Ala Phe Arg His 165 170 175 Leu Phe Thr Gln Pro Ser Arg Leu Leu Ser Leu Phe Tyr Asn Lys Glu 180 185 190 Asn Phe Gln Leu Gly Ala Phe Leu Gly Ser Phe Val Ser Ile Tyr Lys 195 200 205 Gly Thr Ser Cys Phe Leu Arg Trp Ile Arg Asn Leu Asp Asp Glu Leu 210 215 220 His Ala Ile Ile Ala Gly Phe Leu Ala Gly Thr Ser Met Met Phe Tyr 225 230 235 240 Lys Ser Thr Thr Ile Ser Met Tyr Leu Ala Ser Lys Leu Val Glu Thr 245 250 255 Met Tyr Phe Lys Gly Ile Glu Ala Gly Lys Val Pro Tyr Phe Pro His 260 265 270 Ala Asp Thr Ile Ile Tyr Ser Ile Ser Thr Ala Ile Cys Phe Gln Ala 275 280 285 Ala Val Met Glu Val Gln Thr Leu Arg Pro Ser Tyr Trp Lys Phe Leu 290 295 300 Leu Arg Leu Thr Lys Gly Lys Phe Ala Val Met Asn Arg Lys Val Leu 305 310 315 320 Asp Val Phe Gly Thr Gly Ala Ser Lys His Phe Gln Asp Phe Ile Pro 325 330 335 Arg Leu Asp Pro Arg Tyr Thr Thr Val Thr Pro Glu Leu Pro Thr Glu 340 345 350 Phe Ser 99 507 DNA Homo sapiens 99 gattccgcac ctccgagtgc tggccgggcg agaggctggc ggctgggctc tcgcgcccct 60 ccctgcaggg ctcaggctct ccccctcctg tcttctccgc gctgtttttt gtcatggcgg 120 ccctcagcaa gtccatccct cataactgct atgagatcgg ccacacttgg cacccttcct 180 gccgggtctc cttcctgcag atcaccgggg gcgccctgga ggagtccctg aagatctatg 240 ctcctctgta cttgattgca gcaattctcc ggaaacggaa attagactat tatttacaca 300 aactactccc tgagatccta caatccgctt catttctaac tgctaatggg gccttgtata 360 tggctttctt ttgcatttta aggaagatac ttggaaaatt ctactcatgg actcctggct 420 ttggtgccgc tctgccagca tcttatgtgg ccattctcat tgaaagaaaa agcaggagag 480 ggctgctcac aatttatatg gccaact 507 100 23 DNA Homo sapiens 100 cagagtaacc ccgctctcgt gac 23 101 30 DNA Homo sapiens 101 gtgttcaaca taattaactc ttcaagattg 30 102 17 DNA Homo sapiens 102 gtaaaacgac ggccagt 17 103 19 DNA Homo sapiens 103 ggaaacagct atgaccatg 19 104 24 DNA Homo sapiens 104 ccaaagccag gagtccatga gtag 24 105 27 DNA Homo sapiens 105 tggtctagtc aggaaatttg tggattc 27 106 27 DNA Homo sapiens 106 gaatccacaa atttcctgac tagacca 27 107 23 DNA Homo sapiens 107 ctactcatgg actcctggct ttg 23 108 26 DNA Homo sapiens 108 gcacaacaat tcccatgtat ttagcg 26 109 26 DNA Homo sapiens 109 cgctaaatac atgggaattg ttgtgc 26 110 24 DNA Homo sapiens 110 gacggtggta cactcttgag aaaa 24 111 30 DNA Homo sapiens 111 gaagatggga aaacattgta taatttaagc 30 

What is claimed:
 1. A purified nucleic acid comprising SEQ ID NO 1, or the complement thereof.
 2. The nucleic acid of claim 1, wherein said nucleic acid comprises a region encoding for the amino acid sequence of SEQ ID NO
 2. 3. The nucleic acid of claim 1, wherein said nucleotide sequence encodes for a polypeptide consisting of the amino acid sequence of SEQ ID NO
 2. 4. The nucleic acid of claim 1, wherein said nucleotide sequence comprises at least 554 consecutive nucleotides of SEQ ID NO 1, or the complement thereof.
 5. A purified polypeptide comprising an amino acid sequence of SEQ ID NO
 2. 6. The polypeptide of claim 5, wherein said polypeptide consists of amino acid sequence set forth in SEQ ID NO
 2. 7. The polypeptide of claim 5, wherein said polypeptide comprises at least 185 consecutive amino acids of SEQ ID NO
 2. 8. An expression vector comprising a nucleotide sequence encoding amino acid sequence set forth in SEQ ID NO 2, wherein said nucleotide sequence is transcriptionally coupled to an exogenous promoter.
 9. The expression vector of claim 8, wherein said nucleotide sequence encodes for a polypeptide consisting of the amino acid sequence of SEQ ID NO
 2. 10. The expression vector of claim 8, wherein said nucleotide sequence comprises SEQ ID NO
 1. 11. The expression vector of claim 8, wherein said nucleotide sequence consists of the sequence of SEQ ID NO
 1. 12. A recombinant cell comprising the expression vector of claim 8, wherein said cell comprises an RNA polymerase recognized by said promoter.
 13. The recombinant cell of claim 12, wherein said cell is made by a process comprising the step of introducing the expression vector of claim 8 into said cell.
 14. A method of estimating LXR activity in a subject, comprising: (a) measuring a transcript level in a sample of mRNA or nucleic acid derived therefrom from said subject, wherein said transcript comprises a nucleotide sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, SEQ ID NO 21, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37, SEQ ID NO 39, SEQ ID NO 41, SEQ ID NO 43, SEQ ID NO 45, SEQ ID NO 47, SEQ ID NO 49, SEQ ID NO 51, SEQ ID NO 53, SEQ ID NO 55, SEQ ID NO 57, SEQ ID NO 59, SEQ ID NO 61, SEQ ID NO 63, SEQ ID NO 65, SEQ ID NO 67, SEQ ID NO 69, SEQ ID NO 71, SEQ ID NO 73, SEQ ID NO 74, SEQ ID NO 76, SEQ ID NO 77, SEQ ID NO 79, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 84, SEQ ID NO 85, SEQ ID NO 86, SEQ ID NO 87, SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 90, SEQ ID NO 91, SEQ ID NO 92, SEQ ID NO 93, SEQ ID NO 94 and SEQ ID NO 95; and (b) comparing said measured level of said transcript to the level of said transcript measured in a control sample; wherein the level of transcript measured in said sample from said subject as compared to the level of transcript measured in said control sample provides an estimate of LXR activity in said subject sample.
 15. The method of claim 14 wherein said transcript level is measured using a method selected from the group consisting of a microarray, a Northern blot, and RT-PCR.
 16. The method of claim 14 wherein said control sample is contacted with an LXR agonist.
 17. The method of claim 16 wherein said comparing step is performed using a plurality of control samples, said plurality comprising at least one control sample not treated with an LXR agonist.
 18. The method of claim 14 which is used to diagnose a disease or disorder involving LXR activity in a sample by detecting an increase or decrease in said transcript level relative to the amount present in an analogous sample from a subject not having the disease or disorder or not subjected to therapy.
 19. The method of claim 18 wherein said disease or disorder is cholesterol gallstones, atherosclerosis, lipid storage diseases, obesity, diabetes, or hypercholesterolemia.
 20. The method of claim 14 which is used to identify a compound that changes LXR activity, wherein said compound changes the estimated level of LXR activity in a sample from said subject contacted with said compound relative to the estimated level of LXR activity in an analogous sample from said subject not contacted with said compound. 